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Abstract  
 
Asthma is a chronic inflammatory disease characterised by reversible airflow obstruction. 
Based on the relationship between a lack of exercise and chronic diseases, the latest 
guidelines from the Department of Health (DH) recommend physical activity across the 
whole population (DH, 2011). Exercise Induced Bronchoconstriction (EIB) is a ‘sub-type’ of 
asthma which affects approximately 90% of all individuals with asthma and an additional 
10% of the healthy normal population (ATS/ACCP, 2003; Anderson & Kippelen, 2012); 
thus, EIB may be an important limiting factor for physical activity and an important ‘barrier 
to exercise’ for a  number of individuals.  
  
Asthma is identified primarily by the occurrence of symptoms (wheezing breathlessness 
and dyspnoea), peak expiratory flow rates (PEF) and spirometry (Pulmonary Function 
tests – PFT). The current spirometry guidelines for the characterisation of asthma include 
a fixed criteria for the ratio between forced expiratory volume in one second and forced 
vital capacity (FEV1/FVC) (Miller et al., 2005b). This fixed criteria approach lacks specificity 
and is likely to misdiagnose approximately 20% of patients (Miller et al., 2011). The 
American Thoracic Society (ATS) and the European Respiratory Society (ERS) guidelines 
have acknowledged these concerns and have issued position statements for the use of a 
different approach using a ‘lower limit of normality’ (LLN) derived from a matched healthy 
population (Miller et al., 2009). Based on the fixed criteria, it has been shown that there is 
under diagnosis of participants with mild-moderate symptoms participants in the younger 
age group (Cerveri et al., 2009; Hansen et al., 2007; Miller et al., 2011; Roberts et al., 
2006; Swanney et al., 2008). 
 
The currently available pharmacological therapies for asthma and EIB are effective 
(corticosteroids and bronchodilators), however long-term usage of these medications is 
associated with issues of tachyphylaxis and negative side effects (Barnes, 2010; GINA, 
2011). There is some evidence from observational and intervention studies to suggest a 
beneficial effect of fish oil (comprising of omega-3 (n-3) polyunsaturated fatty acids 
(PUFAs)) in inflammatory diseases, (specifically asthma). Marine based n-3 PUFA have 
therefore been proposed as a possible complimentary/alternative therapy for asthma. The 
proposed anti-inflammatory effects of fish oil may be linked to a change in cell membrane 
composition. This altered membrane composition following fish oil supplementation 
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(primarily EPA/DHA) can modify lipid mediator generation via the production of 
eicosanoids with a reduced inflammatory potential/impact (Calder, 2012). A recently 
identified group of lipid mediators derived from EPA include E series resolvins which are 
proposed to be important in the resolution of inflammation (Serhan, 2011). Reduced 
inflammation attenuates the severity of asthma including symptoms (dyspnoea) and exerts 
a bronchodilatory effect.  
  
There is a lack of published data relating to fish oil supplementation in EIB prone 
individuals and most studies within the literature have been focussed predominantly on 
athletes. This thesis addresses issues related to disease severity, classification of EIB, the 
impact of EPA / DHA supplementation on post-exercise pulmonary function in EIB prone 
males and finally the impact of resolvins on EIB prone females.  
  
The first aim of this thesis was to compare the approaches to characterisation of asthma in 
mild-moderate individuals based upon fixed criteria (80% FEV1/FVC ratio) and the LLN, 
using a control population. Sixteen male asthmatic and twenty one healthy normal controls 
were recruited for PFT, estimation of dyspnoea and  measurement of venous blood based 
inflammatory mediators. Using the fixed criteria (80% ratio) the 16 asthmatics were 
demonstrated to have mild to moderate severity with all individuals showing a FEV1/FVC 
ratio to be below the 80% ratio. When the control population (FEV1/FVC ratio = 89%) were 
used to calculate the LNN  then a value of 82% was indicated which meant that all 16 
individuals previously characterised as asthmatics were confirmed as mild to moderate 
asthmatics with the newer approach to asthma characterisation. The asthmatics showed 
significantly elevated levels of serum IL-6 and TNF-α than controls and also exhibited 
worse dyspnoea score. The LLN when used alongside 80% ratio provides a comparable 
method for characterisation of mild-moderate asthma.  
  
To assess the effect of EPA / DHA supplementation on post exercise FEV1 in EIB prone 
males, a randomised crossover trial (RCT) with a three week intervention of n-3 
supplementation (3.2 grams of EPA and 2.2 grams of DHA/ or placebo per day) was 
completed by 9 mild-moderate asthmatics with EIB. A significant improvement in post 
exercise FEV1 for EIB was observed following supplementation and was mirrored by a 
significant reduction in bronchodilator usage and a drop in serum IL-6 levels. PBMC lipid 
composition showed a non-significant trend towards an increase in EPA/DHA content with 
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a concurrent reduction in AA levels. There was no significant improvement in the Fraction 
of Exhaled Breath Nitric Oxide (FeNO), or serum levels of TNF α and IL-10. The 
improvement in pulmonary function demonstrates a benefit to mild-moderate asthmatics of 
fish oil supplementation however, the lack of consistent inflammatory mediator data means 
that possible mechanisms are still not elucidated.  
  
Finally, to investigate the effect of EPA-derived bioactive mediators (E series Resolvins) 
on post exercise FEV1 in EIB-prone females, a RCT with 3 week supplementation with 100 
mg of commercially available Resolvinol (Bionovex)/per day was completed by 8 females 
with EIB. There was a significant improvement in post exercise FEV1, however no changes 
were observed for serum cytokine levels for IL-6 and TNF α and FeNO; while there was a 
significant reduction in serum IL-10 levels. The beneficial effects of E series resolvins on 
pulmonary function may suggest a different mechanism via which the n-3 PUFA exhibit 
anti-inflammatory effects.   
  
In conclusion, both the fixed criteria and LLN are suitable for characterisation of young, 
mild-moderate asthmatics. There is a beneficial role of EPA/DHA supplementation in EIB 
prone males while resolvin supplementation appears to have a similar effect on pulmonary 
function of EIB prone females but an inconsistent impact upon systematic inflammation in 
EIB females. Further mechanistic approaches with a larger sample size are required to 
investigate the role of the n-3 and their lipid mediators on lung function at a population 
level.  
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1.0. Introduction and Literature Review 
 
Asthma is a chronic inflammatory disorder of the airways, which involves both cells and 
cellular elements. The chronic inflammation of asthma is also associated with airway 
hyperresponsiveness (AHR) which together lead to episodes of wheezing, breathlessness, 
chest tightness and coughing. These recurrent episodes are associated with widespread 
but variable obstruction in the lungs which  is often reversible either spontaneously or with 
treatment (Bloemen et al., 2007; Wouters et al., 2009; GINA, 2011). Towards the end of a 
full exhalation an abnormally large amount of air may still be present in the lungs (Ryu & 
Scanlon, 2001). When an asthmatic encounters a trigger, the airway smooth muscles 
(ASMs) contract and the airways become narrower causing bronchoconstriction. An 
asthma trigger may be a substance or an event that sets off asthma symptoms; common 
triggers are cold air, dust, pollen and exercise. Asthma triggers can vary from person to 
person. Bronchoconstriction is accompanied by the airways becoming inflamed and thus 
starting to swell. In most cases, sticky mucus or phlegm develops which can further add to 
the narrowing of the airways. Thus, the three major characteristics associated with asthma 
are bronchoconstriction, inflammation and mucus secretion. These symptoms cause the 
airways to become narrower and irritated making it difficult to breathe, subsequently 
leading to characteristics of asthma (NHLBI, 2007; figure 1.1). 
 
 
Airway at normal state 
During Asthma attack , constriction 
and mucous secretion 
 
Figure 1.1 The respiratory system and status during asthma attack (adapted from Willmore & 
Costill, 2004) 
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1.1. Epidemiology of asthma  
 
Asthma is one of the most common and prevalent problems worldwide affecting over 300 
million individuals. In different countries asthma affects from 1% to 18% of the population 
and it is evident that in both developing and developed countries prevalence of asthma 
increases as communities adopt modern or ‘western lifestyles’, becoming urbanised 
(Bousquet et al., 2005). It has been projected that with urbanisation continuing to increase 
worldwide, there is likely to be a marked increase in the number of people with asthma 
living within the next two decades (GINA, 2011). It is estimated that potentially an 
additional 100 million people worldwide will be affected with asthma by 2025 (Koshy et al, 
2010; Ronchetti et al, 2001). There are large differences in asthma prevalence between 
countries and the rate of asthma mortality does not correlate well with this prevalence, as 
those countries with the highest prevalence often have the greatest developed 
infrastructure for asthma management (figure 1.2) (Beasley, 2004; Masoli et al., 2004; 
Mallola et al., 2012; Pearce et al., 2007). Furthermore, the information on asthma mortality 
is unreliable in many countries due to lack of resources and measurement error; however, 
it is estimated that annual worldwide deaths from asthma are approximately 250,000 
(Antó, 2012; Masoli et al., 2004) 
 
Figure 1.2 Worldwide prevalence and mortality related to asthma (used with permission from 
Bousquet et al., 2005) 
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The countries showing highest mortality rates are the ones where controller therapies (e.g. 
inhaled long-acting β2-agonist (LABA) or leukotriene receptor antagonist (LTRA)) are not 
yet available. There is a higher mortality rate associated with asthma in developing nations 
and in poor compared to affluent communities within developed nations, suggesting a role 
for lifestyle differences such as diet, access to healthcare and exposure to allergens in 
mortality risk. For example, in the USA mortality rates have increased in those areas 
where access to healthcare is limited (Al-Hajjaj, 2008; Braman, 2006; Holgate & Douglass, 
2010). It is estimated that 15 million disability–adjusted life years (DALYs) are lost annually 
due to asthma and this represents 1% of all DALYs lost (Bousquet et al., 2005; 
Murray,1994; Ourania et al.2010). Current estimates suggest that over five million people 
in the UK suffer from asthma and despite the availability of effective treatments; the 
condition is still under-diagnosed and under-treated (Asthma UK, 2011). The economic 
cost of asthma is considerable both in terms of direct medical costs (which include hospital 
admissions and cost of medication) and indirect costs (e.g. time lost from work, disability–
adjusted life years and premature death). 
 
In Europe (excluding UK) the cost of asthma is estimated at 17.7 billion Euros a year in 
addition to lost productivity estimated at 9.8 billion Euros (Bahadori et al., 2009) while in 
the USA the economic burden of asthma was estimated to be US$12.7 billion (Campbell et 
al., 2008). ‘The burden of lung disease report’ by British Thoracic Society (BTS, 2006) 
indicated that the total cost of all respiratory diseases including asthma for the UK National 
Health Service was approximately £2.9 billion. Mortality rates from respiratory disease are 
higher in the UK than the European average. The BTS has identified asthma to be the 
third major reason for mortality due to respiratory diseases in the UK after tuberculosis and 
pneumonia (BTS, 2006).The other countries in Europe who have a worse mortality record 
than the UK are the former Soviet Union countries with relatively under-funded, less 
sophisticated health services. Poor asthma control is a major challenge of asthma 
management and can lead to poor economic and clinical outcomes; consequently a 
number of strategies are being developed by health authorities in different countries to 
better manage the disease in order to reduce associated costs (Bahadori et al., 2009; 
Bousquet et al., 2005; BTS, 2012; Weiss & Sullivan, 2001).  
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1.2. Risk Factors 
 
There are many risk factors for asthma (table 1.1). Factors which influence the risk of 
asthma are divided into the following categories: (1) those that cause the development of 
asthma (primarily genetic factors), (2) those which trigger asthma symptoms (mainly 
environmental factors), and (3) those that do both (Chung & Adcock, 2000). For example, 
atopy is the genetic predisposition for the development of an immunoglobulin E (IgE)-
mediated response to common aeroallergens, and this is a strong identifiable predisposing 
factor for developing asthma (NHLBI, 2007).  
 
There is an interaction of both environmental and genetic factors that influence 
susceptibility to asthma and the development of asthma symptoms (Holgate, 1999; 
Mukherjee & Zhang, 2011). Recent genetic studies have identified a number of genes, 
which influence the inception, progression and severity of the disease (Beghe et al., 2003; 
Kormann et al., 2008; Salam et al., 2007; Wan et al., 2011). Genome-wide association 
studies (GWAS) in mild asthmatic adults, have identified a widely replicated region on 
chromosome 17q12-21 containing genes ORMDL3, CCL11 and GSDML, that influences 
asthma susceptibility (Gudbjartsson et al., 2009; Moffatt et al., 2007; Ober et al., 2008). 
These associated loci have also been replicated in a recent large-scale collaborative study 
published by the GABRIEL consortium (adults, n= 10,365 cases and n=16,110 controls), 
investigating mild asthma and single nucleotide polymorphisms (Moffatt et al., 2010).  
Additionally Wan et al., (2011) completed the largest GWAS of moderate and severe 
asthma sufferers (adults, n = 1026 individuals of European ancestry) and confirmed the 
association between the ORMDL3/GSDMB loci on chromosome 17q12-21 and severe 
asthma (Wan et al., 2011). Given these findings, researchers have established there are 
genetic differences governing the disease severity. However, more comprehensive studies 
are required to understand the relationship between gene expression and symptoms of 
asthma severity for asthma subtypes such as exercise induced asthma and allergic 
asthma.  
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Table 1.1 Risk factors for asthma (adapted from NHLBI, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are a number of environmental factors which also play a significant role in the 
pathogenesis of asthma which include nutrition, pollution and seasonal changes (GINA 
Executive and Science Committees., 2007; Holgate et al., 2007). Additionally factors such 
as the maturation of immune responses and the timing of respiratory infection in the early 
years of life are emerging as important factors affecting susceptibility to asthma (Wood & 
Gibson, 2009). A number of large epidemiological studies have suggested that the dietary 
pattern associated with western cultures (western diet) is negatively associated with 
respiratory health (Allan & Devereux, 2011; Devereux & Seaton, 2005, Kim et al., 2009; 
Miyake et al., 2012) . Western diets high in salt, fat, and low in antioxidants, have been 
shown to increase the risk of developing asthma in children and adults (Hijazi et al., 2000; 
Mickleborough, 2008; Murphy et al., 2002; Wickens et al., 2005).  In the last few decades, 
there has been significant rise in the therapeutic potential of fish oil for various 
inflammatory conditions including cardiovascular rheumatoid arthritis, inflammatory bowel 
disease and asthma. Evidence from observational studies suggests that an increased 
intake of omega 6 (n-6) polyunsaturated fatty acids (PUFAs) accompanied by a low intake 
of fish oil [omega 3 (n-3) PUFA] may play a causal role in increased asthma incidence 
(Black & Sharpe., 1997; Calder., 2006; Hodge et al., 1994; Peroni et al., 2012).  
Risk factor  Examples  
Host factors  Family History & Genetics   
E.g. Genes predisposing to atopy 
Obesity, sex  
Environmental  Factors Allergens  
    Indoor allergens – domestic mites, furred 
animals 
            Outdoor – Pollens, fungi, moulds 
Viral infections  
Tobacco smoke  
          Passive smoking  
           Active smoking  
          Smoking  during pregnancy  
Indoor/outdoor air pollution  
Modern Lifestyle 
            Diet  
            Housing environment   
Irritants at  workplace  Occupational sensitizers  
Chapter 1: Introduction & literature review                                                  A Kumar  
 10
The relationship between dietary PUFAs (n-3 and n-6) and pulmonary function will be the 
major focus of this thesis and these studies will be reviewed, in detail, in the following 
sections.  
 
There are racial and ethnic differences in the prevalence of asthma in addition to the 
socio-economic and environmental factors identified above (Antó, 2012). Researchers 
have shown that African Americans not only have a higher prevalence of asthma than 
Caucasians, they also have higher asthma-associated morbidity and mortality. In addition, 
African Americans living in low-income urban areas have higher prevalence and mortality 
than African Americans living in high-income urban areas (Silvers & Lang, 2012). 
Additionally, upper respiratory tract infections and exposure to allergens to which the 
asthmatic may be sensitive are further risk factors for symptom onset. Some seasonal 
asthma symptoms can be identified such as pollen induced asthma in summer months. 
Occupational asthma is triggered by exposure to work-based environmental stimuli that 
could be a chemical or a protein. There are also some asthmatics that develop 
exacerbations of their symptoms while taking aspirin or other non-steroidal anti-
inflammatory drugs (NHLBI, 2007; Kumari & Rana, 2012).  
 
Sex differences have an influence on the pathophysiology of asthma. It has been shown 
that the prevalence of asthma is higher in males than in females before adolescence, but 
that this trend is reversed post-adolescence (Almqvist et al., 2008; Chen et al., 2008; 
Osman, 2003). The female sex hormones (progesterone and estrogen) can potentially 
amplify asthma and other allergic diseases (Lim & Kobzik, 2008; Macsali et al., 2009; 
Vrieze et al., 2003). In general population, early menarche (<12 years) leads to higher risk 
(2.8 fold) of asthma after puberty compared to late menarche (>14 years) (Salam et al., 
2006). Oestradiol (a sub type of oestrogen) and progesterone can inhibit peripheral 
monocyte production of Interleukin 1(IL-1), which is a strong mediator of inflammation. 
Additionally studies have shown that oestradiol exhibits anti-inflammatory properties in 
human leukocytes (Haggerty et al., 2003; Morishita et al., 1999). Consequently, during 
premenstrual and menstrual phases studies have reported changes in pulmonary function, 
increases in asthma exacerbations and also hospitalisations (Farha et al., 2009). During 
the menstrual cycle, there is variation in skin test response to allergens (Kalogeromitros et 
al., 1995), exhaled breath nitric oxide levels (Mandhane et al., 2009), pulmonary function 
and adenosine-airway hyperresponsiveness (Choi et al., 2011; Stanford et al., 2006; Tan 
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et al.,1997) according to the levels of sex hormones. In several studies, the use of oral 
contraceptives has been found to have a beneficial effect in reducing the variability of 
pulmonary function over the menstrual cycle (Matsuo et al., 1996; Stanford et al., 2006). 
Dravata et al., (2010) also recently reported that women had high AHR in the pre-
menstrual phase (mid-luteal phase) and cyclical variations in AHR were observed to be 
smaller among women taking oral contraceptives. The role of sex hormones and use of 
oral contraceptives (pill) in the severity of asthma symptoms is established. Thus, these 
factors must be considered in future asthma studies.  During this thesis, female 
participants were studied (chapter 5) and considerations were made in assessing the 
relationship between oral contraceptive pill usage and lung function.  
 
1.3 Diagnosis and asthma classification  
 
Diagnosis of asthma is predominantly determined by measuring symptoms (episodic 
breathlessness, wheezing, cough and chest tightness), peak expiratory flow and other 
parameters of spirometry (Miller et al., 2005a,b). Episodic symptoms after allergen 
exposures, seasonal variability and a positive family history and atopy are useful 
diagnostic guidelines (Levy et al., 2006). The presentation of asthma can vary from person 
to person and asthma may be intermittent with mild to severe episodes requiring treatment 
(Chung & Adcock, 2000; Reddel et al., 2009). Asthmatics may experience intermittent 
symptoms for a period of few minutes and in some cases this may be life threatening. 
Asthma sub groups have been characterised to address the complexities of the disease 
and for better understanding of the symptoms. A phenotype or subgroup identifies the 
clinically relevant properties of the disease, but does not show the direct relationship to 
disease aetiology and pathophysiology (Agache et al., 2012; Wenzel et al., 2012). Table 
1.2 shows a classification of asthma into main sub groups including early onset allergic, 
eosinophilic, aspirin triggered, exercise induced, obesity related and asthma related to 
airflow obstruction. Exercise induced bronchoconstriction (EIB) is a sub group of asthma, 
which affects up to 90% of people with asthma and approximately 10% of the healthy 
population (ATS/ACCP, 2003; Anderson & Kippelen, 2005, 2012; Rundell et al., 2002). 
This thesis is focussed on investigating the diagnosis/characterisation of mild-moderate 
asthmatics and once the asthmatics are characterised the effect of omega 3 
supplementation in EIB prone individuals will be investigated. This section will review 
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current diagnostic techniques and the classification of different asthma subtypes with 
particular focus on EIB. 
 
Table 1.2 Asthma sub groups (adapted from Agache et al., 2012; Wark et al., 2005; Wenzel et 
al., 2012) 
 
 
Asthma subgroup Clinical and physiological features  
Early onset allergic  Allergic symptoms and other diseases 
Markers-  Specific IgE, Th2 cytokines 
Late onset eosinophilic  Sinusitis, less allergic 
Markers -  IL-5, corticosteroid –refractory eisonophilia 
Aspirin-exacerbated 
respiratory disease 
(AERD) 
 Severe asthma attacks, rhinorrhea and nasal congestion.  
Infection induced  Enhanced airway eosinophilia  
Asthma associated 
with apparent 
irreversible airflow 
Limitation 
FEV1/FVC ratio below the lower limit of normal for age and 
FEV1 < 90% predicted in a patient taking corticosteroids, 
after acute administration of a rapid onset bronchodilator.  
Exercise-induced  Mild symptoms, intermittent with exercise. 
Reduction in post exercise FEV1  
Markers: Th2 cytokines, mast cell activation, cysteinyl 
leukotrienes 
Note: 10% of healthy population also suffers from exercise 
induced symptoms  
Obesity related 
asthma  
Mainly Women are affected; very symptomatic, AHR  
Eosinophilic asthma Poor asthma control, increased bronchodilator response, 
lower lung function and exacerbations. More common in 
aspirin-sensitive asthma. Some association with expired 
NO levels and requires sputum analysis for diagnosis.   
 
1.3.1 Diagnostic methods  
Pulmonary function test (PFT) 
The main diagnostic technique for asthma is an assessment of pulmonary function to 
identify airflow limitation; this method has been used to demonstrate the reversibility of 
lung function abnormalities. On its own, the lung function test does not lead the clinicians 
directly to an aetiological diagnosis and requires other measurements for confidence. The 
measurement of pulmonary function is combined with an assessment of symptoms such 
as dyspnoea and wheezing, together they provide reliable information about the about 
different aspects of asthma control (Kerstjens et al., 1994; Miler et al., 2005a,b). 
Spirometry is the primary method for pulmonary function test (PFT). The most important 
aspects of spirometry include forced vital capacity (FVC), which is the maximum volume of 
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air an individual can expel from the lungs, during expiration made as forcefully and 
completely starting from full inspiration. The forced expiratory volume (FEV1) in one 
second, which is the maximum volume of expired air volume in the first second of a FVC 
manoeuvre. Peak expiratory flow (PEF) is the maximum expiratory flow achieved from a 
maximum forced expiration, starting from the point of maximal lung inflation, and is 
recorded using a PEF meter. Table 1.3 shows major measures and their definitions 
derived from a FVC manoeuvre. 
 
Table 1.3 Major pulmonary function outcomes, terminology and definitions (adapted from 
ATS/ERS guidelines (Miller et al., 2005a,b)  
Terminology  Definition  
FVC (Forced Vital 
Capacity) 
The maximal volume of air exhaled with maximally forced effort 
from a maximal inspiration, i.e. vital capacity (VC) performed with a 
maximally forced expiratory effort, expressed in litres at body 
temperature and ambient pressure. 
FEV1 (forced 
expiratory volume  
in one second) 
FEV1 is the maximal volume of air exhaled in the first second 
of a forced expiration from a position of full inspiration, expressed in 
litres.  
FEV1/FVC  The ratio of FEV1 to FVC - it indicates what percentage of the total 
FVC was expelled from the lungs during the first second of forced 
exhalation - expressed as FEV1/FVC ratio.  
PEF (Peak 
Expiratory Flow) 
PEF is the maximum expiratory flow achieved from a maximum 
forced expiration, starting without hesitation from the point of 
maximal lung inflation, and is recorded using a PEF meter. It is 
measured in either L/sec or L/min - this is a useful measure to see if 
the treatment is improving obstructive diseases like asthma. 
FEF25%-75% -
Forced expiratory 
flow  
This measurement describes the amount of air expelled from the 
lungs during the middle half of the forced vital capacity test.  
 
Predicted values of FEV1, FVC and PEF based on age, sex and height have been derived 
from population studies (Hankinson et al., 1999) and these values are regularly revised by 
ATS/ERS, BTS and other regulatory authorities. Due to ethnic differences in spirometric 
values appropriate predictive equations for FEV1 and FVC have been established for each 
population. The normal values are higher in young people (age<20 years) and lower in 
older people (>70 years). Since lung disease could potentially result in a decline in FEV1, a 
useful indicator for air flow limitation is the ratio of FEV1/FVC. The normal FEV1/FVC ratio 
is greater than 75-80%, and possibly greater than 90% in children (Miller et al., 2005a; 
GINA, 2011). Any values less than these values suggest airflow limitation. These predicted 
values are useful for judging whether a given value is abnormal or not. Recommendations 
for standardisation have been published and it has been outlined that spirometry is 
reproducible, but is effort dependent (Miller et al., 2005a,b; Pelligrino et al., 2005).  
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Consequently, instructions indicating the correct procedure for a normal inhalation and 
exhalation manoeuvre are provided to all patients prior to the spirometry test . 
Conventionally, a fixed criteria of ≤80%  (for FEV1/FVC ratio has been used for 
distinguishing abnormal pulmonary function from normal, however for more precise and 
accurate estimates, the lower limit of normal (LLN) should be considered as a better 
definition. The LLN is a limit of normality obtained from a matched control population and 
allows for a better characterisation of airflow obstruction (Cerveri et al., 2009, Miller et al., 
2011; Pellegrino et al., 2005). Using this cut off a given test can be abnormal if the 
measured value is below the LLN for FEV1/FVC. The LLN is defined as 1.65 standard 
deviations below the FEV1/FVC ratio (Pellegrino et al., 2005). In PFT the normal reference 
ranges were derived from healthy non-smoking subjects and are dependent on the age, 
sex, height and ethnicity of the subjects (Hankinson et al., 1999; Miller et al., 2009). 
However, in a clinical setting, the use of this LLN diagnosis has been found to be difficult. 
It involves additional statistical calculations that are not yet incorporated into the 
predicated equations for routine PFTs; prohibiting a quick interpretation of the normality of 
an individual’s results. This issue is currently being considered by the ATS/ERS task 
forces who are focussing on designing and updating predictive equations that can be used 
to obtain LLN to ensure accurate diagnosis is made in a clinical environment without any 
bias (Miller et al., 2009). The limitations of the fixed criteria will be discussed in chapter 3 
which was designed to characterise asthmatics based on a fixed criteria (80% ratio) and 
LLN from a control population. For the assessment and monitoring of asthma it is 
important to understand the relationship between asthma severity and control. Asthma 
severity is based upon the criteria described by various regulatory authorities as shown in 
table 1.4 (ATS/ERS, 2005; NHLBI, 2007). The classification of severity is determined by 
symptoms, lung function, reliance on inhalers, and interference with normal activity 
(NHLBI, 2007; GINA, 2011). Asthmatics with mild-moderate asthma have been suggested 
to have an abnormal pulmonary function with a predicted FEV1/FVC ratio of (>70% and 
<100%) (Miller et al.,2005a).  
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Table 1.4 Severity of asthma characterisation based on symptoms, lung function tests, 
inhaler usage and interference with normal activity; normal FEV1/FVC: 8−19 years = 85%, 20 
−39 years = 80%, 40 −59 years = 75%, 60 −80 years = 70% (ATS/ERS, 2005; Miller et al., 
2005a; NHLBI, 2007) 
 
During assessment of asthma severity, moderate asthma symptoms may include one or 
more of the following: deterioration in symptoms, deterioration in lung function and 
increased rescue bronchodilator use. These symptoms could last for 2 days or more, but 
not be severe enough to warrant systemic corticosteroid use and/or hospitalisation 
(Reddel et al., 2009). Furthermore it has been suggested that emergency room visits for 
asthma (e.g., for routine sick care), not requiring systemic corticosteroids, may be 
classified as moderate exacerbations (worsening of symptoms) (Oddera et al., 1996; 
McGrath et al., 2012). Mild asthma symptoms are not justifiable with present methods of 
analysis; this is because symptoms or changes in flow rates during these episodes lie just 
outside the normal range of variation for an individual patient. Thus, it is likely that a 
number of individuals with mild-moderate asthma can be incorrectly classified as normal 
which could have serious implications on the quality of life of these individuals. Mild-
moderate asthmatics may have airway conditions which may result in a temporary loss of 
asthma control rather than early stages of severe asthma symptoms. The extent of change 
in these measures is dependent on the age, gender and population studied (Miller et al., 
2005b; Reddel et al., 2009). Mild-moderate asthmatics are considered ideal subjects when 
conducting research in nonclinical settings where there is no access to severe asthma. For 
this reason, asthmatics with mild-moderate symptoms will make up the study population in 
this thesis. 
Components of 
severity  
Intermittent Mild Persistent Moderate 
Persistent 
Severe 
Persistent 
Symptoms ≤ 2days/week  >2days/week Daily  Throughout the 
day  
Lung Function FEV1 >80% 
predicted and 
normal 
between 
exacerbation 
 
FEV1/FVC 
normal  
FEV1 ≥70% 
predicted 
 
FEV1/FVC 
normal  
FEV1 60-70% 
predicted 
 
FEV1/FVC 
reduced by 5% 
from normal 
FEV1 less than 
60% predicted 
 
FEV1/FVC 
reduced > 5%  
from normal 
Rescue Inhaler 
Use 
≤ 2days/week >2 days per 
week , but not 
daily  
Daily  Several times/day  
Interference 
With Normal 
Activity 
None Minor limitation  Some limitation  Extremely limited  
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1.4 Dyspnoea (symptom of breathlessness) 
 
Dyspnoea scores are collected during asthma assessment in most clinics along with PFTs 
and is used to estimate the condition experienced by individuals who complain of 
unpleasant or uncomfortable respiratory sensations (ATS, 1999; Parshall et al., 2012). 
There is interplay between physiological and behavioural factors in producing respiratory 
discomfort along with spectrum of phrases used by patients to describe their sensations. 
Brain imaging studies have demonstrated that there is an association of activated cortico-
limbic areas with perception. Additionally, there may be a role of exogenous and 
endogenous opioids which could possibly modulate perception of dyspnoea (Parshall et 
al., 2012). Shortness of breath is often triggered by physiological responses such as 
exercise and sometimes individuals just perceive symptoms of breathlessness. In the 
normal population, dyspnoea is intensified as oxygen uptake increases with muscular 
activity and under conditions of heavy exertion (such as exercise) is considered normal. 
The significance of dyspnoea is inversely related to intensity of exercise provoking the 
symptoms; consequently, dyspnoea at rest is considered more severe than dyspnoea 
during intense exercise (ATS, 1999; Scano & Stendardi, 2006; Yorke et al., 2011). A visual 
analogue scale and the category ratio (CR)-10 scale developed by Borg and colleagues 
are major instruments used to quantify symptoms during asthma diagnosis and 
assessment. The Borg scale incorporates non-linear spacing of verbal descriptors of 
severity corresponding to specific numbers (Borg, 1982). Table 1.5 shows the CR-10 
scale.  
 
Table 1.5 Borg scale used for rating perceived breathlessness (Borg, 1982)  
Scale Severity 
0 No Breathlessness( At All) 
0.5 Very Very Slight (Just Noticeable) 
1 Very Slight 
2 Slight Breathlessness 
3 Moderate 
4 Some What Severe 
5 Severe Breathlessness 
6 
Very Severe Breathlessness 7 
8 
9 Very Very Severe (Almost Maximum) 
10 Maximum 
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1.5 Asthma pathophysiology  
 
Asthma is a heterogeneous disease with respect to immunopathology, clinical phenotype, 
response to therapy and natural history. The severity of asthma symptoms are governed 
by environmental factors or are caused by insufficient anti-inflammatory treatment (Barnes, 
2001; Brightling et al., 2011; Grainge et al., 2011; Holgate & Douglass., 2008; Tattersfield 
et al., 2002). Thus, the clinical spectrum of asthma is highly variable with airway 
inflammation being a consistent feature. The pattern of inflammation in asthma is 
associated with AHR (clinically measured by histamine or methacholine challenge) which 
leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing 
particularly at night or early morning. These episodes are generally associated with airflow 
obstruction within the lungs that is often reversible either spontaneously or with treatment. 
In most asthmatics, inflammation is largely restricted to the conducting airways but with an 
increase in disease severity, the inflammatory infiltrate spreads to the small airways and in 
some cases adjacent alveoli (Kraft et al., 1998). T-lymphocytes play a significant role in 
organising the inflammatory response in asthma. The release of specific patterns of 
inflammatory mediators (prostaglandins, cytokines), results in the recruitment and survival 
of eosinophils and in the maintenance of mast cells in the airways (Barnes., 2006).  
 
Lymphocytes can differentiate into two major, phenotypically distinct, memory Th cell 
populations, namely T helper 1 cells and T helper 2 cells (Th1 and Th2, respectively) 
which have distinct inflammatory mediator profiles. Th1 cells characteristically produce 
cytokines including  interleukin-2 (IL-2) and interferon-γ (IFN-γ), induce macrophage 
activation and are very effective in controlling infection caused by intracellular pathogens 
(Holgate & Douglass, 2010; Bloemen et al., 2007). Th2 cells secrete IL-4, IL-5, IL-6, IL-9 
and IL-13 as primary cytokines and the Th2 cells also help B lymphocytes in producing 
antibodies (figure 1.3). 
 
Cytokines are proteins which act as chemical messengers and have been recognised to 
regulate the development, growth or activity of target cells by binding to specific receptors 
on their surface (Calder, 2001). Chemokines are a sub-group of cytokines involved in 
chemotaxis, they are critical for cell migration during routine immune surveillance, 
inflammation, and development activities (Allen et al., 2007). Cytokines are produced as 
response to a trigger and various inflammatory cytokines mediate the systemic effects. 
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However, the overproduction of inflammatory cytokines has been found to play an 
important role in some of the symptoms of chronic inflammatory diseases such as 
rheumatoid arthritis, inflammatory bowel diseases and asthma (Rottem et al., 2002). Many 
inflammatory cells (macrophages, mast cells, eosinophils and peripheral blood 
mononuclear cells (PBMC)) have the ability to synthesise and release these proteins. 
Furthermore, structural cells such as epithelial cells and ASM cells can also produce a 
range of cytokines, subsequently playing a role in the inflammatory response (Barnes, 
2002; Holgate & Douglass, 2010; Szefler et al., 2012).  
 
Another feature of asthma is the response to triggers such as exercise and allergic 
sensitisation; the airways recognise common triggers and in turn generate a Th2 type 
cytokine response to them. Asthma is also found to involve local epithelial, mesenchymal, 
vascular and neurologic events, which direct the Th2 lymphocytes to the lung. Repeated 
bouts of increased inflammation in asthma may lead to damage to the airway epithelium 
and subsequent abnormal repair leads to structural changes in the airway walls of 
asthmatic subjects (collectively referred to as airway remodelling) (Hallstrand et al., 2005; 
Shifren et al., 2012). Figure 1.3 illustrates the role of different cells and mediators involved 
in the asthmatic inflammatory response to a trigger. There is recruitment and activation of 
leukocytes in response to the trigger. Following activation, the cells work actively to 
neutralise the antigens, subsequently they repair any damage; finally, the cells are 
removed with resolution of the inflammatory process (Rasmussen et al., 2009; Widgerow, 
2012).  
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Figure 1.3 Cells and inflammatory mediators involved in inflammation (Asthma 
pathophysiology, Asthma knowledge centre, 2011 with permission) 
 
Th2 derived cytokines such as IL-5 and IL-4 are responsible for eosinophil differentiation 
and survival. Asthmatics will often present with have elevated levels of these cytokines in 
sputum and blood samples (Robinson, 2010). In addition, Asthmatics will have higher 
levels of IL-13 in airway eosinophils and systemic T cells, furthermore IL-13 shares its 
activity with IL-4 in switching B cells to IgE production in asthmatics (Humbert et al., 1997; 
Wills-Karp, 2004). Following therapeutic approaches, blocking the IL-13 receptor a chain 
(with a fusion protein that can also block IL-4 receptor) has been shown to reduce AHR in 
animal models of allergic asthma (Kraft, 2011; Wills-Karp, 1998). IL-6 is produced by Th2 
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cells and other cell types such as epithelial cells and is a marker of airway (local) as well 
as systemic inflammation and elevated levels are found in bronchoalveolar lavage (BAL) 
and blood of asthmatics (Canöz et al., 2008; Tanni et al., 2010). 
 
Another Th2 cytokine, IL-9, may play a vital role in sensitizing responses to the cytokines 
IL-4 and IL-5 and is currently a drug target for asthma (Robinson, 2010). Other cytokines 
such as IL-1ß, TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
are released from different types of cells (e.g. macrophages and epithelial cells), are 
considered important in increasing the inflammatory response, and prolonging eosinophil 
survival in airways. TNF-α can cause an increase in histamine in allergic asthma, causing 
vasoconstriction by secondary production of endothelin-1 (a peptide mediator) (Barnes, 
2011; Chalmers et al., 1997, Goldie & Henry, 1999). Both IL-1ß and TNF-α have the ability 
to activate  pro-inflammatory transcription factors including nuclear factor-kB (NF-kB) and 
activator protein-1 which in turn activate a number of inflammatory genes in the asthmatic 
airway (Janssen-Heininger  et al., 2009; Liu et al., 2010). While cytokines coordinate the 
chronic inflammation, chemokines play an important role in the selective recruitment of 
inflammatory cells from the circulation. For example, eotaxin is relatively selective for 
eosinophils, while thymus- and activation-regulated chemokine and macrophage derived 
chemokines recruit Th2 cells (Barnes, 2008; Lloyd & Hessel, 2010).  
 
Other cytokines including interferon (IFN)-γ, IL-10, IL-12 and IL-18 have a regulatory role 
and can attenuate the inflammatory process. IL-10 is  described as a cytokine synthesis 
inhibitory factor which regulates the expression of a number of inflammatory cytokines (IL-
1ß, TNF-α and GM-CSF), and inflammatory enzymes (prostaglandin desaturase and COX) 
(Baine et al., Barnes, 2001; 2011; Biedermann et al., 2004; Holgate et al, 2010; Larché, 
2007; Ngoc et al., 2005). IL-10 secretion and gene transcription are defective in 
macrophages and monocytes isolated from asthmatics and this could potentially facilitate 
the inflammatory process in asthma (Barnes, 2001; Borish et al., 1996). IL-10 can inhibit 
eosinophilic inflammation by the suppression of IL-5 and GM-CSF and can influence 
eosinophil apoptosis and reduce endogenous nitric oxide (NO) production by down-
regulation of IL-1 (Bloemen et al., 2007; Holgate et al., 2010; John et al., 1998; Oswald et 
al., 1992). Since asthmatics have a distinct inflammatory profile, these cytokines have 
been used to distinguish asthmatics from normal healthy individuals. In this thesis, the 
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levels of IL-10, IL-6 and of TNF- α were measured in asthmatics to evaluate the 
relationship of the cytokines with airway inflammation. 
 
An increase in the activity of Th2 cells in asthma may be due to the reduction in regulatory 
T cells which normally inhibit Th2 cells and an increase in the natural killer (NK) T cells 
(Akbari et al., 2006; Larche et al., 2003). Peripheral blood mononuclear cells (PBMC) 
consist of mononuclear cells, which include monocytes, lymphocytes (T-cells, B-cells) and 
NK cells. Due to their extensive role in inflammatory response, PBMC have emerged in 
recent years as an attractive cell type for investigating several inflammatory disease states 
(Baine et al., 2011; Bluth et al., 2008; Manfred et al., 2009). Macrophages and 
polymorphonuclear neutrophils phagocytose invading pathogens and cellular debris. 
Neutrophils are increased in the airways and sputum of persons with severe asthma, 
during acute exacerbations, and in the presence of smoking (NHLBI, 2007). Inside the 
neutrophils, there is a fusion of the newly formed phagosomes with lysosomes to form 
phagolysosomes, these structures contain degrading enzymes and produce reactive 
oxygen species (ROS) to kill trapped organisms and cellular debris (Pettersen & Kenneth., 
2002;  Serhan et al., 2008; Widgerow, 2012).  
 
Generation of inflammatory mediators, recruitment and activation of inflammatory cells and 
infection can cause epithelial cells to produce more inflammatory mediators or injure the 
epithelium itself (Polito & Proud, 1998). A range of mediators have been implicated in 
asthma, each having different effects on the airways. The epithelial cells, B cells and 
macrophages serve as antigen presenting cells (APCs) to activate T cells at different 
stages during the immune response (figure 1.3). Monocytes are able to differentiate into 
macrophages and dendritic cells in the presence of Granulocyte macrophage-colony 
stimulating factor (GM-CSF), the latter requiring IL-4 (Holgate & Douglass, 2010; 
Robinson, 2004; Webb et al., 2007).  Dendritic cells have been found to sample allergens 
from the airway surface and migrate to regional lymph nodes where they interact with 
regulatory T cells and facilitate the production of Th2 cells (van Rijt et al., 2011). The 
precise role of macrophages in mediating tissue damage and airway pathology is largely 
unknown. There is some evidence from animal and human studies suggesting that these 
cells are a good source of inflammatory mediators such as leukotrienes (LTs), ROS and a 
variety of lysosomal enzymes (Bang et al., 2011, Peters-Golden, 2004, Holgate, 2008).  
LTs are a family of inflammatory lipid mediators synthesized from arachidonic acid by a 
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variety of cells, including mast cells, eosinophils, basophils, and macrophages (Peters-
Golden, 2004).  
 
The LTs, LTC4, LTD4 and LTE4 are potent vasoconstrictors of human airways; these 
mediators affect microvascular and bronchial dilation, increase AHR, and have been 
implicated in the pathogenesis of asthma (Broughton et al., 1997; De Caterina & Basta, 
2001; Wong, 2005). Following the development of potent specific leukotriene antagonists, 
it is now possible to evaluate the role of these mediators in asthma. LTD4 agonists have 
been shown to protect (by up to 50%) against exercise- and allergen-induced 
bronchoconstriction and this confirms that LTs play a role in bronchoconstrictor responses 
(Hansbro et al., 2011; Walsh, 2011). Prostaglandins (PGs) are another group of lipid 
mediators that have been shown to regulate muscle contraction, immune response and 
inflammation (Broughton et al., 1997; De Caterina & Zampolli., 2004; Lunn &Theobald, 
2006). PGs exert strong effects on airway function and there is increased expression of 
the inducible form of cyclooxygenase (COX-2) in asthmatic airways; however, the 
inhibition of their synthesis with COX inhibitors, such as aspirin or ibuprofen, may 
demonstrate some effect in reducing symptoms in some but not all asthmatics (Barnes, 
2011). PGD2 is a bronchoconstrictor produced predominantly by mast cells. Deletion of the 
PGD2 receptors in mice significantly inhibits inflammatory responses to allergen and 
inhibits AHR, suggesting that this mediator may be important in asthma (Bloemen et al., 
2007; Swedin et al., 2009). Furthermore, PGD2 may provide a link between mast cell 
activation and allergic inflammation via activation of chemoattractant receptor of Th2 cells 
(Matsuoka et al., 2000; Ricciotti & FitzGerald, 2011). Overall, while inflammatory mediators 
such as LTs and histamine are suggested to be involved in acute and sub-acute 
inflammatory responses and in exacerbations it is suggested that cytokines are important 
in maintaining chronic inflammation in allergic diseases.  
 
Nitric Oxide (NO) is an endogenous regulatory molecule involved in the pathogenesis of 
asthma. The synthesis of NO in the airways is mediated by a family of enzymes that are 
collectively called nitric oxide synthases (NOS) (Deykin & Kharitonov, 2002; Palmer et al., 
1987). The NOS can exist as constitute isoforms (cNOSs) including endothelial NOS 
(eNOS) and neural NOS or as an inducible isoform (iNOS) (Puckett & George, 2008; 
Ricciardolo, 2003). The inducible isoform (iNOS) is found in the epithelium of the bronchial 
wall, which is the key source for elevated levels of Fraction of exhaled nitric oxide FeNO 
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seen in asthmatics. Alveolar concentration of FeNO is usually low except in diseases such 
as alveolititis (Lehtimaki et al., 2001). During an exhalation process, the air from alveolar 
compartments move to the bronchial compartment; thus, the NO from the bronchial wall 
diffuses inside the airway lumen leading to an increase in NO levels in the expired air. 
Increased concentration of NO is observed when exhalation is slow, as this allows a longer 
time for the NO to diffuse in the airways (Deykin et al., 2002; Kharitonov et al., 1996; Zitt, 
2005). Patients with asthma usually exhibit 2-3 fold higher levels of NO in expired air 
compared to healthy adults (Saleh et al., 1998). Healthy adults can exhibit values between 
5-35 ppb (parts per billion) at the standard flow rate of 50 ml/s (Saleh et al., 1998; Zitt, 
2005). There are a number of factors such as age, gender, lifestyle (including cigarette 
smoking), environment and diet, which affect FeNO levels. For example, there is an 
increase in FeNO levels with age; in addition males appear to have higher levels of FeNO 
levels than women; in addition during exercise there is exhalation of high volumes of NO 
(Franklin et al.,1999; Hoffmeyer et al., 2009). The elevated levels of NO in expired air in 
asthmatics are indicative of eisonophilic inflammation; however, a direct pathogenic role of 
this gas in asthma has not yet been established (Jatakanon et al., 1998; Lim et al., 2000; 
Sandrini et al., 2010). Monitoring of NO levels in expired air is an attractive marker for 
assessing the efficacy of anti-inflammatory treatments (Dweik et al., 2011). In this thesis 
the effect of dietary supplementation with n-3 PUFA on FeNO levels were assessed to 
evaluate the anti-inflammatory effects of n-3 PUFA.  
1.6 Exercise induced bronchoconstriction (EIB)  
 
Exercise-induced bronchoconstriction (EIB) is a sub group of asthma in which there is 
transient narrowing of airways after vigorous exercise (McFadden & Gilbert. 1994, 
Anderson & Holzer, 2000). Occasionally this transient narrowing of airways can occur 
during exercise (Beck et al., 1994; Rundell et al., 2003; Suman et al., 1999). For patients 
with EIB a brief period of exercise or increase in ventilation triggers airflow obstruction 
which lasts for 30-90 minutes in the absence of treatment (Anderson & Kippelen, 2010; 
Hallstrand, 2012). Clinical focus in asthma therapy has been on the severe disease state, 
however a large number of asthmatics have mild to moderate symptoms. Recent public 
health guidelines from the Department of Health (UK) acknowledge the relationship 
between a lack of physical activity and chronic disease including asthma and 
consequently, physical activity is encouraged across the population (Department of Health, 
DH, 2011). EIB is most common in those with clinically diagnosed asthma, and up to 90% 
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of people with asthma experience EIB at some point during their lives. The majority of 
those affected by EIB consider exercising to be a major precipitant of their symptoms, and 
subsequently their involvement in physical activity is affected. EIB has also been reported 
in non-asthmatics including school children, armed force recruits, and athletes and 
approximately 10% of the healthy population show symptoms of EIB at some point during 
their lives (ATS/ACCP, 2003; Anderson & Kippelen, 2005, 2012). Based on the wide 
prevalence of EIB in asthmatic and healthy population, EIB is considered a limiting factor 
for physical activity for a large number of individuals. This thesis will focus on classification 
of mild-moderate asthmatics and EIB using different  PFT classification methods and will 
further evaluate the relationship of n-3 PUFA with EIB to elicit the possibility of using n-3 
as a therapy for EIB.   
 
Diagnosis of EIB – the exercise challenge test  
 
The observed symptoms of EIB include coughing, wheezing, chest tightness, shortness of 
breath or excess mucus production following exercise. However, self-reported symptoms 
are neither reliable nor specific for EIB. Approximately 50% of elite athletes who report 
symptoms related to EIB with exercise do not have EIB. While 50% of those who report no 
symptoms for EIB will test positive on the exercise challenge test for EIB (Parsons et al., 
2007; Rundell et al., 2001). Thus, it is essential to support the diagnosis of EIB by 
performing a relevant exercise challenge test (Rundell & Sue-Chu, 2010).  
 
An exercise challenge test involves exercising at increasing intensities until heart rate 
response of 85-90% of estimated maximal heart rate is achieved. This will usually occur in 
the last 4-6 minutes of the test. Following an exercise challenge test, spirometry is 
performed at 0, 5, 10, 15, 30 and 45 minutes post exercise or until complete recovery; 
whichever is earlier (Rundell & Sue-Chu, 2010).  Following an exercise challenge in 
susceptible individuals, there is a period of bronchodilation with improved air-flow as 
shown in figure 1.4. In addition, there is a decline in airflow after exercise, which may be 
measured by FEV1 or peak flow. The exercise challenge test primarily involves recording a 
post exercise reduction in forced expiratory volume in 1 second (FEV1) of 10% to 15% of 
the pre-exercise value. The value for FEV1 may start falling during exercise however; the 
lowest value will usually be measured 5-12 minutes after the end of the exercise challenge 
test. The reduction in FEV1, if severe, is linked to a decrease in oxygen saturation with 
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hyperinflation of the lungs (Anderson & Kippelen, 2010). In adults, a ≥10% decline in FEV1 
at any time-point within 30 minutes of ceasing exercise is considered a diagnostic of EIB. 
The decline in FEV1 is usually maintained over two time points and any un-sustained 
decline may be due to respiratory muscle fatigue and does not indicate EIB (Crapo et al., 
2000; Sterk et al., 1993; ATS/ACCP., 2003). 
 
 
 
Figure 1.4 Changes in FEV1 following an exercise challenge test (adapted from O'Byrne, 
2000) 
 
Different exercise modes have been investigated to evaluate the most appropriate model 
for assessment of EIB. It has been suggested that when performed at the same metabolic 
rate, running is the most effective exercise model for testing EIB, followed in decreasing 
order by cycling, swimming and walking. With regards to duration and intensity, the 
maximum effect of a treadmill challenge on lung function often occurs within 6-8 minutes of 
running at an incline of approximately 10-15% at a constant speed but this is dependent 
on the level of fitness of the participant (Anderson et al., 1975; Silverman & Anderson, 
1972). In this thesis an exercise challenge test (using a motorised treadmill) was 
conducted for an assessment of EIB in EIB prone participants, further information will be 
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provided in the chapter 2 (general methods). An exercise challenge test is used mainly for 
the diagnosis of EIB, assessment of EIB severity and efficacy of preventative drug therapy 
(Crapo et al., 2000). This test is considered an indirect challenge because it is associated 
with the release of mediators, which act on the airway smooth muscles to cause 
contraction. Thus, the exercise test is unlike the direct challenges of histamine and 
methacholine which act directly on the airway smooth muscle (receptors) to cause 
bronchoconstriction independent of the presence of inflammatory cells (Rundell & Sue-
Chu, 2010).   
Proposed EIB mechanisms  
 
There are two possible mechanisms through which EIB occurs: an osmotic path and a 
thermal path (figure 1.5). Water content and quality of inspired air are additional factors 
affecting the exercise challenge tests. The water content of inspired air (humidity) affects 
the respiratory loss of water during exercise. In susceptible individuals, air with low water 
content is more likely than air with high water content to provoke bronchoconstriction 
(Rundell & Sue-Chu, 2010; Strauss et al., 1978). 
 
Two hypotheses have been suggested as to how exercise results in the narrowing of the 
airways i) the osmotic hypothesis and ii) the thermal hypothesis. In the osmotic pathway, 
EIB is caused due to loss of water by evaporation from the airway surface while inhaling 
large volumes of air in a short period of time. Following water loss there is airway cooling 
and dehydration of the airway surface. On the contrary, when exercise is performed with 
inhalation of hot and humid air, there is a significant reduction or complete inhibition of EIB 
(Anderson & Kippelen, 2010; Carlsen et al., 2008). Overall, the increase in the osmolarity 
of the airway surface results in release of pro-inflammatory mediators from mast cells and 
possibly sensory nerves (Anderson,1984; Anderson & Daviskas, 1992).  Subsequently, 
these mediators can act on bronchial smooth muscle to cause contraction and narrowing 
of airways. In the airway epithelium of asthmatics, there are large numbers of mast cells, 
furthermore  there are other cells such as epithelial cells, glandular cells and sensory 
nerves which are affected by airway dehydration and osmotic changes (Anderson & 
Kippelen, 2012; Anderson & Daviskas, 2000; Chen &Horton, 1977; Strauss et al.,1978).  
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The alternative thermal hypothesis suggests that EIB is a vascular event resulting from 
airway cooling during exercise followed by a reactive hyperaemia that happens after the 
airways re-warm upon competition of exercise (Deal et al., 1979).  
 
 
 
 
 
Figure 1.5 Schematic diagram displaying the two different pathways describing the 
pathophysiologic events leading to EIB in a classic case of a patient with asthma (modified 
from Castro & Kraft, 2008) 
 
During exercise, heat and water move out of the airways to equilibrate the inspired air to 
the temperature and humidity of the lower airways. Exercise serves as a trigger to the 
airway epithelial cells; at the epithelial cell surface there is a transfer of water from the 
osmotically sensitive epithelial cells via the tight junctions, as well as a thermal gradient. In 
the presence of osmotic stimuli, inflammatory cells including mast cells and leukocytes are 
activated leading to sustained inflammatory mediator release in association with smooth 
muscle contraction (Gulliksson et al., 2006; Hallstrand, 2012). Thus, these stimuli arising 
from exercise or hyperpnoea are sensed by the airway epithelium, which leads to 
secretion of inflammatory mediators from leukocytes residing adjacent to the epithelium 
(Bolger et al., 2011; Romberg et al., 2011).  
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Cysteinyl leukotrienes (CysLTs) are a family of inflammatory lipid mediators synthesised 
from arachidonic acid by a variety of cells, including mast cells, eosinophils, basophils, and 
macrophages (Peters-Golden et al., 2006). Based on non-invasive methods such as 
exhaled breath condensate (EBC) and urinary markers it has been shown that cellular 
airway inflammation and generation of CystLTs are associated with severity of EIB 
(Gulliksson et al., 2006). The levels of CysLTs in EBC and urine have been found to be 
elevated in asthmatics with EIB and significantly increase after an exercise challenge test. 
Subsequently, a change in CystLTs in EBC following an exercise challenge test was 
associated with the severity of EIB (Bikov et al., 2010; Mickleborough et al., 2006). 
Induced sputum studies show an increase in CystLTs and other bronchoconstrictive 
eicosanoids such as PGD2 in the airways following the exercise challenge test thus 
supporting the non-invasive findings (Barreto et al., 2009; Hallstrand, 2012).   
 
Mast cells are regarded as effector cells of the immune system, but lately they have been 
shown to have a role in initiating and sustaining complex pathophysiological processes 
underlying asthma, EIB and other allergic diseases (Bradding et al., 2006; Carter and 
Bradding, 2011). Mast cells are activated by allergens through high affinity IgE receptors 
and osmotic stimuli following exercise and increased numbers of mast cells in airway 
smooth muscles may lead to AHR (Anderson & Kippelen, 2010; Hallstrand, 2012). Mast 
cells along with eosinophils are the predominant cells in the inflammation of allergic 
asthma and EIB. When present in increased numbers, these cells release basic proteins 
such as eosinophil peroxidase and also have the ability to synthesisee eicosanoids such 
as prostacyclins (PGI2), CystLTs and PGD2 and thromboxane A2 (TXA2). As described in 
the asthma pathophysiology section of this chapter, there is a release of a range of tissue 
damaging superoxide and a range of cytokines and chemokines which increase 
inflammation and cause bronchoconstriction (Holgate et al., 2009; Kay et al., 2004; 
Kariyawasam & Robinson., 2006). Furthermore, activated mast cells irrespective of their 
phenotype, release preformed granule-associated mediators such as histamine, tryptase 
and other proteases, heparins causing bronchoconstriction (Bradding et al., 2006; Galli et 
al., 2005). The degranulation of these cells has been suggested to occur during the 
exercise challenge and is accompanied by a release of histamine and tryptase into the 
airways after exercise challenge (Hallstrand et al., 2005).  
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Recent studies have improved our understanding about the pathophysiology of asthma 
and EIB and suggest that exercise is a stimulus to the airway epithelium, adjacent 
leukocytes and systemic leukocytes; resulting in sustained production of CystLTs and 
PGD2 release in association with smooth muscle contraction leading to EIB symptoms. It 
has been suggested that mast cells, eisonophils and leukocytes are the principal sources 
of inflammatory cytokines. Over 100 different mediators derived from inflammatory cells 
have been found to play a role in the pathogenesis of asthma, and EIB which have been 
discussed in detail in the asthma pathophysiology section (pages 15-21).. 
 
Implications of airway inflammation in asthma therapy 
 
Resolution of inflammation  
Asthma is a condition of the airways in which persistent chronic inflammation leads to 
changes in airway structure and function (Bloemen et al., 2007; Wouters et al., 2009). As 
previously discussed, in most individuals, this chronic inflammation is expressed as 
symptoms such as coughing, mucous production, chest tightness, wheezing and 
shortness of breath (GINA, 2011). Natural mechanisms and mediators of resolution have 
been studied in recent years highlighting the role of resolution of inflammation in the 
pathophysiology of chronic inflammatory diseases including asthma. Resolution is now 
suggested to be an active process that terminates acute inflammation (Serhan, 2000, 
2011b). Towards the end of an inflammatory process, there is neutralisation and 
elimination of pathogens, followed by removal of cellular components to prevent excessive 
tissue damage. Neutrophils don’t discriminate between microbes and host targets while 
hyper-expression of endothelial and leukocyte adhesion molecules, along with circulation 
of soluble adhesion molecules and production of inflammatory mediators, cause host 
tissue damage (Calder, 2006; Nathan & Ding, 2010). The immune system of the body is 
required to have a strict control of the inflammatory process and an inadequate 
inflammatory response could render the body more susceptible to infection. Insufficient 
resolution is caused by persistent inflammation and there is some evidence to suggest that 
this could be due to problems with suppressor genes signalling mechanisms. (Levy et al., 
2012; Wells et al., 2005). Complete resolution is an ideal outcome of acute inflammation, 
subsequently the resolution of inflammation is very important and the effectiveness of the 
immune system is key to this process. 
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The immune system needs to rapidly ‘switch off’ the inflammatory response to prevent a 
chronic situation from occurring. Macrophages and their activated products such as TNF-
α, IL-6 and IL-1 are important components of the inflammatory process. These products 
are responsible for neutralisation of pathogens and related agents and for limiting tissue 
damage (Anders & Scherer, 2005; Holgate, 2008; Martin & Stockley, 2006; Widgerow, 
2012). Depending on their circumstances, cells and compounds may be pro-inflammatory 
or anti-inflammatory in nature. The mechanism of resolution is continuous with a decrease 
in the cell number there is a reduction in the levels of pro-inflammatory cytokines and 
eicosanoids ‘switch’ from being inflammatory in nature (LTs, PGs etc) to anti-inflammatory 
or specialized pro-resolving mediators  such as  lipoxins (LXs), resolvins (RVs) , protectins 
(PDs) and maresins (Serhan, 2011a, figure 1.6). These mediators have the potential to 
control the duration and magnitude of inflammation (Serhan, 2008; Serhan & Petasis, 
2011a). As a result of inflammatory processes alveolar oedema (abnormal build-up of fluid 
in the air sacs of the lungs) is possible, leading to hypoxaemia (deficiency of oxygen). 
Thus, lung-specific resolution mechanisms include clearance of oedema, repair of the 
airway epithelia, and restoration of pulmonary surfactants (Aoki et al., 2010; Levy et al., 
2012).  
 
 
 
Figure 1.6 Chemical mediators of inflammation and resolution mediators (adapted from  
Serhan, 2011b) 
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Issues related to asthma therapy  
Asthma is emerging as a chronic health problem worldwide and despite effective 
treatments there remains high mortality and morbidity which have implications for public 
health services. Based on the increased understanding of the inflammatory processes in 
asthma, various therapeutic approaches have been targeted at interrupting these 
processes (Barnes, 2002; MacRedmond & Dorscheid, 2011). Current asthma treatments 
target inflammation in one of two ways (acute rescue remedies vs. long-term 
preventatives) as shown in figure 1.7. The existing pharmacological therapies together 
with long and short acting β agonists and corticosteroids have proved effective in asthma 
management in the majority of patients; but they still have issues associated with their use. 
Tachyphylaxis has complicated the use of β-adrenoreceptor agonists while the known 
systemic and local side effects of inhaled corticosteroids include osteoporosis and 
glaucoma (Barnes, 2010; GINA, 2011). Leukotriene modifiers and IgE monoclonal therapy 
for reduction in IgE has been found to be effective in asthma treatment (Holgate, 2008).  
 
There is a current impetus on identifying specific therapies that target a single 
inflammatory mediator and are less likely to have major health side effects (Barnes, 2010). 
These specific therapies have been suggested to be effective for various sub groups of 
asthma including those with mild-moderates symptoms and EIB. Pharmacological 
therapies with widespread effects including kinase inhibitors might be more effective but 
have major health side effects. For the therapy of EIB, inhaled corticosteroids have been 
identified as the most effective anti-inflammatory treatment available, aiming at reducing 
AHR and reducing the severity of symptoms. However, inhaled corticosteroids 
demonstrate both systemic and local health side effects, which affect the sports/physical 
activity of individuals. Adrenal suppression at high doses, growth retardation in children 
and adolescents and reduction in bone density have been reported with some inhaled 
corticosteroids (Carlsen et al., 2008; Egan et al., 1999; Priftis et al., 2006). Although these 
health side effects are not very common, this possibility needs to be considered especially 
during treatment of long term use of corticosteroids, which can increase the risk of 
osteoporosis later in life.  
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Figure 1.7  Targets for anti – inflammatory asthma therapy  
 
The other anti-inflammatory treatments for EIB include leukotriene antagonists, disodium 
cromoglycate, nedocromile sodium, β2-agonists, and ipratropium bromide have well 
established, long term heath side effects  providing an impetus for non-pharmacological 
therapies among researchers and clinical experts  (Millward et al., 2010, Mickleborough et 
al., 2006; Spector & Tan., 2012). In the UK, the NHS and Asthma UK have suggested the 
use of complimentary therapies alongside conventional medication in asthma (Asthma UK, 
2011; NHS, 2012). Consequently, there are both therapeutic and consumer derived 
interests in identifying potential complimentary therapies for asthma. The recognition of the 
role of complementary therapy in asthma is limited because these approaches have been 
insufficiently researched and their effectiveness is largely unproven (GINA, 2011). A range 
of non-pharmacological treatments including physical conditioning, incorporating a warm-
up before and a cool-down period after exercise, performing nasal breathing, avoiding cold 
weather or environmental allergens, using a face mask or other aid to warm and humidify 
inhaled air, and modifying dietary intake with omega -3, salt and antioxidants have been 
identified (Mickleborough et al., 2011).  However, to date the efficiencies of all these 
therapies have not been well established and further investigation is required to validate 
these therapies with conventional standards (Asthma UK, 2011).   
(TGF) 
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Exploring the potential of non-pharmacologic treatments is important due to the 
comparatively low risk associated with their use. Since physical activity is a limiting factor 
for EIB prone individuals, a change in lifestyle and diet could improve the quality of life of 
these individuals and help them meet the physical activity requirements proposed by the 
Department of Health (DH). The following sections of the literature  review will critically 
discuss the relationship between fish oil (n-3), PUFAs and their derived mediators and 
respiratory health in asthmatics, particularly those with EIB. 
 
1.7 Role of omega-3 fatty acids in airway inflammation  
1.7.1 Structure and metabolism of omega-3 fatty acids 
 
Fatty acids, both free and as part of complex lipids play an important role in metabolism, 
storage and transport of energy, gene regulation (Rustan & Drevon, 2001) and  as 
necessary components of all membranes (figure 1.8). Structurally, they are hydrocarbon 
chains with a carboxyl group at one end and methyl group at the other end. Fatty acids 
from dietary sources are stored in the body mainly in the form of triacylglycerols; a glycerol 
molecule backbone to which three, often different, fatty acids are attached (Lunn 
&Theobald, 2006). Fats have often been perceived as bad components of all nutrients 
linked to various disease conditions such as cardiovascular disease, obesity, chronic 
kidney disease (Bagby., 2004), diabetes (López et al., 2010) and other chronic 
inflammatory diseases (Kennedy et al., 2009; Woodside et al., 2008). The characteristics 
of a fatty acid are dependent on the length of carbon chain and the presence or absence 
of double bonds between carbon atoms. Saturated fat has no double bonds and has 
maximum number of hydrogen atoms bonded to the carbons making them ‘saturated’ with 
hydrogen; while unsaturated fatty acids have one or more double bonds between adjacent 
carbon atoms making them vulnerable to peroxidation. Monounsaturated fatty acids 
(MUFAs) (palmitoleic, oleic, eladic, cis/trans vaccenic and euric acid) have one double 
bond present in the fatty acid chain while polyunsaturated fatty acids (PUFAs) have more 
than one double bond present in the fatty acid (Gunstone, 1996; Sanders & Emery, 2003).  
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Figure 1.8 Fatty acids are integral components of the cell membrane (phospholipid bilayer)  
(modified from Jones, 2000) 
 
 
Figure 1.9 Structure of ALA and LA 
 
PUFAs are also known by their shorthand nomenclature, which represents the number of 
carbon atoms in their chain. Figure 1.9 shows the structure of α-linolenic acid (ALA,18:3 n-
3) and  linoleic acid (LA, 18:2n-6) demonstrating the position of the carbon bonds 
responsible for their nomenclature. Omega 3 (n-3) fatty acids are called so because their 
first carbon double bond is present at carbon number 3 counting the methyl carbon as 
carbon number 1 while omega 6 (n-6) are called so as their first carbon double bond is 
present at carbon number 6 (Lunn &Theobald, 2006;  Calder & Yaqoob, 2009). 
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Essential fatty acids and their metabolism  
 
While saturated fatty acids and most MUFA can be synthesised in mammals from non-fat 
precursors (such as glucose and some amino acids) not all fatty acids can be synthesised 
de novo in mammals, as they cannot insert double bonds before carbon 9 in oleic acid 
(18:1n-9). Specifically mammals cannot convert oleic acid into linoleic acid (LA, 18:2n-6) or 
LA into α-linolenic acid (ALA,18:3 n-3) catalysed via delta 12 desaturase and delta 15 
desaturase enzymes, respectively. Since ALA and LA cannot be synthesised de novo, 
their intake from food sources is important and they are classified as essential fatty acids. 
Burr & Burr (1930) conducted experiments on rats and carefully observed the health of the 
rats over several months. They demonstrated that a deficiency of ALA and LAs led to 
various deficiency diseases in animals, including severe skin and kidney problems, and 
some animals often died within weeks. Eventually it was discovered that adding back 
purified LA and ALA restored the sick animals to health, while the other fatty acids were 
unable to create this effect. This led to the recognition of LA and ALA as ‘essential fatty 
acids (EFAs)’ (Burr & Burr, 1930; Burr et al.,1932). Thus, EFAs (LA and ALA) are those 
fatty acids, which must be obtained in the diet by humans and other animals to maintain 
health, these EFA however cannot not be synthesized by the body (Goodhart et al., 1980, 
Neitzel, 2010).  
 
Human EFA deficiency is not very common in western countries, and most research on 
EFA deficiency has been conducted in animal models. In countries where protein 
malnutrition occurs, EFA deficiency may occur owing to either very low dietary EFA intake 
or lack of enzymes for synthesis. Originally, it was hypothesised that ALA could substitute 
for LA in the case of deficiency, however this proved not to be true as the product of the 
metabolism of these two PUFAs differs in function (Holman, 1998; Ratnayake & Galli, 
2009; Shireman, 2003). Some of the causes of EFA deficiency in humans include chronic 
malnutrition (lack of fat and protein, decreased enzyme synthesis), various fat mal-
absorption conditions (secondary to pancreatic insufficiency, bowel cancer or serious 
gastro intestinal disease), and sjogren - larsson syndrome (a genetic enzyme defect in 
desaturation and elongation). Consequences of EFA deficiency include decreased growth 
in infants and children, increased susceptibility to infection, and poor wound healing 
(Cunnane, 2003; Jeppesen et al.,1996;  Shireman., 2003; Smit et al., 2004).  
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Mammalian cells don’t have the ability to synthesise LA and ALA, however once these 
EFAs are obtained from diet they can be metabolised into physiologically active 
compounds via the introduction of extra double bonds through the process of desaturation 
and elongation (Ratnayake & Galli, 2009; Wall et al., 2010). Furthermore, LA appears to 
be an EFA not only because of an immediate cellular function, but because it is the 
precursor of AA (20:4, n-6) that itself has numerous essential functions. Similarly, the 
importance of dietary ALA is that it is the precursor of EPA DHA which are found in the 
phospholipids of cell membranes (e.g. nervous tissue) (Spector, 1999). EPA/DHA have a 
range of biological functions with EPA demonstrating anti-inflammatory effects while DHA 
is recognised to be important in premature and newborn infants. Subsequently AA, 
EPA/DHA have been suggested to be termed as ‘conditionally essential’ (Burke et al., 
1999; Fedacko et al., 2007; Kidd et al, 2007; McCowen & Bistrian, 2005) 
 
Since PUFAs are found in the cell membranes as esterified phosphoglycerides 
(phospholipids) and the degree of unsaturation introduces ‘kinks’ into the  hydrocarbon 
chain,  the potential of the phospholipids to pack together may be affected. The chains 
with multiple double bonds pack together better than chains containing fewer double 
bonds. Hence, membranes comprising greater proportions of long chain PUFAs are more 
stable (Lunn & Theobald, 2006). Approximately 96% of the dietary ALA is absorbed in the 
gut and after absorption they can be incorporated into the phospholipids of cell 
membranes where they affect membrane activities (Burdge, 2006, Burdge & Calder, 2005) 
or are converted to long chain n-3 fatty acids (Burdge et al., 2002, DeLany et al., 2000). LA 
is metabolised via desaturation and elongation reactions in the liver, via gamma linoleic 
acid, to produce arachidonic acid (AA, 20:4n6). In a similar manner, ALA is metabolised in 
humans by further desaturation and elongation in the liver with desaturation occurring at 
carbon atoms lower than 9. ALA is converted to steridonic acid (SDA, 18:4, n3) by delta 6 
desaturase and then steridonic acid can be elongated to eicosatetraenoic acid (20:4 n3) as 
shown in figure 1.10. Eicosatetraenoic acid is further desaturated by delta 5 desaturase to 
yield eicosapentaenoic acid (EPA, 20:5 n3) (figure 1.10). EPA can be further converted to 
docosapentaenoic acid (DPA, 22:5 n3) and docosahexaenoic acid (DHA, 22:6 n3) as 
shown in figure 1.10.(Calder & Yaqoob, 2009, Poudyal et al., 2011) (figure 1.10). Since the 
metabolism of the n-3 and n-6 families requires the same set of enzymes there is 
competition between the two families. An excess of the n-6 or the n-3 family of fatty acids 
could affect the metabolism of the other family which may lead to reduction in the 
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incorporation of these lipids in the tissues which may alter its biological effects (Burdge & 
Calder, 2005; Hussein et al., 2004).  
 
 
 
Figure 1.10  Proposed pathway for the metabolism of n-6 and n-3 PUFA (with permission 
from Poudyal et al., 2011) 
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1.7.2 Biological Effects of n-3 PUFA and the mechanisms involved  
 
 PUFAs are important constituents of the phospholipids of all cell membranes and the 
characteristic fatty acid composition of different cells and tissues is dependent on the 
availability of different fatty acids as well as the metabolic properties of the cells and 
tissues (Calder, 2010b; Calder & Yaqoob, 2009).   
 
The phospholipid component of immune function cells (extracted from the blood) of 
individuals consuming a typical ‘western diet’ is composed of approximately 15-20% of 
fatty acids as AA; 1% EPA and 2-3% DHA per total fatty acid content (Endres et al., 1989; 
Healy et al., 2000; Rees et al., 2006; Yaqoob et al., 2000). However, there are differences 
between the phospholipid classes within single cell types with regard to fatty acid content. 
For example, in neutrophils, alk-1-enylacyl -phosphatidylethanolamine (PE), alkylacyl-
phosphatidylcholine (PC) and phosphatidylinositol (PI) phospholipid classes contain >13% 
AA, while diacyl-PC and diacyl-PE contain <10% AA (Sperling et al., 1993). While immune 
function cells have a high proportion of AA (15-20%), red blood cells (RBCs) and plasma 
have relatively lower AA composition (<10%), approximately 1% EPA and <2.5% DHA 
(Hodson et al., 2008; Poppit et al., 2005; Rees et al., 2006).  
 
Typically, PBMC total lipid composition constitutes of palmitic acid (~20%), stearic acid 
(<20%), oleic acid (~15-20%), LA (~10%) and ALA (<1%) per 100% of fatty acids.  In 
addition, high levels of AA (15-20%) and low levels of EPA (<1%) and DHA (<3%) are 
found in PBMC total lipid composition (Damsgaard et al., 2008; Yaqoob et al., 2000). 
PBMC phospholipid composition is reported to be constituted typically of palmitic acid (15-
20%), stearic acid (~20%), oleic acid (~15-20%), LA (~8%), AA (15-20%), EPA (<1%) and 
DHA (~3%) (Kew et al., 2004; Miles et al., 2004; Thies et al., 2001). Different phospholipid 
classes within PBMC and different subsets of PBMC have also been shown to have 
differences in fatty acid composition (Hon et al., 2009; Miles et al., 2004). Therefore, 
depending on the type of cells analysed, differences in fatty acid content are likely to be 
observed. Since tissue and blood fatty acid profiles have been shown to be modified by 
dietary intake, they have been used as compliance markers for dietary supplementation 
studies (Garcia-Larsen et al., 2011; Hodson et al., 2008; Jeppesen et al., 2012; Meneses 
et al., 2009). However it is important to understand if phospholipid or total lipid content of 
cells are an adequate marker of dietary intake. In adults, there are a number of 
epidemiological and supplementation studies evaluating the effects of dietary n-3 PUFA 
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intake on asthma. In a population based study by McKeever and co-workers (2008) 
(n=13,820, ages 42.2 ±11.2 years), individual fatty acid intakes (estimated by food 
frequency questionnaires; FFQs) were analysed and related to symptoms of asthma. The 
results show that high intake of n-3 fatty acids does not protect against asthma, however 
higher consumption of several n-6 fatty acids including LA and AA were found to be 
associated with a significant reduction in FEV1, particularly in smokers (McKeever et al., 
2008). In another population-based study of Respiratory Health in Northern Europe, 
16,187 subjects aged 23–54 years completed a postal FFQ and it was reported that a 
minimum level of weekly fish intake (>1 serving per week) in adulthood was associated 
with protection against asthma. Participants who never had fish were found to have an 
increased risk for asthma (Laerum et al., 2007). It should be highlighted that the 
inconsistencies from the population-based studies are possibly due to the methods used. 
Most studies that have found associations between fatty acid intake and asthma have 
used indirect measurements of fatty acid intake including FFQs or other dietary recall 
methods (Wood et al., 2004).  
 
The presence of n-3 fatty acids in the phospholipids of plasma, RBCs and even whole 
blood has been used as a marker for compliance in various supplementation studies. In 
addition incorporation of fatty acids in inflammatory cells/membranes have been studied in 
inflammatory disease states (Harris, 2010; Miles et al., 2011; Mickleborough et al., 2006; 
Rizzo et al., 2010; Schubert et al., 2009; Stenius-Aarniala et al., 1989; Versleijen et al., 
2012). Thus, it can be argued that studies using a direct marker of fat intake may provide a 
reliable method for evaluating the relationship between asthma and dietary n-3 PUFA.  
Some but not all studies show evidence  to suggest  there is a possible agreement 
between dietary FFQs and plasma fatty acid levels; in a study by Wood and co-workers, 
(2004), it was found that the n-3 PUFAs and n-6/n-3 ratio in plasma phospholipids were 
not consistently associated with asthma or atopy. The only positive association with 
current asthma was found with dihomoγ-linolenic acid in plasma phospholipids. In this 
study, there was a good agreement between the dietary FFQ estimated fatty acid intake 
and the plasma fatty acid levels (Wood et al., 2004). Recently the Global Allergy and 
Asthma European Network of Excellence (GA2LEN) have shown that a reasonable 
association exists between estimates of dietary n-3 PUFA and total plasma phospholipid 
composition using the GA2LEN FFQ within the European countries that took part in the 
study (Garcia-Larsen et al., 2011). During supplementation studies, while dietary estimates 
Chapter 1: Introduction & literature review                                                  A Kumar  
 40
provide  information about the dietary behaviour of individuals, the total cell or 
phospholipid content of fatty acids can be used as a reliable marker of incorporation. In 
this thesis (chapter 4), the effect the n-3 PUFA supplementation on the pulmonary function 
of EIB prone individuals will be investigated and to support the study; incorporation of 
EPA/DHA will be evaluated in the total PBMC lipid composition.  
 
Dietary supplementation with fish oil can alter fatty acid profiles and there is an increase in 
overall EPA and DHA in different cell types including PBMC following supplementation 
(Damsgaard et al., 2008; Yaqoob et al., 2000). The time-course studies demonstrate that 
incorporation of EPA and DHA into human inflammatory cells starts within days after 
supplementation; and reaches near maximum within four weeks  and the incorporation 
occurs in a dose response manner (Kew et al., 2004; Rees., et al. 2006; Thies et al., 2001; 
Yaqoob et al., 2000). Within the cell membranes, EPA and DHA can compete with and 
replace n-6 PUFAs (primarily AA)  (Blonk et al., 1990; Harris et al., 1991; Calder, 2012; 
Katan et al., 1997; Sanders et al., 1983; Healy et al., 2000; Mickleborough et al., 2006; 
Witte et al., 2010). The modification of phospholipid content can influence the membrane-
linked enzyme systems and cell signalling pathways that affect the physiological 
responses of cells (Mickleborough & Rundell, 2005; Surette, 2008).  
 
One of the mechanisms for the action of n-3 PUFA is the altered pattern of lipid mediator 
synthesis; subsequently the fatty acid composition of cell membranes has an important 
role for the regulation of the response and functions of these cells (Tvrzicka et al., 2011). 
The metabolites from EPA and AA form the basis for regulatory signals (eicosanoids). 
Eicosanoid synthesis involves PUFA mobilisation from the cell membrane by various 
phospholipase enzymes, most notably phospholipase A2 (PlA2). Following the mobilisation; 
the free AA or EPA/DHA acts as a substrate for eicosanoid production via COX 
(cyclooxygenase) and LOX (lipoxygenase) pathway. PGs, prostacylins and TXs are 
formed by the action of COX while LTs and hydroxy fatty acids are formed by the action of 
LOX enzymes. 
 
Eicosanoid production from the two families of fatty acids (n-3 and n-6) follow different 
pathways; however they share the same set of enzymes and the content of n-3 to n-6 in 
the diet will affect which pathway will be active (Wall et al., 2010). The nature of the 
eicosanoids produced from the two families of fatty acids varies in biological activity. For 
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the pathophysiology of any inflammatory condition, the timing of eicosanoid generation, 
the concentration of eicosanoids produced and the subsequent sensitivity of the target 
cells and tissues to the eicosanoids produced is important (Calder, 2006, 2012). AA is one 
of the most tightly regulated fatty acids in cell membrane phospholipids as it affects the 
way cells behave, and its actions have far ranging effects (Calder., 2012; Seeds & Bass, 
1999). Diets high in LA or AA could potentially result in over-activity of AA derived 
eicosanoids which could lead to an over active immune system which has been 
hypothesised to form the basis of chronic inflammatory disease states such as asthma, 
CVD, diabetes, and cancer (Calder, 2006; Levick et al., 2007; Mickleborough, 2008; Miller, 
2006; Reiss & Edelman, 2006). 
 
There is a competition between n-6 and n-3 fatty acids for the production of eicosanoids 
via the COX and LOX enzymes (figure 1.11). Since inflammatory cells contain a high 
proportion of AA and a low proportion of EPA, AA is the major substrate for eicosanoid 
synthesis (Lee et al., 1985; Calder., 2012; Endres et al., 1989; Rees et al., 2006; Sperling 
et al., 1993). AA metabolised via COX produces 2-series PGs and the 2-series TXs. 
Monocytes and macrophages produce large amounts of prostaglandin E2 (PGE2) and 
prostaglandin F2a (PGF2a) while neutrophils and mast cells produce prostaglandin E2 
(PGE2) and prostaglandin D2 (PGD2) respectively (Pavord, et al., 1993,1995; Sastre & 
Pozo., 2012; Wall et al., 2010). Increased levels of these PGs have been found in urine 
and sputum samples of individuals with EIB compared to healthy individuals (Anderson & 
Kippelen, 2010; Haverkampet al., 2012; Kippelen et al., 2010). Following the LOX pathway 
(5-LOX), AA is metabolised to hydroxy and hydroperoxy derivatives, such as 5-HETE and 
5-hydroperoxyeicosatetraenoic acid (5-HPETE), and the CystLTs - LTA4, LTB4, LTC4, LTD4 
and LTE4). Neutrophils, monocytes and macrophages produce LTB4, while LTC4, LTD4, 
and LTE4 are produced by mast cells, basophils, and eosinophils. LTB4 is a strong 
leukocyte chemotactic agent and an activator of neutrophils. LTB4 increases vascular 
permeability, enhances blood flow, acts as chemotactic agent for leukocytes and induces 
release of reactive oxygen species ROS and lysosymal enzyme. In addition, LTB4 
promotes secretion of inflammatory cytokines such as TNF-α, IL-1ß and IL-6 by 
macrophages (Tilley et al., 2001; Wall et al., 2010). Similarly other CystLTs (LTC4, D4 and 
E4) increase vascular permeability, increase mucous secretion, increase hypersensitivity 
and cause bronchoconstriction (Anderson & Kippelen, 2010; Duong et al., 2008; Moloney 
et al., 2003; Gulliksson et al., 2006).  
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Figure 1.11 Suggested mechanism of the inhibitory effect of EPA on AA, COX and LOX 
pathways (from Calder with permission, 2006) 
 
When present in excessive concentrations, the AA derived eicosanoids can cause damage 
to host tissues, lead to formation of thrombi, and facilitate inflammatory disorders (Bagga 
et al., 2003; Calder, 2006; Levick et al., 2007 Miller, 2006;). Despite the pro-inflammatory 
effects of AA derived eicosanoids, it is now recognised that not all the metabolites from AA 
act in the same manner. Inhaled PGE2 has been found to promote bronchodilation in 
normal subjects (Walters & Davies, 1982) but may cause constriction in patients with 
asthma because of activation of reflex cholinergic bronchoconstriction (Pavord & 
Tattersfield, 1995; Tilley et al., 2001). However, recent studies have shown a contradictory 
outcome; for example inhalation of PGE2  is shown to improve abnormal airway physiology 
and inflammation that characterise asthma (Bloemen et al., 2007; Ying et al., 2004). 
Additionally, it has been suggested that PGE2 acts as an inhibitor of the production of two 
important pro-inflammatory cytokines (TNF-α and IL-1β) by monocytes and macrophages 
(Calder & Yaqoob., 2009; Dooper et al., 2002; Miles et al., 2002). Gauvreau and co-
workers (1999) have shown that there is a significant decline in pulmonary function 
(immediate and late phase FEV1 and methacholine responsiveness) 24 hours after 
allergen challenge. In atopic asthmatic subjects, inhaled PGE2 before an allergen 
challenge test results in decreased eosinophils and PGD2 in the BAL, which suggests that 
PGE2 restrains allergic inflammation (Hartert et al., 2000). Furthermore, PGE2 is also found 
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to inhibit 5-LOX, and to henceforth reduce the production of 4 series LTs (Levy et al., 
2002), and to induce 15-LOX production of lipoxins (Levy et al.,  2002; Vachier et al.,  
2002) which have anti-inflammatory effects (Calder, 2010b; Gewirtz et al., 2001; Vachier et 
al., 2002).  
 
PGI2 has been found in some studies to reduce allergic inflammation and it is 
hypothesised that PGI2 can possibly suppress Th2 activity and eosinophil recruitment 
(Kremmyda et al., 2011; Moore & Peebles, 2006; Park & Christman, 2006;  Wang et al., 
2011; Yeh et al., 2011). There is increasing evidence from in vitro studies to suggest that 
PGI2 analogues have therapeutic value for asthma due to their anti-inflammatory effects. 
Kuo and co-workers (2010 a, b), for example, have recently reported that PGI2 analogues 
can enhance the expression of a regulatory cytokine (IL-10) and suppress the activity of 
pro-inflammatory TNF-α via epigenetic regulation. Since, however, a few studies have 
conversely shown pro-inflammatory effects of PGI2, including enhanced expression of a 
Th2-related chemokine in vitro and increased neutrophil recruitment (Kuo et al., 2010 a, b) 
the mechanisms for the anti-inflammatory effects of PGI2 observed in some studies require 
further verification to establish their exact role in Th2 regulation. It appears, therefore, that 
some AA derived metabolites may have both pro- and anti-inflammatory effects affecting 
inflammatory processes. Some AA derived eicosanoids such as lipoxins (e.g. Lipoxin A4) 
have only reduced inflammatory effects which could be important in resolution of 
inflammation associated with asthma. It has been demonstrated that lower levels of lipoxin 
A4 are associated with increased asthma severity, EIB and related respiratory disorders 
(Bozinovsk et al., 2011; Levy, 2010; Hallstrand, 2012; Tahan et al., 2008).  
 
 EPA is a competing substrate for cyclooxygenase (COX) and Lipoxygenase (LOX) 
enzymes and this competition with AA leads to decreased expression of COX-2 and 5-
LOX. This in of itself has been suggested as a potential mechanism for the proposed anti-
inflammatory benefits of n-3 PUFA, in that this competition leads to an altered eicosanoid 
production. Ordinarily, AA is metabolised by COX into biologically active 2-series 
prostanoids, however when EPA is utilised as a COX substrate the resultant prostanoids 
are of the alternative 3-series. There is some evidence to suggest that PGE2 has both pro 
and anti-inflammatory functions depending upon the nature of the inflammatory insult 
(Fujitani et al., 2002; Rajakariar  et al., 2007) and while there is less know about the 
inflammatory activity of the equivalent 3-series prostanoids  some studies have presented 
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data to show that PGE3 is a less potent inducer of IL-6 production by macrophages than 
PGE2 (Bagga et al., 2003).  
  
In an in vitro study by Wada et al., (2007) specificities of prostanoid enzymes and 
receptors towards EPA-derived (3-series PGs) and AA-derived (2-series PGs) were 
compared. There was a significant decrease in the formation of 2-series PGs via PGHS-2 
(PG endoperoxide H synthase - 2) and this was demonstrated to occur only to the extent 
that AA levels in phospholipids were decreased by EPA replacing AA (Wada et al., 2007). 
Approximately two- to three-fold higher activities were observed for AA derived mediators 
compared to EPA derived ones with the different receptors studied. For example, lower 
potencies were observed for PGE3 compared with PGE2 towards the EP1, EP2, EP3 and 
EP4 receptors (Wada et al., 2007). In a separate in vitro study it has been demonstrated 
that EPA derived PGD3 antagonises the effect of PGD2-mediated migration of neutrophils 
across endothelial cells (Tull et al., 2009). These studies directly comparing the effect of 
EPA and AA derived lipid mediators provide some evidence to confirm the competition 
between n-6 and n-3 fatty acids for the production of eicosanoids and go some way 
towards identifying the possible mechanisms involved.  
  
It has also been shown that 5 series LTs can be produced in the macrophages of fish oil 
fed mice (Chapkin et al., 1992) and in the neutrophils of humans supplemented with fish oil 
for several weeks (Lee et al., 1985; Sperling et al., 1993). LTB5 derived from EPA has 
been shown to be 10-100 fold less potent as a neutrophil chemotactic agent than AA 
derived LTB4, thus LTB5 is a much weaker inducer of inflammation (Goldman et al., 1983; 
Lee et al., 1985; Wall et al., 2010). In a n-3 supplementation study using EIB it was found 
that there was a significant reduction in LTB4 and significant increase in LTB5 level in 
activated polymorphonulcear cells by the end of 3 weeks of supplementation and this 
reduced inflammatory effect was accompanied by an improvement in post exercise EIB 
symptoms (Mickleborough et al., 2006). 
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Effect of n-3 PUFA supplementation on Th1 and Th2 responses and cytokines and 
lipid rafts  
 
The modified cell membrane phospholipid fatty acid content with n-3 PUFA 
supplementation facilitates the formation of ‘lipid rafts’ which have been studied in T cells. 
The relationship between lipid rafts and the immunomodulatory effects of n-3 PUFA have 
been of considerable interest. These rafts are formed by the movement of receptors, 
accessory proteins, and enzymes within the plane of the cell membrane to co-localise into 
signalling platforms (Katagiri et al., 2001; Yaqoob, 2009). These rafts in turn influence the 
activity of membrane proteins including receptors, transporters, ion channels and cell 
signalling enzymes, these result in the transfer of intracellular signals into the cytosol 
(Miles et al., 2002).  Based on the evidence from cell culture and animal feeding models it 
has been shown that n-3 PUFA supplementation modifies raft formation in T cells, which in 
turn impairs the signalling mechanism of these cells (Stulnig et al., 1998, 2001). Thus, the 
exposure of T cells to modified n-3 PUFA (after supplementation) can alter the chemical 
structure of rafts which can consequently affect their function (Fan et al., 2003, 2004; 
Zeyda et al,. 2002). Additionally, the supplementation of  n-3 PUFA has been reported to 
affect cell signalling pathways either by altering the expression and activity of membrane 
receptors or by modifying  the expression of genes by the activation of transcription factors 
such as NFқB and PPAR-α (Michaud & Renier, 2001; Rudkowska  et al., 2009; Tai et al., 
2005; Calder, 2012). 
 
Since the eicosanoids have an effect on Th1 and Th2 responses it is hypothesised that 
fish oils containing n-3 PUFA could potentially influence T cell functions through 
eicosanoid production. Human supplementation studies with n-3 (EPA and DHA) have 
shown differential effects on lymphocyte functions. Meydani et al., (1991) showed that with 
three months of supplementation with 2.4 grams n-3 (EPA+DHA) per day in healthy 
volunteers, there was a decrease in  lymphocyte proliferation and decreased production of 
IL-2 in women aged 51-68 years but not in younger women. In a different study, Meydani 
et al., (1993) showed that supplementation of a low fat diet with n-3 PUFA decreased T-
cell proliferation in subjects older than 40 years. Furthermore, Thies et al., (2001) have 
shown that with a low dose (1 g n-3/day (720 mg EPA plus 280 mg DHA) for 12 weeks 
there was a decrease in  lymphocyte proliferation, but IL-2 and IFN-γ production were 
unaffected in healthy subjects aged 55-75 years. Although there are a number of studies 
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showing that dietary n-3 PUFA supplementation in humans significantly reduces 
lymphocyte proliferation in response to mitogens; there are studies, which showed no 
effect of dietary n-3 supplementation on cytokine production in healthy individuals and 
those with chronic disease states (Cooper et al., 1993; Blok et al., 1997; Stapleton et al., 
2011).  
 
There is some evidence to suggest that EPA is effective in suppressing pro-inflammatory 
mediator generation and cytokine expression from lipopolysaccharide -stimulated human 
asthmatic alveolar macrophages (Mickleborough et al,. 2009). The study by Mickleborough 
et al., shows that pure EPA and EPA-rich media significantly suppressed TNF-α and IL-1β 
mRNA expression and the production of LTB4, PGD2 and TNF-α and IL-1β  in 
lipopolysaccharide-stimulated primary alveolar macrophages obtained from asthmatic 
patients to a much greater extent than pure DHA and DHA-rich media respectively 
(Mickleborough et al,. 2009). Several supplementation studies with EPA/DHA in healthy 
volunteers have shown decreased production of TNF-α, of IL-1β and IL-6 by endotoxin-
stimulated monocytes or mononuclear cells (Caughley et al., 1996; Endres et al., 1989; 
Trebble et al., 2003). However the study by Mickleborough et al., (2009) shows that  high 
or low levels of DHA supplementation alone do not affect T cell proliferation and cytokine 
production, there is therefore the potential to use  EPA alone for inhibiting cytokine 
synthesis in vitro (Mickleborough et al., 2009). 
 
 Overall, the evidence from in vitro and in vivo studies show that n-3 PUFA 
supplementation has a potential for inhibiting T cell proliferation and production of 
cytokines. Inhibition of T cell responses has been observed with higher dosage of n-3 
while this effect is not observed at low n-3 levels. These inconsistencies may be related to 
differences in subject characteristics including age, gender, heath, diet, differences in 
study design (dose and duration) as well as experimental methods (cell preparation, cell 
culture, cytokine assays). In conclusion, there is evidence to suggest that fish oils may 
modulate T cell response and functions independently of eicosanoid production (Alexander 
et al., 1988; Jolly et al., 1997; Wallace et al., 2001; Kelley et al., 1999; Versleijen et al., 
2012). Furthermore, increasing phospholipid EPA/AA ratios in inflammatory cells with 
dietary n-3 supplementation is likely to be one of the mechanisms, which can potentially 
facilitate the production of weaker eicosanoids that may exhibit anti-inflammatory effects. 
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Thus, there are different mechanisms for the immunomodulatory action of n-3 PUFAs, 
which require further verification in in vivo human studies.  
 
1.8 Studies investigating the effect of fish oil (n-3) on asthma  
 
The adult n-3 intervention trials in the last two decades have provided a contradictory 
picture of efficacy with respect to FEV1 or PEF. Table 1.6 shows relevant n-3 intervention 
trials in asthma and EIB with three or more weeks of supplementation, the information 
included in the table is as complete as possible. Kirsch et al. (1988) compared a high dose 
n-3 PUFA supplementation (4 gram EPA/day, n=6) with a low dose (0.1 grams/day, n=6) 
for 8 weeks on asthmatics in a small study (n=12, age 42 to 73 years) and found there was 
no difference in FEV1 or symptom scores between the two groups. There was no 
difference in the lung function determined by PEF between the two groups before the start 
of supplementation (Kirsch et al. 1988). Hodge and co-workers (1998) reported no change 
in lung function values in asthmatic children (8-12 years, n=45) however, there was a 
reduction in TNFα production (by cultured PBMC) compared to baseline; however, the 
magnitude of change between groups was not significant (Hodge et al. 1998). Peak 
expiratory flow (PEF) has been reported in some studies as a marker for lung function. 
Emelynov et al., (2002) showed a significant increase in  morning PEF with 8 week 
supplementation with a low dose of n-3 (50mg EPA+ DHA per day) in mild-moderate 
atopic asthmatics (n=46; 18-56 years). In addition, Surette et al., (2008) reported a 
significant improvement in quality of life and asthma management scores (including 
symptoms) assessed by questionnaires after 3 weeks of supplementation (0.5 gram EPA + 
0.75 gram DHA per day; n = 65 mild-moderate asthmatics). Conversely, in two cross over 
trials there was no significant change in PEF after 10 week n-3 supplementation with > 
2grams EPA+ DHA per day (see table 1.6) (McDonald, 1990; Stenius-Aarniala, 1989). 
Overall, although some literature and our knowledge of the physiological action of n-3 fatty 
acids suggest that we should potentially see effects of supplementation on lung function 
there is no consistent effect of n-3 supplementation on FEV1 or PEF reported which could 
be attributed to the heterogeneity between the studies. These studies have used a range 
of doses, as low as 50 mg to > 3grams of EPA/DHA per day and have studied different 
sub group of asthmatics such as mild-moderate, severe and atopic populations.  
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In a study by Schubert and co-workers, (2009) (n=23, atopic asthma, table 1.6) dietary 
supplementation with either an n–3 PUFA-enriched fat blend (0.69 g/day, comprising 
450mg EPA and 180 mg DHA/day; n=12 participants) or placebo (n=13 participants) for 5 
weeks was provided. After 3-weeks of supplementation, the participants underwent two 
allergen challenge tests in the remaining two weeks of supplementation. FeNO was 
significantly lower in the n–3 PUFA group (p=0.01); though the levels of FeNO increased 
during allergen exposure in both groups, the mean values were 5-fold lower in the n–3 
PUFA group. No differences were observed between the asthmatic and control group with 
regards to asthma symptoms, FEV1 or the allergen dose required to induce deterioration of 
lung function challenge. Furthermore, compliance was monitored by plasma and RBC cell 
membrane fatty acid composition and it was found that two weeks of supplementation led 
to a 3-fold higher value of EPA in the n-3 PUFA group compared to placebo and these 
levels were maintained till the end of supplementation in plasma and RBC cell membrane 
(Schubert et al., 2009).  
 
In another double blind, placebo-controlled pilot study, a shorter duration of 
supplementation was used (n=20; dose – 0.9 g EPA and 0.65 g DHA/day) for 2 weeks 
(Moreira et al., 2007). The study showed no changes in FeNO levels, FEV1 or asthma 
quality of life questionnaires. However, this study was not a well-controlled study as the 
participants were on their regular medication of inhaled corticosteroids, which makes it 
difficult to evaluate the true effect of n-3 PUFA supplementation on pulmonary function and 
other outcomes. Furthermore, the low dose and duration of supplementation could be a 
reason why no effect of n-3 supplementation was observed. In addition, the participants in 
this study had stable asthma following their corticosteroid usage and their FeNO levels 
were not significantly elevated (28 ppb) compared to healthy individuals (25 ppb). Due to 
these reasons the exact relationship of n-3 PUFA supplementation on FeNO was difficult 
to evaluate. In this thesis, asthmatics with elevated FeNO levels will supplemented with 
EPA/DHA to assess the effect of n-3 on FeNO levels.  
 
Asthmatics have a reliance on pharmacological medication and despite the significant 
advancement in asthma medication during the last two decades the treatments are still far 
from ideal (GINA, 2011; Mickleborough, 2008). The asthma medications provide modest 
protection when taken daily; however prolonged usage of these can result in reduced 
effectiveness or tachyphylaxis. Some of the earlier intervention trials have not shown any 
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significant changes to reliance on medication (Arm et al., 1988; McDonald et al., 1999; 
Thien et al., 1993, table 1.6). Hodge et al (1998) have shown a significant reduction in 
medication use in asthmatic children  after 9 month supplementation with 1.2 gram 
EPA+DHA per day; while Mickleborough et al (2006) have reported that bronchodilator use 
was significantly reduced during the last 2 weeks of  n-3 supplementation (3.2 grams 
EPA+2.2 grams DHA per day) in EIB-prone adults. Furthermore, it has been reported that 
there are improvements in self-reported asthma status and bronchodilator use in subjects 
consuming a fish oil emulsion (1gram EPA + 1.5 grm GLA per day) for 4 weeks compared 
to a placebo(Surette et al., 2008). The authors have also reported results from another trial 
showing an improvement in the asthma quality of life and asthma control based on non-
validated questionnaires (primarily based on bronchodilator usage) (Surette et al., 2008).  
 
Chronic inflammation is associated with AHR, which is responsible for recurrent episodes 
of wheezing, breathlessness, chest tightness, and coughing among asthmatics (Brannan, 
2010). The majority of intervention studies show inconsistencies when reporting effects of 
n-3 on AHR (Thien et al., 2011). Studies (Arm et al., 1988; Thien et al., 1993) have 
reported AHR in terms of the provocation dose of histamine required to produce a 35% fall 
in specific conductance and showed no effect of n-3 supplementation on AHR. However, 
Nagakura et al., (2000) reported AHR as the provocative concentration of acetylcholine 
causing a 20% fall in FEV1 for each subject and saw a reduction in acetylcholine 
responsiveness in the fish oil group but not in the control group. Schubert et al., (2009) 
reported a reduction in AHR after an allergen challenge with n-3 supplementation 
however, this change failed to reach significance (Schubert et al., 2009).  
 
Based on the above discussed trials it can be concluded that there is a possibly a 
beneficial role of omega -3 on asthma and EIB. It is widely shown that n-3 PUFA exert a 
range of anti-inflammatory effects and do not show any health side effects. The 
advantages of using n-3 PUFA supplementation in asthma has been widely reviewed and 
their effectives as a complementary therapy for is acknowledged (Schachter et al., 2004; 
Thien et al., 2011). Furthermore, there are some studies which show that there may be 
subgroups of asthmatics (EIB and allergic asthma) benefit greatly and others who do not 
benefit from long-chain n-3 PUFA (Broughton et al., 1997; Mickleborough et al., 2003, 
2006; Schubert et al., 2009). These inconsistencies in the studies are possibly due to the 
different dosages and duration studied. In addition, the studies have investigated different 
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sub groups of asthma with each having its own characteristic inflammatory pattern. Further 
studies pertaining to different sub groups are required where specific physiological and 
biochemical characteristics of these groups are monitored with n-3 supplementation. In 
addition, a number of studies on inflammation have suggested a threshold for an anti-
inflammatory effect exhibited by n-3 to be exerted in the range of 1.3 -2.7 grams EPA per 
day (Calder, 2006, 2012; Dignass et al,. 2004; Kelley et al., 1998; Grimble et al., 2003). 
Thus, appropriate dose should be considered when designing the studies. In this thesis, 
the effect of EPA/DHA supplementation was assessed in EIB prone individuals and a 
justification of dosage and duration of study based on evidence from other trial is 
discussed in chapter 4.  
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Table 1.6 Lists relevant intervention trials of omega-3 supplementation and asthma. 
Studies reporting benefits of n-3 supplementation 
Author  Study design  Intervention  Participants  Outcomes  
Arm et al., 1989 RCT, double blind, placebo 
controlled, parallel design.  
 
Comparison of n-3 capsules 
with placebo supplementation                                   
 
 
2-week run-in period followed 
by 10-week treatment period  
Omega 3:  
3.2g EPA and 2.2g 
DHA/day 
 
Placebo:  
Matched capsules 
with olive oil/day  
N=22 atopic, non-smoking 
asthmatic volunteers 
entered and 17 completed 
the trial  
 
Age = 18-42 years.                       
 
Asthma severity 
determined from asthma 
symptoms and PEF 
measurements.                                             
 
No participants were 
using oral steroids or 
theophylline or gave 
history of aspirin 
sensitivity 
No changes were observed for 
lung function outcomes, 
medication usage , dyspnoea 
 
10 fold increase in neutrophil 
phospholipid EPA content with 
supplementation. 
  
50% inhibition of total LTB 
(LTB4 and LTB5) generation by 
stimulated neutrophils 
 
Suppression of neutrophil 
chemotaxis 
Stenius-
Aarniala et al. 
1989 
 
 
 
 
 
 
 
 
 
 
RCT crossover design.   
 
Three arm comparison of fish 
oil versus evening primrose 
oil (omega-6 group) versus 
olive oil using liquid oil 
supplementation.   
                                  
Two week run-in period 
followed by 30 week 
intervention (10 weeks per 
treatment arm) period.                                 
 
No wash out period  
Omega 3: 20 
mL/day (3.6g EPA 
and 2.2 gram DHA) 
 
Evening Primrose 
oil: 20 mL/day 
(72% cis linoleic, 
9% gamma linoleic) 
 
 
Olive oil: 20 
mL/day (mainly 
oleic) 
n=40 asthmatics selected, 
36 entered study and 29 
completed study.     
 
Age = 19-61 years.                            
 
Asthma severity 
determined from asthma 
symptoms and PEF 
measurements 
 
No differences in PEF, symptoms 
or medication usage.  
 
Plasma PGE2 levels increased 
during the fish oil treatment 
but there were no changes in 
other TxB2, PGF2 αand 6 keto-
PGF1 α in plasma or urine.     
 
The plasma fatty acid results 
for cholesterol esters showed 
significant increase in EPA and 
DHA levels. 
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Studies reporting benefits of n-3 supplementation 
Author  Study design  Intervention  Participants  Outcomes  
Schubert et al., 
2009 
RCT, double blind, parallel 
study.  
 
5 week supplementation, 
after 3 weeks, participants 
were challenged daily with 
low dose house dust mite 
allergen (2 weeks).   
 
 
 
 
 
 
 
 
 
Omega 3: 450mg 
EPA and 180 mg 
DHA/day  
 
Placebo: 
Unsaturated and 
monounsaturated 
fatty acids  
 
 
 
 
 
N = 23 house dust mite-
allergic asthmatics (13 
females and 10 males) 
 
Age = 22-29 years;  
 
Asthma severity 
determined from asthma 
symptom, skin prick, lung 
function and methacholine 
challenge  
With 3-week supplementation 
with n-3, FeNO was lower in n-
3 group compared to placebo.  
 
FeNO was lower in n-3 group 
compared to placebo during 
allergen challenge. . 
 
Significant reduction in 
eosinophilic cation protein and 
in vitro  CystLT  release    
 
Significant increase in EPA 
levels in RBC and plasma 
membrane  
 
No improvement in PFT, AHR, 
and number of serum neutrophils.  
 
Emelyanov et 
al., 2002 
 
RCT, double-blind, parallel 
study, placebo-controlled  
 
2 week un-in period, 8-week 
supplementation 
 
Omega 3:  New 
Zealand green-
lipped mussel 
extract (50 mg EPA 
and DHA per day) 
 
Placebo : 150 mg 
olive oil per day  
 
n=46 mild-moderate 
atopic asthmatics            
 
Age = 18-56 years                                      
 
Asthma diagnosis based 
on ATS guidelines 
(clinical history, 
reversibility of (FEV1 of 
15% and diurnal variability 
of PEF of>20%,                                                         
skin prick test to common 
inhalant allergens 
 
 
Mean daytime wheeze was 
significantly reduced in n-3 
group compared to placebo.            
 
Mean morning PEF was 
significantly higher during the 
treatment with n-3 with placebo 
 
No change in mean FEV1 and 
evening PEF during the treatment 
with n-3
 
.  
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Studies reporting benefits of n-3 supplementation 
Author  Study design  Intervention  Participants  Outcomes  
Surette et al., 
2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two trials were reported:  
Trial 1: Randomized, 
prospective, double-blind, 
placebo-controlled, parallel 
group trial                                    
 
 
Supplementation for 4 weeks 
 
Subjects were questioned 
about their asthma 
management using a non-
validated questionnaire after 
2 and 4 weeks.                                                         
 
 Omega 3 :  
Low-dose medical 
food emulsion-   
containing 0.75 g 
GLA + 0.5 g EPA, 
or  1.13 g GLA + 
0.75g EPA 
 
Placebo: olive oil.  
Trial 1: n = 35 atopic 
subjects with mild-to-
moderate asthma.                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dose of 1.13 g GLA + 0.75g 
EPA was effective in blocking 
LT biosynthesis.  
 
Fasting plasma GLA and EPA 
levels plateaued within 7 days' 
daily consumption at all levels 
of intake, whereas the time to 
maximum plasma 
concentration was shorter for 
GLA than for EPA. 
 
Significant increase in plasma 
EPA content with 4 week 
supplementation  
 
 
 
 
Trial 2:  
 
 
Supplementation duration  – 
4 weeks  
 
 
 
 
 
 
 
Low-dose medical 
food emulsion 
(same as trial 1)), 
daily.  
 
Quality of life and 
asthma 
management were 
measured using 
validated 
questionnaires,  
 
Trial 2:  n = 65 mild-
moderate asthma 
subjects 
 
Self-reported asthma status 
and mediation use improved in 
participants consuming low- 
and high-dose emulsion 
between week 2 and week 4.  
 
Medication use decreased with 
high dose.  
 
Quality of life and asthma 
management scores improved 
significantly.  
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Studies reporting benefits of n-3 supplementation 
Author  Study design  Intervention  Participants  Outcomes 
Mickleborough 
et al.,  2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCT,  double-blind, 
crossover, placebo controlled 
trial. 
 
 
 
3 week supplementation 
period in each arm  
 
 
2 week washout phase  
 
 
 
 
 
 
 
Omega 3: 3.2 g 
EPA and 2.0 g of 
DHA) 
 
Placebo: Olive oil 
(volume not 
specified)  
 
 
 
 
 
 
 
 
 
 
 
 
 N=16, subjects  
 
Age =  23 ±1.6 years 
 
Participants with clinically 
treated mild- moderate 
asthma with a FEV1>70% 
predicted 
 
 
 
 
 
 
 
 
 
 
 
n-3 improved pulmonary 
function to below the 
diagnostic EIB threshold 
 
Reduction in medication usage  
 
Reduction in induced sputum 
differential cell count 
percentage and concentrations 
of 
LTC4-LTE4, PGD2, IL-1β, and 
TNF-α before and following 
exercise on the n-3 diet  
 
Significant reduction in LTB4 
and a significant increase in 
LTB5 generation from activated 
plymorphonuclear cells on the 
n-3 diet  
Mickleborough 
et al., 2003 
 
 
 
 
 
 
 
 
 
 
RCT, double-blind, crossover 
study.  
 
Subjects entered the study on 
their normal diet, and then 
received either fish oil 
capsules containing 
  
Omega 3: 3.2 g 
EPA and 2.0 g of 
DHA) 
 
Placebo: Olive oil 
(volume not 
specified)  
. 
N=10 athletes and n=10 
controls.  
 
Age (asthmatics =  23.2 ± 
1.9 years ; controls =  
22.4 ± 1.7 years). 
 
Participants with clinically 
diagnosed EIB.  
No effect on pre exercise 
pulmonary function 
in either groups  
 
Improvement  in post exercise 
pulmonary function In n-3 
group 
 
Reduction in LTE4, 9α, 11β-PG 
F2, LTB4,TNF–α, and IL-1β, on 
the n-3 PUFA diet compared 
with baseline and placebo 
diets and after exercise 
challenge 
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Studies reporting benefits of n-3 supplementation (in children) 
Author 
 
Study design 
 
Intervention 
 
Participants 
 
Outcomes 
Hodge et al., 
1998 
 
RCT, double blind, parallel 
design 
 
Comparison of diet high in 
omega-6 fatty acids (and diet 
high in omega-3 fatty acids 
 
2 week run in period followed 
by six month intervention 
period 
Dietary control: n-3 diet 
participants advised to eat 
fish at least once per month, 
omega-6 group to avoid fish. 
Omega-3 :  1.2g n-
3/day ( MaxEPA 
capsules 
 
Omega 6 : placebo 
capsules: 
safflower/palm/olive 
oil 
 
. 
n=45 asthmatic children 
Age = 8 to 12 years. 
 
Asthma defined as 
reported episodic wheeze 
in past 12 months and 
AHR, PFTs, day and night 
symptoms and medication 
and medication usage. 
 
No change in lung function 
values.                                                                
 
Drop in TNFα production (cell 
culture for PBMC) compared 
with baseline (however the 
magnitude of change between 
groups was not significant.)         
 
Incorporation of n-3 in the 
plasma phospholipid at 3 
months, group at 3 and 6 
months compared to the 
omega-6 group.     
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction & literature review                                                  A Kumar  
 56
Studies reporting no benefits of n-3 supplementation 
Author 
 
Study design 
 
Intervention 
 
Participants 
 
Outcomes 
McDonald et al., 
1990 
RCT, crossover design, 
double blind, placebo 
controlled  
 
Comparison of omega-3 
supplementation with placebo 
supplementation.                                    
                                                
10 week intervention 
period, 6 week washout and 
then 10 week cross-over 
intervention  
Omega 3:  2.7g 
EPA & 1.8g 
DHA/day 
 
Placebo:15g olive 
oil/day. 
 
Subjects asked to 
keep their dietary 
fish intake 
unchanged 
throughout study  
n=15 non-smoking 
asthmatics.                  
 
Age= 28 to 72 years 
completed the study.                                                     
n=7 subjects were ex-
smokers 
 
Asthma severity 
determined from asthma 
symptoms and PEF 
measurements.                                             
There was no significant change 
in PEF, medication usage or 
asthma symptoms after n-3 
supplementation  
 
(Kirsch, et al. 
1988) 
 
 
 
 
 
 
 
 
 
RCT, double blind, parallel 
design.  
 
Compared high dose of EPA 
vs. low dose of EPA 
supplementation.                                        
 
6 week run in period, 8-week 
treatment period.  
2 week wash out                    
High dose of EPA : 
4grams EPA/day 
Low dose of EPA: 
0.1grams EPA/day  
 N=12 patients, aged    42-
73 years. 
 
Asthma severity 
determined from symptom 
index and physical 
evaluation.  
 
 
 
 
No difference observed in clinical 
status (symptoms, hospital 
admissions) or pulmonary 
function between groups at the 
start of the study/ at the end of 8 
weeks of n-3 supplementation  
 
 
 
 
 
Thien, et al., 
1993 
RCT, double blind, placebo 
controlled, parallel design,  
 
Comparison of n-3 
supplementation with placebo 
supplementation. 
 
Six month supplementation.   
Omega 3: 3.2 
gram EPA + 2.2 
gram  DHA per day  
 
Placebo:  Olive oil , 
(volume  not 
specified)  
 N=37, non-smoking, 
pollen sensitive adults,  
 
Age = 19-42 years.  
 
Asthma severity 
determined by symptom, 
medication usage, PEF 
measurements and AHR.  
No changes in PFT, medication 
usage or other parameters 
including symptoms, airway 
conductance and  AHR  
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1.8.1 Dietary consumption of n-3 PUFAs and recommendations  
 
Dietary sources and conversion from ALA to long chain n-3 PUFAs 
 
The major dietary sources of LA include plant oils (sunflower and corn oils), cereals, 
animal fat and wholegrain bread while ALA is found primarily in green leafy vegetables, 
flaxseed, walnut, and rapeseed oils (Lunn &Theobald, 2006; Sanders & Emery, 2003; Wall 
et al., 2010). Based on short term isotope labelled studies and long term ALA 
supplementation trials, it has been demonstrated that there is poor conversion of dietary 
ALA to EPA, DHA and DPA with limited conversion to all the way to DHA (Brenna et al., 
2009; Burdge & Calder, 2005; Goyens et al., 2006). Several studies have shown that 
supplementation with ALA in adults leads to an increase in EPA and DPA but little or no 
effect on DHA content in plasma fractions and in circulating blood (Brenna et al., 2009). It 
is estimated that the amount of ALA converted to EPA ranges from 0.2% to 8% (Burdge & 
Calder, 2005: Lunn & Theobald, 2006) with young women appearing to have a higher 
conversion efficacy of up to 21% (Burdge & Wootton, 2002). This greater conversion rate 
in females is potentially due to the up regulation of delta 6 desaturase by female sex 
hormones (Calder, 2010a). Supplementation trials with purified EPA ethyl esters 
consistently show an increase in both EPA and DPA but no change in DHA in the blood 
(Brenna et al., 2009; Grimsgaard et al., 1997).   
 
Although humans have some ability to elongate dietary ALA to the long chain n-3 
polyunsaturated fatty acids (EPA and DHA), the rate of synthesis may not be sufficient to 
meet the requirements of the body (Lunn &Theobald, 2006). Compared to other food 
products, seafood presents a rich source of long chain PUFA including EPA, DPA and 
DHA; however, different types of fish contain different content and ratios of EPA and DHA. 
For example, oily fish such as mackerel or salmon are rich sources of EPA  and DHA and 
can provide 1.5-3.0 grams of these fatty acids per serving compared to a meal of lean fish 
(such as cod) which can yield only 0.2-0.3 grams of long chain PUFA per serving (Calder 
& Yaqoob, 2009). Some effects on cardiovascular risk factors and inflammatory markers 
have been observed with ALA supplementation studies; however, these effects are weaker 
in relation to the effects achieved by increasing EPA and DHA (Calder & Yaqoob, 2009; 
McEvoy et al., 2012; Wang et al., 2006). For example in healthy volunteers, ALA 
supplementation (~13.4 grams/day) can reduce the production of inflammatory cytokines 
such as TNF-α and IL-1β by approximately 30% while EPA and DHA (~2.7 grams/day) can 
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reduce the production of these two markers by >70% (Caughey et al., 1996; Zhao et al., 
2004). However due to the poor conversion of ALA to EPA and DHA, it is not possible to 
achieve adequate EPA and DHA in the body. This emphasises the importance of dietary 
EPA and DHA and thus justifies the classification of these fatty acids as ‘conditionally 
essential’.  
 
Dietary pattern in the UK for n-3 and n-6 PUFA 
 
The National Diet and Nutrition Survey (NDNS) of adults conducted in 2008/2009 reported 
on the dietary behaviours and nutritional status of the British population including children 
over the age of 1.5 years and adults (Pot et al., 2012). The surveys suggest that intake of 
n-6 PUFA as a percentage of food energy has changed slightly from the previous survey 
(2001-2002) with a lower percentage reported for all age groups. The absolute intake as a 
percentage of food energy ranged from 3.9% for toddlers to 5.3% for adults. The direction 
of change for n-3 PUFA was upwards for all groups compared with previous surveys, 
although the differences in absolute terms were very small. Thus, the dietary ratio of n-3/n-
6 in current UK population is approximately 1/5. Additionally, the survey demonstrated that 
the most common dietary supplementation consumed in all age groups was fish oils 
(including cod liver oil) along with multivitamins and /or minerals. Cod liver oil and other 
fish oils were consumed by 9% of toddlers and 7% of those aged 4 -10 years,3% of those 
aged 11-18 years, 11% of adult men and 13% of adult women (Pot et al., 2012).   
 
The present dietary recommendation in the UK for EPA and DHA are in the range of 
approximately 0.45 grams/day (3.15 grams/week). And this can be achieved by the 
consumption of at least two servings of fish per week (one white and the other oily fish) 
(Lunn & Theobald, 2006; Wall et al., 2010). What the current and/or previous NDNS 
surveys do not provide, however, is intake data for individual n-3/n-6 fatty acids. This limits 
our knowledge about the consumption of long chain n-3 and n-6 PUFA in UK population, a 
limitation which been highlighted previously by the British Nutrition Foundation (Lunn & 
Theobald, 2006). Based on the data available from the NDNS survey, adults in the UK 
consume either approximately 100 grams of lean fish or approximately 50 grams of oily 
fish per week. This consumption pattern is similar to intakes in Eastern European, North 
American and Australian countries. Lean fish intake is higher is Southern European 
countries while oily fish intake is higher in Japan (Calder &Yaqoob, 2009; Givens & Gibbs, 
2006; SACN, 2004). This recommendation is primarily based on epidemiological evidence 
Chapter 1: Introduction & literature review                                                  A Kumar  
 59 
and supplementation studies demonstrating reduced cardiovascular mortality, morbidity 
and risk with increased dietary consumption of fish or fish oil supplementation (SACN, 
2004; Lunn &Theobald, 2006). Those individuals who may not be willing to change their 
dietary habits and eat more oily fish could potentially achieve the recommended intake of 
EPA and DHA by consumption of fish oil capsules/liquid. A typical 1-gram fish oil capsule 
per day can provide 0.3 grams of EPA+DHA/day which would allow many individuals to 
meet the basic recommendations (de Decker et al., 1998). Furthermore, encapsulated 
preparations of fish oil with a higher amount of EPA and/or DHA are also available and it is 
possible to achieve intake 5 times higher (or more) than the recommended levels of EPA 
and DHA by taking a single fatty acid supplement per day (Calder, 2010a).  
 
There are other sources of EPA and DHA for those who do not eat fish or are vegetarians. 
Enrichment of food products that are not naturally rich with n-3 (EPA and DHA) is an 
upcoming method to provide dietary n-3 supplementation, for example, fish oils can be 
added to food products such as yoghurts, milk, bread etc. In addition, farm animals can be 
fed with n-3 PUFA resulting in enrichment of eggs, milk, etc. with n-3 (Gibbs et al., 2010; 
Givens et al., 2005; Calder & Yaqoob, 2009). These enriched food products have the 
advantage that individuals do not need to alter their dietary pattern to increase their n-3 
levels. However, the levels of enrichment may be limited in animal feeding approaches 
due to the metabolic processes in animals (Givens & Gibbs, 2008).  
 
Due to increased awareness of n-3 PUFAs from fish and fish oils being an important 
dietary component, it is questioned whether fish-oil producers will be able to meet the 
future demands (Surette, 2008). Consequently, there is a potential for alternative n-3 
sources which have been developed or are in progress. For example, oils naturally 
enriched in DHA have been extracted from cultured microorganisms like the algae 
Crypthecodinium cohnii are used in infant formulations (Fedorova-Dahms et al., 2011; 
Nitsan et al., 1999). Similarly, novel plants like Echium plantagineum have a potential for 
cultivation as their seed oil naturally contains stearidonic acid (SDA) which is an 
intermediate in the metabolism of n-3 PUFA. Though SDA is found in very small quantities 
in the diet, it has been shown to be metabolised more effectively than ALA, resulting in 
enrichment of cells and tissues with EPA and DHA (Surette, 2008). Moreover, transgenic 
varieties of common plants including canola, soybean and safflower are being developed 
that can produce seed oils enriched with SDA, EPA, and DHA (Surette, 2008; Taneja & 
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Singh, 2012). Thus, with the levels of current enrichment it is possible to achieve additional 
intake of a few hundred milligrams of n-3 per day when combinations of different enriched 
food products are consumed.  Overall the intake of long chain n-3 PUFA is UK is still 
considerably below the recommended and there is a potential for dietary change (DH, 
1991; Lunn & Theobalth, 2006) 
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1.8.2 The role of new lipid mediators (resolvins, protectins and maresins) in 
resolution of inflammation  
 
In the last decade, several lipid mediators have been identified that have a potential role in 
the resolution of inflammation. Towards the end of an inflammatory process, there is 
neutralisation and elimination of pathogens, followed by removal of cellular components to 
prevent excessive tissue damage (Calder, 2006; Nathan & Ding, 2010). The mechanism of 
resolution is continuous with a decrease in the number of inflammatory cells,  there is a 
reduction in the levels of pro- inflammatory cytokines and eicosanoids ‘switch’ from being 
inflammatory in nature (LTs, PGs etc.) to anti-inflammatory or specialized pro resolving 
mediators such as  LXs, Rvs, PDs and maresins (Serhan, 2011, Figure 1.12). These 
mediators have the potential to control the duration and magnitude of inflammation 
(Serhan, 2008; Serhan & Petasis, 2011a). 
 
These Rvs, PDs and maresin mediators are produced in humans from n- 3 PUFAs (EPA 
and DHA). The accessibility, affordability and lack of health side effects related to fish oil 
supplementation have generated interest in these potent mediators for research studies in 
humans with or without inflammatory diseases (Calderon et al., 2012). Serhan and 
collaborators identified, characterised and explained families of pro resolving lipid 
metabolites from EPA and DHA using lipidomics approach (Serhan et al., 2010, 2011; 
Serhan & Savill, 2005). There are two classes of resolvins, the E series derived from EPA 
and D series derived from DHA (figure 1.12). Although the focus of this thesis is on the 
mediators derived from n-3 PUFA, this figure highlights that AA derived lipid mediator 
called lipoxin can also exhibit inflammation-resolving effects. It has been suggested that 
once the inflammatory process reaches initial resolution phases, there is a ‘switch’ from 
the inflammatory nature of AA derived metabolites (LTs, PGs etc) to anti-inflammatory or 
specialized pro resolving lipoxins  which stop leukocyte recruitment and help promote 
generation of lipid mediators such as Rvs and PDs (Levy et al., 2012; Serhan & Savill, 
2005).  
 
Resolution of inflammation in airway diseases involves the removal of inflammatory cells 
from injured tissues/wounds, which is driven by apoptosis of leukocytes and elimination 
from the tissues (Rossi et al., 2006; Uller et al., 2006). The LXs demonstrate their anti-
inflammatory effects by reducing the formation of ROS by leukocytes, decreasing 
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transendothelial migration of white cells, and promoting non-phlogistic phagocytosis (Kohli 
& Levy, 2009). It is now evident that monocytes act in a non-phlogistic manner under the 
influence of anti-inflammatory metabolites such as LXs and are recruited as mature 
macrophages to phagocytose apoptotic cells and infectious agents (Maddox & Serhan, 
1996; Serhan et al, 2011a,b). LXs also stop neutrophil infiltration and hence stop local 
inflammatory signals (Takano et al., 1997, 1998; Serhan, 2011). In asthmatics, there is 
decreased generation of LXs and this is particularly explained by the deregulated 
expression of LX biosynthetic genes which vary by disease severity and anatomic 
compartment (Planaguma et al., 2008). The only study assessing the relationship between 
LXs and EIB has been conducted in children (6-17 years, n=12) and it was reported that 
children with EIB have lower levels of lipoxin A4 (LXA4) than healthy controls (Tahan et al., 
2008). Overall, it has been suggested that LXs are generated in airways during airway 
inflammation and any reduction in the generation of LXs could lead to persistent 
inflammation and contribute to the pathogenesis of asthma (Christie et al., 1992; Celik et 
al., 2007; Levy et al., 2012; Tahan et al., 2008).   
 
 
 
 
 
 
 
Figure 1.12 Lipid mediators derived from AA, EPA and DHA.  
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The DHA derived D series resolvins are involved in resolution by preventing TNF-α from 
making pro inflammatory cytokines  which would be responsible for cascading neutrophil 
infiltration (Arita et al., 2005, Serhan, 2011a; Uddin & Levy, 2011; Van Dyke & Serhan, 
2003). A group of D series resolvins are aspirin triggered after acylation of the COX-2 
enzyme by aspirin and its interaction with DHA. It has been hypothesised that Rvs and 
PDs are a part of molecular mechanisms that highlight the role of aspirin in enhancing the 
conversion of EPA and DHA to Rvs of E and D series (Aoki et al., 2010; Ariel & Serhan, 
2007;Kohli & Levy, 2009). The E series resolvins are found in two major forms – resolvin 
E1 (Rv E1) and resolvin E2 (Rv E2). The RvE1 has been found to exhibit its activity by 
responding to neutrophils. RvE1 impedes the migration of polymorphonuclear cells (PMN) 
to the site of inflammation, stops the PMN response to inflammatory cytokines and 
promotes the clearance of inflammatory cells via phagocytosis by macrophages (Levy, 
2010). Furthermore, RvE1 has been found to block the synthesis of pro inflammatory 
cytokines and induce apoptosis and phagocytosis by up-regulation of chemokine receptor 
type 5 (Ariel, 2006). Fredman and co-workers have recently demonstrated regulatory 
functions of RvE1 by inhibition of adenosine diphosphate activation of human platelets. 
This highlights a new cellular mechanism of action by EPA, which leads to resolution of 
vascular inflammation. This may be vital for management of inflammatory disease states 
(Fredman et al., 2010). 
 
RvE1 has been shown to be involved in the suppression of the production of cytokines 
such as IL-1, IL-2, IL-6 and TNF-α (Arita et al., 2005; Hong et al., 2003; Marcheselli et al., 
2003), as well as facilitating wound healing (Gronert, 2005). Recent animal models have 
shown that RvE1 regulates IL-23 and LXA4 to promote resolution of allergic airway 
inflammation in a mouse model of asthma (Haworth et al., 2008; Hisada et al., 2009). 
RvE1 can act along with LXs as resolution phase mediators to regulate IL-17 while only 
RVs have the ability to regulate IL-23 and IFN-γ levels (Haworth et al., 2008). In other 
animal models, it has been shown that RvE1 is highly potent when supplied 
intraperitoneally before and during sensitization and aeroallergen challenge phases (Aoki 
et al., 2008). This concept has been further investigated to confirm that administration with 
RvE1 in allergic asthma (murine models) can prevent the development of AHR, mucous 
metaplasia, eosinophil accumulation, and Th2 cytokine generation e.g. IL-13 (Aoki et al., 
2010). Haworth and co-workers have reported in murine models that NK cells expresses 
CMKLR1 (a receptor for RvE1), and depletion of NK cells lead to a reduction in RvE1 
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mediated resolution of allergic inflammation. Subsequently these findings signify novel 
functions of NK cells in facilitating resolution of adaptive immune responses and 
emphasise that NK cells are possible targets for specialized resolution phase lipid 
mediators for clearance of activated T cells from injured or inflamed lungs (Haworth et al., 
2011). While the functions of RvE1 have been investigated thoroughly, there is less 
information available about the specific activity of RvE2. This mediator has been reported 
to be produced by neutrophils and acts in similar manner as RvE1 (Calderon et al., 2012; 
Serhan & Petasis, 2012).Rvs  have been reported to  reduce leukocyte endothelial 
interactions and leukocyte adhesion in turn  promoting the resolution of inflammation (Van 
Dyke & Serhan, 2003;  Widgerow, 2012).  The two forms of E series resolvins have been 
hypothesised to have separate receptors as there is an additive effect when the two types 
of resolvins are administered together (Levy, 2012). 
 
PDs, maresins and D series resolvins are DHA derived lipid mediators and they function 
as anti-inflammatory molecules by blocking the activation and migration of neutrophils to 
sites of inflammation and reduce the production of pro-inflammatory cytokines (Serhan et 
al., 2011; Stables & Gilroy, 2011). In healthy individuals, airways and other mucosal 
surfaces have been found to be enriched with DHA while those individuals with 
asthma/cystic fibrosis have low levels of DHA (Freedman et al., 2004). There is little 
evidence related to the effects of D-series resolvins, maresins, and other DHA-derived 
mediators in asthma and only protectin D1 (PD1) has been investigated. To date no 
receptors for PDs have been found, although like RvE2 there is a combined effect with 
RvE1 suggesting distinct receptors for the two mediators (Fredman et al., 2010; Levy et al. 
2012). PD1 has been reported to facilitate the expression of CCR5 ligands on neutrophils 
and inhibit NF-κβ induction, which prevents the migration of neutrophils (Hong et al., 2003; 
Serhan et al., 2006). Based on murine models of allergic asthma in vivo, low PD1 levels 
are found during asthma exacerbations and PD1 has been shown to display 
broncoprotective effects (Levy et al., 2007). In a direct comparison with Lx stable analogue 
and RvE1 in acute self limited murine peritonitis, PD1 has displayed the lowest infiltration 
for leukocytes and the shortest resolution time interval  (time taken from maximal 
leukocyte infiltration to 50% of maximum) and these functions are suggestive of effective 
biological activity of PD1 in resolution of inflammation (Bannenberg et al., 2005).  
The biological characteristics of these new anti-inflammatory and pro-resolving mediators 
and the pathways, which drive the formation and actions of these molecules, have 
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provided a new concept for treating inflammatory diseases. The majority of studies 
conducted have been in animal models including mice, rats and rabbits, with limited 
studies on humans. Most recently, in a clinical trial designed by Resolvyx, the phase 2 
results show that the agonist resolvin produced dose-dependent improvement in both the 
signs and symptoms of dry eye in humans, and didn’t show any health side effects 
(Brooks,  2009; Resolvyx, 2012;  ClinicalTrials.gov identifier : NCT00799552). This first 
clinical study of the effect of resolvins in humans will help improve the understanding of the 
agents that can stimulate the resolution mechanisms and resolve acute inflammation along 
with chronic inflammation to reduce human diseases where uncontrolled inflammation 
forms the basis of their pathophysiology (Serhan, 2011a). Early phase trials are currently 
on going using natural and synthetic resolvins in various disease conditions such as 
asthma, inflammatory bowel disease, and other related inflammatory diseases; however, 
no information about the appropriate dosage of these compounds have been publicised. 
Based on a renal re-perfusion study with 23-28 g mice, intravenous resolvin dosage 
ranged from 0.01-0.1 mg/kg (Duffield  et al., 2006),while in another study investigating the 
effect of RvE1 in the asthma mouse model, a reduction in airway mucous, AHR and 
leukocyte bronchoalevolar lavage was achieved with intravenous dosages of 50-200 
ng/mouse (Haworth et al., 2008). Furthermore, Xu and colleagues have recently shown 
that a dose of only 10 ng/mouse of RvE1 and RvD1 is sufficient to reduce inflammation 
and pain via regulation of the central and peripheral nervous system (Xu et al., 2010).  
 
To summarise, these lipid mediators have been identified to have potent action (in the 
nanomolar and picomolar range) in a variety of cell types in vitro, as well as in many in 
vivo models of inflammatory diseases (Serhan, 2008). These include conditions such as 
periodontitis colitis and intestinal inflammation (Arita et al., 2005; Gewirtz et al., 2002), 
asthma and airway inflammation (Levy et al., 2012), cystic fibrosis, acute lung injury (El 
Kebir et al., 2009) and Alzheimer’s disease (Lukiw et al., 2005). Human supplementation 
studies are required to evaluate the action of these novel lipid mediators in other diseases 
including EIB. Furthermore, dose response studies are required to elucidate the most 
appropriate dose for the anti-inflammatory effects. Since Rvs, PDs and maresins are 
biological molecules derived from n-3 PUFA which are integral components of cell 
membrane phospholipids, these lipid mediators can play a possible role in cell signalling, 
which modulate more than one (and often several) tissues via pleotrophic effects. 
Furthermore, these characteristics distinguish the lipid mediators from industrially 
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produced drugs and what have been conventionally regarded as primary biological 
therapeutic agents, which have shown to exhibit more limited and specific effects (Serhan, 
2011b). However, the major challenges that have limited the application of these new 
mediators are the standardisation of appropriate methods for measurement of these in a 
laboratory setting. Other areas of interest in recent years have been a comparison of the 
health benefits of EPA and DHA supplementation versus treatment with Rvs or PDs. The 
differences, similarity and acceptance of health benefits of dietary n-3 PUFAs and/or their 
mediators will be dependent on factors such as costs, safety and public health implications 
that are affected as a result of adopting a particular treatment approach (Calderon et al., 
2012). Thus, well designed trials are required to understand the efficacy of these novel 
mediators in inflammation.  
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1.9 Summary, aims and hypothesis  
 
Asthma is a chronic inflammatory disease that has serious implications for quality of life 
and public health. The standard classification guidelines for asthma are based on fixed 
criteria for FEV1/FVC ratio (80% ratio) derived from predicted equations from a reference 
population. There are issues related to the reliability of predicted values and 80% ratio; for 
this reason, the classification guidelines have been questioned. A LLN derived from 
healthy control population is proposed for asthma classification to minimise these issues.  
 
Clinical focus in asthma therapy has been on the severe disease state, however a large 
number of asthmatics have mild to moderate symptoms. Recent public health guidelines 
from the Department of Health (UK) acknowledge the relationship between lack of physical 
activity and chronic diseases including asthma and consequently, physical activity is 
encouraged across the population. EIB is a sub type of asthma that affects approximately 
90% of asthmatics and 10% of the healthy population; thus, EIB is a limiting factor for 
physical activity for a large number of individuals. 
 
Though the currently available pharmacological therapies for asthma and EIB are 
effective, long-term usage of these therapies are associated with issues of tachyphylaxis 
and health side effects. Complementary therapies are becoming gradually more popular 
among asthmatics for asthma management. Increasing evidence from observational and 
intervention studies have suggested the possible anti-inflammatory effects of fish oil on 
various chronic inflammatory diseases including asthma and there is, therefore, an 
impetus towards using fish oil as a complimentary therapy. There is no major health side 
effects associated with the intake of fish oil, consequently fish oil is an attractive non-
pharmacological intervention which could benefit asthma. The anti-inflammatory effect of 
fish oil has been suggested to be linked with a change in cell membrane composition. The 
altered membrane composition with fish oil supplementation (primarily EPA and DHA) can 
modify lipid mediator generation by producing less inflammatory eicosanoids.  
 
 
A newly identified group of lipid mediators produced from the oxidation of n-3 (EPA and 
DHA) include resolvins and protectins, which have been suggested to be key players in 
the resolution of inflammation. Reduced inflammation attenuates the severity of asthma 
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including symptoms (dyspnoea) and exerts a bronchodilatory effect. There is a paucity of 
data relating to fish oil supplementation and EIB with studies that have been conducted 
focussing primarily on athletes. To address some of the issues highlighted above and to 
respond to identified gaps in current literature, this thesis consists of a series of studies 
designed to move forward the field of asthma research. This thesis addresses issues 
related to disease severity, classification of EIB, the impact of EPA and DHA 
supplementation on post exercise pulmonary function in EIB prone males and finally the 
impact of resolvins on EIB prone females. The aims and hypotheses for this thesis are 
listed below. The details of how each of these three research hypotheses were addressed 
are summarised here and expanded upon in chapter 3, 4 and 5 where study findings are 
presented and discussed.  
 
The first aim of this thesis was to characterise mild-moderate asthmatics based on 
80% ratio and then separately characterise the same individuals using the lower 
limit of normality (LLN) from a control population.  
Once the asthmatic population was identified, it was hypothesised that there would be a 
statistical difference between the dyspnoea score and circulating levels of inflammatory 
cytokines (IL-6 and TNF-α) of asthmatics and controls.  
 
The second aim of this thesis was to assess the effect of EPA/DHA supplementation 
on post exercise FEV1 in mild – moderate EIB prone males. 
It was hypothesised that there would be a statistically significant improvement in post-
exercise FEV1 after three-weeks of EPA/DHA supplementation. To support this study EIB 
prone, mild – moderate asthmatic males were recruited using the previously derived LLN. 
To evaluate the effects of EPA/DHA supplementation on pulmonary function in EIB-prone 
males, dyspnoea score, and FeNO levels were simultaneously measured. Additionally, the 
effect of EPA/DHA supplementation was assessed on the lipid composition in PBMC. 
Circulating levels of IL-6, IL-10 and TNF-α were measured to evaluate the changes in 
cytokines with supplementation.  
 
The third aim of this thesis was to investigate the effect of EPA-derived bioactive 
mediators (E series Resolvins) on post exercise FEV1 in mild – moderate EIB-prone 
females.  
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 It was hypothesised that there would be a statistically significant improvement in post- 
exercise FEV1 after three-weeks of resolvin supplementation. To support this study, EIB 
prone mild –moderate asthmatic females were recruited using fixed cut off value of 80% 
for FEV1/FVC. To evaluate the effects of resolvin supplementation, dyspnoea score and 
FeNO levels were simultaneously measured. Circulating levels of IL-6, IL-10 and TNF-α 
were measured to evaluate the changes in cytokines with supplementation.  
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2 General Methods  
2.1 Study overview  
This chapter provides a summary of the general methods used in this thesis and gives 
details of procedures and rationale for the methods used. The methods described are in 
the order they were developed, modified and applied during the study.  A summary of 
methods and statistical analysis for each separate study are presented in the relevant 
chapters. Risk assessments were conducted for phlebotomy and analysis of blood 
products, and were annually reviewed by the departmental safety officer. For all the 
chemicals used in the testing, relevant Control of Substances Hazardous to Health forms 
were completed and reviewed by the laboratory manager. Standard operating procedures 
were followed for the existing lab protocols, and relevant instruction manuals were 
followed when using commercial kits.  When conducting tests with participants, a safe 
system of work was maintained taking particular note of requirements for protective 
clothing and equipment and appropriate ventilation. 
2.2 Ethical approval  
The study protocols were approved by the Loughborough University Ethical Advisory 
Committee. Generic protocols were used for venepuncture (G03-P8), and specific 
protocols were used for exercise testing (GO9-P8) and Omega 3 supplementation (GO9-
P7). 
2.3 Participant recruitment 
 
Participants were recruited from a population of Loughborough University’s students and 
residents of Leicestershire, UK with the help of student support groups, advertisements 
and talks (see appendix 2). There was no financial incentive offered and full written 
consent was obtained from all participants. The participants completed standard health 
screen questionnaires and other related procedures (appendix 2). Male and female 
participants aged 18-30 years were recruited as per the requirements of individual studies, 
and the details are provided in respective chapters.  
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2.4 Venous blood sampling  
 
A certified phlebotomist following standard health and safety procedures outlined by the 
Loughborough University collected venous blood. Blood for PBMC analysis was collected 
in an anti-coagulant treated tube (K-EDTA), and coagulated blood was collected for serum 
separation for ELISA. A NVQ in Phlebotomy was obtained during the course of this thesis 
and the course involved two day training followed by a day of supervised practical session; 
the certificate is attached in appendix 2. The research design for the studies conducted in 
this thesis was such that the blood samples were collected at the same time of the day at 
each collection point (±30 minutes), and the sample analysis was conducted within 2 hours 
of collection. 
 
2.5 Physiological measurements 
2.5.1 Pulmonary Function Tests (PFTs) 
 
Spirometry is a physiological test that measures how an individual inhales or exhales 
volumes of air as a function of time. Volume or flow may be the main signal measurement 
in spirometry. This is invaluable as a screening test of general respiratory health in the 
same way that blood pressure provides important information about general 
cardiovascular health. In clinical practices, spiormetry may be supported by other tests 
such as symptom score, FeNO measurements and allergy tests for aetiological diagnosis. 
Spirometry was performed on all participants in a sitting position using a calibrated 
computerised spirometer (Superspiro; Micro Medical; Rochester, Kent, UK). These 
spirometers are gold standard devices based on the American Thoracic Society 
(ATS)/European Respiratory Society (ERS) guidelines. The entire protocol for PFTs was 
performed as per the guidelines (Miller et al., 2005a,b). The main quality control and 
testing parameters are reported below. 
 
The spirometer was evaluated for calibration on a monthly basis by a laboratory technician 
using a mechanical syringe to test the range of exhalations that are likely to be produced 
by the test population. Quality control was maintained in the laboratory by recording and 
maintaining the following: 1) a log of calibration results; 2) the documentation of repairs 
and other alterations which returned the spirometer to original configuration;  3) computer 
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hardware and software changes; 4) if the spirometer was relocated (taken on field trips 
etc). Calibration checks were performed before further tests began. The spirometer 
specification was maintained as per the ATS/ERS guidelines and was capable of 
accumulating volume for >15 s (longer times are recommended) and measuring volumes 
of ≥8 L with an accuracy of at least ±3% of the reading or ±0.05 L, whichever was greater.  
 
FEV1 and FVC manoeuvres are the two main aspects of PFTs used in the assessment of 
respiratory disorders. FVC is the maximal force of air exhaled with maximally forced effort 
from maximal inspiration (vital capacity) and is expressed in litres at body temperature and 
ambient pressure. FEV1 is the maximal volume of air exhaled in the first second of a forced 
expiration and is expressed in litres. There are three distinct phases to the FVC 
manoeuvre, which are as follows: 1) maximal inspiration; 2) a ‘‘blast’’ of exhalation; and 3) 
continued complete exhalation to the end of the test. To ensure the accuracy of the test, 
the participants were instructed to inhale rapidly and completely, the breathing tube 
(mouthpiece) was inserted into the participant’s mouth and it was ensured that the lips 
were sealed around the mouthpiece. The FVC manoeuvre started with no hesitation, the 
participants were prompted to ‘blast’ and not just ‘blow’ the air from their lungs, and then 
he/she was encouraged to fully exhale. As per the guidelines, enthusiastic coaching of 
participants was done to ensure that the participant provided the maximum effort. If the 
participants felt ‘dizzy’ during the manoeuvre, the procedure was stopped and testing was 
scheduled for a different day. Loss of consciousness could follow this dizziness due to 
prolonged interruption of venous return to the thorax; subsequently the participants were 
closely monitored during the manoeuvre. Participants were required to perform three 
acceptable FVC manoeuvres based on the ATS/ERS recommendation of ≤5% variation in 
between-manoeuvre recoded values (Miller et al., 2005a,b). By the end of a typical 
manoeuvre, a flow volume curve is generated which is used in the interpretation of a PFT.  
The main parameters tested were FEV1, FVC, PEF and FEF 25-75%. Curves depicting the 
parameters tested in lung function tests are shown in figure 2.1, and flow  volume loops in 
the lung function of asthmatics compared to normal individuals are shown in figure 2.2.  
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Figure 2.1 A flow volume loop showing the parameters tested during a pulmonary function 
test. PEF = Peak Expiratory Flow, FEV1 = Forced expiratory volume in 1 second, FVC = 
forced vital capacity, FEF 25-75% = forced expiratory flow between 25% and 75% of the FVC 
(FEF 25–75%) has also been known as the maximum mid-expiratory flow (adapted from 
Miller et al., 2005a) 
 
 
                 
                    2.2. (A)                                                    2.2. (B)  
 
Figure 2.2 (A) Flow–volume loop of a normal subject (B) Moderate airflow limitation in a 
subject with asthma (adapted from Miller et al., 2005a) 
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2.5.2 Exercise challenge testing  
 
Exercise testing was performed based on the ATS/ACCP (American College of Chest 
Physicians) statement on cardiopulmonary exercise testing (2003) and Rundell & 
Sue-Chu, 2010. The purpose of the exercise challenge test was to assess EIB symptoms 
in adults with stable asthma.  
 
Participant preparation  
 
Participants were requested to avoid alcohol, coffee (for 8hrs) and strenuous physical 
exertion (for 24 hours) before the exercise challenge, and medication usage was reported 
before testing. Caffeine is classified as a methylxanthine drug (like theophylline, a long 
acting bronchodilator) which has been shown to improve pulmonary function for up to four 
hours (Welsh et al., 2010). Furthermore, moderate alcohol consumption is also found to 
exhibit anti-inflammatory effects, improved mucociliary clearance, direct bronchodilator, 
and antioxidant effects (Sisson et al., 2007; Stanton et al, 2010). In addition, respiratory 
muscle training and physical activity could improve lung function (Emtner et al., 1996; 
Sutbeyaz et al., 2010). Inclusion criteria for participants for each study are reported in 
respective chapters.  
 
Pulmonary function tests (PFTs) 
 
PFT procedures were followed as described in the section above. Spirometry was 
performed at baseline prior to the exercise challenge test. For the exercise challenge test 
the participant exercised on a motorised treadmill at increasing intensities until they 
attained a level that elicited a heart rate response of 85-90% of maximal heart rate in the 
last 4-6 minutes of the session. Target heart rate was elicited from a calculated estimate of 
maximal heart rate (Gellish et al., 2007). The desired work intensity was achieved by 
increasing the incline while running at a constant speed within the first two minutes of the 
challenge. The relative humidity of the room was constant (approximately 50%), as was 
the room temperature (18-22°C). During the exercise test, heart rate was continuously 
monitored by a polar heart rate monitor.  
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Spirometry was performed at 0, 5, 10, 15, 30 and 45 minutes post-exercise or until 
complete recovery; whichever was earlier. At each time point three repeatable FEV1 values 
were measured and the greater of the two was recorded. The participants were not 
released from the lab until the FEV1 had returned to 95% of the baseline value. If a 
participant shows a decrease of >50% in FEV1, the administration of short acting ß2 
agonists (bronchodilator) to reverse the response is recommended, and participants were 
instructed to bring their bronchodilator during testing to ensure medication was available if 
required. However, during the study there were no instances where administration of 
medication post-exercise was necessary. 
 
Post exercise FEV1 values were compared to pre-exercise baseline values and 
percentage change was calculated using the following equation. A ≥10% fall in FEV1 at 
any time point after exercise is considered diagnostic for EIB (Haby et al., 1994; Sterk et 
al., 1993), and this criteria was used during the testing.    
 
 
 
 
 
....................equation 1  
 
2.5.3 Fraction of exhaled breath nitric oxide (FeNO) measurement  
 
Airway inflammation is a central characteristic of asthma and related lung diseases. As a 
consequence, monitoring of airway inflammation using FeNO measurements is becoming 
popular as an adjunct test to routine spirometry. Invasive techniques like bronchoscopy 
with lavage and biopsy, or the analysis of induced sputum can be used for direct sampling 
of airway cell and inflammatory mediators. Exhaled breath nitric oxide measurement is a 
suitable non-invasive measurement technique ideal for repeated monitoring of patient 
groups. ATS have highlighted FeNO measurement as progressing from being a research 
tool to having a clinical application in asthma and suggest that it may be used as an 
additional test in asthma diagnosis (ATS/ERS, 2005; Dweik et al., 2011). Online 
measurement of exhaled breath was conducted using the portable NIOX MINO analyser 
(NIOX MINO, Product code 03-1000). The NIOX MINO is a newer, smaller, hand held 
Pre-exercise FEV1 – post-exercise FEV1 
                                                                        X 100 
Pre-exercise FEV1 
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portable device for the measurement of airway inflammation based on the established 
NIOX monitoring system, which detects and measures levels of exhaled nitric oxide. The 
NIOX system uses a chemiluminescence gas analyser, which can measure low 
concentrations of NO while the NIOX MINO uses electrochemical sensor technology. It 
has been suggested that there is a good agreement between the FeNO values measured 
with the stationary chemiluminescence gas analysers and hand held NIOX MINO (Kim et 
al., 2012). The built in controls of the NIOX MINO provide reliable values as per the 
ATS/ERS guidelines. 
 
Ambient NO levels may affect a single breath analysis of FeNO, so the use of NO free air 
(containing <5ppb) for inhalation is preferred (Silkoff et al., 1997). The quality controls 
system of the NIOX MINO provided filtered air to eliminate any influence from ambient NO. 
The participant sat on a chair in an upright position, wearing a nose clip to minimise any 
nasal NO inhalation. The participants inserted a mouthpiece and inhaled over 2-3 seconds 
through the month to total lung capacity (TLC) or near TLC if TLC was difficult, and 
exhaled through a mouthpiece that was connected to the analyser. Exhalation was 
immediate as breath holding may affect FeNO levels. Inhaling to TLC is recommended as 
this is a constant point in the respiratory cycle and most asthmatics accustomed to 
spirometry are familiar with inhaling this volume.  
 
The other two critical factors to ensure that reproducible and standardised measurements 
of lower respiratory tract FeNO are achieved are that there must be exclusion of nasal NO 
and standardisation of flow rate. The exclusion of nasal NO is important in view of high 
nasal NO levels relative to lower respiratory tract. FENO values vary considerably with 
exhalation flow rate because of variation of airway NO diffusion with transit time in the 
airway, thus standardisation of the exhalation flow rate is required. The NIOX MINO flow 
control system maintained an exhalation rate of 0.005 L/second regardless of the patient’s 
skill. A visual display guided the patient to maintain an appropriate pressure range while 
exhaling. The results for FeNO are expressed in parts per billion. Three acceptable 
manoeuvres based on the ATS/ERS recommendations were carried out as per the (ATS, 
2005). Quality control procedures were completed as per the manufactures guidelines.  
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2.5.4  Dyspnoea 
 
Dyspnoea is a subjective experience of breathing discomfort that consists of qualitatively 
distinct sensations that vary in intensity. The experience derives from interactions among 
multiple physiological, psychological, social, and environmental factors, and may induce 
secondary physiological and behavioural responses (ATS/ERS, 1999). In asthma, the 
assessment of dyspnoea is an integral part of assessment and management of the 
disease. The severity of dyspnoea and the qualitative aspects of unpleasant breathing 
experiences differ widely among patients. Physical exercise can potentially act as a 
stimulus for both, physiological and perceptual responses. The significance of dyspnoea 
as a clinical marker of asthma is inversely related to the intensity of exercise provoking the 
symptom; subsequently dyspnoea at rest is considered more severe than dyspnoea during 
intense exercise. In the 1970s, Borg first described a scale ranging from 6-20 to measure 
perceived exertion during exercise (Borg, 1970) and this scale has been modified to a 10 
point scale with verbal expressions of severity anchored to specific numbers (Borg, 1976; 
1982). The reliability and validity for Borg ratings of breathlessness have been widely 
accepted (LeBlanc et al., 1986; Muza et al., 1990; Silverman et al., 1988; Skiner et al., 
1973). For this study, a standard Borg scale for breathlessness was used (chapter 3, 4 
and 5) and care was taken to provide consistent, specific instructions when using the 
scale.    
 
2.6 Biochemical methods 
2.6.1 Estimation of levels of omega 3 and omega 6 in PBMC 
 
The method employed here involved isolation of PBMC followed by extraction of the lipid 
and esterification of the fatty acids. Quantification of the n-3 and n-6 was performed by gas 
chromatography-flame ionisation detection (GC-FID). Specifically, this method required 
isolation of PBMC from whole blood followed by fatty acid transesterification to produce 
volatile fatty acid methyl esters (FAME), which could be identified and quantified by GC-
FID. The protocol for esterification and GC-FID was modified from Masood et al., 2005 and 
was validated to ensure that the method was appropriate to meet the requirements of the 
study. The original fatty acids of interest were ALA, LA, EPA, DHA and AA only. In the 
literature, DPA is considered to be an important fatty acid but was not specifically 
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identifiable using the modified method. Caution is warranted while interpreting the findings 
as only 70% of the peaks were identified using the modified method.   
2.6.2 Specimen collection and handling 
 
Fresh blood was collected and processed within 2 hours of collection as stipulated in 
research protocol (reported on page 72) in order to extract PBMC. PBMC are a group of 
circulating mononuclear cells and typically constitute 85-90% lymphocytes and 10-15% 
monocytes (Calder et al., 2002). Different subsets of monocytes and lymphocytes show 
significant diurnal variations with higher counts in the evening compared to the morning 
(Shantsila et al., 2012; Watson et al., 2010). In addition, a delay of greater than 2-4 hours 
in sample analysis has been shown to increase the number of mononuclear cell subsets 
significantly (Shantsila et al., 2012). The research design for the studies conducted in the 
thesis was such that the blood samples were collected at the same time of the day at each 
collection point (±30 minutes), and the sample analysis was conducted within 2 hours of 
collection. Furthermore, monocyte numbers for different subsets such as Mon1 (CD14++, 
CD16- and CCR2+), increase after exercise followed by a significant reduction after 1 hour 
(Scharhag et al., 2005; Smith et al., 1998; Shantsila et al., 2012). Blood was collected 
before exercise from each participant for this study. PBMC were not counted; and the 
results for n-3 and n-6 fatty acids were expressed as percentages.  
 
2.6.3 Isolation of PBMC 
 
The Ficoll Paque PREMIUM (Catalogue number 28-4039-56 AA, GE Healthcare, UK) 
method was used for isolation of PBMC in this study. This method involves layering of 
anticoagulant-treated blood on the Ficoll-Paque PREMIUM solution, followed by 
centrifugation for a short period of time (30-40 minutes) (Figure 2.3, A). Differential 
migration during centrifugation results in the formation of layers containing different cell 
types. The lowermost layer comprises the RBCs that have been aggregated by the Ficoll, 
and therefore sediment completely in the Ficoll-Paque PREMIUM layer. The layer 
immediately above the erythrocyte layer contains granulocytes, which at the osmotic 
pressure of the Ficoll-Paque PREMIUM solution attain a density great enough to migrate 
through the Ficoll-Paque PREMIUM layer. The mononuclear cells are found at the 
interface between the plasma and the Ficoll-Paque PREMIUM layer (Figure 2.3, B). The 
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other slowly sedimenting particles that are found at the interface are washed in a balanced 
salt solution removing platelets, density gradient medium, and plasma leaving a pellet of 
mononuclear cells. A balanced salt solution was prepared for washing of PBMC, made 
from two stock solutions (appendix 1) 
 
 
                                A                                                 B 
 
Figure 2.3 (A) Layering the diluted blood sample on Ficoll-Paque PREMIUM, (B) After 
centrifugation, the phase separation.  
 
2.6.4 Procedure for isolation of mononuclear cells 
 
The Ficoll-Paque PREMIUM was shaken several times to ensure thorough mixing. Ficoll 
(13.5 mL) was added to a 50ml centrifuge tube. In a separate 50mL centrifuge tube, 9 mL 
of anticoagulant-treated blood (K-EDTA) was added to an equal volume of balanced salt 
solution to make a final volume of 18 mL. The blood was mixed gently and thoroughly 
using a Pasteur pipette. Care was taken while mixing to ensure minimal damage to the 
blood cells. The diluted blood samples (18 mL) were slowly layered on to the Ficoll-Paque. 
It is important to assure when layering the sample not to mix Ficoll-Paque and the diluted 
blood sample. The mixture was centrifuged at 400 x g for 30 min at 18–20°C. Following 
centrifugation, the upper layer containing plasma and platelets was extracted using a 
sterile Pasteur pipette, leaving the layer of mononuclear cells undisturbed at the interface. 
There was a very fine layer of mononuclear cells obtained from 9 mL of blood and the 
extraction step required careful handling of the test tube. The technique required 3-5 
minutes, and a micropipette was used to extract mononuclear cells with precision to avoid 
any mixing with plasma and the Ficoll layer.  
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Washing the mononuclear cells to remove platelets 
 
Using a sterile Pasteur pipette the layer of mononuclear cells was transferred to a sterile 
centrifuge tube. Attention was paid to remove the entire interface except for a small 
amount of Ficoll-Paque PREMIUM and supernatant. Removing excess Ficoll-Paque 
PREMIUM causes granulocyte contamination, removing excess supernatant results in 
unnecessary contamination by platelets and plasma proteins. This step was optimised by 
extracting 1-3 mL of the mononuclear cell layer containing Ficoll-Paque, and finally 1-1.5 
mL of mononuclear was considered optimum for washing. 
 
 Wash 1:  At least three volumes (27 mL) of balanced salt solution was added to the 
mononuclear cells in the centrifuge tube. The cells were suspended by gently drawing 
them in and out of a Pasteur pipette. After centrifugation at 100 x g for 10 min at 18–20°C, 
the supernatant was removed. 
 
Wash 2: The mononuclear cells were re-suspended in ~27 ml balanced salt solution by 
gently drawing them in and out of the Pasteur pipette. This second density centrifugation 
step was important to remove any red blood cell contamination. After centrifugation at 60 –
100 × g for 10 min at 18–20°C, the supernatant was removed. The extracted mononuclear 
cells settled at the bottom of the centrifuge tube were suspended in the 1:1 phosphate 
buffer saline (PBS). Two aliquots were made depending on cell recovery, one aliquot with 
1.1 dilutions and one with no dilution (cells only).  Any excess buffer was evaporated under 
nitrogen and stored at -20ºC until further analysis. 
 
2.6.5 One step fatty acid esterification  
 
After isolating the PBMC, the next step was to extract the total cell fatty acids from the 
PBMC and derivatise them to volatile methyl esters that could then be identified by GC 
based upon their molecular size. Fatty acids in their free, underivatised form may be 
difficult to analyse because these highly polar compounds tend to form hydrogen bonds, 
leading to adsorption issues. Reducing their polarity makes them more amenable to 
analysis. In addition, derivatisation of fatty acids to volatile esters is helpful to distinguish 
between the very slight structural differences exhibited by unsaturated fatty acids 
(Gunstone, 1993; Knapp, 1979).  
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For the extraction of fatty acids from cells and tissues, most methods are based on the 
principals and techniques used by Folch (1959) or Bligh & Dyer (1959), although there is 
no one particular method which can be accepted as the most appropriate method for fatty 
acid extraction. The choice of the method is dependent on the type of fatty acids to be 
analysed, and whichever method is adopted, validation is required to determine its 
suitability for the intended use. These methods have been widely applied and used in the 
preparation of FAMEs for a range of laboratory analyses using different types of cells 
(Damsgaard et al., 2008; Garcia-Larsen., 2011; Healy et al., 2000; Lee et al., 1985; 
Mickleborough et al., 2006; Rees et al., 2006). There are standard methods for 
derivatisation of lipids from cells and tissues in a quantitative manner (Blau & Halket, 1993; 
Christie, 2003), and the most widely used methods are acid catalysed esterification or 
transesterification (& Roy, 1986; Morrison & Smith, 1964). Masood et al. (2005) have 
proposed a modified method for measurement of fatty acids in plasma samples. This 
method is derived from Lepage & Roy (1986) and had the advantage over the original of 
being faster, more efficient and cost effective for plasma samples. In addition, the Masood 
et al., (2005) method does not require the use of any toxic chemicals, which were 
previously necessary in the Lepage & Roy (1986) protocol. For this thesis, the Masood et 
al., (2005) method was further adapted for PBMC analysis and subsequently optimised 
and validated to assess its suitability for the current study.  
Masood et al. (2005) method adaptation:  
 
A simplified, one-step transesterification reaction proposed by Masood et al. (2005) 
required the same stock solutions that were conventionally required by the Lepage and 
Roy (1986) method. The 1.9 ml of stock solution required for each sample included 1.7 ml 
of methanol, 100µl of acetyl chloride, and 100 µl of the internal standard solution 
(containing 10µg of 23:0 methyl ester). Briefly, 50µl of PBMC and 1.9 ml of the stock 
solution were combined in screw-capped glass tubes. The tubes were capped tightly and 
heated at 100ºC for 60 min. The tubes were cooled down to room temperature. Hexane 
(0.75 ml) was added, and the tubes were vortexed for about 30 seconds. The upper 
organic phase was collected, and re-extraction with hexane was done for the lower phase 
to enhance lipid extraction. The combined hexane solution was evaporated under nitrogen 
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to dryness, and the dry residue was then re-dissolved in 60µl of hexane. A maximum of 
1µl of this sample was injected into GC  
 
The modified method developed for this thesis had limited level of toxicity due to the use of 
non-toxic reagents. Condensation lids were used with a constant supply of water to 
prevent any evaporation of esters. The Masood et al. (2005) method was scaled up to 
esterify 100µl of PBMC samples. For this, a stock solution of 3.6 ml was made up 
comprising of 200µl of acetyl chloride that was added to 3.4 ml of methanol. PMBC (100µl) 
was added to the 3.6 ml of the stock solution in screw-capped glass tubes. The tube was 
capped and heated at 100 °C for 60 min. After the methylation, the tube was cooled on ice. 
Analytical grade n-Hexane (1.5 ml) was added to the tube and vortxed for 30 seconds. The 
upper organic phase was collected with a Pasteur pipette. This extraction procedure was 
repeated to maximise lipid yield. The hexane phases were combined for absolute 
recovery, and finally nitrogen gas was passed through to reduce the volume (~20-30µl).  
 
Cell counting was not carried out to estimate the concentration of the extracted PBMC. 
This was considered as not required because only the percentages of each fatty acid 
relative to all fatty acids in a chromatogram were required for estimation of the ratio of fatty 
acids of interest. This provides only an estimate of the percentage of each fatty acid 
present in the PBMC and does not provide the concentration or quantification of the cells. 
To achieve quantification, the cells are required to be counted using an appropriate 
technique (e.g. hemocytometer). This could be considered for future studies. Furthermore, 
no internal standard was used, as relative percentages of different fatty acids were 
required for the analysis. In the absence of an internal standard, relative quantification was 
used in GC analysis by the use of an external 37-component FAME mix (Supelco, 
catalogue number 47885-U). The modified method was fast and efficient requiring less 
than 4 hours for isolating PBMC samples followed by esterification and analysis by GC-
FID. The method was also relatively cheaper than other methods published in the literature 
for isolation and analysis of PBMC. The cost per sample for processing was less than 
£4.00 including all reagents and materials required for isolation and analysis of PBMC 
using GC-FID.  
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2.6.6 Gas chromatography-flame ionization detection (GC-FID) 
 
After the esterification, the samples (1µl) were loaded into a GC-FID (HP 5890 Series) for 
analysis. The samples were run on an HP-5 column 30 m, 0.32 mm, 0.10 µm (Agilent, 
catalogue number 19091J-313) followed by FID analysis. Helium was initially used as a 
carrier gas, and later on replaced by nitrogen to meet the requirements of the laboratories. 
A comparison was undertaken to assess the efficiency of the two carrier gases, and it was 
found that the resolution of fatty acids was similar irrespective of the carrier gas; the 
results will be shown in the validation section of this chapter. There was 5% variation in 
resolution with nitrogen compared to helium; however, the overall CV% was less than 10% 
for all identified peaks.  The carrier gas was set at 80 bars and hydrogen was used as the 
make-up gas. The split ratio was adjusted to 15:1 to prevent overloading of the column. A 
temperature programme was used with a starting temperature of 160°C and a ramp of 
10°C/minute to achieve a final temperature of 270°C in 11 minutes. The run was held at 
270°C for the following 4-5 minutes. The total run time was up to 18 minutes; in addition, 
the purge valve was switched off for 0.3 min in the beginning to ensure most of the FAME 
sample was put on the column. This method allowed identification of approximately 80% of 
the total fatty acids in the FAME and this included the n-3 and n-6 PUFAs of interest for 
analysis in this thesis. A range of different injection techniques and syringes were tested to 
obtain quantifiable sharp peaks. Finally, a 1 cm needle was used with up to 1µl sample 
injection.  This standardisation was important for accurate measurement of the area under 
the curve, which would affect resolution and henceforth influence identification of the 
peaks.   
 
2.6.7 Result interpretation  
 
Each sample, when run on a GC, results in individual peaks corresponding to fatty acids 
(as FAMEs), as shown in figures 2.4-2.10. Each peak is characteristic and unique for each 
fatty acid and these peaks appear according to the order in which the FAMEs are detected 
by the FID of GC. The time required by each FAME to appear on the chromatogram 
(retention time) is equal to the time each fatty acid is retained inside the column, and is 
characteristic of each fatty acid. FAMEs with shorter chains and fewer or no double bonds 
have a shorter retention time than the fatty acids with a longer hydrocarbon chain; 
consequently, they appear first on the chromatogram. The identification of specific fatty 
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acids is done by comparison of the retention times of FAMEs within a known standard mix 
of fatty acids.  
 
A standard calibration GC-FID graph was generated with the 37-component FAME mix 
(Supelco, catalogue number 47885-U). There was no information from the manufacturer 
(Supleco) about the resolution of 37-component FAME mix on an HP-column. The 
manufacturer of the standard mix has however reported their resolution on a fused silica 
column ‘equity -1’ (15m x 0.10mm, df 0.10mm, catalogue number 28039-U, Sigma). The 
properties of the equity -1 column are comparable to that of HP-5 as per the manufactures 
guidelines. Both the columns support temperatures as high as 250-270 °C and have a 
bonded matrix of poly methyl siloxane phase. The two columns have been suggested for 
use as multi-purpose columns that can be utilised for FAME analysis. The main difference 
between the two columns was the column length, compared to equity-1, HP-5 is a longer 
column (30m x 0.32mm, df 0.25mm), which suggests that there would be a better 
efficiency and resolution of samples on HP-5. Additionally, there could be a longer 
retention time for the components tested on HP-5. Thus, the resolution of 37-component 
mix was compared to that of HP-5 and subsequently all the FAMEs were identified. To 
accurately identify the order of elution of the fatty acids on HP-5, standard FAMEs for pure 
DHA, LA and ALA were tested and subsequently their retention times were used for 
reference. Neat FAMEs for pure DHA and LA were also spiked on the 37-component 
standard mix to assess the accuracy of resolution of these FAMEs. The retention times 
were comparable when neat FAMEs were run and when these FAMEs were spiked on the 
37-component FAME mix. There were up to ± 0.05 minute differences in the resolution of 
FAMEs between the two runs, which were considered acceptable for analysis.   
 
After the identification was complete, adjustments were made to remove solvent peaks for 
analysis. The area under each peak was calculated and the proportion of each peak area 
to the sum of the area of all peaks was calculated. This proportion represented the 
percentage of each fatty acid in the total fatty acids analysed (total PBMC lipid content). 
The data was analysed by the Clarity Lite software (Clarity v.2.4.1.77, DataApex Ltd, 
2005). The area under the curve was measured for the samples and standard, and 
percentage fatty acid content for each of the fatty acids of interest were recorded from the 
graph and analysed in MS Excel. Docosapentanoic acid (DPA) was not one of the fatty 
acids of focus in the original research design; the fact that it was not present in the 37-
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component FAME mix should not impact the current analysis. However, it would be 
possible in a follow up study to specifically focus on DPA and identify it in subsequent 
samples.  
 
2.6.8 Validation of the modified method 
The esterification and GC-FID method reported in this thesis is modified from Masood et 
al., (2005). A validation was required after the modification to the existing method to 
confirm the performance specifications when compared to the original method. In addition, 
the validation aimed to evaluate if the method was suitable for use in routine analysis.. 
Parameters such as accuracy, precision, reportable range, linearity, interference, recovery 
and analytical specificity should be assessed. There were limitations as to what could be 
achieved as part of the validation due to constraints on available materials and costs. 
Justification has been provided in the following section to support decisions not to 
undertake a particular validation experiment. A 37-component FAME mix obtained from 
Sigma Aaldrich (ISO 9001: 2008 registration) was used as a reference standard and a 
measure of quality control during the experiments. All samples were analysed in duplicate 
to control for intra-assay variations.  
Validation parameters 
The following parameters were determined for the original [Masood et al., (2005)] and the 
modified method.  
 
Precision and allowable error based on biological variation  
 
Precision of a method is the degree of agreement among the individual test results, when 
the procedure is applied repeatedly to multiple samplings of a homogenous sample. Within 
assay and between assay precision was determined by analysis of replicates of the 37-
component FAME mix within a day and between two different days. Mean standard 
deviation and the coefficient of variation (CV) were recorded for each test. There may be 
error due to both the imprecision and inaccuracy of the method, therefore the combination 
of the two errors, or the total analytical error (TEa), determines the quality of the test result 
(Westgard, 2004). The TEa may be derived from biological variation or derived from 
manufacturers’ specifications. For analytical techniques a mean CV is routinely set at 20% 
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to account for TEa (NIH, 2010). Since there was no manufacturers’ guidance about TEa 
for FAMEs derived from PBMC on HP-5 column, an acceptable CV of 20% was set as 
standard to allow for imprecision, bias, manual error and total error of the tests. This CV 
was set as the highest error limit for each assay, which reflected the realistic performance 
expectations of the modified method based on the biological variation. 
 
Accuracy and linearity  
 Accuracy is the measure of exactness of an analytical method or the closeness of 
agreement between the measured value and the value that is accepted as a conventional 
or accepted reference value. The determination of accuracy requires an accepted method 
compared against the modified method. For this purpose the modified method was 
compared to Masood et al. (2005) method. A range of standards including the 37-
component FAME mix and in house esterified reference oil standards (fish, sunflower and 
olive oil) were analysed using GC-FID. The test material (PBMC) was analysed using the 
two GC-FID methods. Additionally, plasma and red blood cells (RBCs) were analysed for 
comparison. The components of the capsules used in the intervention study (fish oil: 
Biocare and placebo) were also esterified and analysed using the two methods. Linearity 
of a method is its ability, within a given range, to obtain results that are directly proportional 
to the concentration of an analyte in the sample. Linearity describes the degree of the 
linear relationship between the test results and the concentration. Since the 37-component 
FAME mix was a complex mixture of different FAMEs it was not practical to efficiently 
assess the linearity of the experiment. Henceforth linearity was not assessed during this 
validation. 
 
Interference (specificity) 
 
The interference of a method is defined as the ability of the method to measure the analyte 
of interest to the exclusion of other components. The aim of this study was to determine 
the relative percentages of omega 3 and omega 6 PUFAs of interest (AA, EPA and DHA). 
A temperature program was used for the GC-FID as described in the previous section 
2.6.6 which allowed better resolution of the PUFAs of interest. Only those peaks were 
identified in samples which corresponded to the ones with the same retention time in the 
37 component FAME mix as standard. FAMEs derived from PBMC showed some 
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unidentified peaks as they did not correspond to any of the FAMES in the standard and 
these peaks were subsequently excluded from analysis.  
Validation results 
Composition of 37 component FAME mix (standard) 
 
Using the original Masood et al. (2005) method and the modified method on a 37 
component FAME mix, up to approximately 70% of peaks were identified in the GC-FID 
chromatographs respectively. For the modified method there was difficulty in the resolution 
of the low molecular weight fatty acids due to the nature of the GC-FID programme. The 
programme was targeted to resolve high molecular weight FAMEs of interest and this 
could be considered a major technical limitation due to the parameter of GC-FID 
programme and column used. In future studies, this significant limitation may be resolved 
with the use of different analytical application in order to resolve more fatty acids. Table 
2.1 shows percent of fatty acids in the 37 component FAME mix relative to all fatty acids in 
the chromatogram based on the manufacturers guidance. A total of 30 FAMEs out of the 
37 FAMEs listed by the manufacturer were identified using the modified method and the 
area covered by these peaks was estimated to be 70% of the total peak area of the GC 
trace. The within batch precision calculated by observing the mean CV% of all the FAMEs 
identified on the same day was <5% run on the same day (in five different runs). A 
between batch precision was calculated by measuring CV% over two different days was 
less than 20%. Lists of important fatty acids based on their degree of saturation were 
identified with their mean values and CV% listed in table 2.1.  Intra assay CV% for 
saturated, monounsaturated, and polyunsaturated FAMEs using the modified method were 
calculated as 10%, 5% and 6% respectively. The mean CV% of total n-3 FAMEs 
(calculated as a sum of the mean CV% of ALA, EPA and DHA) was 10% and mean CV% 
for total n-6s (calculated as a sum of the mean CV% of LA and AA) was 7%. The mean 
CV% of all fatty acids using the Masood et al. (2005) method was less than 10% which is 
approximately 5% higher than the values reported by Masood et al.,. The inter-assay CV% 
for all fatty acids identified using the two methods was <20%. The GC-FID graphs showing 
the fatty acid profiles from the 37 component FAME mix are displayed in figures 2.4, 2.5 
and 2.6. The two methods (modified and Masood et al., (2005) method) were directly 
compared using two sample paired t-tests (p≤0.05).        
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Since the manufacturers did not provide any standard reference graph or retention time for 
the 37-component standard mix on an HP-5 column it was important to check the elution 
order for the FAMEs. The graph was compared to the output from an equity 1 column 
(catalogue number 28039-U Sigma) with a similar specification. To assess the accuracy of 
elution of FAMEs, neat DHA (all-cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester, 
catalogue number 47570-U, Supelco) was spiked on to the 37 component FAME mix. The 
37-component FAME mix contained DHA at 2% by weight and the 1:1 volume/volume 
spiking enhanced the peak. The neat DHA FAME was analysed by GC-FID separately and 
the retention time was comparable to the retention time for DHA in the 37-component 
FAME mix.  There was less than 1% CV in the retention times between two runs 
completed on the same day or different days. Thus, neat DHA FAME served as a standard 
reference material for determining the accuracy of the modified method.  
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Table 2.1.  Percentage fatty acid composition in a 37 component FAME mix using the two 
methods, mean % shows the% of each fatty acid in the 37 component FAME mix relative to 
total fatty acid content. SFA= saturated fatty acids, MUFA= mono unsaturated fatty acids and 
PUFA=polyunsaturated fatty acids 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
 
Comparison of standard reference oils (olive oil, sunflower oil and fish oil) with 
manufacturers specifications.  
 
A range of standard reference oils including olive, sunflower and fish oil were esterified 
and analysed by GC-FID using both methods, the modified and the Masood et al. (2005) 
method. Olive oil and sunflower oil were obtained from the supermarket, and compared 
against compositions specified by Sigma Aldrich (specified below) for pure olive oil and 
sunflower oil respectively. This may not provide an exact comparison owing to the purity of 
the oils; however, the basic composition of the oil in terms of the main components should 
be comparable. In addition, the composition mentioned by Sigma Aldrich is for neat oil, 
and there could have been a particle loss of components during the esterification process. 
  Manufacturers 
guidance                  
(% by weight) 
Percentage (%) of fatty acids in a 37 
component FAME mix relative to all fatty 
acids in a chromatogram   
Fatty Acid 
 
Modified 
method 
  Masood et al. (2005)  
method 
SFA 
 
Mean% CV% Mean% CV% 
Lauric acid  4 3.8 9.1 3.3 5.1 
Myristic acid 4 4.6 17.1 4.1 8.7 
Pentadecanoic acid 2 2.7 23.1 2.4 17.4 
Palmitic acid 6 6.7 2.1 7.0 9.8 
Heptadecanoic acid 2 3.4 0.9 2.5    3.8 
Stearic acid  4 3.8 7.4 5.1 0.8 
 
 
    
MUFA 
     
Palmitoleic acid 2 3.1 7.1 2.0 11.4 
Oleic acid 4 3.9 5.3 5.4 9.2 
 
 
    
PUFA 
     
Linoleic Acid (LA) 2 2.7 12.8 1.9 14.4 
Alpha - linoleic Acid (ALA) 2 1.7 20.2 3.4 0.29 
Arachidonic acid (AA) 2 3.4 6.5 2.1 7.3 
Eicosapentaenoic Acid 
(EPA) 
2 2.2 9.4 2.4 10.1 
Docosahexaenoic Acid 
(DHA) 
2 1.9 3.6 1.81 7.3 
Mean ± SD 
 
3.4 ± 1.30               3.3 ± 1.61  
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Hence, considering biological variation, a CV% of up to 20% of the basic composition for 
olive oil and sunflower oil when compared to Sigma Aldrich values was considered 
acceptable for this experiment. The esterified standard reference oil FAMEs were diluted 
in n-hexane (1/10) prior to GC-FID analysis.  
 
Fish oil  
Menhaden fish oil (catalogue number: 47116 Sigma Aldrich) was used for this experiment. 
The fish oil was esterified and analysed by GC-FID using both methods. The GC-FID 
traces were compared to the manufacturer’s specifications. Only 80% of peaks were 
reported by the manufacturer, and remaining 20% were suggested to be derived from 
unidentified n-3 fatty acids. The modified method identified a majority of the peaks that 
were comparable to the manufacturer’s specifications and there was greater than 80% 
recovery for the major fatty acids of interest (EPA/DHA). Oleic acid was not resolved using 
either of the two methods. The values are reported (in table 2.2) as a comparison to 
manufacturer’s specifications and the GC-FID graph is shown in figure 2.5. Using the 
modified method approximately 79% of the trace was identified and matched up with the 
manufacturers’ specifications. The remaining 21% of the GC trace was not identified as it 
did not match up with any of the components listed in the 37-component FAME mix. EPA 
and DHA were the two main components in the menhaden fish oil corresponding to 16 and 
19% of the total respectively. Subsequently, the recovery percentage was between 80-
120% and the mean CV% between two runs was calculated as less than 4%. Using the 
Masood et al. (2005) method, approximately 70% of the peaks in the GC trace were 
identified with a CV% of less than 5%.  EPA and DHA were identified as being 14% and 
12% of the total respectively providing 80-120% recovery of these fatty acids in the 
esterified fish oil standard.  
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Table 2.2 Percentage fatty acid composition for Menhaden Fish oil, values reported for the 
two methods are expressed as percentage of each fatty acid relative to all fatty acids in a 
chromatogram. 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
 
 
Olive oil 
The olive oil analysed for this experiment was obtained from Napolina Ltd., UK and the 
manufacturers stated that the pack contained extra virgin olive oil with no indication to 
purity. Table 2.3 shows recovery of fatty acids in the olive oil standard when compared 
against manufacturer’s specifications (olive oil, catalogue number: 47118, sigma aldrich). 
There was a greater than 80% recovery for oleic acid using both methods. Using the 
modified method, oleic acid corresponded to 69% while the remaining 31% of the peak 
area was covered by stearic acid (3%), linoleic acid (14%) and palmitic acid (14%). The 
mean CV% between two runs was calculated as less than 5%. Using the modified method 
there was a recovery of >80% for all fatty acids with oleic acid corresponding to 66% of 
peak area.  
 
 
 
 
 
 
  Menhaden Fish oil  
Composition - 
Percentage by weight  
Manufactures 
guidance                  
(% by weight) 
Modified method Masood et al. 
(2005)  method 
 
 
Mean CV% Mean CV% 
Myristic acid  6-9% 8 8 1 1 
Palmitic acid  15-20% 17 7 19 4 
Palmitoleic acid  9-14% 13 3 12 1 
Stearic acid  3-4% 3 1 3 5 
Oleic acid  5-12% 1 5   
LA  <3% 0 4 5 1 
ALA  <3% 1 3 4 20 
Octadecatrtranoicacid  2-4% -- --   
AA  <3% -- --   
EPA  10-15% 16 6 14 3 
DHA  8-15% 19 5 12 6 
Mean ± SD  8.67±7.70  8.75±6.36  
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Table 2.3 Percentage fatty acid composition for olive oil, values reported for the two 
methods are expressed as percentage of each fatty acid relative to all fatty acids in a 
chromatogram 
 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
 
Sunflower oil  
The sunflower oil analysed for this experiment was obtained from Flora, UK and the 
manufacturers stated that the pack contained pure sunflower oil with vitamin E. The 
analysed GC-FID trace was compared to sunflower seed oil (catalogue number: 47123; 
Sigma Aldrich). There was no pure sunflower oil available from the manufacturer and this 
was the closest match to sunflower oil. Table 2.4 reports the profile of sunflower oil derived 
from the GC-FID graph. There was > 80% recovery for linoleic acid, which was the major 
fatty acid in the sunflower oil using the two methods.  Using the modified method, linoleic 
acid was identified as the primary component (56%) and the remaining 44% of the peak 
area was contributed by palmitic acid (14%), oleic acid (25%) and stearic acid (5%). When 
compared to the manufactures composition, there was a 10% difference in the value of the 
primary component (linoleic acid). Using the Masood et al. (2005) method, linoleic acid 
was identified as the major peak (63%) followed by oleic acid (26%), palmitic, and stearic 
acid (4% each). The mean CV% between two runs was calculated as less than 5% for 
both the methods.  
 
 
 
 
 
Olive oil  
Composition - 
Percentage by weight 
Manufacturers 
guidance                  
(% by weight) 
Modified 
method 
Masood et al. (2005)  
method 
Mean CV% Mean CV% 
Palmitic Acid <13% 14 6 13 7 
Palmitoleic Acid - - - - - 
Stearic Acid <3% 3 5 3 2 
Oleic Acid 71% 69 3 66 2 
LA <10% 14 6 18 5 
ALA - - - - - 
Mean ±SD 
 
25±27.8 
 
25± 28.0 
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Table 2.4 Percentage fatty acid composition for sunflower oil, values reported for the two 
methods are expressed as percentage of each fatty acid relative to all fatty acids in a 
chromatogram 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
 
PBMC total lipids 
PBMC total lipids expressed as percentage of a fatty acid relative to all fatty acids in a 
chromatogram are shown in table 2.5. Approximately 80% of peaks were identified using 
the modified method while the Masood et al. (2005) method resolved up to 85% of peaks, 
GC-FID traces are shown in figure 2.3. Some of the low molecular weight fatty acids 
(butyric, capric, and lauric acid) were not identified using the modified method due to the 
limitations of the temperature program for GC. These fatty acids were also difficult to 
resolve when analysed by the Massod et al. (2005) method. Additionally, plasma and red 
blood cells (RBCs) were analysed using both the methods, and >80% of peaks were 
identified by both the methods with a CV% of less than 20%. The capsules used in the 
intervention study (Biocare and placebo) were also esterified and analysed using the two 
methods; both methods provided >80% recovery of the total fatty acids. 
 
 
 
 
 
 
 
 
 
 
 
 
Sunflower oil  
Composition - 
Percentage by weight  
Manufacturers 
guidance                  
(% by weight) 
Modified method Masood et al. (2005)  
method 
Mean CV% Mean CV% 
Palmitic Acid  7% 14 0 4 9 
Palmitoleic Acid  -- -- -- -- -- 
Stearic Acid  5% 6 2 4 2 
Oleic Acid  19% 25 5 26 5 
LA  68% 56 5 63 1 
ALA  1% -- -- -- -- 
Mean ± SD  25.3 ± 21.9  24.2 ± 27.8  
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Table 2.5 PBMC total lipids expressed as percentage of a fatty acid relative to all fatty acids 
in a chromatogram. 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
 
Composition of Biocare and Placebo capsules compared against manufacturers 
specifications 
The capsules used in the intervention study were received free of charge from Biocare 
(catalogue code: 52730) while the placebo capsules were received from Bionovate. The 
compositions of the capsules as per manufactures guidelines are reported in table 2.6. 
Applying the modified method, 100 µl of the components from the capsules were esterified 
and analysed using the GC-FID method. The Bionovex capsules containing resolvinol (E 
series resolvins) were not analysed since there was no manufacturers GC report for 
comparison. Biocare capsules when analysed were found to primarily constitute EPA and 
DHA. The capsule contained 43.65% EPA and 29.10% DHA making up approximately 
73% of the total peak area. This accounted for the approximately 2:1 ratio of EPA: DHA, 
which was suggested by the manufacturer. The remaining 27% constituted of grapeseed 
oil, which was suggested as a vehicle for the two primary constituents of the capsule. The 
 Fatty acids  Modified method  Masood et al. (2005)  method 
  
SFA  Mean CV% Mean CV% 
Myristic acid 9.1 3.7 9.3 0.3 
Pentadecanoic acid 2.3 5.3 - - 
Plamitic acid  16.7 2.0 17.8 2.3 
Heptadecanoic acid  0.6 0.3 0.3 1.5 
Stearic acid  6.5 0.9 10.7 2.3 
 
    
MUFA 
      
Palmitoleic acid  3.3 3.9 -  
Oleic acid  16.2 1.1 15.6 0.3 
PUFA 
      
LA 8.5 1.0 10.0 0.6 
ALA 0.9 1.2 0.6 3.3 
AA 4.6 2.7 7.0 0.6 
EPA 1.6 2.3 1.6 4.1 
DHA 0.8 0.5 1.0 2.6 
Mean ±SD 5.92 ± 5.7  7.3 ± 6.3  
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mean CV% of all the fatty acids identified was less than 8%. There were no differences 
between the means for the two methods when analysed using paired t-test (p>0.05). 
 
Table 2.6 Composition of the capsules used in the intervention study 
 
Capsules Manufacturer Ingredients per capsule 
Mega 
EPA  Biocare  1000 mg Fish Oil Concentrate  
Catalogue Code: 
52730 
Containing 310mg EPA and 210mg DHA (relative 
ratio – 2:1) 
 50mg lecithin and 10mg vitamin E 15i.u. (d-alpha 
tocopherol) 
Capsule: gelatine, glycerine and chlorophyll 
Bionovex Bionovate  Derived from Green Lipped Mussels  
Containing  10mg Resolvinol  
0.5% natural vit E (antioxidant) with the oil vehicle 
being olive oil. Capsule: gelatine 
Placebo  Bionovate  Olive oil filled only, with 0.5% vit E. 
    Capsule: gelatine 
 
Nitrogen vs. Helium as carrier gas  
 
Using nitrogen as a carrier gas in chromatography is more cost effective than using 
helium. An assessment of the efficiency of the GC-FID method using nitrogen as an 
alternative for helium was conducted. The same GC-FID programme using the modified 
method was applied and the percentage recovery of fatty acids in the 37-component 
FAME mix was compared for the two gases. The data suggests that the resolution of 
peaks are 5% better with helium, however the total CV% for all fatty acids when using 
nitrogen is under 10%, which was acceptable under the allowable error based on 
biological variation for this experiment. Thus, nitrogen can be used as an alternative for 
helium in GC-FID analysis. For the supplementation study, helium was used as the carrier 
gas with a HP-5 column, however for additional validation results nitrogen was used as the 
carrier gas. The data comparing efficiency of the two carrier gases is reported in table 2.7.  
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Table 2.7 Percentage recovery of key fatty acids using nitrogen and helium as carrier gases  
 
 Manufacturer’s 
guidance (% by 
weight) 
Percentage of fatty acids in 37 component 
FAME mix relative to all fatty acids in a 
chromatogram  
         Using Helium                  Using Nitrogen  
SFA   Mean CV% Mean CV% 
 Lauric acid  4 4.6 2.1 3.8 9.1 
Myristic acid 4 4.6 3.7 4.7 17.1 
Pentadecanoic acid 2 2.4 0.3 2.8 23.1 
Palmitic acid 6 7.3 0.2 6.7 2.1 
Heptadecanoic acid 2 2.3 6.3 3.4 0.9 
Stearic acid  4 4.8 8.8 3.8 7.4 
       
MUFA       
Plamitoleic acid 2 2.6 2.3 3.2 7.1 
oleic acid 4 6.4 2 4 5.4 
       
PUFA       
LA 2 2.5 7.9 2.8 12.9 
ALA 2 1.0 5.3 1.8 20.2 
AA 2 1.9 0.7 3.5 6.5 
EPA 2 2.1 4.7 2.3 9.4 
 DHA 2 2.0 5.0 2.0 3.6 
Mean ± SD  3.42 ± 1.9  3.44 ± 1.3  
 
There were no differences between the means for the two methods when analysed using paired t-
test (p>0.05). 
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 Sample GC-FID traces from the validation  
 
 
 
 
Figure 2.4 2A GC-FID graph showing a profile of 37 component FAME mix on Equity 1 column provided by the manufacturers. 
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Figure 2.5 A GC-FID graph showing a profile of 37component FAME mix on HP-5 column using the modified method. Key to the 
profile is shown on next page.  
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Figure 2.5 a) A GC-FID graph showing a profile of 37component FAME mix on 
HP-5 column using the modified method.  
Key  
1. Lauric Acid  
2. Tridecanoic Acid  
5. Myristic Acid 
4. Myristoleic Acid  
5. Pentadecanoic Acid  
6. cis-10-Pentadecenoic  
9. Palmitic Acid 
8. Palmitoleic Acid  
11. Heptadecanoic Acid  
10. cis-10-Heptadecenoic Acid 
19. Stearic Acid  
17. Oleic Acid  
14 α-Linolenic Acid 
13.  Linoleic Acid 
15. Linolelaidic Acid  
16. γ-Linolenic Acid  
18. Elaidic Acid  
26. Arachidic Acid  
24 Eicosenoic Acid  
23. Eicosadienoic Acid 
22. Eicosatrienoic Acid  
25. Eicosatrienoic Acid  
20. Arachidonic Acid 
21. Eicosapentaenoic Acid 
27. Heneicosanoic Acid  
31. Behenic Acid  
30. Erucic Acid  
29. Docosadienoic Acid  
28. Docosahexaenoic Acid 
32. Tricosanoic Acid Methyl Ester (C23:0)  
34. Lignoceric Acid Methyl Ester 
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Figure 2.6 A GC-FID graph showing a profile of 37 component FAME mix on HP-5 using the Masood et al (2005) method. Key to the 
profile is shown on next page.  
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2.6 a) A GC-FID graph showing a profile of 37 component FAME mix on HP-5 using the  
Masood et al., (2005) method. 
 
 
Key  
3. Lauric Acid 
4. Tridecanoic Acid  
5. Myristic Acid  
6. Myristoleic Acid  
7. Pentadecanoic Acid  
8. cis-10-Pentadecenoic Acid  
10. Palmitic Acid  
9.  Palmitoleic Acid  
11. Heptadecanoic Acid  
12. cis-10-Heptadecenoic Acid  
19. Stearic Acid  
17. Oleic Acid  
13. Linoleic Acid  
14  α-Linolenic Acid 
15. Linolelaidic Acid  
16. γ-Linolenic Acid  
18. Elaidic Acid  
26. Arachidic Acid  
24. Eicosenoic Acid  
23. Eicosadienoic Acid  
22. Eicosatrienoic Acid 
25  Eicosatrienoic Acid  
32. Tricosanoic Acid  
33. Nervonic Acid  
34. Lignoceric Acid  
20. Arachidonic Acid  
21. Eicosapentaenoic Acid 
27. Heneicosanoic Acid  
31. Behenic Acid  
30. Erucic Acid  
29. Docosadienoic Acid  
28. Docosahexaenoic Acid  
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Figure 2.7 A GC-FID graph showing a profile of menhaden fish oil FAMEs on Omegawax 100 column (there were no comparable 
traces available from the manufacturers on HP-5 or related column).  
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Figure 2.8 A GC-FID graph showing a profile Menhaden fish oil FAMEs on HP-5 column using the modified method 
 
 
 
 
 
 
Key  
1. Myristic Acid                           
2. Palmitoleic Acid  
3. Palmitic Acid  
4. Linoleic Acid  
5. α-Linolenic Acid  
7.  Oleic Acid  
10. Stearic Acid  
12. Eicosapentaenoic Acid  
15. Docosahexaenoic Acid  
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Figure 2.9 A representative GC-FID graph showing a total fatty acid profile for PBMC on HP-5 column  
using Masood et al (2005) method. 
 
 
 
 
Key  
 
2. Myristic Acid  
3. Pentadecanoic Acid  
4. Palmitic Acid  
6. Heptadecanoic Acid 
5. Linoleic Acid  
7. α-Linolenic Acid  
 9. Oleic Acid  
11. Stearic Acid  
15. Arachidonic Acid  
16. Eicosapentaenoic Acid 
19. Docosahexaenoic Acid  
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Figure 2.10 A representative GC-FID graph showing a total fatty acid profile for PBMC on HP-5 column using the modified method.  
 
 
 
Key  
 
2. Myristic Acid  
3. Palmitic Acid  
5. Pentadecanoic Acid  
6. Heptadecanoic  
7. Linoleic Acid  
8. α-Linolenic Acid  
11. Oleic Acid  
13. Stearic Acid  
14. Arachidonic Acid  
15. Eicosapentaenoic Acid  
17. Docosahexaenoic Acid  
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2.6.9 Limitations of the modified method  
 
 
The modified method was fast and economical providing a reliable and accurate 
identification of the fatty acids. However, there were certain limitations that need to be 
highlighted. There was co-elution of some peaks and to address the issues of column 
temperature and operating conditions, the temperature programme was adjusted 
(Ackman, 1988, 2006). These modifications to the GC-FID parameters showed no 
improvement in peak co-elution and increased the retention time. The reference graph 
provided by the manufacturer (on Equity 1, a fused silica column) showed similar co-
elution of the C18/C20 fatty acids requiring manual integration of peaks (figure 2.4).The 
original aim of the study was to report relative ratios of EPA, DHA and AA, therefore the 
37- component FAME mix was considered a suitable standard. Due to limitation of co 
elution, although approximately 70% of peaks were identified (based on their retention 
times) it was not possible to measure the area under the curve for all of these fatty acids. 
Consequently, only selected fatty acids are reported and these include (saturated fatty 
acids – mysteric acid, pentadecanoic acid, palmitic acid, heptadecanoic acid and steric 
acid; monounsaturated fatty acids – plamitoleic acid and oleic acid; polyunsaturated fatty 
acids – LA, ALA, AA, EPA and DHA).  
 
Although the method produced reproducible results, it is important to evaluate the PBMC 
fatty acid composition in relation to other studies. Within literature, total PBMC total lipid 
composition is found to made up of palmitic acid (~20%), stearic acid (<20%), oleic acid 
(~15-20%) linoleic acid (~10%) and alpha linoleic acid (<1%) per 100% of fatty acids. In 
addition, high levels of AA (15-20%) and low levels of EPA (<1) and DHA (<3%) are 
usually found in PBMC total lipid composition (Damsgaard et al., 2008; Kew et al., 2004; 
Yaqoob et al., 2000). In this thesis, using the modified method the following composition 
was found for total PBMC lipid: palmitic acid (17%), stearic acid (7%), oleic acid (16%), 
linoleic acid (9%), AA (5%), EPA (1.6%) and DHA (0.8%). Since immune function cells 
have been demonstrated to have high levels of AA (~20%) these low levels measured in 
this study suggest a technical limitation of GC-FID method which could affect the 
interpretation of our results. In addition, docosapentanoic acid (DPA) is another n-3 PUFA 
which has been shown to be present in PBMC, however this fatty acid was not present in 
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the 37-component FAME mix or in any of the biological standards tested; consequently it 
was not possible to identify this fatty acid in our samples.  
 
Losses of long chain n-3 PUFA (EPA & DHA) due to high temperature (>180°C) of GC 
columns has been reported. This may result in a number of small minor peaks that 
separate from the main peaks and could account for the small peak area for DHA in our 
findings (Ackman., 1988, 2006; AOCS., 1997; Fournier et al., .2006). Similarly, there may 
be thermal degradation of AA methyl esters as AA is a long chain PUFA with 20 carbons. 
To overcome this issue of loss of PUFA in future, it may be possible to use empirical 
correction factors (chemical/instrumental deviations, determined by means of calibration 
with pools of standards/internal standard) which could then be adapted for accurate FAME 
analyses conducted at temperatures causing thermal losses (Ackman, 2006; Aued-
Pimentel et al., 2010). Despite the limitations of co-elution and lower recovery of long 
chain n-6 and n-3 PUFAs, the method demonstrated reproducibility and it was expected 
that similar analytical effect would be observed at baseline and after supplementation with 
EPA/DHA; therefore the findings of this thesis will be consistent across all phases of the 
study. However, the interpretation of fatty acid composition requires a great deal of caution 
when comparing it with other published studies. 
 
2.7 Measurement of circulating inflammatory cytokines by ELISA 
In chapter 3, 4 and 5, inflammatory cytokines including IL-6, TNF-α and IL-10 were 
measured in serum samples using the commercially available ELISA kits as described in 
the sections below. ELISA is a fundamental, validated technique used for the 
measurement of a wide range of cytokines in blood or urine samples. The method is based 
on the principle of antibody-antibody interaction. For sample preparation whole blood was 
collected in a serum tube (with no anti-coagulant) and allowed to coagulate for up to an 
hour. The tubes were centrifuged at 1300 x g for 10 minutes. Serum was separated and 
aliquots were made and stored at -20ºC until further analysis. To minimise the effect of 
inter-plate variation, all the samples from each individual collected at different time points 
of the study were analysed on the same ELISA plate. 
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2.7.1 Determination of serum TNF-α concentrations 
 
The TNF-α assay was used to determine the differences in serum TNF- α concentration 
between asthmatics and healthy individuals (chapter 3).  In the supplementation study, 
(Chapter 4/5) this method was used to measure circulating levels of serum TNF- α in 
phases of pre- and post-supplementation with Omega 3. The materials and reagents 
required for this kit are listed in appendix 1. Human TNF-α Quantikine ELISA Kit (cat. no # 
HSTA00D, R & D systems) and  ELISA MAX™ Deluxe Set (BioLegend, cat. no. 430204) 
were used for quantitative determination of TNF-α in the serum samples. The lowest 
detectable limit of the Quantikine ELISA kit was 0.106 pg/mL (range 0.11- 32 pg/mL) and 
the manufacturers guaranteed no cross-reactivity or interference in the assay. The 
recovery for the assay was suggested to be between 80-120%. The Biolegend kit was 
reported to provide a sensitivity of less than 2 pg/mL and was guaranteed to have no cross 
–reactivity or interference. The samples were run in duplicate on two plates for 
reproducibility and the intra-assay variation (CV%) was calculated as <10%, which was 
acceptable as per  manufacturers guidelines.  
Assay procedure  
 
Quantikine ELISA Kit: All reagents and samples were brought to room temperature 
before use. All samples, standards, and controls were assayed in duplicate to assess the 
reproducibility of the assay. All reagents, samples, and working standards were prepared 
as directed in the table shown in appendix 1. Assay diluent RD1F (50 µl) was added to 
each well followed by the addition of 200 µl of standard, sample, or control per well. The 
plate was covered with an adhesive tape and incubated for 3 hours at room temperature. 
All liquid from the wells was removed by aspirating or inverting the plate and decanting the 
contents. Excess liquid was removed by grasping the plate firmly and smartly tapping the 
inverted plate on a clean paper towel at least 5 times. Each well was filled with 400 µl of 
wash buffer using a squirt bottle. Liquid was removed from the wells by aspirating or 
inverting the plate and decanting the contents. The wash was repeated 5 times, for a total 
of 6 washes. After the last wash, the inverted plate was tapped on to a clean paper towel 
at least 10 times to remove excess wash buffer. TNF-α HS Conjugate (200 µl) was added 
to each well; the plate was covered and incubated for further 2 hours at room temperature. 
After incubation, the wash step was repeated. In the next step, 50 µl of Substrate Solution 
was added to each well and the plates were covered and incubated for 1 hour at room 
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temperature. The plate was not washed after this step. Finally, 50 µl of amplifier solution 
was added to each well, the plate was covered and incubated for 30 minutes at room 
temperature. This leads to colour development. At the end of incubation, 50 µl of Stop 
Solution was added to each well. The optical density of each well was measured with a 
microplate plate reader set at 490 nm within 30 minutes. Since wavelength correction was 
not available, readings were subtracted at 650 nm or 690 nm from the readings at 490 nm. 
This subtraction was undertaken to correct for optical imperfections in the plate. 
 
BioLegend’s ELISA MAX™ Deluxe Set:  This method required an overnight coating of 
the plate (96 well) with human TNF-α specific monoclonal antibody. Standards and 
samples were added to wells in the plate (100µl) the next day and TNF-α bound to the 
immobilized capture antibody. Next, a biotinylated anti-human TNF-α detection antibody 
(100µl) was added, producing an antibody-antigen-antibody “sandwich”. Avidin-
horseradish peroxidise (100µl) was  subsequently added, followed by TMB Substrate 
Solution, producing a blue colour in proportion to the concentration of TNF-α present in the 
sample. Finally, a stop solution was added which changed the colour from blue to yellow, 
and the microwell absorbance was read at 450 nm with a microplate reader.  
 
The two kits performed up to the recommended specifications provided by the 
manufacturers determined by a linear standard curve with correlation coefficient (r) r ≥ 
0.99 (for Quantikine ELISA Kit) and 0.98 (for BioLegend’s ELISA MAX™ Deluxe Set), 
respectively. When multiple plates were run, the standard curves were compared to 
assess intra assay variations. The BioLegend’s ELISA MAX™ Deluxe Set provided a good 
correlation for standard curves generated on different plates (r ≥ 0.95).  
 
2.7.2 Determination of serum IL-6 concentrations 
 
A Quantikine HS Human IL-6 Immunoassay (R &D systems, cat. No. HS600B) was used 
for determination of IL-6 levels in serum samples for distinguishing differences between 
asthmatics and controls (chapter 3).Human IL-6 High Sensitivity ELISA (Diaclone cat no. 
950 035 096) was used for assessing changes in levels following n-3 supplementation 
(chapter 4 and 5). The sensitivity of the Quantikine ELISA kit was 0.04 pg/mL (range 0.04-
10 pg/mL), and the manufacturers guaranteed no cross-reactivity or interference in the 
assay. The recovery for the assay was suggested to be between 80-120%. The sensitivity 
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of the Human IL-6 High Sensitivity ELISA (diaclone) was 0.8 pg/mL (range 0.8-50 pg/mL), 
and the manufacturers guaranteed no cross-reactivity or interference in the assay. The 
mean recovery for the assay was 115%.The samples were run in duplicate on two plates 
for reproducibility and the intra-assay variation (CV %) was calculated as 10%, which was 
acceptable as per manufacturer’s guidelines.  
Assay procedure  
 
Quantikine HS Human IL-6 Immunoassay: An antibody specific for IL-6 was pre-coated 
onto a microplate, standards and samples were subsequently pipetted into the wells and 
any non-specific IL-6 present was bound by the immobilised antibody. All reagents and 
samples were brought to room temperature before use. All samples, standards, and 
controls were assayed in duplicate to assess the reproducibility of the assay. All reagents 
and working standards were prepared as per the manufacturers guidelines. Assay Diluent 
-75 (100 µl) was added to each well followed by the addition of 100 µl of standard or 
sample per well. The plate was sealed with the adhesive strip provided and incubated for 2 
hours at room temperature on an orbital shaker (speed 4). All liquid was removed from the 
wells by inverting the plate and decanting the contents. Excess liquid was removed by 
grasping the plate firmly and smartly rapping the plate inverted on a clean paper towel at 
least 5 times. Each well was filled with 400 µl of Wash Buffer using a squirt bottle. Excess 
liquid from the wells was removed by inverting the plate and decanting the contents, a total 
of 6 washes were done and after the last wash, the inverted plate was rapped on a clean 
paper towel at least 10 times to remove excess wash Buffer. After the wash, 200µl of IL-6 
conjugate was added to each well. The plate was covered with a fresh adhesive seal and 
incubated for 2 hours at room temperature on the shaker. Washing was done 6 times as 
described earlier. Substrate solution (50µl) was added to each well; the plate was covered 
and incubated for 60 minutes at room temperature on the benchtop. After the incubation, 
50 µl of amplifier Solution was added to each well. The plate was covered and incubated 
for 30 minutes at room temperature on the benchtop. Addition of the amplifier Solution 
initiated colour development. Finally, 50 µl of stop solution was added to each well. 
Addition of stop solution did not affect colour in the wells. The optical density of each well 
was measured within 30 minutes using a microplate reader set to 490 nm. Since 
wavelength correction was not available, readings were subtracted at 650 nm or 690 nm 
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from the readings at 490 nm. This subtraction was done to correct for optical imperfections 
in the plate as per manufacturer’s guidance.  
 
Human IL-6 High Sensitivity ELISA (Diaclone):  An appropriate standard (100 µl) 
provided in the kit was added to the standard wells to create a standard curve. A 
monoclonal antibody specific for IL-6 was coated onto the wells of the microtiter strips 
provided. During the first incubation, IL-6 present in the sample or standard and a 
monoclonal IL-6 antibody conjugated to biotin were simultaneously incubated (50 µl of 
diluted biotinylated anti IL-6 and 100 µl of sample). Following incubation, unbound 
biotinylated anti-IL-6 was removed during a wash step. Streptavidin-HRP (100 µl) was 
added and bound to the biotinylated anti IL-6. After incubation and a wash step, a 
substrate solution reactive with HRP (100 µl) was added to the wells. A coloured product 
was formed in proportion to the amount of IL-6 present in the sample. The reaction was 
terminated by addition of stop solution and absorbance was measured at 450 nm.   
  
The two kits performed up to the recommended specifications provided by the 
manufacturers, determined by a linear standard curve with correlation coefficient (r) r ≥ 
0.99 for the two kits. When multiple plates were run, the standard curves were compared 
to assess intra assay variations. The Human IL-6 High Sensitivity ELISA (Diaclone) 
showed a good correlation between standard curves generated on different plates on the 
same day (r ≥ 0.90).  
 
2.7.3 Determination of serum IL-10 concentrations 
 
Human IL-10 ELISA MAX™ Deluxe Sets (cat. no. 430604, Biolegend UK) were used for 
assessing changes in serum IL-10 levels following n-3 supplementation (chapter 4 and 5). 
The sensitivity of the Quantikine ELISA kit was 0.04pg/mL, (range 0.04 - 10pg/mL) and the 
manufacturers guaranteed no cross-reactivity or interference in the assay.  
Assay procedure  
 
A human IL-10 specific monoclonal antibody was first coated on to a 96-well plate. 
Standards and samples (100µl) were added to the wells, and IL-10 bound to the 
immobilized capture antibody. Next, a biotinylated anti-human IL-10 detection antibody 
was added producing an antibody-antigen-antibody “sandwich”. Avidin-horseradish 
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peroxidase was subsequently added, followed by TMB Substrate Solution, producing a 
blue colour in proportion to the concentration of IL-10 present in the sample. Finally, a 
Stop Solution changed the reaction colour from blue to yellow, and the microwell 
absorbance was read at 450 nm with a microplate reader.  
 
The kits performed up to the recommended specifications provided by the manufacturers 
and determined by a linear standard curve with correlation coefficient (r) r ≥ 0.98. When 
multiple plates were run, the standard curves were compared to assess intra assay 
variations and the assay showed a good correlation between standard curves generated 
on different plates on the same day (r ≥ 0.90).  
 
 
2.8 Design for the supplementation studies   
 
For the omega 3 intervention study, a double blinded, randomised cross over study design 
was used (figure 2.11). Different study designs were considered, such as parallel study 
designs, randomised cross over studies with single blinding, and time point studies. In a 
cross over trial, each experimental participant receives two or more different treatments. 
The order in which each participant receives a treatment is dependent on the particular 
design chosen for the trial. For this study, a standard 2X2 crossover design was used as 
explained by Kenward & Jones (1996) who explain the advantages of comparing ‘within-
participant’ differences (each participant serves as their control and provides direct 
comparison of treatments). Within-participant difference was also considered for the 
comparison of two different treatment periods.  The cross over study design considers 
period differences when estimating the treatment difference, based on the fact that half of 
the participants received treatment in the order AB while the others received it in the order 
BA. The minimisation of the effect of any period and treatment differences within 
participants is an advantage of the cross over trials. 
 
To achieve the cross over design, each subject acted as their own control and underwent 
both of the supplementation phases. A power analysis was performed to approximate the 
appropriate sample size using pulmonary function as an outcome based on previous 
studies showing the effect of n-3 on pulmonary function in EIB subjects (Mickleborough et 
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al., 2003, 2006). Based on findings of Mickleborough et al., (2006), our study was 
designed to detect a minimum change of at least 0.3 litres in post exercise FEV1 when 
participants were supplemented with n-3 PUFA for 3 weeks. The significant level was set 
at alpha = 0.05 and the power at 0.80. A sample size of eight participants was appropriate 
to identify a difference of this magnitude. To allow for fluctuations in participant 
compliance, withdrawal and unsuitable data, the target sample size was set at 12 
participants. Considering the sample size was small, the participants were randomly 
allocated in minimisation scheme (Altman & Bland, 2005), whereby next allocation of 
supplementation capsules was dependent on the supplementation provided to the 
previous participant. This scheme of randomisation has been found to be appropriate to 
achieve balance between treatment groups.  
 
 
 
Figure 2.11 Crossover design used in the supplementation study 
 
The participants, investigator (I) and outcome assessors (supervisors), were blinded to the 
study. The randomisation patterns were only known to the technician in charge of 
randomisation. All participants entered the study on their normal diet (phase 1/baseline1), 
after which they were randomly allocated to receive soft gelatin capsules: either 10 
capsules per day of n-3 (3.2 gram EPA and 2.2 grams DHA, chapter 4) or Resolvin E1 
(100 mg Resolvinol and 0.5% Vitamin E, chapter 5), or a placebo (olive oil and 0.5% 
Vitamin E) [phase 2]. There was a 3-week washout phase following the first 
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supplementation (normal diet; phase 3, baseline 2). Thereafter, the participants switched 
over to alternate supplementation for the remaining 3 weeks (Phase4). The participants 
reported to the lab at the end of each phase and completed the physiological and 
biochemical tests.  
 
There were enough provisions in this method to ensure that whenever possible important 
comparisons of interest were estimated using the differences between the within-
participant measurements. This is contrasted with another popular ‘parallel study design’ 
where each participant would have received only one type of treatment and to evaluate the 
differences in measurements, between-participant comparisons would be required. ‘Wash-
out’ periods between the two periods were used to avoid ‘carry over’ effects. A 3-week 
‘washout’ period was used between the treatment periods for this study. This duration was 
based on previous results from a similar n-3 intervention study conducted by 
Mickleborough et al. (2003, 2006). The measurements at the washout were compared with 
the measures taken at the beginning of the treatments (baseline data), and will be 
considered during analysis to assess if the participants had returned to their original 
physiological and biochemical parameters.  
 
A ‘run-in’ period was used to familiarise the participants with procedures that they would 
follow during the study. The study was double-blinded, and a number of measurements 
were taken pre and post supplementation and during washout phases (figure 2.12). Each 
of the total five visits to the lab at each of the testing phases lasted for up to 2 hours. The 
measurements taken at each visit are described in the figure 2.12. These methods will be 
discussed in further detail in respective chapters for clarity. The n-3 and placebo capsules 
were received free of charge from Biocare and Bionovate. The details of the capsules are 
provided in table 2.6 as per manufacturers’ guidance. The capsules were made of gelatin 
and were not suitable for vegetarians or individuals allergic to fish or fish by-products. 
Subsequently participants in the supplementation study were made aware of the 
composition of capsules and were screened out if they were any dietary concerns.  
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Figure 2.12 Study visit design  
 
2.9 Statistical Analysis 
Data was analysed using statistical software (SPSS, version 19; SPSS; Chicago, IL). 
Unpaired two tailed t-tests at a 95% level of significance were carried out to compare 
differences between asthmatics and controls (chapter 3) using the different 
characterisation techniques (fixed cut off values and LLN). A frequency count was carried 
for dyspnoea assessment and a chi square test was conducted to compare the differences 
between the two groups.  
 
Analysis for n-3 and resolvin supplementation studies 
 
The double blinded, placebo controlled, and crossover trial was designed to assess the 
effects of 3 weeks of supplementation with n-3 (EPA/DHA) on post exercise FEV1 in EIB 
participants. A two-way repeated measures analysis of variance was used to analyse the 
data, with both treatment and time as “within-subject” effects. Mauchly’s test was 
conducted to determine whether sphericity was violated. In the cases where sphericity was 
violated, the repeated measures analysis of variance was corrected using the 
Greenhouse–Geiser correction factor.  
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Order effect was assessed by using the order as a variable during analysis. The 
relationship of oral contraceptive pill use with lung function improvements was assessed 
by using contraceptive pill usage as a variable for RM ANOVA. Student’s paired t-tests 
were conducted to compare the physiological and biochemical outcomes of the group 
using contraceptives and the group without it. 
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Chapter 3 
 
Classification of mild/moderate asthmatics 
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3 Classification of mild/moderate asthmatics 
 
3.1 Abstract 
 
Asthma is a reversible obstructive disease characterised by inflammation. Various 
guidelines suggest the use of fixed criteria and predicated equations derived from a 
reference population for the clinical diagnosis of asthma. The predicted equations are 
found to over or under-classify asthmatics due to factors such as stature, body mass, age 
and ethnicity; thus the measured values for pulmonary function provide a more reliable 
diagnosis. In addition, fixed ratios (80% ratio for FEV1/FVC) have limited reliability, as 
there can be poor diagnosis of borderline asthmatics (those with mild-moderate 
symptoms). A lower limit of normality (LLN) derived from a reference population has been 
suggested to be used alongside 80% ratio for diagnosis of asthma. Though there are no 
guidelines so far for the usage of LLN in clinical settings, the LLN criteria has been found 
to be specific and reliable for asthma diagnosis. In this study, 16 male asthmatic and 21 
healthy normal controls were recruited for pulmonary function testing, estimation of 
dyspnoea (symptoms) and measurement of venous blood based inflammatory mediators. 
Using the fixed criteria (80% ratio), the 16 asthmatics were demonstrated to have mild - 
moderate severity with all individuals showing a FEV1/FVC ratio to be below the 80% ratio. 
When the control population (FEV1/FVC = 89%) were used to calculate the LNN  then a 
value of 82% was indicated which meant that all 16 individuals previously characterised as 
asthmatics were confirmed as mild to moderate asthmatics with the newer approach to 
asthma characterisation. The asthmatics showed worse dyspnoea and significantly 
elevated levels for and IL-6 and TNF-α than controls. The characteristics of mild-moderate 
asthmatics including pulmonary function, dyspnoea and levels of inflammatory cytokines 
confirm airflow obstruction and increased inflammation in asthma. The LLN criteria for 
asthma characterisation is comparable with standard fixed criteria for young males with 
mild-moderate asthmatics. Therefore, LLN can be used alongside fixed criteria for reliable 
characterisation of asthma for this population. 
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3.2 Background 
 
The WHO estimates that respiratory diseases are the third major cause of mortality in the 
world and accounts for approximately 4.2 million deaths annually (WHO, 2010). Asthma is 
an obstructive respiratory disease characterised by airway obstruction. Other types of 
obstructive diseases include bronchiectasis, bronchitis and chronic obstructive pulmonary 
disease (COPD). Asthma is primarily characterised by acute eosinophilic and mast cell 
inflammation, mucus production and bronchoconstriction (Barnes, 2011; Bradding et al., 
2006; Jeffery, 2000). The presence or absence of irreversible airflow is a major distinction 
between asthma and COPD with asthma showing a reversible airflow feature (Bereznicki 
& Bereznicki, 2009; Cazzola et al, 2008). In clinical settings airway obstruction is routinely 
assessed by symptoms (dyspnoea) and pulmonary function tests (PFTs) with the use of a 
spirometer (ATS, 1999; GINA, 2012; Miller et al, 2005a; NHLBI, 2007). The main PFT 
parameters are FEV1, FVC, PEF, FEV1/FVC ratio and FEF25-75%; details regarding these 
parameters are described in chapter 1, page 11.   
 
3.2.1 Interpretation of pulmonary function results  
 
In clinical setup, the PFT results or the ‘measured data’ are interpreted based on 
comparison with a ‘reference or predicted value’ based on healthy participants. Predicted 
values must be obtained from data from ‘’normal’’ or ‘’healthy individuals’’ with ‘same’ 
anthropometric characteristics such as age, sex and height and where possible relevant 
ethnic characteristics of patients being tested (Pellegrino et al., 2005). The reference 
values are normally calculated with equations derived from measurements observed in 
matched or representative healthy volunteers from the general population. The ATS/ERS 
have included detailed guidelines on the strategies for interpretation of PFTs that have 
been widely used in the clinical and research settings (Miller et al., 2005a,b). The currently 
available electronic spirometers such as Superspiro (Micro Medical; Rochester, Kent, UK) 
are integrated with the choice of predicted values as per the ATS/ERS guidelines. This 
allows a very easy comparison of the ‘measured data’ with the ‘predicted values’.  
The ATS/ERS have issued specific recommendations for selecting predicting values to be 
used, and these include matching age-range, anthropometric, race/ethnic, socio-economic 
and environmental characteristics between subjects tested by the laboratory 
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and the reference population from which the prediction has been derived (Wanger et al., 
2005). A reference equation developed by Hankinson et al., (1999) is one of the widely 
used equations for predicted values and are specific for Caucasians, African-Americans, 
and Mexican-Americans (8 to 80 years of age, n = 7,429 asymptomatic, lifelong non-
smoking participants, derived from  the third National Health and Nutrition Examination 
Survey (NHANES III)). These reference values are specific for only three ethnicities; 
however, correction factors are available for other ethnicities.  
 
3.2.2 Limitations of the predicted values for mild-moderate asthma 
 
The ATS/ERS recommends the use of predicted values for characterisation of asthma 
severity with mild-moderate asthmatics 60-80% of predicted forced expiratory volume in 1 
sec/forced vital capacity (FEV1/ FVC) (Miller et al., 2005a, b). Values higher than 100% of 
predicted are sometimes seen in ‘healthy individuals’ and this may be due to dysanaptic 
growth or unequal growth of airways and lung parenchyma (Hyatt et al., 1986). This 
pattern is labelled as a potential ‘normal physiologic variant’ and is suggested as being not 
unusual among physically fit non-smoking individuals (Pellegrino et al., 2005). In a study 
by Mickleborough et al., (2006) recreationally active mild-moderate mixed group of young 
asthmatics with EIB showed predicted values in the range of 83 - 94% (mean = 90%). 
Stanford et al., (2006), reported mean predicted values of 104% (st dev = 3.9) in female 
athletes with atopic asthma. In another mixed group of mild-moderate elite athletes mean 
values of 92.4% (stdev = 3.6) was reported (Mickleborough et al., 2003). These high-
predicted values in mild-moderate asthmatics are because of difference in the 
anthropometric characteristics of the reference equations used for the calculation of 
predicted values.  
 
There are ethnic differences  in lung volumes however, these differences are not clearly 
established (Cotes, 1993; Yang et al., 1991). These differences could be due to factors 
such as differences in trunk length relative to stature; differences in fat-free mass, chest 
dimensions and strength of respiratory muscles. In the current predictive equations, 
correction factors for African Americans and Asians have been recommended (Pellegrino 
et al., 2005; Stocks & Quanjer, 1995), however due to lack of studies pertaining to 
relationships between ethnicity and lung volumes these corrections may not be accurate. 
The ATS/ERS guidelines recommend that the predicted values must be obtained from 
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‘’normal’’ or ‘’healthy individuals’’ with ‘same’ anthropometric characteristics such as age, 
sex and height and where relevant ethnic characteristics of patients being tested 
(Pellegrino et al., 2005).  However, it is not possible to have ‘same’ anthropometric and 
ethnic characteristics in a reference equation; therefore, predicted equations do not 
provide reliable values. 
 
As a result, it is more reliable to use the ‘measured values’ for FEV1/FVC instead of 
predicted values; subsequently, in this thesis, ‘measured values’ were used for 
asthma characterisation.  
 
3.2.3 Current diagnostic criteria for asthma  
 
Fixed criteria (80% ratio) 
The current diagnostic ATS/ERS guidelines for asthma use a fixed criteria based on 80% 
FEV1/FVC ratio; any individuals below the 80% ratio are characterised as asthmatics 
(Pellegrino et al., 2005). For this thesis the 80% FEV1/FVC ratio will be used to 
characterise asthmatics and this will be referred as ‘80% ratio’.  
 
There are other criteria for asthma characterisation that include Global Initiative for Asthma 
(GINA) criteria which states that the normal FEV1/FVC ratio is 75-80% in adults and lower 
values are indicative of airflow obstruction (GINA, 2011). In several studies, fixed criteria 
(70% FEV1/FVC) suggested by the guidelines from the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) have also been applied to asthmatic subjects (Roberts 
et al., 2006; Vollmer et al., 2009).  In the USA, UK and the rest of Europe, ATS/ERS 80% 
ratio is widely used for diagnosis/characterisation of asthma, however; the validity of this 
80% ratio in determining airway obstruction is questioned. Cerveri and co-workers 
evaluated the pulmonary function characteristics and longitudinal outcomes of subjects 
aged 20–44 years from in the European Community Respiratory Health Survey dataset 
(ECRHS, n=6249) and found that an 80% ratio overestimates and conversely fixed criteria 
(70%) underestimates airflow obstruction in young adults (Cerveri et al., 2008). The use of 
these generalised fixed criteria have been acknowledged as source of misinterpretations 
and over/under diagnosis of asthma in different age groups (Hansen et al., 2007; Roberts 
et al., 2006; Swanney et al., 2008).  
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Lower limit of normality (LLN) criteria for asthma classification  
 
The ATS/ERS have acknowledged these issues and have issued position statements for 
the use of a different characterisation approach using a ‘lower limit of normal’ (LLN) which 
is a value for a diagnostic value for the FEV1/FVC ratio, derived from a matched healthy 
population (Miller et al., 2011; Pellegrino et al., 2005).  A given PFT is said to be 
abnormal when the measured value is below the lower limit of normality (LLN), 
defined as 1.645 standard deviations FEV1/FVC ratio (Miller et al., 2009).  
3.2.4 Fixed vs. LLN criteria 
 
The sensitivity and specificity of fixed criteria have been calculated for ECRHS data set 
using the LLN as the gold standard for defining airflow obstruction (Cerveri et al., 2009). 
The authors suggest that a fixed criteria (70%) demonstrates low sensitivity and specificity 
compared to 75% criteria (100.0% sensitivity and 92.4% specificity), while 80% ratio 
provides 100% sensitivity but 58% specificity in males and similar patterns are observed in 
females. Though the importance of using LLN alongside fixed criteria, especially in the 
extremes of a population (i.e. age, stature) has been identified, there is currently no 
consensus on the use of LLN for diagnosing obstructive diseases (Celli et al., 2003; 
Margolis et al., 1997; Miller et al., 2009). In addition, different sub groups of asthma such 
as mild-moderate/EIB show variability in symptom presentation; subsequently 
classification based on fixed criteria may lack sensitivity and under classify these 
individuals. In the absence of asthma diagnosis, these sub groups of asthmatics may 
experience loss in the quality of life. For example, the DH recommends physical activity 
across the population (DH, 2011); in the absence of timely asthma diagnosis and relevant 
treatment, those susceptible to EIB (EIB-prone) will not be able to engage in physical 
activity  
 
The use of LLN alongside the 80% ratio has the potential to overcome these issues, 
however the LLN is dependent on a comparable control population (matched for age, sex 
and ethnicity) to achieve specificity and sensitivity. This is a limiting factor for the 
application of LLN in diagnostic purposes and so far, the LLN criteria has only been used 
for research purposes. Thus, application of LLN is complicated in a clinical sector to 
quickly interpret if a patient’s results are abnormal, however LLN has been widely applied 
in research for characterisation of asthma (Mannino, 2008; Miller et al., 2009).  
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In view of these arguments, this study classified asthmatics based on both, the 80% 
ratio and LLN.  
3.2.5 Airway inflammation in asthma 
 
Airway inflammation is a persistent feature in asthma pathophysiology and involves a 
number of inflammatory cells and their products; details on the pathophysiology of asthma 
are discussed in detail the literature review, chapter 1, page 15. A range of LTs (LTC4, 
LTD4 and LTE4)  are potent vasocontstrictors of human airways; these mediators affect 
microvascular and bronchial dilation, increase AHR and have been implicated in the 
pathogenesis of asthma (Barnes et al., 2006; Broughton et al., 1997; De Caterina & Basta, 
2001). The 2 series PGs and 4 series LTs derived from AA (20:4, n-6) exert strong effects 
on airway function and increase airway inflammation (Barnes, 2008; Bloemen et al., 2007; 
Matsuoka et al., 2000; Ricciotti & FitzGerald, 2011; Swedin et al., 2009). In contrast, the 3 
series PGS and TXs and 5 series LTs derived from EPA (20: 5, n-3) have a reduced 
biological activity (Bagga et al., 2003; Calder, 2010a; Robinson & Stone, 2006). The 
reduced biological potency of EPA generated eicosanoids is because the eicosanoid 
receptors typically have a lower affinity to EPA derived mediators than those generated by 
AA (Tull et al., 2009; Wada et al., 2007). Overall the n-3 PUFA can exhibit a range of anti-
inflammatory and pro-resolution effects and these are discussed in chapter 1 (page 28).  
 
While inflammatory mediators such as LTs and histamine are suggested to be involved in 
acute and sub-acute inflammatory responses and in exacerbations, cytokines are 
important in maintaining chronic inflammation in allergic diseases. Many inflammatory cells 
(macrophages, mast cells, eosinophils and peripheral blood mononuclear cells, PBMC) 
have the ability to synthesise and these cytokines. Th1 derived cytokines  including  
interleukin-2 (IL-2) and interferon-γ (IFN-γ), induce macrophage activation and are very 
effective in controlling infection with intracellular pathogens (Holgate., 2009; Bloemen et 
al., 2007). Th2 cells secrete IL-4, IL-5, IL-6, IL-9 and IL-13 as primary cytokines and also 
help B cells in producing antibodies. Other cytokines such as IL-1ß, TNF-α and GM-CSF 
are released from different types of cells (e.g. macrophages and epithelial cells), and are 
considered important in increasing the inflammatory response, and prolong eosinophil 
survival in airways. TNF-α can cause an increase of histamine in allergic asthma causing 
vasoconstriction by secondary production of endothelin-1 (a peptide mediator) (Barnes, 
2011; Chalmers et al., 1997, Goldie & Henry, 1999). An increase in the activity of Th2 cells 
Chapter 3: Mild-moderate asthmatics                                                            A Kumar  
 125 
in asthma may be due to the reduction in regulatory T cells, which normally inhibit Th2 
cells and increase in the natural killer (NK) T cells (Akbari et al., 2006; Larche et al., 2003). 
In this thesis the differences in the levels of inflammatory cytokines (IL-6 and TNF-α) will 
be measured in asthmatics and controls 
3.2.6 Aims and hypothesis  
 
The aim of this chapter was to characterise mild-moderate asthmatics based on 80% 
ratio and then separately characterise the same individuals using the lower limit of 
normality (LLN) from a control population.  
 
Once the asthmatic population was identified, it was hypothesised that there would be a 
statistical difference between the dyspnoea score and circulating levels of inflammatory 
cytokines (IL-6 and TNF-α) of asthmatics and controls.  
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3.3 Methods 
This section gives a brief description of the methods used in this study, for details refer to 
chapter 2.  
 
3.3.1 Study protocol  
 
The study was approved by Loughborough University’s ethics committee; generic 
protocols were used for venepuncture (G03-P8) and specific protocols were used for 
pulmonary function testing (GO9-P8). The study was advertised in accordance with the 
University’s policies through flyers, emails, meetings, presentations and personal contact. 
All participants gave full written consent for the study. Asthmatic and control participants 
were recruited based on previous clinical diagnoses and history of asthma (figure 3.1).  
Participants visited the laboratory on one occasion, lasting up to 1-2 hours, where they 
were briefed on the study procedure and were given an opportunity to familiarise 
themselves with the testing procedures; specifically spirometry. Anthropometric 
measurements (stature and body mass) were collected.  Spirometry was conducted in 
accordance with ATS/ERS guidelines (Miller et al., 2005a,b). Venous blood was drawn 
from the antecubital vein for the analysis of inflammatory markers (IL-6 and TNF-α). 
 
 
 
Figure 3.1 Study design to compare the validity of fixed cut off values and LLN 
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3.3.2 Participants  
 
Thirty one males were recruited from Loughborough University and the local community. 
All participants in the asthmatic group had previously been clinically diagnosed as 
asthmatic and a history of shortness of breath, chest tightness and wheezing at some time 
on a weekly basis. The asthmatics had prescribed medication (n= 3 on bronchodilator and 
preventative; n=13 on bronchodilator only); there were 5 asthmatics out of the 13 (on 
bronchodilators) who were not regularly using their prescribed medication. Bronchodilator 
use was reported and testing was rescheduled if inhaler medication was used within the 
48 hours preceding the testing. Additionally, the recruitment was completed within a short 
3-month period to avoid the effect of seasonal variation. For the inclusion criteria, 
participants were recruited if they were between 18-30 years, had not taken any 
medication. The study design was such that an age range of 18-30 years was chosen to 
maintain consistent pulmonary function tests keeping in view maturation and ageing of 
lungs. Maturation of lungs is reached by 18 years and ageing of lungs begins after 30 
years of age (Sharma & Goodwin, 2006). Participants were excluded if they had any 
respiratory infection within the past 8 weeks. The controls were healthy volunteers with no 
history of asthma and the two groups of participants demonstrated matching demographic 
and anthropometric characteristics. Participants were asked to refrain from coffee/alcohol 
and physical exercise 8 hours prior to testing to avoid any misinterpretation of the results 
(Rundell & Sue, 2010). Recruitment flyers and participant information sheets are attached 
in appendix 1.  
 
3.3.3 Pulmonary function tests (PFTs) 
 
Spirometry was performed by all participants in a seated position using a calibrated 
computerised spirometer (Superspiro; Micro Medical; Rochester, Kent, UK) following 
ATS/ERS guidelines (Miller et al., 2005a,b). Participants were required to perform three 
acceptable FVC manoeuvres with no greater than 5% variation for reproducibility and 
details of the technique are provided in chapter 2 (page 70). FEV1 is an important 
pulmonary function value that is critically significant in the diagnosis of obstructive and 
restrictive diseases such as asthma, similarly PEF is a useful measure to assess the full 
potential of lungs. FEF 25-75% is an important measurement of airway function that 
describes the amount of air expelled from the lungs during the middle half of the FVC test. 
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Asthmatics have a reduced FEV1, PEF and FEF 25-75% due to airflow obstruction 
because of inflammation, mucus and bronchoconstriction. The parameters recorded in this 
study were FEV1, FVC, PEF and FEF 25-75%.   
 Characterisation based on 80% ratio  
 
According to established guidelines for asthma severity, a fixed criteria of ≤ 80% for 
FEV1/FVC ratio is representative of mild-moderate airflow obstruction (Miller et al., 
2005a,b). Consequently, a fixed criterion of ≤ 80% was chosen in this study to characterise 
asthmatics. Any participants who exhibited an FEV1/FVC ratio > 80% were characterised 
as controls.   
 Characterisation based on LLN 
 
To confirm the characterisation with fixed criteria, a LLN was calculated from the 
measured values (litres) for FEV1/FVC ratio of the control population based on ATS/ERS 
suggestions. All participants in the study groups were between 18-30 years of age; 
subsequently the calculated LLN was age specific representing age group of 18-30 years. 
The standard deviation of the FEV1/FVC ratio of the control group was used in the 
calculation of LLN to identify the 5% of the ‘‘normal’’ subjects with the lowest values in the 
control  population (Pellegrino et al., 2005). The equation used is shown below:  
 
 
 
 
3.3.4 Dyspnoea 
 
A Borg analogue scale was used by the participants to report symptoms before a PFT. 
The participants selected a number from 0-10 to report their perception of breathlessness 
(dyspnoea) at that time. A frequency count was carried out to compare dyspnoea between 
the asthmatics and controls.  
 
 
 
 
 
LLN = (FEV1/FVC) ─ 1.645*standard deviation of the control population                                                                                                             
……............equation 2  
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3.3.5 Cytokine measurement 
 
Cytokine levels in serum were measured using Standard ELISA techniques as described 
in chapter 2, page 106. IL-6 and TNF-α were determined using high-sensitivity ELISA (R& 
D Systems Europe Ltd, Abingdon, U.K., catalogue number HS600B and HSTA00D). 
Whole blood was collected in a serum tube and allowed to coagulate for up to an hour 
following which the tubes were centrifuged at 1300 x g for 10 minutes. Serum was 
separated and aliquots were made and stored at -20ºC until further analysis.  
  
3.3.6 Data analysis 
 
Differences between asthmatics and controls were analysed using unpaired two-tailed t-
tests at a significance level of p<0.05 with equal variances assumed (Levine’s test). All 
statistical analysis was undertaken using SPSS version 19.0 (SPSS Inc.; Chicago, IL). A 
chi-squared test was used to assess the difference in reported dyspnoea score between 
asthmatics and controls at significance level of p<0.05.   
.  
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3.4 Results  
The following section presents the main findings from this study. All results are reported as 
mean ± SEM unless stated otherwise.  
 
3.4.1 Descriptive statistics  
 
There was no difference between the asthmatics and controls in terms of age, stature, 
body mass, or BMI (table 3.1). The PFTs showed significant differences in lung function 
between the two groups. The asthmatics showed significantly lower values for FEV1 
(asthmatics = 3.79 ± 0.16 litres, controls = 4.45 ± 0.11 litres, p <0.05), PEF (asthmatics = 
533 ± 13 litres/min, controls = 575 ± 8 litres/min; p=0.06) and FEF 25-75% (asthmatics = 
4.18 ± 0.15 l/sec, controls = 4.61 ± 0.10 l/sec) than controls. The asthmatics also showed 
a lower FEV1/FVC ratio compared to controls (asthmatics = 71.23 ± 1.17%; controls = 
88.74 ± 0.95%).  FVC represents the vital capability of the lungs and as expected there 
were no significant differences in FVC for the two groups (asthmatics = 5.32 ± 0.20 litres, 
controls = 5.02 ±  0.14 litres; p=0.21). These data demonstrate that the study population 
comprised of individuals matched for age and body size with significant differences in 
pulmonary function. The results clearly indicate the presence of airway obstruction in 
asthmatics. 
 
Table 3.1 Participant characteristics  
 
 Controls (n=21)         Asthmatics (n=16) 
Age (years) 21.67  ±  1.68 25.81 ± 1.07 
Stature (metres) 1.78  ±  0.02 1.76 ± 0.02 
Body mass (kg) 74.92  ±  2.02 75.81 ± 1.78 
BMI (kg/m2) 23.64  ±  0.50 24.56 ± 0.38 
FEV1 (litres) 4.45  ±  0.11 3.79 ± 0.16 * 
FVC (litres) 5.02  ±  0.14 5.32 ± 0.20 
PEF (l/min) 575  ±  8 533 ± 13 * 
FEV1/FVC 88.74  ±  0.95 71.23  ± 1.17* 
FEF25-75%(l/sec) 4.61  ±  0.10 4.18  ±  0.15* 
 *statistically significant difference (p<0.05) 
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3.4.2 Justification for excluding predicted values for FEV1/FVC ratio from the 
analysis 
 
The mean predicted values of FEV1/FVC ratio for controls was 106 (range 100 – 120) 
Values higher than 100% of predicted are sometimes seen in ‘healthy individuals’ and this 
may be due to dysanaptic growth or unequal growth of airways and lung parenchyma 
(Hyatt et al., 1986).  This pattern is labelled as a potential ‘normal physiologic variant’’ and 
is suggested as being not unusual among physically fit non-smoking individuals (Pellegrino 
et al., 2005). Since the study population in this thesis comprised of young healthy 
individuals with mild-moderate asthma, higher predicted values than 100%, subsequently, 
under-classification can occur based on fixed criteria that have proven issues of under 
diagnosis in young adults. Thus, higher predicted values in the study population 
comprising of healthy males (106% for controls and 86% for asthmatics) was considered 
unreliable for analysis in this thesis, which could cause under diagnosis of asthma. 
Therefore, measured values were used for further characterisation and analysis  
 
3.4.3 Characterisation based on 80% ratio 
 
Using a fixed ratio, 21 participants were characterised to have a normal pulmonary 
function with a FEV1/FVC ratio of >80 and constituted the control group (mean = 88.74 ± 
0.95).  A total of 16 participants showed ≤80% FEV1/FVC ratio (mean = 71.23 ± 1.17%). 
The two groups were statistically different with asthmatics having a lower mean value of 
FEV1/FVC ratio (p<0.05, figure 3.2). As expected, the asthmatics showed significantly 
lower FEV1, PEF and FEF 25-75% as shown in table 3.1. 
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Figure 3.2 Graph showing differences in a FEV1/FVC ratio of asthmatics and controls based 
on the fixed criteria of 80% 
* Statistically significant difference in asthmatics compared to controls (p<0.05) 
 
3.4.4 Characterisation based on LLN criteria 
 
When the control population (FEV1/FVC ratio = 88.74  ±  0.95) were used to calculate the 
LNN  then a value of 82% was indicated which meant that all 16 individuals previously 
characterised as asthmatics were confirmed as mild to moderate asthmatics with the LLN 
criteria for  asthma characterisation. The calculated LLN was specific to a 18-30 year age 
group and was derived from the control population comprising of healthy individuals with 
no history of asthma (n = 21).  
 
The FEV1/FVC ratio of all the participants previously characterised by fixed criteria were 
below the LLN of 82% (mean = 71% range 65-80%). Therefore all asthmatics within the 
age group of 18-30 years previously characterised by fixed criteria were confirmed as 
asthmatics as their FEV1/FVC ratio fell below the LLN criteria (n=16).  
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3.4.5 Dyspnoea score  
 
The distribution of the dyspnoea score for the two groups on the day of testing, prior to the 
PFTs is shown in figure 3.3. There were 57% participants in the control group with a score 
of 0 suggesting no breathlessness compared to only 6% asthmatics reporting the 0 score. 
There were 33% of controls reporting very very slight breathless compared to 25% of 
asthmatics (score = 0.5). While 10% of controls reported very slight breathlessness, there 
were 19% of asthmatics reporting the same score (score =1). There were 44% of 
asthmatics with slight breathlessness (score =2) and 6% with moderate breathlessness 
(score = 3). None of the control participants reported scores greater than 1. The most 
frequently reported score for asthmatics was 2 representing slight breathless while the 
most frequent score for controls was 0 representing no breathlessness. Score of  2 and 3 
were combined for analysis as only 12% of the  expected values fell within these ranges, 
based on the chi square analysis there was a significant difference between the dyspnoea 
scores of the two groups (χ² = 18, df = 3, p < 0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Pie chart showing the frequency of dyspnoea score for the two groups, the 
numbers inside the chart represents the percentage of participants showing a score. 
 
 
 
 
Frequency of dyspnoea score (%) 
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3.4.6 Serum cytokine levels  
 
As expected, the asthmatics showed a significantly higher level for IL-6 (mean = 1.66 ± 
0.08 pg/mL) than controls (mean = 1.38 ± 0.06 pg/mL) (p<0.05). Similarly asthmatics had 
elevated levels for TNF-α than controls (asthmatics, mean = 4.28 ± 0.25pg/mL, controls, 
mean = 3.35 ± 0.26) (<0.05). Mean data is displayed in figure 3.4. 
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Figure 3.4 Differences in serum cytokine levels for asthmatics and controls based on the 
fixed cut off value of 80%; respectively  
* statistically significant difference between controls and asthmatics (p<0.05)  
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3.5 Discussion  
Asthma is an obstructive lung disease that is routinely assessed by symptoms (dyspnoea) 
and pulmonary function tests. Fixed criteria (80% ratio) are conventionally used in the 
clinical set up for diagnosis of asthma. Mild-moderate asthma and EIB are subtypes of 
asthma that represents a large proportion of asthmatics. EIB affects approximately 90% of 
asthmatics and 10% of healthy population. The public health guidelines from Department 
of Health (UK) acknowledge the relationship between lack of physical activity and chronic 
diseases including asthma; consequently physical activity is encouraged across the 
population. Accurate and timely diagnosis of asthma and other respiratory diseases are 
vital to ensure appropriate therapies are provided. Symptoms and PFTs alone do not 
provide a correct diagnosis of the varied and complex respiratory conditions such as mild-
moderate asthma and EIB. Furthermore, there are issues of non-specificity associated 
with 80% ratio and ATS/ERS have issued position statements to address this. Most 
recently, LLN derived from a control population had been suggested as an ‘alternative 
criteria’ to be used alongside 80% ratio for assessment for respiratory diseases (Miller et 
al., 2009; Pellegrino et al., 2005). A LLN can be derived from a matched control population 
that allows for a reliable diagnosis of asthma. In this study mild-moderate asthmatics were 
characterised by an 80% ratio with asthmatics showing a significantly lower  FEV1/FVC 
ratio (mean = 71% , range: 65-80%) than controls. In addition, asthmatics showed lower 
PEF, FEV1 and FEF 25-75% which confirmed airflow obstruction. A LLN was derived using 
the control population included in this study and was specific for 18-30 year old males. All 
the participants in this study were recruited in a short 3 month period to avoid the effect of 
seasonal variation. In this study, the 16 asthmatics classified using 80% ratio were 
confirmed by LLN and this suggests that both, the fixed criteria and the LLN provide 
comparable diagnosis of mild-moderate asthma. 
 
To address the limitations of predicted values derived from reference population, these 
values were excluded from analysis and only measured values were used. In this study 
though the 16 asthmatics classified using fixed criteria were confirmed by LLN, a number 
of studies have shown under or over diagnosis based on fixed criteria. Since the predicted 
FEV1/FVC ratios are derived from reference population (comprising of healthy individuals) 
and is dependent on stature and age, subsequently the validity of the fixed criteria has 
been questioned (Cerveri et al., 2009; Miller et al., 2009; Roberts et al.2006). Mild-
moderate asthmatics have been suggested to have a predicted FEV1/FVC ratio of 61-69% 
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(moderate asthma) and >70% (mild asthma). Since predicted values are dependent on 
age and stature, there is a likelihood that underestimation of airway obstruction can occur 
for young adults (18-30 years) when using a fixed criteria based on predicted values 
(Cerveri et al., 2009). Based on these issues, predicted equations were not measured in 
our study.  
 
If the dyspnoea scores recorded in this study were matched  to the FEV1/FVC ratio, 
individuals with a poor FEV1/FVC ratio (<70%) show worst symptoms and lower PEF (518 
l/min) than those who have a relatively better FEV1/FVC ratio (>72%, PEF = 558l/min). 
This suggests that possible mischaracterisation could occur if fixed criteria were used 
using the GOLD fixed criteria (70%). Participants with FEV1/FVC ratio (72-80%) 
representing mild asthma may not be accurately classified as the symptoms of these 
participants are minimal, subsequently there is a likelihood of “under called” obstruction 
leading to false negatives. This pattern is in line with the findings that suggest an 80% ratio 
overestimates and conversely fixed criteria (70%) underestimates airflow obstruction in 
young adults (Cerveri et al., 2008). Additionally, Hansen and co-workers have shown using 
a GOLD fixed criteria (70%) results in high prevalence of airway obstruction in older adults 
(>70 years of age). The authors have demonstrated that the fixed criteria has a strong 
negative age dependency, and the frequently used fixed criteria (70%) may not be attained 
till 50 years of age in males and later in females (Hansen et al., 2007). This suggests that 
airway obstruction in younger adults may be missed if a fixed criteria (70%) is used. In our 
study, the mean FEV1/FVC ratio of the asthmatic group was 71.23 ± 1.17% and had the 
GOLD criteria been used, a number of individuals would have been under characterised.  
 
Similarly, for other obstructive diseases such as COPD, Miller and co-workers., (2011) 
have reported significant discrepancy rates in PFT interpretation between the fixed criteria 
(70%) and LLN methods in populations from the UK, New Zealand, and the USA (Miller et 
al., 2011). Approximately 24% of the older participants from these countries were 
misclassified and the analysis showed that about 10% of younger patients with normal 
lung function were falsely characterised for airway obstruction and were subsequently 
included in the disease category. Therefore, there are proven risks of over diagnosis in 
younger adults using fixed criteria values and the ATS/ERS statements (Miler et al., 2009) 
have acknowledged these issues; it is likely that future guidelines will address this topic. 
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Thus, use of these generalised fixed criteria has been rightly identified to cause 
misinterpretations and over/under diagnosis of asthma in different age groups.  
 
To evaluate the discrepancies related to predicted values, the LLN from this study can be 
compared with similar studies. The LLN derived from predicted equations have varied 
widely between studies but consistently dropped with age. In an analysis based on 57 
studies on healthy males and females worldwide between the ages 20-80 years, the LLN 
has been found to be lower than 70% at various ages in a number of studies (Swanney et 
al., 2008).  In addition, for younger age group (20-30 years) the LLN was found in the 
range of approximately 68 - 87% (Swanney et al., 2008). In another study, Cerveri and co-
workers calculated a LLN of approximately 76% for males aged 20-30 years from a large 
European cohort using very rigid inclusion criteria for obstructive lung diseases, smoking 
history, breathlessness, cough and wheeze (Cerveri et al., 2008). This clearly 
demonstrates the variation in LLN across different studies for the same age group. These 
differences could be attributed due to the heterogeneity in height, sex and ethnicity in the 
‘predicted equations’ used in different studies (Collen et al., 2008; Miler et al., 2011).  
 
Based on the discrepancies in asthma characterisation, symptoms and spirometry are not 
sufficient to appropriately diagnose different sub types of asthma, thus additional markers 
of airway inflammation and symptoms can support the diagnosis of asthma. Asthma is now 
characterised to exhibit localised as well as systemic inflammation. The strength of our 
study was that both the 80% ratio and LLN were used to characterise asthmatics, in 
addition, the circulating levels of inflammatory cytokines were measured and asthmatics 
showed elevated levels of inflammatory cytokines (TNF-α, and IL-6) than controls (IL-6, 
asthmatics = 1.66 ± 0.08 pg/mL; controls = 1.38 ± 0.06 pg/mL; TNF-α (asthmatics = 4.28 ± 
0.25pg/mL, controls = 3.35 ± 0.26). These values demonstrate that asthmatics have a 
higher level of inflammation, which underlines the pathophysiology of asthma.  
 
In a recent study by Subrrahmanyam et al., (2011), levels of inflammatory cytokines 
including IL-6 and TNF-α were compared in atopic and non-atopic adult asthmatics; the 
non-atopic asthmatics showed serum levels of 0.81 ± 0.47pg/mL and 5.16-± 4.40pg/mL for 
IL-6 and TNF-α respectively. In another case control study asthmatics have been shown to 
have approximately 7 fold higher value for serum IL-6 than controls (asthmatics =15.49 ± 
1.65pg/ml, controls = 2.10 ± 0.45pg/ml) (Canöz et al., 2008). In our study, the observed 
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value for IL-6 and TNF-α is representative of normal healthy participants when compared 
to other studies. Kim et al., (2011) have reported values of 2.91 ± 6.45 pg/mL and 3.21 ± 
4.04 pg/mL for IL-6 and TNF-α respectively in healthy males (<45 years), which is 
comparable to the values measured to our study. For TNF-α, a recent study comparing the 
levels in asthma and controls have shown a slightly elevated level in asthmatics 
(asthmatics = 5.7(4-8) pg/mL, controls = 4.9(4-8) pg/mL) (Pukelsheim et al., 2010). 
Another study evaluating the role of airway hyperreactivity has reported values of 4.12 ± 
0.43pg/mL in asthmatics (Halasz et al., 2002). Therefore, the values measured in this 
study represent normal values for mild-moderate asthmatics that have been reported 
within the literature.   
 
Depending on the severity of asthma, differences in the levels of these circulating markers 
have been observed. In COPD, asthmatics have shown to have serum IL-6 and TNF-α 
values in the range of 1.77-11.26 pg/mL and 3.62 - 7.84 pg/mL respectively and this was 
found to be dependent upon the stage of COPD (Samy et al., 2010). Similarly for lung 
cancer risk, a case–control study within the prospective Prostate, Lung, Colorectal, and 
Ovarian (PLCO) Cancer Screening trial reported serum IL-6  levels of 3.7 pg/mL(2.3-
7.2pg/mL) in asthmatics and suggested an association between elevated serum IL-6 levels 
and  lung cancer (Pine et al., 2011). Several reports have shown that elevated IL-6 levels 
are found in plasma, bronchoalveolar lavage, and lung epithelial cells of asthmatics (Kicic 
et al., 2006; Marini et al., 1992; Neveu et al., 2010). There is some evidence from severe 
and mild-moderate asthmatics that there is an inverse association between induced 
sputum IL-6 levels and pulmonary function outcomes including FEV1/FVC ratio or PEF 
(Dixon et al., 2006,2008; Neveu et al., 2010), however further studies are required to 
assess to confirm associations between circulating levels of inflammatory cytokines and 
pulmonary function outcomes. Thus, measurement of inflammatory cytokines may be 
important measures for assessment of asthma severity and could be conducted parallel 
with physiological assessment (dyspnoea and spirometry). Though systemic markers have 
gained interest in present times there are limitations which need to be addressed. These 
systemic markers may provide the information about the general inflammatory state; 
however more specific localised markers derived from localised cells and tissues (such as 
alveolar macrophages) provide a detail insight into any structural and functional 
abnormities of the pulmonary system. However in non-clinical research setting, access to 
airway cells and tissues may be limited, subsequently systemic markers can be 
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considered. Besides, circulating biomarkers are associated with asthma onset and are 
considered good candidates as predictors for rapid decline of FEV1 in obstructive lung 
diseases (Pukelsheim et al 2010; Samy et al., 2010); subsequently monitoring changes in 
the cytokine levels during intervention trials can be considered a useful indicator of 
response to treatment. Recently indirect estimation of inflammation in the lung via exhaled 
breath nitric oxide (FeNO) has been suggested to be used for characterising asthma 
(ATS/ERS, 2005; Dweik et al., 2011; Zitt et al., 2005). This measurement can now be 
conducted by using a portable device in clinical settings or in patient’s home and has been 
shown to be accurate for monitoring changes to therapy (Chen et al., 2007; Kim et al., 
2012). If this study was repeated then FeNO measurements could be obtained to 
characterise mild-moderate asthmatics and distinguish them from the healthy non-
asthmatics. FeNO measurements were conducted in the supplementation studies 
presented in this thesis (chapter 4 and 5) to evaluate the changes related to inflammation.  
 
Currently the clinical application of the LLN criteria is limited for diagnosis as there are no 
guidelines provided by the regulatory authorities such at ATS/ERS, BTS and GOLD (Miller 
et al., 2009).  However, the application of LLN is widely recognised and applied in 
research settings. When LLN are used along with standard reference equations for 
predicted values, there is a much reliable diagnosis of airway obstruction. The strength of 
this study was a characterisation of the asthmatics based on 80% ratio and LLN derived 
from a healthy control population (matched for age). In addition, this characterisation 
included participants aged 18-30 years to allow for an age specific characterisation. This 
study has formed the basis of classification for the next chapter in this thesis (chapter 4) 
which was aimed to assess the effect of n-3 supplementation in mild to moderate EIB - 
prone asthmatic males. The LLN derived from the population of healthy males in our study 
can only be used for assessment of airflow obstruction in males and cannot be applied to 
females due to differences in stature and physiology (chapter 5).  
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3.6 Conclusions  
 
Both the 80% ratio and LLN criteria were found to be comparable methods for assessing 
airflow obstruction in young adults with mild-moderate asthma. Therefore, LLN can be 
used alongside fixed criteria for reliable characterisation of asthma for this population. To 
support the physiological assessment, circulating levels of IL-6 and TNF-α provide an 
indication of inflammation; asthmatics demonstrate significantly elevated levels of these 
cytokines compared to controls. The LLN derived from a healthy control population in this 
chapter was used to recruit and characterise asthmatics for the next study (chapter 4) to 
assess the effect of n-3 supplementation in asthmatics. In addition, LLN derived from this 
study is specific for males only (aged 18-30 years) and should not be used for females.  
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Effect of a three-week dietary 
supplementation with EPA/DHA on exercise 
induced bronchoconstriction in mild-
moderate asthmatic males 
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4 Effect of a three-week dietary supplementation with EPA/DHA on exercise 
induced bronchoconstriction in mild-moderate asthmatic males 
4.1 Abstract 
 
There is limited evidence suggesting the beneficial effects of two n-3 PUFAs namely EPA 
and DHA on EIB. EIB affects approximately 90% of asthmatics and approximately 10% of 
healthy individuals with no history of asthma, consequently this limits the ability of a large 
proportion of the population to meet physical activity guidelines. Due to health side effects 
related to pharmacological medication, the use of complementary therapies including 
omega 3 supplementation are gaining impetus. This study was designed to assess the 
impact of dietary supplementation with EPA/DHA on EIB participants to evaluate changes 
in their post exercise pulmonary function. Participants were included based on lower limit 
of normal (LLN) derived from a control population used to confirm abnormal spirometry 
(chapter 3), a drop of >10% in FEV1 following exercise challenge tests, and elevated levels 
of FeNO (>40ppb). A randomised crossover trial (RCT) design with three weeks of 
supplementation (3.2 grams of EPA and 2.2 grams of DHA or placebo) with a three week 
of wash phase was used. Post exercise changes in pulmonary function were measured at 
baseline and after n-3, placebo and wash phases to assess changes after 
supplementation. Secondary markers of pulmonary function, namely FeNO and dyspnoea, 
were measured to monitor any changes across all phases. Venous blood samples were 
collected at all time-points to estimate changes in concentration of n-3 and n-6 PUFAs of 
interest (LA, ALA, AA, EPA and DHA) within the PBMC total lipids. Additionally, serum 
levels of inflammatory markers (IL-6, TNF-α and IL-10) were measured. Results showed a 
significant improvement in post exercise pulmonary function in participants with EIB after 
EPA/DHA supplementation, which was supported by a significant reduction in serum IL-6 
levels. There were no significant changes to total lipid composition of PBMC for key fatty 
acids assessed in this thesis; however, there was a non-significant trend showing 
increases in total PBMC EPA and DHA with a reduction in AA after supplementation. 
There was no significant improvement in exhaled breath nitric oxide or serum levels of 
TNF α and IL-10. Three weeks of dietary n-3 supplementation showed a beneficial impact 
on pulmonary function for EIB participants.  
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4.2 Introduction  
 
Exercise-induced bronchoconstriction (EIB) is characterised by transient narrowing of 
airways after exercise (Anderson et al., 1975; McFadden & Gilbert, 1994). Occasionally 
the narrowing of airways can occur during exercise (Beck et al., 1994; Rundell et al., 2003; 
Suman et al., 1999). For individuals with EIB a brief period of exercise or hyperventilation 
triggers airflow obstruction, which lasts for 30-90 minutes in the absence of treatment 
(Anderson, 2010; Hallstrand, 2012). Up to 90% of people with clinically diagnosed asthma 
experience EIB at some point during their lives. The majority of those affected by EIB 
consider exercising to be a major precipitant of their symptoms and as a result, their 
involvement in physical activity is affected. Approximately 10% of the healthy population 
with no history of asthma also show symptoms of EIB at some point during their lives 
following exercise or hyperventilation (ATS/ACCP, 2003; Anderson & Kippelen, 2005, 
Rundell & Jenkinson, 2002). EIB is primarily identified by recording a post exercise 
reduction in forced expiratory volume in 1 second (FEV1) of 10% to 15% of the pre 
exercise value (Haby et al., 1994; Sterk et al., 1993). The value for FEV1 may start falling 
during exercise; however, the lowest value is usually measured 5-12 minutes after the end 
of exercise. 
 
EIB results from the loss of water by evaporation from the airway surface while inhaling 
large volumes of air in a short period of time. Detailed mechanisms underlying the 
pathophysiology of EIB are described in chapter 1(page 24) (Anderson, 1984; Anderson & 
Daviskas, 1992; Anderson & Kippelen, 2010; Carlsen et al., 2008; Deal et al., 1979). There 
are a number of lipid mediators (derived from AA, 20:4, n-6 PUFA) in the cell membranes 
which an act on bronchial smooth muscle to cause contraction and narrowing of airways. 
In the airway epithelium of asthmatics, there are large numbers of mast cells, epithelial 
cells, glandular cells and sensory nerves that are affected by airway dehydration and 
osmotic changes. Increased levels of PGD2 and PGF2a have been found in urine and 
sputum samples of EIB subjects suggesting a key role of these mediators in the severity of 
EIB symptoms (Haverkamp et al., 2005; Kippelen et al., 2010; Pavord et al.1993, 1995; 
Sastre & Pozo, 2012). In addition, neutrophils, monocytes and macrophages produce 
LTB4, while LTC4, LTD4, and LTE4 are produced by mast cells, basophils, and eosinophils. 
LTB4 is a strong leukocyte chemotactic agent and an activator of neutrophils, which 
induces release of ROS and lysosymal enzyme. In addition LTB4 promotes secretion of 
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inflammatory cytokine such as TNF-α, IL-1(ß) and IL-6 by macrophages (Calder, 2012; 
Tilley et al., 2001). LTC4, D4 and E4 increase vascular permeability, increase mucous 
secretion, increase hypersensitivity and cause bronchoconstriction.  Thus, LTs, histamine 
and PGs help determine the severity of loss in FEV1 after exercise and are important in the 
persistence of EIB symptoms (Duong et al., 2008; Gulliksson et al., 2006; Moloney et al., 
2003). The modifying effects of specific antagonists and COX inhibitors on EIB suggest a 
potential role of these mediators in EIB severity and incidence. An increased concentration 
of AA derived mediators is found in arterial plasma, induced sputum, and urine following 
exercise (Anderson & Kippelen, 2010). 
 
The Department of Health (DH) guidelines  have suggested a role for diet and physical 
activity in maintaining health. Those with asthma and EIB often do not achieve the 
recommended targets for daily physical activity and this has implications for quality of life. 
Current therapies for asthma and EIB include short acting bronchodilators (including short 
acting β agonists) and long-term control medication (such as corticosteroids, LT modifiers, 
long acting β agonists). Though these therapies are effective in the short term, issues such 
as tachyphylaxis have complicated usage of β agonists; in addition, serious systemic and 
local side effects of inhaled corticosteroids include conditions such as osteoporosis and 
glaucoma. Another issue related to current pharmacological therapies is that these 
medications are broad spectrum and not specific, thus, there is an impetus towards 
specific therapies that target a single inflammatory mediator and are less likely to have 
major health side effects (Barnes, 2002, 2010; MacRedmond & Dorscheid, 2011). Many 
asthmatics are not satisfied with the long-term side effects of these pharmacological 
therapies and are resorting to alternative therapies (GINA, 2011; Mickleborough et al., 
2008). 
 
Evidence from observational studies have suggested a beneficial role of fish oil (omega -3 
fatty acids) in asthma. There are no major health side effects associated with the short 
term or long-term administration of fish oil, subsequently the use of fish oil as a 
complementary therapy for asthma is becoming popular. Omega 3 (n-3) PUFAs form the 
structural components of cells and have been shown to exert a range of anti-inflammatory 
and pro resolution effects following different mechanisms as described in the literature 
review. There are only a limited number studies investigating the effect of n-3 (EPA/DHA) 
on EIB subjects and relevant trials are described in the literature review, (page 45). Lung 
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function measurements have been the primary outcome of asthma supplementation trials 
and are assessed by variables such as FEV1, FVC and PEF. While some studies have 
shown improvement in pulmonary function outcomes, these results are not consistent. In 
two studies reported by Mickleborough and co-workers, (2003, 2006), no changes in 
pulmonary function were reported after 3 weeks of n-3 supplementation (3.2 gram EPA 
and 2.2 gram DHA/day) in asthmatics with EIB. However, these studies have shown 
significant improvement in post exercise FEV1 in EIB athletes and recreationally active 
subjects (Mickleborough et al., 2003, 2006).  
 
FeNO is considered a non-invasive marker for airway inflammation and is increasingly 
becoming an adjunct diagnostic technique used alongside spirometry. Schubert and co-
workers (2009) (n=23, atopic asthma) have shown that dietary supplementation with  n–3 
PUFA-enriched fat blend (0.69 g/day, n=12 participants) for 5 weeks was effective in 
reducing FeNO levels within 3 weeks of n-3 supplementation. Though the levels of FeNO 
increased during allergen exposure in both groups (n-3 and placebo), the mean increase 
was significantly lower in the n–3 PUFA group. In another double blind, placebo-controlled 
pilot study, a shorter duration of supplementation was used (n=20; dose 0.9 g EPA and 
0.65 g DHA/day) for 2 weeks (Moreira et al., 2008).  The study showed no changes to 
FeNO levels, FEV1 or self-reported asthma quality of life questionnaire scores. However, 
this study was not a well-controlled trial and the participants were on their regular 
medication of inhaled corticosteroids. In addition, the dose and duration of 
supplementation was not sufficient to compare this study to other studies.  
 
These prior studies, and others reviewed in the literature review suggest that dietary 
supplementation with n-3 PUFA may lead to some improvement in asthma symptoms 
(PEF and FEV1) and other markers of inflammation (FeNO). These studies are particularly 
suggestive of the protective effects in asthmatics with EIB symptoms. The inconsistencies 
in findings can likely be attributed to heterogeneity among the studies. These 
inconsistencies in the findings of the studies are possibly due to the different dosages, 
duration of the studies, mixed groups (males/females) and the sub group of asthmatics 
studied.  
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An obvious gap in the current literature is a lack of studies investigating the effects of n-3 
supplementation in EIB individuals with a non-athletic background who represent a large 
proportion of the asthmatic population and a significant amount of the healthy population. 
Therefore, this study was designed to assess the effect of a 3 week EPA/DHA 
supplementation in recreationally active EIB prone males.  
  
4.2.1 Aims and hypothesis  
 
The aim of this study was to assess the effect of EPA/DHA supplementation on post 
exercise FEV1 in mild – moderate EIB prone males. 
 
 It was hypothesised that there would be a statistically significant improvement in post 
exercise FEV1 after a three-week EPA/DHA supplementation.  
 
To support this study, EIB prone mild – moderate asthmatic males were recruited using 
the previously derived LLN. To evaluate the effects of EPA/DHA supplementation on 
pulmonary function in EIB-prone males, dyspnoea score and FeNO levels were 
simultaneously measured. Additionally, the effect of EPA/DHA supplementation on the 
total lipid composition in PBMC was assessed. Circulating levels of IL-6, IL-10 and TNF-α 
were measured to evaluate the changes in cytokines with supplementation.  
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4.3 Methods 
This section contains a brief description of the methods used during this study and will 
refer to chapter 2 for further particulars.  
 
4.3.1 Sample size calculation  
 
A double blinded, placebo controlled, randomised, crossover trial was carried out to 
assess the effects of a 3 week supplementation with n-3 (EPA/DHA) on EIB participants. 
The method for randomisation by minimisation and double blinding is described in chapter 
2; page 111. A power analysis was completed to approximate the appropriate sample size 
based on previous studies showing the effect of n-3 PUFAs on pulmonary function in EIB 
subjects (Mickleborough et al,. 2003, 2006). The design aimed to observe a minimum 
detectable difference or change of 0.3 litres in FEV1 after exercise with the 
supplementation. The significance level was set at alpha = 0.05 and the power at 0.80. 
Using these data, a sample size of 8 participants was necessary to detect a difference of 
this magnitude. To allow for fluctuations in participant compliance, withdrawals and 
incomplete data, a target sample size was set at 12 participants. Considering the sample 
size was small, the participants were randomly allocated using a minimisation scheme 
(Altman & Bland, 2005), whereby next allocation of supplementation capsules was 
dependent on the supplementation provided to the previous participant. This scheme of 
randomisation has been found to be appropriate to achieve balance between the treatment 
groups. The participants, investigator (I) and outcome assessors (supervisors) were 
blinded to the study; the randomisation pattern was kept with the technician in charge of 
randomisation. 
 
4.3.2 Study Design 
 
The placebo-controlled crossover trial was conducted over 12 consecutive weeks wherein 
each subject acted as their own control and underwent both of the supplementation 
phases (figure 4.1). All participants entered the study on their normal diet (phase 
1/baseline1), after which they were randomly allocated to receive 10 soft gelatin capsules 
per day containing either n-3 (3.2 grams of EPA, 2.2 grams of DHA and tocopherol 
(Biocare, UK) or Placebo (olive oil, Bionovate, UK) [phase 2]) with a 3 week washout 
phase in between (normal diet; phase 3, baseline 2). Thereafter the participants switched 
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over to the alternate supplementation for the remaining 3 weeks (phase 4). A 3 week end 
of study washout followed the second supplementation phase (normal diet; phase 5). The 
study design is shown in Figure 4.1. The participants were screened for EIB (≥ 10% drop 
in post exercise FEV1) and high FeNO (≥ 40ppb) at baseline 1. The participants reported 
to the lab for physiological testing at the two baselines, after the completion of 
supplementation phases and after washout. PFTs were assessed pre-exercise and post 
exercise at 1, 5, 10, 15, 30 and 45 minutes or until recovery (whichever was earlier). 
 
 
Figure 4.1 Study design for n-3 supplementation 
 
At each visit, blood was drawn before exercise by a certified phlebotomist from the 
antecubital vein for PBMC extraction and measurement of serum cytokines, namely TNF-
α, IL-6 and IL-10. All subjects recorded bronchodilator use during the supplementation 
phases (Phase 2 and 4). Additional samples were collected at the end of washout phases 
to establish that individuals had returned to their baseline level for all the physiological 
parameters. 
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Justification for dose and duration of study  
 
A dose of between 0.5 to 3.5 grams of EPA/DHA per day has been shown to improve 
pulmonary function, inhibit CystLT production by neutrophils and polymorphonuclear cells 
in vitro and decrease inflammatory cytokine production (Arm et al., 1989; Emelyanov et al., 
2002; Hodge et al., 1998; Mickleborough et al., 2003, 2006; Surette et al., 2008; Schubert 
et al., 2009). In rheumatoid arthritis a dose of approximately 3.5 grams of EPA+DHA per 
day has been shown to have anti-inflammatory effects via decreased IL-1 production by 
monocytes, decreased plasma IL-1β concentrations and decreased serum TNF-a 
concentrations (Esperson et al., 1992; Kolahi et al., 2010; Peter et al., 1999). In a dose 
response study by Rees et al. (2006) using healthy participants supplementing with a 
‘’high dose’’ of 2.7 gram/day for EPA resulted in reduced ex vivo PGE2 production by 
stimulated mononuclear cells compared to a ‘’low dose’’ of 1.35 grams of EPA/day. A 
number of studies looking at inflammation have suggested a threshold for an anti-
inflammatory effect to be exhibited by n-3 supplementation and this is expected to be in 
range of 1.3 -2.7 grams EPA per day (Calder, 2006, 2012; Dignass et al., 2004; Kelley et 
al., 1999; Kew et al., 2004; Grimble et al., 2002).  In athletes with EIB, a dose of 3.2 grams 
EPA and 2.2 grams DHA has been shown to be effective in improving post exercise 
pulmonary function (Mickleborough et al., 2003, 2006). Therefore, a dose of 3.2 grams 
EPA + 2.2 gram DHA was used in this thesis in an attempt to reduce the severity of EIB.  
 
The major supplementation studies in asthma (as outlined in chapter 1) have used 
supplementation duration ranging from 3 weeks up to 9 months. There is a significant 
incorporation of EPA and DHA in inflammatory cell phospholipid, plasma, erythrocyte 
membrane content  with 3 , 4 and 5 weeks of supplementation (Mickleborough et al., 2006; 
Schubert et al., 2009; Surette et al., 2008). Since the biological properties of n-3 PUFA are 
mediated by the incorporation of n-3 PUFA in the phospholipids of the cell membranes, 
beneficial effects are observed within a 3-4 weeks of supplementation. In a randomised 
cross over trial with EIB prone individuals Mickleborough et al., (2006) reported an 
improvement in post exercise FEV1, reduction in bronchodilator use, improvement in 
symptoms with reduction in sputum pro-inflammatory mediator concentration (LTC4,LTE4, 
PGD2, IL-1β, and TNF-α) after three weeks of supplementation. In another trial by 
Schubert et al. (2009) on allergic asthma, significant improvement in FeNO levels and a 
reduction in eosinophilic cationic protein and in vitro CystLTs release were observed by 
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the end of 3 weeks of supplementation. Therefore, a duration of 3 weeks was chosen for 
EPA/DHA supplementation in this thesis.  
 
For a cross over study design in intervention studies, washout phases are important and 
must be sufficiently long enough for complete reversibility of the supplementation effect. 
Washout periods ranging from 2-16 weeks have been used in supplementation studies. 
There is, however, a progressive decline in the levels of EPA and DHA after the 
completion of supplementation period with a steep decline within the first 2 weeks (in 
plasma phospholipids and RBC membranes) (Cao et al., 2006). Mickleborough et al. 
(2006) demonstrated a washout of n-3 PUFA in neutrophils after 2 weeks following 
supplementation in EIB prone males. The washout of n-3 PUFA from plasma and cell 
membranes of platelets and leukocytes after parenteral supplementation of n-3 is found to 
be ≥5–7 days (Roulet et al., 1997; Senkal et al., 2007) and rapid washout may be 
attributed to disease severity (van der et al, 2011). Furthermore, in a cross over trial, due 
to the added length of the study, participant drop out is an important issue (due to changes 
in disease severity and voluntary withdrawals), compared to parallel group studies. A 
shorter duration of intervention and washout was implemented in light of the previous 
studies and to maximise participant retention (Max et al., 1991).  
 
4.3.3 Outcome measures  
 
The primary outcomes for this study were changes in post exercise FEV1 and pre exercise 
pulmonary function measures (FEV1, FVC, FEV1 /FVC ratio and PEF) following a 3-week 
supplementation with EPA and DHA. In addition, pre exercise symptom scores 
(dyspnoea), bronchodilator use (during each supplementation and washout phase), pre 
and post exercise FeNO, levels of inflammatory cytokines and PBMC lipid composition 
were analysed.  
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4.4 Participants 
All participants completed a health screen questionnaire and gave written informed 
consent before participating in the study (appendix 1). Loughborough University’s ethics 
committee approved the protocol for the study. The recruitment flyer, health screen 
questionnaire, participant information sheet and consent form are attached in appendix 
1.Twelve male participants with physician diagnosed asthma and a history of EIB were 
recruited from Loughborough University, East Midlands, UK. Participants were included if 
they were 18-30 years old, had physician diagnosed mild-moderate asthma, had no 
respiratory infection within the past 8 weeks and had not taken steroids in the last 4 weeks 
of any kind, Hay-fever or other allergy medication in the past 7 days, and dietary n-3 
supplementation in the last  year. Twelve participants were recruited, however, only nine 
participants successfully completed the entire protocol (mean age 21 ± 2.7 years, mean 
height 1.8 ± 0.1 meters). The basic characteristics of the participants are listed in table 4.1. 
One participant did not complete the study due to injury; another participant was excluded 
because his asthma symptoms worsened (self-reported) for unexplained reasons during 
the study; a recommendation was made to this participant to discuss his situation with his 
clinician. Another participant was affected by seasonal changes and withdrew from the 
study on personal grounds. All participants showed abnormal lung function (FEV1/FVC 
ratio of ≤ 80%) and fell below the LLN (82%) derived from a population of healthy 
individuals, and were characterised as asthmatic in accordance with the latest ERS/ATS 
suggestions (Miller et al., 2009). All participants tested positive for EIB (≥ 10% drop in post 
exercise FEV1) and had high FeNO concentrations (≥ 40ppb).  
 
At recruitment all participants reported accounts of shortness of breath, chest tightness, 
and intermittent wheezing post exercise on a regular basis, which was normally relieved by 
administration of a bronchodilator. There were 4 participants currently reliant on 
bronchodilators (β2 agonist), and 5 participants were using a preventative medication and 
bronchodilators (β2 agonist  and short acting steroids). Participants refrained from their 
medication 48 hours (for short acting β2 agonists) prior to testing and were advised to 
discuss the situation with their medical practitioner prior to the participation in the study. 
Testing was rescheduled if participants used medication 48 hours prior to testing and a log 
of medicine usage was maintained until the participant was tested. Participants were also 
asked to refrain from caffeine intake (for 8 hours) and physical activity (for 24 hours) prior 
to the exercise challenge test following the rationale listed in chapter 2, page 73. The 
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research design for this study was such that the blood samples were collected at the same 
time of the day at each collection point (±30 minutes) and the sample analysis was 
conducted within 2 hours of collection. There were no dietary restrictions during the study 
other than personal n-3 supplementation.  
 
The participants in this study were comparable for age, stature, body mass and pulmonary 
function parameters (FEV1/FVC, PEF) with the asthmatics from chapter 3 and no 
differences were found in the between the asthmatics from both the studies. .   
 
Table 4.1 Baseline characteristics of Participants, FEV1 = Forced Expiratory Volume in 1 sec, 
FVC = Forced Vital Capacity, PFT = Peak Expiratory Flow, FEF 25-75% = Forced Expiratory 
Flow (showing 25% and 75 % of FVC). Values are shown as mean ± SEM and were recorded 
before exercise challenge test 
Characteristics  Measurement (n =9) 
Stature (m) 1.8 ± 0.1 
Age (years) 21.0 ± 0.9 
Weight (kg) 74.4 ± 2.0 
FEV1/FVC 77 ± 1.4 
% predicted FEV1/FVC 101.8 ± 3.4 
Predicted FEV1 84.8 ± 1.2 
FEF 25-75 (l/second) 4.9 ± 0.1 
PEF (l/minute) 574 ± 28.7 
FeNO (ppb) 52.1 ± 3.7 
4.4.1 Physiological tests  
 Exercise challenge test 
 
Each participant ran on a motorized treadmill until they achieved 80-90% of their estimated 
maximum heart rate for up to 6 minutes and the total testing time was between 8-10 
minutes (Miller et al., 2005a,b). Participants wore a heart rate monitor (Polar F4 Heart 
Rate Monitor Watch and strap, Polar Ltd, USA), and their heart rate was constantly 
monitored during the test following ATS/ERS safety guidelines on exercise testing (Crapo 
et al., 2000; Sterk et al., 1993). Full details of this procedure are given in chapter 2 (page 
70).  
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 Pulmonary function test 
 
Spirometry was performed using a calibrated spirometer (Superspiro; Micro Medical; 
Rochester, Kent, UK), and all participants remained in an upright seated position during 
the procedure wearing a nose clip. These devices were calibrated as ‘gold standard’ 
providing reproducible volume measurements for asthma patients and they comply with 
ATS/ERS guidelines (for details refer to general methods, page 70. Participants were 
required to perform three acceptable FVC manoeuvres according to ATS/ERS 
recommendations (Miller et al., 2005a,b). The percentage drop in post exercise FEV1 
compared to pre exercise values was calculated based on the following formula as 
described by Mickleborough and co-workers, (2006):  
 
(pre-exercise FEV1 – lowest postexercise FEV1)  X 100 
                                              (Pre-exercise FEV1)………………………………Equation 1 
  
  Fraction of exhaled breath nitric oxide (FeNO) measurement  
 
FeNO measurements were conducted using a portable NIOX MINO analyzer ((Aerocrine 
Inc., Solna, Sweden) according to ATS/ERS guidelines (ATS, 2005). Each participant sat 
on a chair in an upright position, wearing a nose clip to minimise any nasal NO 
contamination. The participants completed a prolonged inspiration of NO free air (NIOX 
MINO removes ambient NO, which ensures accuracy and follows the ATS 
recommendations) followed by expiration into the NO analyser against an expiratory 
resistance achieving the recommended expiratory flow rate of approximately 0.05 
l/second. Three acceptable manoeuvres were performed to control intra subject variability 
based on ATS/ERS recommendations (Miller et al., 2005b). The values were expressed in 
ppb (for details of the procedure and quality control, refer to chapter 2, page 70. 
 Perception of breathlessness (dyspnoea) 
  
A standard Borg analogue scale was used to record the asthma symptoms of the 
participants before and after exercise (Borg, 1982). Each participant gave a score from 0 
(no symptoms) to 10 (being worst asthma symptoms).  
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4.4.2 Biochemical analysis  
 PBMC total lipid analysis 
 
PBMC total lipid analysis was carried out at all time-points using venous blood. PBMC 
were extracted using a density centrifugation method and esterified to FAMEs and 
analysed by GC-FID (method chapter, page 76). A 37-component standard (Supelco, 
catalogue number 47885-U) was used as reference. The area under the curve was 
measured for the samples and the results were expressed as percentage of each fatty 
acid content relative to total fatty acid content.  
 Serum cytokine analysis for IL-6, TNF α and IL-10 
 
Venous blood was collected in serum gel-tubes and the blood was allowed to clot for 45-
90 minutes before separation of serum following centrifugation. Serum levels for TNF-α 
and IL-10 were measured using an ELISA kit (Biolegend, UK) while IL-6 was measured 
using a high sensitivity ELISA kit (Tepnel/Diaclone), UK). For details of procedures, please 
see methods chapter (page 106).  
4.4.3 Compliance monitoring  
 
The participants were provided with an approximate number of capsules necessary to 
complete the supplementation phases and were asked to return the remaining capsules 
after the n-3 supplementation and placebo phase. The remaining capsules were counted 
to estimate compliance.  
4.4.4 Statistical Analysis 
 
Data were analysed using SPSS version 19 statistical software (SPSS Inc., Chicago, IL).  
A two-way repeated measures analysis of variance (RM ANOVA) was used to measure 
changes in physiological and biochemical parameters within the same individuals as a 
result of  n-3/placebo supplementation over a period of time (within-subject effects).  
Mauchly’s test was conducted to determine whether sphericity was violated. In the cases 
where sphericity was violated, the repeated measures analysis of variance was corrected 
using the Greenhouse–Geiser correction factor. Order effect was assessed by using the 
order as a variable in the analysis.  
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4.5 Results  
Out of the twelve participants recruited, nine participants successfully completed the entire 
study protocol. The participants were given clear instructions about the supplementation 
(n-3 and placebo) and were provided with necessary number of capsules in a pot. 
Additionally, the participants were sent reminders at the end of each week of 
supplementation and the remaining capsules in the returned pots were counted to 
estimate compliance. All participants had less than 5 capsules returned, which was 
considered an acceptable marker of compliance. In addition, there was no effect of order 
in which supplementation was provided (p>0.05). All results reported in this section are 
expressed as mean ± SEM unless stated otherwise  
 
4.5.1 Primary outcomes 
4.5.2  Pulmonary function Test and Exercise challenge 
 
No Carry over effects  
 
Reduction in FEV1 in excess of 10% post exercise represents abnormal pulmonary 
function. Mean percentage change from pre exercise to post exercise FEV1 was 
calculated, and the change in FEV1 after n-3 supplementation is shown in figure 4.3. There 
were no differences in either the pre exercise (rest) or post exercise FEV1 between the two 
baselines based on RM ANOVA, demonstrating no carry over effects as shown in figure 
4.2 (p>0.05). Subsequently, all comparisons after supplementation were made with 
baseline1. There was also no differences between the two baselines, placebo and the end 
of study washout (p>0.05, figure 4.2)  
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Figure 4.2. No carry over effects: There were no significant differences observed for % change in 
FEV1 after exercise at baseline1, baseline 2, and end of washout phase for all participants using 
RM ANOVA. Reduction in FEV1>10% shows a positive diagnosis for EIB.  
 
 
 Improvement in post exercise FEV1 with EPA/DHA supplementation  
 
With the existence of abnormal pulmonary function, the decline in FEV1 is usually 
maintained over two time points post exercise. All participants had a >10% drop for post 
exercise FEV1 at two time points (between 5-15 minutes) at the baselines and placebo, 
and the mean of the two time points where the percentage dropped the lowest (post 
exercise FEV1) were used for further analysis. All participants met the diagnostic criteria 
for EIB at baseline (mean drop = 14.8%) and after the placebo phase (mean drop = 
12.4%; figure 4.2). There was a significant improvement in post exercise FEV1 at 5, 10 and 
15 minutes post exercise after the EPA/DHA supplementation phase compared to 
baseline1 for all participants (p<0.05, figure 4.3), individual data is shown in appendix 3. 
The mean percentage drop in FEV1 post n-3 intervention was 6.6%, which is indicative of 
attenuated EIB response. 
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Figure 4.3 Mean  percentage change in FEV1 before and after exercise at baseline1, placebo and omega – 3 (EPA/DHA) phase for 
all participants. Reduction in FEV1>10% shows a positive diagnosis for EIB  
*shows significant improvement from baseline (p<0.05). There were no significant differences between the baseline 1 and baseline2 
(p>0.05). All comparisons were made with baseline 1. 
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Pulmonary function tests (pre exercise) 
 No changes in FEV1/FVC ratio with supplementation  
 
FEV1 and PEF are measures to assess the full potential of the lungs. There was no 
significant change in mean FEV1 and PEF across all time points based on RM ANOVA 
(p>0.05). FVC represents the vital capability of the lungs and there was no change 
observed in the FVC value at any time point (p>0.05). FEV1/FVC ratio is an important 
parameter for asthma diagnosis and no changes were observed in the FEV1/FVC ratio 
across all time-points (p>0.05, figure 4.5). The FEV1/FVC ratio fell below the LLN criteria 
(82%) derived from a matched reference population in chapter 3 and this clearly 
demonstrated that the participants showed airway obstruction all time points of the study. 
Overall, there was no effect of n-3 supplementation on the pulmonary function outcomes; 
however, there was substantial improvement in post exercise FEV1 as presented in the 
last section (figure 4.4).  
  
 
Figure 4.4 Changes in FEV1/FVC ratio all time points, LLN = lower limit of normality 
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4.5.3 No change in dyspnoea but reduced bronchodilator usage after EPA/DHA 
supplementation  
 
There was no improvement in dyspnoea score with n-3 supplementation (mean score = 1) 
compared to baseline, placebo or other wash phases (mean score =1) (p>0.05). Thus, all 
participants reported very slight breathlessness before the exercise test at each time of the 
study.  
 
Participants recorded bronchodilator usage during the supplementation phases and each 
usage accounted two puffs on average. There was no change in the bronchodilator usage 
between placebo, baseline 2 and the washout (p>0.05, figure 4.6). There was  no data 
collected for baseline 1 measurement. The total bronchodilator usage during the three 
week n-3 supplementation phase (4 times, 8 puffs was lower than the total usage during 
placebo phase (7 times, 14 puffs).  Significant reduction (50%) in bronchodilator use was 
observed during the last week of n-3 supplementation (1 times, 2 puffs) compared to 
placebo phase (2 times, 4 puffs) (p<0.05). Mean bronchodilator use across all time points 
is shown in figure 4.6.  
 
 
  Figure 4.5 Bronchodilator use at different time points  
* Significant reduction in bronchodilator usage with n-3 supplementation compared to baseline 2, 
washout  and placebo phases (p<0.05).   
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4.5.4 Secondary outcomes  
 No change in FeNO with EPA/DHA supplementation  
 
All participants had elevated levels of resting FeNO compared to upper threshold of 
healthy individuals as per ATS/ERS guidelines (upper threshold = 25ppb; ATS, 2005) 
before the start of supplementation. Measurements of FeNO were collected at rest and 
post exercise challenge test at all-time points.  
 
At rest, the values measured for baseline (52 ± 3.7 ppb) was comparable to values 
measured after n-3 supplementation (57 ± 9.3 ppb) or placebo (47.0 ± 8.0 ppb) and there 
were no significant differences between the two baselines and washout (p>0.05) . 
Similarly, there was no change in the post exercise FeNO levels measured at each time 
point (p>0.05). There was no overall reduction in FeNO levels with a 3-week EPA/DHA 
supplementation. 
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Figure 4.6 FeNO levels at all-time points 
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 PBMC lipid analysis 
 
Changes in EPA, DHA and AA 
 
PBMC levels for all fatty acids were expressed as percentage (%) of total fatty acids 
across all time-points in the study and figure 4.8 shows content of EPA, DHA and AA at all 
time-points. The mean CV% for all PBMC samples analysed was found to be <10% on the 
same day. Example profiles are shown in appendix 3.  
 
Although there was an increase in overall EPA  and DHA levels after supplementation with 
EPA/DHA, the mean EPA and DHA levels didn’t differ statistically between the time points 
(p>0.05,figure 4.8). There was a reduction in AA levels post n-3 supplementation, however 
this change was also not statistically significant (p>0.05).  
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Figure 4.7 Fatty acid content for EPA, DHA and AA expressed as a percentage (%) of total 
fatty acid content 
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Changes in ALA and LA  
Mean ALA levels did not change significantly across the time points during the study 
(p>0.05) (figure 4.9). In addition, there was no change in LA levels during the study 
(p>0.05) 
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Figure 4.8 Fatty acid content for ALA and LA expressed as a percentage (%) of total fatty 
acid content 
 
 
Changes in the levels of other fatty acids  
 
No significant differences were observed for the proportions of lauric acid, myristic acid, 
pentadecanoic acid, palmitic acid, stearic acid or palmitoleic acid. There were marginally 
significant changes observed in oleic acid levels between baseline1 and baseline2 
(p=0.047) possibly due to some technical error in measurement. The mean data is shown 
in appendix 3. 
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 Serum cytokine levels  
 
Figure 4.10 shows serum levels of IL-6, IL-10 and TNF-α at different time points of study, 
hence all the comparisons were made with the baseline. The IL-10 and TNF-α levels 
remain unchanged (p>0.05) across all time points as shown in the figure 4.10. There was 
a statistically significant reduction in IL-6 levels after n-3 supplementation (37% reduction) 
compared to baseline (p<0.05).  
 
The IL-6 estimates in this chapter are higher than those obtained in chapter 3 for a 
matched mild-moderate asthma population, however, these results are still within the 
range for asthmatics. The differences are possibly due to the differences in the kits. In this 
study and the next study (chapter 5) the TNF-α and IL-10 were measured using an ELISA 
kit (Biolegend, UK) while IL-6 was measured using a high sensitivity ELISA kit (Tepnel, 
UK), which provided consistency within all phases of the supplementation studies. 
 
  
Figure 4.9 Serum levels of IL-6, IL-10 and TNF-α at different time points of the study 
* p<0.05, significant difference in IL-6 level after n-3 supplementation compared to baseline 
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4.6 Discussion  
 
This thesis presents a dietary supplementation study with EPA/DHA in mild-moderate EIB 
males. There are few studies conducted to assess the efficacy of n-3 in EIB prone 
participants and most prior studies have focussed on athletes. The primary reason for the 
EPA/DHA supplementation was to determine the improvement in post exercise pulmonary 
function (FEV1), so as to test the hypothesis that three-weeks of EPA/DHA 
supplementation would result in a significant improvement in post exercise FEV1. The 
study has demonstrated that a supplementation with n-3 (3.2 grams of EPA and 2.2 grams 
of DHA) for three weeks reduces the severity of EIB in participants with mild-moderate 
asthma. The supplementation improved pulmonary function post exercise to below the 
diagnostic threshold value for EIB, i.e. 10% fall in post exercise FEV1. There was 
approximately 71% improvement in FEV1 at 15 minutes after exercise. The mean level for 
the two time points where the percentage dropped the lowest in FEV1 after exercise at 
post n-3 supplementation was 6.6%, compared to a drop of 14.8% at baseline when 
participants were on their regular diet. This improvement in post exercise FEV1 is 
accompanied by >60% reduction in bronchodilator use. This trend in improvement in post 
exercise FEV1 is consistent with the findings of Mickleborough and colleagues where 3 
weeks of fish oil supplementation improved pulmonary function to below the EIB threshold 
of 10% in athletes (Mickleborough et al., 2003, 2006). 
 
There was no change in the pulmonary function outcomes for FEV1, FVC and PEF before 
exercise (at rest) after three-week supplementation with n-3. FVC represents the vital 
capability of the lungs and asthmatics with obstructive disease (asthma) do not usually 
have reduced FVC. Consequently, it was not expected that a change would be observed 
in FVC with any treatment or supplementation. If changes are observed it is possible that 
measurement errors have occurred. Recommendations for standardisation have been 
published and it has been determined that spirometry is reproducible, but is effort 
dependent (ATS, 1999; GINA, 2011; Miller et al., 2005; Pellegrino et al., 2005). In the 
present study, the participants were given guidance and practice prior to the PFTs; repeat 
measures were collected and the best out of the three measures were used analysis as 
per ATS/ERS guidelines. The lack of variation in FVC observed here suggests that 
measurements of pulmonary function carried out in this study were accurate. 
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Asthmatics have a reduced FEV1 and PEF due to airflow obstruction as confirmed from the 
data in chapter 3 where asthmatics were compared to matched healthy controls. Thus, 
improvements in these parameters of the pulmonary function are important while 
assessing the benefits of EPA/DHA intervention. The adult n-3 intervention trials in asthma 
have provided inclusive information with regard FEV1 or PEF. In a number of trials with 
varying dose and duration of n-3 supplementation, no significant changes have been 
observed for FEV1 or PEF (Hodge et al., 1998; Kirsch et al., 1988; McDonald, 1990; 
Mickleborough et al., 2003, 2006; Stenius-Aarniala, 1989). There are some studies that 
have shown positive outcomes; Emelynov et al., (2002) showed a significant increase in 
morning PEF with 8-week supplementation with a low dose of n-3 (50mg EPA+ DHA per 
day) in mild-moderate atopic asthmatics. Surette et al., (2008) reported a significant 
improvement in quality of life and asthma management scores (including symptoms) 
assessed by questionnaires after 3 weeks of supplementation (0.5 gram EPA + 0.75 gram 
DHA per day). Mickleborough et al., (2003, 2006) have reported significant improvement in 
post exercise FEV1 after 3-week supplementation with a dose similar to the present study 
(chapter 4); however no changes were observed for resting pulmonary function values for 
FEV1 and PEF reported by Mickleborough et al., which was confirmed in the present study 
(chapter 4). Although some literature and our knowledge of the physiological action of n-3 
fatty acids suggest that we should potentially see effects of supplementation on lung 
function there is no consistent effect of n-3 supplementation on FEV1 or PEF reported. 
This could be attributed to the heterogeneity between the studies. These studies have 
used a range of doses, as low as 50 mg to > 3grams of EPA/DHA per day and have 
studied different sub group of asthmatics such as mild-moderate, EIB and atopic 
populations from 3 weeks to months.  
 
Symptoms of dyspnoea are an important diagnostic marker and a number of clinicians rely 
on this outcome along with spirometry for the diagnosis of asthma and other respiratory 
diseases. In previous studies, n-3 supplementation has been accompanied by some 
improvement in symptoms assessed by reduction in daytime wheezing and quality of life 
questionnaires. Two studies have shown an improvement in mean daytime wheeze, 
morning PEF and improvement in quality of life (Emelyanov et al., 2002; Surette et al., 
2008). The study by Emelyanov et al, (2002), the study comprised of a group of mild-
moderate atopic asthmatics (18-56 years, n=46) supplemented with green lipped mussel 
extract with 50mg EPA+DHA /day for 8 weeks. Despite the relatively lower dose of EPA 
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and DHA used by Emelyanov et al., (2002) the longer duration of the study could be a 
reason why beneficial effects were seen in mean daytime wheeze and morning PEF. 
Surette et al., (2008) had a 3 week supplementation period with 0.75 gram GLA+ 0.5gram 
EPA or 1.3 gram GLA + 0.75 gram EPA in mild-moderate asthmatics (n=65) and showed 
improvement in self-reported status and medication use, and based on quality of life 
questionnaires there was an improvement in symptoms. The major limitation for this study 
was that no PFT measurements were taken and the results are based on self-reported 
outcomes. Since symptoms (or perception) have been suggested to be not a true indicator 
of the status of pulmonary function, the results from the Surette et al, study can be 
considered to have serious limitations. Furthermore, the lack of improvement in PFT 
outcomes in the n-3 supplementation studies conducted in the last two decades could be 
due to the nature of asthmatics used. These studies have been conducted mainly on mild-
moderate (Mickleborough et al., 2003,2006; Surette et al., 2008) or atopic/allergic (Arm et 
al., 1989; Emelyanov et al., 2002; Schubert et al., 2009; Thien et al., 1993) participants.  
As discussed in the previous chapter (chapter 3) there are issues relating to the diagnosis 
of asthma using a fixed criteria or 80% ratio. It is likely that the individuals in these prior 
studies were mild-moderate asthmatics or not asthmatic at all. If incorrect characterisation 
was the case, then it is not likely to see a major change in the PFT values. To see 
substantial changes in PFT outcomes, a larger sample size with participants with severe 
airflow obstruction are required to assess the effect of EPA/DHA on PFT outcomes. The 
study conducted in this chapter involved characterisation of asthmatics based on LLN, in 
addition, the inclusion criteria included  EIB (with exercise testing) and high FeNO levels 
(>40ppb). Thus, the asthmatics recruited in the study were representative of a mild-
moderate asthmatic young population (18-30 years) with EIB being the major 
characteristic. Therefore, improvement in post exercise FEV1 is indicative of the beneficial 
effect of n-3 supplementation.  
 
Although the supplementation studies have not shown major improvement in PFT values, 
substantial improvement in reduced medication usage has been observed. Hodge et 
al.(1998) showed a significant reduction in medication use in asthmatic children after 6 
month supplementation (1.2gram EPA per day) while Mickleborough and co-workers, 
(2006) reported that bronchodilator use was significantly reduced during the last 2 weeks 
of a fish oil supplementation compared to baseline for EIB using a dose similar to the 
present study. However, some of the earlier intervention trials have not shown any 
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significant changes to medication (Arm et al., 1989; McDonald et al., 1999; Thien et al. 
1993). These inconsistencies once again highlight the differences among these studies 
relating to dose, duration and nature of asthmatics studies, as discussed above. In this 
thesis by the third week of n-3 supplementation there was approximately 50% reduction in 
bronchodilator usage compared to placebo phase that support the previous findings that n-
3 supplementation exerts bronchodilatory effects within 2-3 weeks of supplementation. 
 
In this chapter, no changes were observed in symptoms after supplementation and the 
nature of the asthma experienced by the participants could explain why no change was 
observed in the reported dyspnoea score. The average dyspnoea score reported in this 
chapter at baseline was already very low. All participants displayed a score between 0-3, 
which corresponds to no symptoms to mild symptoms of perceived breathlessness (the 
mean was 1 on a 0-10 scale). This fits well with mild-moderate asthma status of the 
individuals. The likelihood of improvement in the mean symptom score from this already 
very low value to reporting no symptoms on average was unlikely. All participants had 
mild-moderate asthma and had been living with and managing the condition for several 
years. Because of this, the perception of symptoms was also possibly under reported by 
the participants. Though self-reported symptoms are widely used in asthma diagnosis it is 
suggested that symptom score cannot be independently used to assess the severity of 
asthma, thus these need to be used in conjunction with standard pulmonary function tests 
(ATS, 1999, Parshall et al., 2012). Despite no changes in symptoms, this reduced 
bronchodilator usage with n-3 supplementation suggests a possibility of reducing the 
reliance on pharmacological medications which has proven issues with health side effects. 
The improvement in post exercise FEV1 in EIB prone individuals is suggestive of the 
possibility of EPA/DHA supplementation being used as a treatment for EIB, which would 
significantly improve the quality of life and prove beneficial in physical activity, particularly 
to help achieve the recommended levels proposed by the Department of Health for 
maintaining a healthy lifestyle.  
 
FeNO is now becoming accepted as a non-invasive marker of airway inflammation and is 
recommended by the National Institutes of Health as a supplemental outcome for the 
characterisation of study populations, for prospective clinical trials, and for observational 
studies, and there are standard testing guidelines available (ATS/ERS, 1999, 2005; Dweik 
et al., 2011; Szefler et al., 2012). Low sputum eosinophilia and low FeNO are strongly 
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linked however, FeNO and sputum eoisinophila are not duplicate outcomes. FeNO and 
eosinophil levels are significantly reduced with corticosteroid treatment, unlike anti–IL-5 
and anti-IgE therapies, which reduce sputum eosinophilia without affecting FeNO  (Berry 
et al., 2005; Brightling et al., 2003). There are issues related to tachyphylaxis and side 
effects due to prolonged usage of corticosteroids, which is making non –pharmacological 
interventions attractive to users. Thus, there is an interest in the potential role of dietary 
supplementation with EPA/DHA for reducing FeNO levels. In the present study, there were 
no changes in FeNO levels at any time point. The study population displayed FeNO levels 
higher than normal (>25ppb) and values remained constant across the 10-12 weeks of the 
study, and these results match with the lack of effect shown in the results by Moreira and 
colleagues with 2 week dietary n-3 supplementation (Moreira et al., 2007).  
 
A previous parallel prospective study has shown a significant difference between the 
FeNO levels of placebo and n-3 group after a 3-week supplementation (450mg of EPA and 
180mg DHA per day) (Schubert et al., 2009). Though there was an increase in FeNO 
levels during low dose allergen exposure after 3 weeks in both groups, the n-3 
supplementation group displayed an attenuated response, which indicates a beneficial 
effect of n-3 PUFA on FeNO levels (Schubert et al., 2009). The positive results shown by 
Schubert et al., (2009) in three weeks with a relatively lower dose of n-3 could be due to 
the mild inflammation in the house dust allergic asthma study group (baseline FeNO = 
~25ppb); on the contrary the present study included those with substantially elevated 
levels of FeNO (52 ± 3.7 ppb).  
 
There is a lack of studies confirming the positive effects of n-3 supplementation on FeNO 
levels and further studies are required to address this. A recent cross sectional study by 
Barros et al., (2011) using validated FFQs it was reported that higher dietary intake of n-3 
PUFA (0·94 g/day of EPA+DHA) and ALA (1·96 g/day) can reduce the odds of non-
controlled asthma (unstable PFT and FeNO>35 ppb with asthma medication). The study 
has suggested that the prevalence of non-controlled asthma in their study was high; 
subsequently it is likely that the risk was overestimated (Barros et al., 2011). In clinical 
practice, it has been observed that long term medication use (corticosteroids) can stabilise 
FeNO levels (Dweik  et al., 2011;Zitt et al., 2005). Subsequently it is likely that the effect of 
EPA/DHA supplementation if measured over a longer period may improve FeNo levels. In 
future, studies are required with long-term supplementation to explore this possibility to 
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elicit the role of n-3 PUFA as a complimentary therapy for asthma by reducing reliance on 
corticosteroids which have proven long term health side effects.  
 
A possible limitation of this study was that the FeNO measurements in this thesis were 
conducted using a hand-held potable device that was available within the budget of this 
thesis research. The major advantage of these devices is that they can be used to monitor 
airway inflammation in clinics, in the field and in the patient’s home (Kim et al., 2012). 
There are some concerns about the reliability of these devices due to their limited ability to 
control flow rates, and it is suggested that a stationary chemiluminescence device such as 
‘Sievers nitric oxide analyser’ may be a more reliable method for assessment. While there 
are a number of studies showing a good association between FeNO values measured with 
the two devices, a few studies reported that there were differences in the FeNO values 
obtained with the hand-held NIOX MINO compared to those measured with stationary 
devices (Chen et al., 2007; Menzies et al., 2007; Schiller et al., 2009). In a recent study by 
Kim et al. (2012) it was demonstrated that there is a good correlation (r = 0.876, P < 0.001) 
but only moderate agreement between the FeNO values measured by the hand-held and 
stationary devices. The NIOX MINO values are significantly lower than stationary devices, 
thus it is important that results must be carefully interpreted (Kim et al., 2012). The mean 
value of the asthmatics in this thesis was >40 ppb and if these measurements were 
conducted using a stationary device, as Kim et al. suggests, it would have been relatively 
higher. This suggests high levels of inflammation in the study population (chapter 4) 
compared to healthy individuals (25 ppb). Consequently, the duration and the dose of 
supplementation given here may not have been sufficient to reduce FeNO values. Dose 
response and time course studies are required to evaluate the dose and duration required 
to reduce FeNO levels significantly in groups with high levels of inflammation.  
 
When PBMC lipid composition was studied, no significant changes in EPA and DHA levels 
after n-3 supplementation were observed, however there was a trend toward an increase 
in EPA (3 fold) and DHA (2 fold), which is suggestive of changes in cellular total lipid 
composition. There was also a non-significant trend showing a reduction in AA (2 fold) 
levels with EPA/DHA supplementation. It is documented that different cells and tissues 
have their characteristic fatty acid composition and their composition is dependent on the 
availability of different fatty acids as well as the metabolic properties of the cells and 
tissues (Calder, 2012; Calder & Yaqoob, 2009). Dietary supplementation with fish oil can 
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alter cellular fatty acid profiles, and their incorporation is in a dose response manner.  EPA 
and DHA have the ability to compete and replace AA and there is an increase in overall 
EPA and DHA in different cells and tissues (Blonk et al., 1990; Calder et al., 1991; Katan 
et al., 1997; Mickleborough et al., 2006; Sanders et al., 1983; Witte et al., 2010). The lack 
of significant change in EPA, DHA and AA could be attributed to measurement error, 
shorter duration of supplementation (than has been used in other studies with positive 
outcome) or small sample size and low power. It is demonstrated that incorporation of fatty 
acids in PBMC membrane reaches near maximum in 4 weeks (Rees., et al. 2006; Thies et 
al., 2001; Yaqoob et al., 2000), and so it was expected that after 3 weeks there would be a 
substantial incorporation of EPA and DHA into the PBMC. The results from this thesis do 
show a positive trend in the incorporation of EPA alongside a reduction in AA levels, 
demonstrating a positive direction in the study and the likelihood that with continued 
supplementation the findings would have reached significance. The absence of significant 
changes outcome could be attributed to possible limitations of the GC-FID method, 
particularly low recovery of AA and DHA due to possible loses in esterification and/or due 
to high temperature of GC parameters. In future studies, to address these issues longer 
duration of supplementation can be included, also an improvement in the GC-FID method 
can improve the findings.  
 
The modification of cell and tissue fatty acid composition is suggested to influence cell 
behaviour, which can, affect their physiological responses. In a previous double blinded, 
cross over supplementation study in EIB individuals using the same dose as the present 
study, there was a significant increase in EPA and DHA content in neutrophil 
phospholipids with a 3-week supplementation accompanied by a reduction in LA and AA 
(Mickleborough et al., 2006). This study also showed improvement in post exercise FEV1 
and reduction in bronchodilator usage; there was a significant reduction in induced sputum 
differential cell count percentage and concentrations of inflammatory lipid mediators (LTC4-
LTE4, PGD2) and inflammatory cytokines (IL-1β, and TNF-α)  before and following exercise 
on the n-3 diet. There was a reduction in AA derived LTB4 along with an increase in LTB5 
generation from activated polymorphonuclear cells on the n-3 diet. Arm et al. (1989) 
reported a 10 fold increase in neutrophil phospholipid EPA content with supplementation 
with 50% attenuation of total LTB (LTB4 and LTB5) generation by stimulated neutrophils 
and suppression of neutrophil chemotaxis with n-3 supplementation using a dose similar to 
the present study.  In another study, doses of <1 gram EPA/day were effective in reducing 
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stimulated whole blood LTB4 biosynthesis after a 4-week supplementation; additionally, 
there was a significant incorporation of EPA in plasma and RBC phospholipids with 4-
week supplementation (Surette et al., 2008).  
  
In a prospective double blind, parallel study on atopic asthmatics with 5 week n-3 
supplementation (fat blend - 450mg of EPA and 180mg DHA per day), there was a 
significant increase in EPA levels after 3 weeks of supplementation compared to the 
placebo group (Schubert et al., 2009). Furthermore, other fatty acids showed no trend in 
plasma lipid composition while there was an overall increase in DHA values after 
supplementation. There was an overall reduction in allergen-induced airway inflammation 
verified by lower levels of FeNO, serum and sputum eosinophils and suppression of the in 
vitro CystLTs release by leukocytes (Schubert et al., 2009). Thus, there is evidence to 
suggest that there is incorporation of EPA and DHA in the different types of cells and 
tissues following supplementation. Though our study failed to show significant differences 
in PBMC fatty acid composition, there is an encouraging trend to suggest that compliance 
to supplements was good. The improvement in post exercise pulmonary function, reduced 
reliance on bronchodilator usage and reduction in circulating IL-6 levels is encouraging 
and suggests a beneficial role of EPA and DHA in EIB. The present study was powered to 
detect differences in post exercise pulmonary function outcomes and has met the 
expected outcome. The insignificant PBMC fatty acid incorporation for EPA and DHA 
could be due to the small sample size of the study. The  observed power based on post 
hoc analysis was found to be  less than 0.4 for EPA and DHA; thus, a larger sample size 
would warranted to carry out a comprehensive study to illustrate changes in total lipid 
composition of PBMC.  
 
Asthmatics have shown to have elevated levels of inflammatory cytokines such as IL-6 
and TNF-α compared to healthy non-asthmatic controls and this was confirmed in the 
previous study (chapter 3). In addition, asthmatics have shown to have lower levels of IL-
10, which is a regulatory cytokine. Therefore monitoring the changes in the levels of these 
cytokines is important when assessing the effect of any anti-inflammatory treatment. Our 
results show a significant reduction in the levels of IL-6 (approximately 37% reduction) with 
three week EPA/DHA supplementation. This study confirms the recent findings from Gray 
et al., (2012) where 6-week supplementation with n-3 (1.3 gram EPA + 0.3 gram DHA/ 
day) was shown to reduce circulating IL-6 level in young males before and after exercise. 
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Several supplementation studies with EPA and DHA in healthy volunteers have shown 
decreased production of TNF-α, of IL-1β and IL-6 by endotoxin-stimulated monocytes or 
mononuclear cells (Caughley et al., 1996; Endres et al., 1989; Trebble et al., 2004). 
Mickleborugh et al., (2003) reported no changes in the circulating levels of IL-6 with 3-
week supplementation at a dose and duration similar to the present study however there 
was a significant reduction in TNF-α levels. In a type 2 diabetes n-3 supplementation (4 
gram EPA or DHA/day) study, there was a significant decrease plasma TNF-α levels after 
six weeks (Mori et al., 2003). There are a number of studies which have shown no effect of 
EPA and DHA supplementation on the reduction of inflammatory cytokine production in 
humans (Deike et al., 2012; Wallace et al., 2003). Some of these studies have used low 
dose (<2gram EPA+DHA) (Deike  et al., 2012; Kew et al., 2003; Schmidt et al., 1996; 
Wallace et al., 2003); however some studies have provided a higher dose (>2gram 
EPA+DHA per day)  (Kew et al., 2004; Mickleborough et al., 2003).  
 
The inconsistencies in these findings could be due to dose and duration of the study or 
could be due to technical errors in measurement (Calder, 2012). Additionally the relative 
effect of EPA and DHA is also considered an important factor in determining the effects 
associated with fish oil supplementation. In cell culture work by Mickleborough et al., 
(2009) has demonstrated that 120 mM pure EPA and EPA-rich media can significantly 
supress TNF-α and IL-1β mRNA expression and the production of  LTB4, PGD2 and TNF-α 
and IL-1β in stimulated alveolar macrophages obtained from asthmatic patients. In the last 
decade, a number of studies have used multiplex approaches for gene expression to gain 
insight into the regulation of genes involved in the inflammatory process. In a study on fish 
oil supplementation 26 weeks supplementation (0.4 g EPA/DHA (n=36) and 1.8 g 
EPA/DHA (n=37)) it was demonstrated that approximately the expression of 1000 genes 
including TNF-α and IL-6 were down regulated (Bouwens et al., 2009). It is likely that the 
 effect of n-3 PUFA on pro-inflammatory cytokines is independent of eicosanoid activity 
and is associated with regulation of signalling pathways (such as NFkB-mediated 
pathways) and transcription factors (e.g. peroxisome proliferator activated receptor 
(PPAR)-γ)  (Afman & Muller, 2012;  Michaud & Renier, 2001; Rudkowska  et al., 2009; Tai 
et al., 2005).  
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In our study there were no changes observed in the level of IL-10. This Th2 cytokine is 
found to have a critical role in limiting the immune response to pathogens to prevent host 
damage; in addition, IL-10 is involved in regulation of the expression of a number of 
inflammatory cytokines (IL-1ß, TNF-α and GM-CSF) and inflammatory enzymes 
(prostaglandin desaturase and COX) (Baine et al., 2011; Larché., 2007; Holgate et al., 
2010). In animal models of inflammatory bowel disease supplementation with fish oil has 
shown to increase levels of IL-10 (Barros et al., 2010) and reduce ex vivo production of 
TNF-α,IL-6 IL-10 and IFN-γ levels in plasma (Folador et al., 2009). These studies show 
that fish oil supplementation can affect lymphocyte function by affecting cytokine 
production. Using the whole genome and gene expression approaches the 
regulation/expression of IL-10 genes can be studied in relation to n-3 supplementation.      
 
The findings from this chapter confirm previous findings relating to the beneficial effects of 
n-3 supplementation in asthma and EIB. Furthermore, this chapter presents data from  the 
first study in ’mild-moderate asthmatic males with EIB’ where a 3 week EPA/DHA 
supplementation has shown to have beneficial effects EIB. The previous studies on EIB 
have been based on athletes and recreationally active mixed groups (males and females). 
The current pharmacological therapies for EIB include long and short acting β agonists 
and corticosteroids, which have proved effective in asthma management in the majority of 
patients; but they still have issues associated with their use. Complementary and 
alternative therapies are becoming popular in present times as they have the potential to 
reduce dosage and reliance on pharmacological therapies (Barnes, 2008; Mickleborough 
& Rundell, 2005). Thus, the results from this chapter provide evidence for the beneficial 
effects of EPA/DHA supplementation in EIB prone males; and suggest the use of 
EPA/DHA supplementation as a complimentary therapy in management of EIB symptoms.  
 
4.7 Conclusions 
 
Three weeks of dietary supplementation with EPA/DHA reduced severity of EIB in 
recreationally active male asthmatics, marked by an improvement in their post exercise 
FEV1 and bronchodilator usage. The supplementation did not alter FeNO levels and 
cytokine profiles for TNF-α and IL-10; however, there was a reduction in IL-6 levels 
suggesting a potential role of EPA/DHA in Th-2 regulation. There was no conclusive 
evidence about changes in PBMC lipid composition for EPA/DHA, with a trend showing an 
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increase in EPA and a reduction in AA following supplementation. The improvement in 
pulmonary function demonstrates a benefit to mild-moderate asthmatics of EPA/DHA 
supplementation however, the lack of consistent inflammatory mediator data means that 
possible mechanisms are still not elucidated. To further assess the modification of PBMC 
total lipid composition by n-3 supplementation, a larger sample size and modified study 
methods are required.  
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5 Effect of 3-week resolvin supplementation on exercise induced 
bronchoconstriction in asthmatic females 
5.1 Abstract 
 
Studies using animal models suggest that E series resolvins derived from EPA have anti-
inflammatory effects in small quantities. There is limited evidence from human studies to 
confirm these protective effects. The study aimed to investigate the impact of resolvins on 
the pulmonary function of mild-moderate asthmatic females with EIB. Eight female 
participants were recruited based on exercise challenge tests, spirometry and exhaled 
breath nitric oxide (FeNO) values. The participants entered a randomised crossover trial 
(RCT) with three weeks of E series resolvin supplementation (100 mg Resolvinol and 0.5% 
Vitamin E) / or placebo containing olive oil per day) and they crossed over to 
placebo/Resolvinol with a 3 week washout phase in between. A record of menstrual cycle 
(normal/abnormal) and oral contraceptive pill usage was made prior to the 
supplementation. Additionally, venous blood samples were collected to measure  
circulating levels of inflammatory markers (IL-6, TNF-α and IL-10). Results show a 
significant improvement in post exercise FEV1 for EIB after 3-weeks of resolvin 
supplementation. There was a significant reduction in serum IL-10 levels; but no overall 
change in serum TNF- α, IL-6 or FeNO levels. There was no impact of oral contraceptive 
pill usage on any of the study outcomes. The study demonstrates for the first time that a 3-
week resolvin supplementation can improve post exercise pulmonary function in EIB 
females.  
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5.2 Introduction 
 
Asthma is a complex disease characterised by airflow obstruction, airway 
hyperresponsiveness (AHR), mucous production and airway inflammation (Hisada et al., 
2009: Miller et al., 2005a,b). Mild-moderate asthma symptoms result in temporary change 
in treatment, in an effort to prevent the condition from becoming severe (NHLBI, 2007; 
Reddel et al., 2009).This sub group of asthmatics show a reduced pulmonary function 
(FEV1 /FVC ratio= 60-80%) and their symptoms persist for >2 days per week and are 
attenuated by bronchodilator use. Exercise-induced bronchoconstriction (EIB) is a sub 
group of asthma in which there is transient narrowing of airways after exercise, 
occasionally this transient narrowing of airways can occur during exercise (Anderson & 
Kippelen, 2005; Beck et al., 1994; McFadden & Gilbert, 1994; Rundell et al., 2003; Suman 
et al., 1999). The eicosanoids (2 series PGs and 4 series LTs) derived from arachidonic 
acid (20:4, n-6 PUFA) which is present in the phospholipids of inflammatory cells are 
involved in the pathophyisiology of airway inflammation (Bradding et al., 2006; Carter & 
Bradding ,2011; Mickleborough & Rundell, 2005). A review of the pathophysiology of 
asthma and EIB is presented in chapter 1 (page 24). Elevated levels of CystLTs are 
detected in exhaled breath condensate (EBC), urine, blood and BAL fluid of asthmatics 
and those with EIB after an exercise challenge (Anderson & Kippelen, 2010; Gulliksson et 
al., 2006; Hallstrand et al., 2005. Consequently, change in CystLTs in EBC following an 
exercise challenge has been related to the severity of EIB (Bikov et al., 2010; 
Mickleborugh et al., 2006). Based on the involvement of AA derived lipid mediators in 
inflammation, it has been hypothesised that increased dietary intake of n-6 PUFA 
accompanied by a low intake of n-3 PUFA has played a causal role in increased asthma 
incidence in the last 30 to 40 years (Black & Sharpe, 1997; Hodge et al., 1994; Peroni et 
al., 2012).  
 
Pharmacological therapies for asthma are associated with issues of tachyphylaxis and 
health side effects (Barnes, 2002; MacRedmond & Dorscheid, 2011). There is an 
increased public health interest in the benefits of dietary fish oil (n-3) and a number of 
supplementation studies have been conducted to understand the associations between n-
3 and inflammation. Studies have reported anti-inflammatory effects of n-3 in asthmatics 
with decreased production of CystLTs and leuckocyte chemotaxis (Arm et al., 1989; Kirsch 
et al., 1988; Micklebough et al., 2006). Overall, the n-3 supplementation studies in the last 
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two decades have reported some beneficial effect on PEF, FEV1, self-reported symptoms 
and quality of life (Emelynov et al., 2002; Dry et al., 1991; Hodge et al., 1998 Surette et al., 
2008). However the findings of these studies are not consistent and some studies show no 
effect on pulmonary function outcomes (Arm et al. 1988, Kirsch et al. 1988, McDonald et 
al. 1990). Despite the inconsistencies in pulmonary function outcomes, a number of these 
n-3 supplementation studies have shown significant in vitro reduction of CystLT generation 
by stimulated neutrophils and polymorphonuclear cells, thereby confirming the anti-
inflammatory effect of n-3 PUFA (Arm et al., 1989; Schubert et al., 2009; Mickleborough et 
al., 2006).  
 
There are a very few studies to our knowledge which have evaluated the role of n-3 on 
pulmonary function in EIB prone females. In a cross over study with 10 asthmatics with 
EIB and 10 controls (male and female elite athletes; mean age of EIB group = 23.2 ± 1.9 
years), three week supplementation with 3.2 gram EPA and 2.2 gram DHA per day 
improved post exercise pulmonary function (FEV1) compared to placebo and baseline 
phases. There was a reduction in LTE4, LTB4, 9α 11β-PGF2, TNF-α and IL-1β with 
supplementation (Mickleborough et al., 2003). In another study by the same group (n=16 
recreationally active EIB participants, 10 males and 6 females, mean age 23 ± 1.6 years) 
their previous findings were confirmed and they reported a significant improvement in post 
exercise pulmonary function, following three week n-3 supplementation with the same 
dose. There was also a reduction in bronchodilator usage, induced sputum differential cell 
count percentage, concentrations of CystLTs and inflammatory cytokines (TNF-α and IL-
1β). These studies suggest that dietary supplementation with n-3 PUFA has a beneficial 
effect in reducing EIB in males and females (Mickleborough et al., 2006). Although there 
are limited number of studies focussed on the effect of n-3 supplementation in females 
with asthma or EIB there are numerous studies describing variations in asthma during the 
menstrual cycle, figure 5.1 illustrates hormonal activity during menstrual cycle. Gibbs and 
co-workers have demonstrated that 30-40 % of asthmatic patients attending the 
outpatients department reported a pre-menstrual deterioration in their asthma symptoms 
(Gibbs et al., 1984). In a survey conducted by Eliasson & co-workers, (1986) it was found 
that 33% of women had significantly higher symptom scores during the premenstrual 
phase and the worsening of asthma symptoms were correlated with dysmenorrhea 
(menstrual pain) and premenstrual syndrome (Eliasson et al., 1986). In a recent study by 
Dratva et al., (2010), a large population-based sample of women with AHR was 
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investigated with reference to menstrual phase. It was found that women had high AHR in 
the pre-menstrual phase (mid-luteal phase) and cyclical variations in AHR were observed 
to be smaller among women taking oral contraceptives (Dratva et al., 2010). In another 
analysis conducted with a general population, fluctuations in pulmonary symptoms during 
the menstrual cycle were more severe during mid-luteal to mid-follicular stages, often with 
a dip near time of ovulation. It was suggested that the peaks varied between subgroups 
with different cyclical patterns according to asthma status, smoking status and BMI 
(Macsali et al., 2009). The mechanisms underlying the menstrual cycle, asthma and AHR 
are not clear and there appears to be reduced symptoms for those taking oral 
contraceptives; the two reproductive hormones oestrogen and progesterone are likely to 
have an effect (Lim & Kobzik., 2008; Stanford et al., 2006; Tan et al., 1997; Vrieze et al., 
1997).  
 
 
Figure 5.1: Hormonal activity during the menstrual cycle LH= luteinising hormone, FSH = 
follicle stimulating hormone. 
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Mandhane and co-workers (2009) have shown that elevated FeNO is a marker of airway 
inflammation and inversely related to oestrogen in the menstrual cycle, while the opposite 
was true for progesterone. Progesterone receptors found on the proximal region of the cilia 
of airway epithelia and when exposed to progesterone reduce cilia beating tendency. This 
reduced efficiency of cilia could impede airway clearance making individuals more 
susceptible to abnormal lung function and AHR (Jain et al., 2011). However, no consistent 
results have been reported when sex hormones are compared against various clinical and 
diagnostic outcomes of asthma (Macsali et al., 2012). Trials involving assessment of 
pulmonary function in females include monitoring and or adjustments based on menstrual 
cycle and may indirectly have implications for the study design. Potentially, this could be 
the reason behind the lack of intervention trials on females to assess the effect of n-3 on 
lung function in asthma. In this thesis, a record of menstruation (normal/abnormal) and use 
of oral contraceptive (pill) usage was collected to assess their effect on the study 
outcomes. 
 
Increasing phospholipid EPA/AA ratios in inflammatory cells with dietary n-3 
supplementation is likely to be one of the mechanisms that can potentially facilitate the 
production of weaker eicosanoids that may exhibit anti-inflammatory effects.  Additionally 
fish oils may modulate T cell response and functions independently of eicosanoid 
production (Alexander et al., 1988; Jolly et al., 1997; Fan et al., 2003, 2004, Zeyda et al., 
2002; Versleijen et al., 2012). The exposure to n-3 PUFA (with supplementation) has been 
reported to affect cell-signalling pathways by altering the expression and activity of 
membranes receptors. In addition these PUFAs can modify the expression of genes by the 
activation of transcription factors such as NFқB and PPAR-α (Calder, 2012; Rudkowska  et 
al., 2009; Michaud & Renier, 2001; Mickleborough et al., 2008; Tai et al,. 2005).  
 
In addition to the anti-inflammatory action of n-3 PUFAs via eicosanoid generation, in the 
last decade new families of lipid mediators produced from PUFAs have been discovered.  
These novel lipid mediators are endogenously generated during inflammation have potent 
anti-inflammatory effects; acting as specialised pro-resolving lipid mediators promoting 
resolution of inflammation (Hisada et al, 2009; Serhan., 2008, 2011). Serhan and 
collaborators identified, characterised, and elucidated families of novel pro-resolving lipid 
mediators from EPA/DHA (Bannenberg et al., 2010; Serhan et al., 2010). These include 
the E-series resolvins (RvE1 and RvE2) derived from EPA, D series resolvins 
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(RvD1,RvD2,RvD3,RvD4, RvD5, RvD6);  protectins and the maresins which are all derived 
from DHA (Hong et al, 2003; Marcheselli et al., 2003; Serhan et al., 2002). There are 
additional series of lipid mediators generated in the presence of aspirin including the D-
series Rvs, PDs and their aspirin-triggered forms. These mediators are synthesised from 
PUFA and via the aspirin mediated COX-2 pathway (Ariel & Serhan, 2007; Kohli & Levy, 
2009; Serhan, 2011). In animal models, it has been shown that Rv synthesis is increased 
by feeding fish oil diets to rodents (Hudert et al., 2006). RvE1 can regulate IL- 23 and LxA4 
to promote resolution of allergic airway inflammation in a murine model of asthma 
(Haworth et al., 2008; Hisada et al., 2009). RvE1 can act on several phases of asthmatic 
inflammation and may have anti-inflammatory effects on various cell types such as 
lymphocytes, macrophages, eosinophils and neutrophils. Furthermore, it has been shown 
that RvE1 can bind to and block leukocyte B4 receptor 1 and is involved in the dampening 
of airway inflammation and in the resolution of inflammation (Aoki et al., 2008; Haworth et 
al., 2008).  
 
The biological characteristics of these new anti-inflammatory and pro-resolving mediators 
derived from n-3 PUFAs and the pathways that drive the formation and actions of these 
molecules have provided a new concept for treating airway inflammation. The majority of 
studies conducted have been in animal models including murine, feline and rabbits, with 
limited studies on humans. Following the identification of pro-resolving and anti-
inflammatory effects of RvE1, a clinical trial is currently being conducted to assess the 
effect of RvE1 on dry eye. Dry eye is a common ocular surface disease, common in 
women and the elderly, with chronic symptoms of eye irritation and in severe cases, 
blurred vision; it is suggested that there is an inflammatory component underlying this 
disease (Li et al., 2011). The phase 2 results from the clinical trial provide an indication 
that the agonist Rv has the ability to produce a dose-dependent improvement in both the 
signs and symptoms of dry eye. Furthermore, no health side effects are reported in this 
trial (Brooks, 2009; Resolvyx, 2012: ClinicalTrials.gov identifier: NCT00799552). This first 
clinical study of the effect of Rv in humans will help improve the understanding of the 
agents that can stimulate the resolution mechanisms and resolve acute inflammation along 
with chronic inflammation to reduce human diseases where uncontrolled inflammation 
forms the basis of their pathophysiology (Serhan, 2011). Early phase trials are currently on 
going for natural and synthetic resolvins for various disease conditions such as asthma, 
inflammatory bowel disease and other related inflammatory diseases; however, no 
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information about the appropriate dosage of these compounds have been publicised. 
Based on animal model studies a dosage ranging from 10ng - 0.1mg/kg is found to have 
anti-inflammatory effects by reducing pain, mucus, AHR and leukocyte infiltration (Duffield  
et al., 2006; Haworth et al., 2008; Xu et al., 2010).  
 
These results from animal model are encouraging and highlight the anti-inflammatory and 
pro resolution effects of Rvs and other lipid mediators. Additionally, these mediators have 
no proven health side effects making them attractive as alternative treatments for 
inflammation. Thus, well-designed studies are required to investigate the relationship of 
these new mediators with asthma in humans. However, due to lack of guidance on 
dosage, the preliminary findings from animal models are required for careful translation 
and application for research in humans.   
 
Aims and hypothesis  
 
The third aim of this chapter was to investigate the effect of EPA-derived bioactive 
mediators (E series Resolvins) on post exercise FEV1 in mild – moderate EIB-prone 
females.  
 
It was hypothesised that there would be a statistically significant improvement in post- 
exercise FEV1  after three-weeks of resolvin supplementation. To support this study, EIB 
prone mild – moderate asthmatic females were recruited using fixed criteria (80%  ratio for 
FEV1/FVC). To evaluate the effects of resolvin supplementation dyspnoea score and 
FeNO levels were simultaneously measured. Circulating levels of IL-6, IL-10 and TNF-α 
were measured to evaluate the changes in cytokines with supplementation.  
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5.3 Methods 
This section contains brief description of the methods used during this study and will refer 
to chapter 2 for further particulars.  
 
5.3.1 Study Design and sample size estimation 
 
A double blinded, placebo controlled, randomised, crossover trial was designed to assess 
the effects of a 3 week supplementation with E series resovins on EIB prone participants. 
The method for randomisation by minimisation and double blinding is described in chapter 
2; page 111. A power analysis was completed to approximate the appropriate sample size 
based on previous studies showing the effect of n-3 PUFAs on pulmonary function in EIB 
subjects (Mickleborough et al., 2003, 2006). The design aimed to observe a minimum 
detectable difference or change of 0.3 litres in FEV1 after exercise with the 
supplementation. The significance level was set at alpha = 0.05 and the power at 0.80. 
Using these data, a sample size of 8 participants necessary to detect a difference of this 
magnitude. To allow for fluctuations in participant compliance, withdrawals and incomplete 
data, a target sample size was set to 12 participants. Considering the sample size was 
small, the participants were randomly allocated using a minimisation scheme (Altman & 
Bland, 2005) whereby the next allocation of supplementation capsules were dependent on 
the supplementation provided to the previous participant. This scheme of randomisation 
has been found to be appropriate to achieve balance between the treatment groups. The 
participants, investigator (I) and outcome assessors (supervisors) were blinded to the 
study; the randomisation pattern was kept with the technician in charge of randomisation. 
 
5.3.2 Dose and duration of supplementation 
 
All participants entered the study on their normal diet (phase 1/baseline1), after which they 
were randomly allocated to receive soft gelatine capsules: either 10 capsules per day of 
Resolvin E1 (containing 100 mg Resolvinol and 0.5% Vitamin E) or Placebo (olive oil and 
0.5% Vitamin E, Bionovate, UK) [phase 2]. After the initial supplementation, participants 
completed a 3 week washout phase [phase 3, baseline 2]. Thereafter the participants 
switched over to alternate supplementation for the remaining 3 weeks [Phase4] (figure 
5.2). The dosage was determined by the preliminary findings (from animal models and 
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human studies) reported by Bionovate Inc. who supplied the supplements for the study. 
Another three-week end of study washout followed completion of the second 
supplementation phase (normal diet; phase 5). In a number of well-designed n-3 
supplementation studies washout phases ranging from 2-10 weeks are used (McDonald et 
al., 1990; Mickleborough et al., 2003, 2006; Kirsch et al., 1988; Yaqoob et al., 2000). A 
shorter duration was chosen for participant retention as longer washout or intervention 
phases have a likelihood of drop out (Max et al., 1991).  
 
 
 Figure 5.2 Study design for resolvin supplementation 
 
5.3.3 Participants  
 
Considering the issues of lung maturation and ageing, female participants were included if 
they were between 18-30 years of age to represent young adults. All participants  had 
previous physician diagnosed mild-moderate asthma , had no respiratory infection within 
the past 8 weeks and had not taken any medication [steroids, of any kind in last four 
weeks, hay-fever or other allergy medication (in the past 7 days)] and dietary n-3 
supplementation in last one year. There were no dietary restrictions during the study other 
than personal n-3 supplementation. All participants completed a health screen 
questionnaire and gave written informed consent before participating in the study 
(appendix 1). The information about menstrual cycle and oral contraceptive pill usage 
upon entry to the trial (at baseline) collected from the health screen questionnaire were 
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used for analysis. The Loughborough University’s ethics committee approved the protocol 
for the study, recruitment flyer, health screen questionnaire, participant information sheet 
and consent form are attached in appendix 1. All the participants were screened for EIB (≥ 
10% drop in post exercise FEV1) and FeNO (≥ 40ppb) at baseline.  
 
At the baseline and following completion of the supplementation and washout, the subjects 
reported to the lab for testing. PFTs were assessed pre exercise and post exercise (at 1, 
5,10,15,30 and 45 minutes or until recovery (whichever was earlier). Blood was drawn 
before exercise by a certified phlebotomist from the antecubital vein for ELISA for 
measurement of serum cytokines (TNF-α, IL-6 and IL-10). Bronchodilator use was 
recorded by participants during all the study phases. The participants also reported to the 
lab at the end of washout and underwent all physiological tests; in addition blood samples 
were collected for measurement of serum cytokines. These tests were conducted to 
assess if individuals had returned to the baseline level for all the physiological parameters 
to determine any carry-over effects. 
 
Nine female participants with mild-moderate asthma and a history of EIB were recruited 
from the Loughborough University, East Midlands, UK. One participant dropped out due to 
difficulties with swallowing of the capsules and dropped after 3 weeks.  Eight participants 
(mean age 21.8 ± 1.14 years, and mean height 1.6 ± 0.01 meters successfully completed 
the entire protocol as they met all the inclusion criteria for the study. Relevant 
anthropometric and pulmonary function characteristics of participants are reported in table 
5.1 
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Table 5.1 Anthropometric and pulmonary function characteristics of Participants, FEV1 = 
Forced Expiratory Volume in 1 sec, FVC = Forced Vital Capacity, PFT = Peak Expiratory 
Flow, FEF 25-75% = Forced Expiratory Flow (showing 25% and 75 % of FVC). Values are 
reported in mean ± SEM 
 
Characteristics  Measurement (n =8) 
Stature (m) 1.6 ± 0.01 
Age (years) 21.8 ± 1.14 
Weight (kg) 64.3 ± 4.18 
FEV1/FVC 75.27 ± 1.02 
% predicted FEV1/FVC 85.8 ± 0.36 
FEF 25-75 (l/second) 3.8 ± 0.10 
PEF (l/minute) 393.0 ± 24.09 
FeNO (ppb) 46.5 ± 2.74 
Medication usage        n = 4 on β2 agonist only;                                           
n = 4 on β2 agonist  and short acting steroids 
 
Since the LLN derived from a reference population in chapter 3 was specific to males only, 
therefore the LLN criteria was not used for asthma characterisation in this study. All 
participants were tested positive for asthma in the laboratory, with a FEV1 of ≤ 80% in 
accordance with the latest ERS/ATS guidelines (2009), tested positive for EIB (≥ 10% drop 
in post exercise FEV1) and showed high FeNO (≥ 40ppb). In addition, participants reported 
accounts of shortness of breath, chest tightness, and intermittent wheezing post exercise 
which was relieved by bronchodilator. Participants were advised to refrain from medication 
usage (for short acting β2 agonists) for 48 hours prior to testing and their medication use 
was recorded. The participants were advised to discuss the situation with their medical 
practitioner before coming off medication. Testing was rescheduled if participants used 
medication 48 hours prior to testing and a log of medicine usage was maintained till the 
participant was tested. Participants were also asked to refrain from caffeine intake (8 
hours) and physical activity (for 24 hours) prior to the exercise challenge test. The 
research design for the studies conducted in the thesis was such that the physiological 
tests were conducted at similar times and blood samples were collected at the same time 
of the day at each collection point (±30 minutes); and the sample analysis was conducted 
within 2 hours of collection.  
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5.3.4 Outcome measures  
 
The primary outcomes for this study were changes in baseline pulmonary function 
measures (FEV1, FVC, and PEF) and post exercise change in FEV1 following 3 weeks of 
supplementation with  RvE1. In addition, symptom scores, bronchodilator use, fraction of 
exhaled breath nitric oxide (FeNO) and levels of cytokines were measured.  Additionally, 
the relationship of oral contraceptive pill usage and its potential effect on the study 
outcomes were also assessed. 
 
5.3.5 Physiological and biochemical measurements  
 
Physiological measurements including the exercise challenge test, pulmonary function 
tests, FeNO test and perceived symptoms score (dyspnoea) were completed following 
procedures outlined in  chapter 2, page 72-76. Serum cytokine analysis for IL-6, TNF α 
and IL-10 and compliance monitoring were conducted following procedures outlined in 
chapter 4, page 152. Information about oral contraceptive (pill) usage was collected from 
the health screen questionnaires collected prior to the study.  
 
5.3.6 Statistical Analysis 
 
Data was analysed using SPSS version 19 statistical software (SPSS Inc., Chicago, IL). A 
two-way repeated measures analysis of variance (RM ANOVA) was used to measure 
changes in physiological and biochemical parameters within the same individuals as a 
result of  resolvin/placebo supplementation over a period of time (within-subject effects).  
Mauchly’s test was conducted to determine whether sphericity was violated. In the cases 
where sphericity was violated, the repeated measures analysis of variance was corrected 
using the Greenhouse–Geiser correction factor. Owing to the small sample size of the test, 
the least significant difference was applied for adjustment during pair-wise comparison of 
data using estimated marginal mean. Order effect was assessed by using the order as a 
variable during analysis. The relationship of oral contraceptive pill use to lung function 
improvements was assessed by using contraceptive pill usage as a variable for RM 
ANOVA. Student’s paired t test were conducted to compare the physiological and 
biochemical outcomes of the group using contraceptive and the group without it. 
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5.4 Results  
Out of the nine participants recruited, eight participants successfully completed the entire 
study protocol. The participants were given clear instructions about the supplementation 
(resolvin and placebo) and were provided with approximate number of capsules in a pot. 
Additionally, the participants were sent reminders by end of each week of supplementation 
and the remaining capsules in the returned pots were counted to estimate compliance. All 
participants had less than 5 capsules returned which was considered acceptable. Also, 
there was no effect of order in which supplementation was provided (p>0.05). All results 
reported in this section are expressed as mean ± SEM unless stated otherwise. The 
following section describes the findings from this study 
 
5.4.1 Primary outcomes 
5.4.2 Pulmonary function test and exercise challenge 
 
  No Carry over effects  
 
Reduction in FEV1 in excess of 10% post exercise represents abnormal pulmonary 
function. Furthermore, two time-points showing >10% drop in FEV1 are considered 
indicative of EIB and are reliable for EIB diagnosis. Mean percentage change from pre 
exercise to post exercise FEV1 was calculated, and the change in FEV1 after resolvin 
supplementation is shown in figure 5.4. There were no differences in either the pre 
exercise (rest) or post exercise FEV1 between the two baselines based on RM ANOVA, 
demonstrating no carry over effects as shown in figure 5.3(p>0.05). Subsequently, all 
comparisons after supplementation were made with baseline1. There was also no 
differences between the two baselines, placebo and the end of study washout (p>0.05, 
figure 5.3)  
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Figure 5.3 No carry over effects: There were no significant differences observed for % change in 
FEV1 after exercise at baseline1, baseline 2, and end of washout phase for all participants using  
RM ANOVA. Reduction in FEV1>10% shows a positive diagnosis for EIB.  
  
 Improvement in post exercise FEV1 with Rv supplementation  
Mean percentage change from pre exercise to post exercise FEV1 was calculated. At the 
two baselines and after the placebo phase all participants demonstrated EIB symptoms 
with a >10% drop in post exercise FEV1 at two time points (10 and 15 minutes). The mean 
values are displayed in figure 5.4. The reduction in FEV1 at baseline and after the placebo 
phase was 13.1 % and 12.9 % respectively .The percentage drop in FEV1 post Rv 
supplementation was only 9.4 % which is below the diagnostic threshold for EIB and 
indicates an attenuated EIB response. This value was significantly lower than the values 
recorded at baseline and after the placebo phase (p=0.02) and suggests a 30% 
improvement in post exercise FEV1 with Rv supplementation. There was no difference 
observed between the two baselines, placebo and washout phase (p>0.05). Overall, the 
mean values of the group show an improvement in post exercise FEV1 after 
supplementation and this is the first study in females with EIB demonstrating this effect.
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Figure 5.4 The percentage change in FEV1 from before and after exercise at baseline, placebo and resolvin phase for all 
participants. Reduction in FEV1 >10% shows a positive diagnosis for EIB  
* Statistically significant difference in post exercise FEV1 compared to baseline (p<0.05) 
Chapter 5: Intervention study in EIB females                                                         A Kumar  
 191 
Pulmonary function tests  
 No changes in pre exercise FEV1/FVC ratio with supplementation  
 
FEV1 and PEF are measures to assess the full potential of the lungs and there was no 
change in mean FEV1 and PEF across all time points (p>0.05). FVC represents the vital 
capability of the lungs and as expected there was no change observed in the FVC value at 
any time point (p>0.05). FEV1/FVC ratio is an important parameter for asthma diagnosis 
and no changes were observed in the FEV1/FVC ratio across all time-points as shown in 
figure 5.5 (p>0.05). Overall; there was no effect of Rv supplementation on the pre exercise 
pulmonary function outcomes, however there was substantial improvement in post 
exercise FEV1 as presented in the last section (figure 5.3).  
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Figure 5.5 Changes in FEV1/FVC ratio at all-time points; no change was observed after Rv 
supplementation or at any other time-point.  
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Bronchodilator usage changed within the first week of supplementation 
The participants reported the number of puffs of bronchodilator used per week and each 
usage represents two puffs. There was no overall change in the mean bronchodilator 
usage across all time points (p=0.15, figure 5.6). There was  no data collected for baseline 
1 measurement.There was a reduced use of bronchodilators reported in week 1 of Rv 
supplementation (3 times or 6 puffs, figure 5.5). However, the pattern did not continue 
across the entire supplementation phase. The total bronchodilator usage was 11 times (22 
puffs) during the placebo phase while it was 13 times (26 puffs) during the Rv 
supplementation phase. Bronchodilator usage was reported 17 times (34 puffs) during the 
washout after placebo phase and 15 times (30 puffs) during washout following the Rv 
supplementation phase.  
 
 
   
Figure 5.6. Changes in bronchodilator usage across all time-points 
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5.4.3 Secondary outcomes  
 No change in FeNO with Rv supplementation  
 
All participants had elevated levels of FeNO compared to upper threshold of healthy 
individuals (25ppb) before the start of supplementation. Measurements for FeNO were 
collected at rest and post exercise challenge test at all-time points.  
 
At rest, the values measured for baseline (46.5 ± 2.75ppb) were comparable to values 
measured after Rv supplementation (49.2 ± 11.58ppb) or placebo (43.75 ± 5.69ppb). 
Overall, there was no change in the FeNO levels at rest at any time points as displayed in 
figure 5.7, (p=0.59). Similarly, there was no change in the post exercise FeNO levels 
measured at each time point (p=0.29). Thus, there was no overall reduction in FeNO levels 
with 3-week Rv supplementation.  
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Figure 5.7 Changes in FeNO levels across all time points, normal levels for FeNO in healthy 
individuals is marked at 25ppb  
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5.4.4  A reduction in serum IL-10 and no change in serum IL-6 and TNF-α levels 
with Rv supplementation   
 
There were no changes in the mean levels of serum TNF-α, IL-6 and IL-10 across the two 
baselines, placebo and the washout phases (p>0.05), subsequently all comparisons are 
reported with reference to baseline.  
 
Though there was a reduction in TNF-α levels with Rv supplementation (4.99 ± 
0.64pg/mL), this was not statistically different to baseline (7.26 ±1.02 pg/mL) (p=0.09). 
There was no significant change in IL-6 levels with Rv supplementation (4.43 ± 1.04 
pg/mL) compared to baseline (2.67 ± 0.28 pg/mL). There was, however, a statistically 
significant reduction in IL-10 levels with Rv supplementation (4.63 ± 0.32 pg/mL) 
compared to baseline (6.22 ± 0.58) (p=0.014) as shown in figure 5.7.  
 
 
 
Figure 5.8 Serum cytokine levels across all time points;  
* statistically significant difference between baseline and resolvin phase for IL-10 (p<0.05) 
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5.4.5 Relationship of oral contraceptive (pill) usage to study outcomes 
 
Eight eumenorrheic participants (experiencing normal menstruation) completed the study 
and, of these, there were 5 participants currently taking an oral contraceptive (pill). There 
was no information available for the nature of the pill i.e. oestrogen only, progesterone only 
or a combination. The participants were grouped based upon whether they used a 
contraceptive  pill or not, and the data was compared  for the different study outcomes as 
reported below. It is important to note here that this study was not powered to detect the 
impact of oral contraceptive pill on pulmonary function. Thus, due to the small sample size 
recruited, it is difficult to make suitable inferences and caution is required while interpreting 
these findings.   
 
Pill and pulmonary function  
 
The pre exercise pulmonary function parameters including PEF, FEV1 and FEV1/FVC 
ratios were compared between the participants taking a contraceptive pill and those who 
were not.  At baseline, there was no difference in mean PEF between the participants 
taking oral contraceptives (438 ± 26.81 l/min) and those who were not (398 ± 3.38 l/min) 
(p=0.30) suggesting no effect of oral contraceptives. Also, no differences were observed in 
FEV1 values at baseline for the two groups (pill = 2.84 ±0.12 litres, no pill= 2.82 ± 0.05 
litres; p=0.90). The FEV1/FVC ratio of the two groups also showed no difference at 
baseline (pill =74.6 ± 1.5%; no pill =73.6 ± 1.6%, p>0.05). No difference in FEV1/FVC ratio, 
PEF and FEV1 were observed between the washout phases and placebo compared to 
baseline for those on or without an oral contraceptive pill (p>0.05).  
 
The maximum percentage drop in post exercise FEV1 at baseline for the group on pill was 
recorded as -13.96 ± 0.09% (group mean) which was similar to the drop demonstrated by 
the group without any pill [-12.25 ± 0.80%(group mean)]. Although there was an overall 
improvement in the post exercise FEV1 for the entire study population following resolvin 
supplementation compared to baseline (p<0.05), there were no differences observed in the 
magnitude of the improvement between the two groups (pill = -8.82 ± 2.98%, no pill = -
10.27 ± 2.12%). There were no differences in the washout or the placebo phase compared 
to the two baseline as displayed in figure 5.9 (p>0.05).  
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Figure 5.9 Post exercise change in FEV1 across all time points for those on the pill and those 
without 
 
Pill and FeNO 
 
The group taking an oral contraceptive pill showed a mean baseline (pre exercise) FeNO 
level of 49 ± 4 ppb which was no different to the mean value measured for the group who 
were not taking the pill (42 ± 1 ppb) (p=0.27). These values remained unchanged across 
all time-points for both the groups (p>0.05). There was also no difference in the change in 
FeNO levels with resolvin supplementation between the two groups (pill=56 ± 18 ppb; no 
pill = 36 ± 7ppb).There was also no difference between the post exercise FeNO values of 
the two groups across any time point of the study (p>0.05).  Overall, these data show that 
there was no relationship between FeNO levels and oral contraceptive intake.  
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Pill and cytokines  
 
There were no differences in serum TNF-α levels for those taking an oral contraceptive pill 
or not at baseline (pill= 8.11 ± 1.51 pg/mL, no pill= 5.83 ± 0.78 pg/mL). Similarly, there 
were no differences measured in the IL-6 levels for those on an pill (2.68 ± 0.47 pg/mL) or 
those not (2.67 ± 0.13 pg/mL). In addition, the levels of IL-10 showed no differences 
between the two groups at baseline (pill= 5.19 ± 0.42 pg/mL, no pill = 7.60 ± 0.80). There 
were no differences in the levels of these cytokines after resolvin supplementation 
(p>0.05). On the whole, there was no relationship between oral contraceptive use and 
cytokine levels. Although there was a significant reduction in IL-10 levels for the two 
groups combined together as shown in figure 5.8 there were no differences between the 
two groups in terms of their response to supplementation (p>0.05). 
 
5.5 Discussion  
 
The aim of this chapter was to investigate the effect of EPA-derived bioactive mediators (E 
series Resolvins) on post exercise FEV1 in EIB-prone females. This study was designed to 
test the hypothesis that there would be a statistically significant improvement in post- 
exercise FEV1 after three-weeks of resolvin supplementation To investigate the hypothesis, 
a randomised, placebo controlled, double blind, cross over study was conducted 
comparing physiological and biochemical variables before and after 3-week 
resolvin/placebo supplementation phases. Additionally, the possible relationship between 
oral contraceptive pill use with pulmonary function changes and other outcomes of the 
study were evaluated. This is the first study to demonstrate a beneficial effect of 3-week of 
supplementation with E series resolvins in EIB prone females. The beneficial effect was 
marked by a significant improvement in post exercise FEV1 (30% improvement) following 
supplementation which meant that the mean FEV1 value for the group was below the 
diagnostic threshold for EIB. Although there was a significant improvement in post 
exercise FEV1, the other outcomes (bronchodilator usage and FeNO levels) did not show 
any changes following supplementation. However, there was also a reduction in the levels 
of cytokine IL-10 but there were no changes in the levels of inflammatory cytokines (TNF-α 
and IL-6).  
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There are currently no prior studies, which have assessed the effect of resolvin 
supplementation in EIB prone females, thus it is difficult to compare the results to external, 
validated findings. Mickleborough and co-workers (2006) have demonstrated  a 36% 
improvement in post exercise FEV1  following three week supplementation with n-3 PUFA 
(3.2 grams EPA and 2.2 gram DHA) in EIB males and females. These changes were 
accompanied by a reduction in sputum concentrations of CystLTs (LTC4-LTE4), PGD2 and 
circulating levels of IL-1β, and TNF-α before and after exercise following n-3 
supplementation (Mickleborough et al., 2006). These findings are a confirmation of similar 
findings in elite athletes (males and females) with EPA/DHA supplementation using the 
same dose (Mickleborugh et al., 2003). In the study presented in chapter 4, it is reported 
that an approximately 45% improvement in post exercise FEV1  is observed with three 
weeks of EPA/DHA supplementation in a dose similar to that given by Mickleborough et al 
., (2006). Asthma is characterised as an airway disorder with airway and systemic 
inflammation (Macsali et al., 2012). The two prior studies discussed here, as well as this 
work, have provided some  indication of an improvement in post exercise pulmonary 
function following n-3 supplementation. This beneficial effect as displayed by reduction in 
pro inflammatory eicosanoid production is signifying the hypothesis that n-3 PUFA have 
the ability to alter the eicosanoid synthesis by changing cellular composition (Bagga et al., 
2003; Chapkin et al., 1992; Lee et al., 1985; Robinson& Stone, 2006; Sperling et al., 
1993).  
 
Rvs belong to a class of lipid mediators generated from EPA which are able to reduce and 
resolve inflammation and are found to be active in small concentrations (Bannenberg et 
al., 2005; Hisada et al., 2009, Serhan, 2011b). Resolvins along with protectins act during 
an inflammatory process in small quantities to facilitate the production of pro-inflammatory 
mediators and regulate the trafficking of inflammatory cells and mediators to sites of 
inflammation (Serhan et al., 2008, 2012; Levy et al., 2007). Airway responses to exercise 
(EIB), injury, noxious stimuli, or microbes lead to leukocyte recruitment for host defence 
and as leukocytes respond, they may react with resident cells of the lungs and can 
produce a cascade of specific mediators such as Rvs. The Rvs may be enzymatically 
generated from EPA/DHA which could subsequently account for the anti-inflammatory 
effects of resolvins (Ariel & Serhan, 2007, Aoki et al.,  2010). These bioactive, lipid-derived 
small molecules serve as agonists at specific receptors and are involved in resolution of 
localised inflammation (Kohli &Levy 2009, Serhan, 2011b). There is little information on 
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role of Rvs in lung diseases such as asthma; however Rvs are shown to exert anti-
inflammatory effects on models of operitonitis, renal ischaemia–perfusion injury and dry 
eye (Bannenberg et al., 2005; Carlo & Levy, 2010; Resolvyx, 2012: ClinicalTrials.gov 
identifier: NCT00799552; Serhan, 2008). Based on these demonstrated anti-inflammatory 
effects, it is likely that resolvins would also be protective in the lungs and promote the 
resolution of airway injury and inflammation. 
 
Our study shows that 3-week resolvin supplementation reduced the severity of EIB in 
female participants. In this study, resolvin supplementation improved lung function to 
below the diagnostic threshold of EIB which is a 10% fall in post exercise at FEV1 at two 
time points after exercise. Consequently, there appears to be a suggestion that there is an 
effect of supplementation with n-3 or their bioactive metabolites on lung function.  
 
Fractional exhaled breath nitric oxide (FeNO) is a non- invasive, clinically validated marker 
of airway inflammation. In our study no changes were observed in FeNO levels across any 
time point. Recent studies have used FeNO levels as a surrogate marker of eosinophilic 
airway inflammation and airflow obstruction in asthma based on the ATS, (2005) 
guidelines. The endogenously produced NO, as measured by FeNO, may reflect overall 
gas transfer across the alveoli in women with asthma (Borland & Higenbottam, 1989, 
Farha et al., 2009). However it has been shown that menstrual cycle has an impact over 
lung function which may also be affecting FeNO levels (Farha et al. 2009; Mickleborough 
et al. 2006). Stanford and co-workers (2006) have shown that pulmonary function in 
females is affected by menstrual cycle. The maximal percentage decline in post-exercise 
FEV1 and forced expiratory flow from 25 to 75% of forced vital capacity (FEF (25-75%) 
was found to be significantly greater (P<0.05) on day 21 (mid-luteal phase), when salivary 
progesterone concentration was highest compared to day 5 (mid-follicular phase). This 
deterioration in the severity of EIB during the mid-luteal phase was mirrored by worsening 
asthma symptoms and increased bronchodilator use. Hence, a record of the menstrual 
cycle phase or control of the timing of experiments with regard to the menstrual cycle may 
be important when testing female participants for EIB and other respiratory ailments. 
Additionally, the frequency and severity of asthma symptoms is reduced when serum 
levels of oestrogen (oestradiol) are high, as observed after exogenous eostradiol 
administration, oral contraceptive use and during ovulation (de Oliveira et al., 2010; 
Matsuo et al., 1999).  
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Mandhane and co-workers (2009) monitored asthmatic females throughout a complete 
menstrual cycle and observed that increasing oestrogen levels were associated with 
decreasing FeNO values, whereas increasing progesterone levels were associated with 
increases in FeNO and atopy (measured by skin-prick tests). Additionally, it was found that 
participants using oral contraceptives showed no significant progesterone-associated 
increase in FeNO throughout their menstrual cycle (Mandhane et al., 2009). Asthmatics in 
our study were grouped based on their pill usage and there was no difference in the 
pulmonary function outcomes, cytokines as well as FeNO levels at  baseline. Following 
resolvin supplementation for three weeks, no changes were observed in the overall FeNO 
levels as well as between the groups. A limitation of the present study was that a record of 
menstrual cycle was not maintained which could limit the understanding of changes in 
study outcomes during different phases of the menstrual cycle, although, again, this was 
not the primary focus of this supplementation study. Contraceptive pill usage was, 
however, recorded in the study but no relationships were observed between the pill usage 
and any of the study outcomes. Thus, whether the participants were taking oral 
contraceptive pills or not it made no difference to any of the outcomes of the study. This 
could be attributed to the small sample size of the study.  
 
The FeNO measurements were conducted using hand held potable device that are widely 
used in fieldwork and clinical settings. However there are some concerns about limitations 
of this method arising due to their inability to control flow rates and it has been suggested 
that interpretations should be cautiously done for the results generated by hand held 
devices compared to stationary devices. This limitation of the procedure is discussed in 
chapter 4 (pages 164-165), however throughout the study the same hand held device was 
used so the likelihood of having variations is minimal and caution is required if these 
results are compared to results from stationary devices. It is suggested that the portable 
devices show relatively lower values than stationary devices (Kim et al., 2012). 
Considering this argument, the asthmatics in this thesis showed values >40 ppb for FeNO 
which suggests a high inflammation in the study population compared to healthy 
individuals (25 ppb). Subsequently, the duration or the dose of resolvin supplementation 
could be one of the reasons for observing no improvement in FeNO. Dose response and 
time course studies are required to evaluate the dose and duration of resolvins required to 
reduce FeNO levels significantly.  
 
Chapter 5: Intervention study in EIB females                                                         A Kumar  
 201 
Levels of inflammatory cytokines including TNF-alpha, IL-6 and IL-10 were monitored 
before and after resolvin supplementation and only a reduction in serum IL-10 levels 
(p<0.05) was documented. No changes to IL-6 and TNF-alpha levels were observed.  
Thus, there is inconclusive evidence suggestive of further work is required with larger 
sample size and improved methods. The values recorded for these cytokines in our study 
represents the normal range for asthmatics found within the literature as discussed in 
chapter 4.Though the participants in the study were eumenorrheic with five out of eight on 
the pill, no adjustment was made for menstrual cycle phase. Owing to the cross-over 
nature of the study, it was considered important to start the resolvin supplementation on 
the individuals at the same time. Thus, the participants could possibly have been at 
different points of their menstrual cycle during the 3-week supplementation that could 
possibly account for poor improvement in cytokine and FeNO levels. Future studies should 
emphasise on recording and monitoring hormonal changes to appropriately evaluate 
menstrual factors in their analysis.  
 
Conclusions  
 
This study has shown for the first time that with three week Rv supplementation there is an 
improvement in post exercise pulmonary function in females with EIB. This was supported 
by a reduction in bronchodilator usage during the first week of Rv supplementation; 
however this trend was not maintained throughout that phase. No changes were observed 
in FeNO and inflammatory cytokine levels. There was a significant reduction in the levels 
of IL-10. There was no relationship of contraceptive pill usage to any of the study 
outcomes. Further studies with a larger sample size and control of timing during the 
menstrual cycle are required to assess dose response and duration of supplementation 
necessary to observe differences in other physiological and biochemical markers related to 
pulmonary function in EIB prone females 
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6 General discussion 
6.1 Summary Background  
 
Asthma is a large and increasing worldwide health problem to such an extent that despite 
medication being very effective in treating symptoms, there is still a major burden with 
regard to morbidity and mortality that is putting substantial pressure on public health 
services (Barnes et al., 2010; Masoli et al., 2004). As in many other common diseases, 
diagnosis presents with a range of issues. The characterisation of asthma in a majority of 
clinics is carried out via simple symptom scores and pulmonary function tests (PFTs). 
Asthma is primarily characterised by a fixed criteria (80% ratio for FEV1/FVC) and due to 
the non-specificity of this ratio for asthma severity, a large proportion of young and old 
adults may be under or over characterised respectively (Cerveri et al., 2009). In addition, 
‘sub groups’ including mild – moderate, atopic, allergic and exercise induced ‘asthma’ 
have the likelihood of under classification due to the variant nature of the symptoms 
(Pellegrino et al., 2005). The issues relating to the fixed criteria may be overcome by the 
introduction of a derived ‘lower limit of normality’ (LLN) criterion calculated from a matched 
control population (Miller et al., 2011; Pellegrino et al., 2005). Despite the American 
Thoracic Society and the European Respiratory Society (ATS/ERS) having issued position 
statements (Miller et al., 2009) encouraging the application of LLN for the diagnosis of 
respiratory diseases there are no specific guidelines for the use of LNN.  
 
To address this issue, a study was conducted to characterise mild-moderate asthmatics 
based on a standard fixed criteria (80% ratio) and then separately characterise the same 
individuals using the LLN derived from a reference control population. Once the asthmatic 
population was identified using the 80% ratio and LLN, differences in pulmonary function, 
dyspnoea and cytokine levels were compared between asthmatics and controls. Young 
male participants (18-30 years) were recruited for this study, including mild – moderate 
asthmatics (based upon a previous clinical diagnosis and a history of asthma) and healthy 
controls. Using the 80% ratio based on ATS/ERS guidelines, 16 mild-moderate asthmatics 
(FEV1/FVC ratio 60-80%) and 21 healthy controls (FEV1/FVC ratio 80% and above) were 
characterised. The control population was used to calculate the LNN and a ratio of 82% 
was indicated meaning that all 16 individuals previously characterised as mild-moderate 
asthmatics were confirmed as mild-moderate asthmatics using this approach (below 82%). 
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The asthmatics, as identified by both the 80% ratio and LLN, displayed worse dyspnoea 
scores and elevated levels of serum cytokines (IL- 6 and  TNF- α) than controls.  
 
A number of recent studies have investigated the discrepancy in classification using fixed 
criteria and LLN; these studies document a range of false negatives (7-24%) in younger 
populations using different fixed criteria (Cerveri et al., 2009; Hansen et al., 2007; Miller et 
al., 2011; Roberts et al., 2006; Swanney et al., 2008). There is evidence that current 
airflow obstruction characterisation criteria are not adequate and alternative 
characterisation criteria should be investigated for defining airway obstruction in diseases 
such as asthma and COPD. LLN is one such alternative that may be used alongside the 
fixed criteria as demonstrated in this thesis (chapter 3). The lung matures by age 20–25 
years, after which there is a progressive decline in the lung function due to various 
anatomical, physiological and immunological changes (Sharma & Goodwin, 2006). An age 
specific LLN may therefore be important for making a correct diagnosis. In our study, all of 
the 18-30 year old males previously characterised as mild-moderate asthmatics using an 
80% ratio were confirmed as mild-moderate asthmatics using the LLN. This suggests that 
the two methods of characterisation are comparable for the classification of young, mild-
moderate asthmatics; therefore, the LLN when used alongside 80% ratio may provide a 
reliable characterisation of mild-moderate asthmatics.  
 
The discrepancy between our data and the studies described above (Cerveri et al., 2009; 
Hansen et al., 2007; Miller et al., 2011; Roberts et al., 2006; Swanney et al., 2008) may 
relate to a number of issues. The majority of the studies cited use ‘predicted values’ as 
opposed to ‘measured values’ for the calculation of LLN. Our study used a separate 
population of controls for calculation of LLN (using ‘measured values’), and applied it to the 
previously characterised mild-moderate asthmatics (by 80% ratio). This methodological 
difference may partly explain the discrepancies. Additionally, the current study used an 
age group of 18-30 years while larger studies have used an upper age range (up to 39 
years) denoting younger population. This relates to the issue of lung age; although it could 
be argued that our samples include some young participants (18 years), however the 
narrow age band centred at the lower end of the range gives rise to a homogeneous 
sample in our study. 
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Clinically, the use of a predicted value is common; however, in young and or athletic 
populations these values are inappropriate due to the high proportion of individuals gaining 
values very close to and above 100% of predicted (Mickleborough et al., 2003; Stanford et 
al., 2006). It is not uncommon to observe values higher than 100% of predicted in young, 
fit, non-smoking population and this pattern is labelled as a ‘normal physiologic variant’ 
(Pellegrino et al., 2005). It is suggested that this is possibly due to dysanaptic growth or 
unequal growth of airways and lung parenchyma (Hyatt et al., 1986). In our study (chapter 
3) the asthmatics displayed a mean predicted value of 86% for FEV1/FVC ratio while the 
controls showed mean values of 106% for FEV1/FVC ratio. Had the predicted values been 
used, a number of mild-moderate asthmatics would have been under characterised (false 
negatives) if an 80% ratio was used. This clearly demonstrates the limitation of using 
reference equations and may explain the comparable results for 80% ratio and LLN 
observed in our study due to the use of ‘measured values’.  
 
It could be argued that the comparable results observed for the two criteria for 
classification in our study (lack of difference between groups) could be attributed to a small 
sample size. However, despite the small sample size, there were significant differences in 
the FEV1/FVC ratio of the asthmatics and controls (asthmatics = 71.23. ± 1.17%; controls 
= 88.74 ± 0.95%). In addition, there were worse symptom scores and elevated levels of 
inflammatory cytokines within the mild-moderate asthmatic group compared to healthy 
controls. Therefore, irrespective of the small sample size, the comparable findings in our 
results for the 80% ratio and LLN provides evidence that if matched reference population 
is used then an accurate characterisation of mild-moderate asthma may be achieved.  
 
Markers of airway inflammation  
 
Though pulmonary function tests are recognised worldwide as a diagnostic tool for the 
measurement of asthma it is suggested that other markers of asthma may help in a clearer 
definition of individual asthma subtype (such as EIB) and its severity/control (symptoms 
and medications) (GINA, 2011; Cerveri et al., 2009). In this thesis, asthma symptoms 
(dyspnoea) and levels of inflammatory cytokines were compared and asthmatics showed 
significantly elevated levels of inflammatory cytokines and poorer symptom scores. The 
asthmatics showed a significantly higher level of serum IL-6 (mean = 1.66 ± 0.08 pg/mL) 
than controls (mean = 1.38 ± 0.06 pg/mL) (p<0.05). Similarly, asthmatics had elevated 
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levels of TNF-α compared to controls (asthmatics, mean = 4.28 ± 0.25 pg/mL, controls, 
mean = 3.35 ± 0.26 pg/mL) (<0.05). The elevated levels of IL-6 and TNF-α reported in this 
study (chapter 3) are within the ranges found in previous literature for asthmatics and 
controls. For asthmatics, previous studies have reported a range of values for IL-6 
(between 0.8 pg/mL to 15.49 pg/mL) and TNF-α values within the range of 3.6 – 8.0 pg/mL 
(Canoz et al., 2008; Halasz et al., 2002; Pukelsheim et al., 2010; Samy et al., 2010; 
Subrrahmanyam et al., 2011). The values obtained for controls (in chapter 3) also fall 
within the observed range from the literature (0.8 – 3 pg/mL for IL-6 and 3 – 8 pg/mL for 
TNF-α) (Kim et al., 2011; Pukelsheim et al., 2010). These results demonstrate that the 
‘mild-moderate’ asthmatic group have elevated levels of inflammation; consequently, 
monitoring of inflammation may be important for assessing improvement with therapy. In 
clinical settings, it is not always possible to conduct measurement of venous blood based 
inflammatory mediators as a part of a routine assessment of asthma. Recently, indirect 
estimation of inflammation in the lung via exhaled breath nitric oxide (FeNO) has been 
suggested as a useful marker for assessing the efficacy of anti-inflammatory treatments 
(Dweik et al., 2011; Kharitonov et al., 1996; Zitt, 2005). FeNO levels were assessed in the 
supplementation studies reported in chapters 4 and 5 to evaluate the suitability of FeNO 
as a marker of inflammation. 
 
Asthma and EPA/DHA supplementation  
 
The currently available therapies for asthma and EIB are effective, however long-term use 
of these is associated with issues of tachyphylaxis and numerous health side effects 
(Barnes, 2010; GINA, 2011). There is evidence from supplementation studies to suggest a 
beneficial effect of fish oil [comprising of omega-3 (n-3) polyunsaturated fatty acids 
(PUFAs)] in asthma and other inflammatory diseases (Arm et al., 1989; Hodge et al., 1998; 
Mickleborough et al., 2003, 2006; Surette et al., 2008), therefore, there is an impetus 
towards using fish oil as a ‘complimentary therapy’ for asthma. The anti-inflammatory 
effects of fish oil are hypothesised to be linked with the alteration of cell membrane 
composition (primarily EPA/DHA) which can modify lipid mediator generation by producing 
less inflammatory eicosanoids. A newly identified group of lipid mediators derived from 
EPA/DHA (include resolvins, protectins and maresins) are proposed to be important in the 
resolution of inflammation (Serhan, 2011b). The reduced inflammatory and pro resolution 
effects of n-3 PUFA may attenuate the severity of asthma including symptoms (dyspnoea) 
Chapter 6: General discussion                                                                       A Kumar  
 207 
and exert a bronchodilatory effect (Hodge et al., 1998; Mickleborough et al., 2006). There 
is a lack of studies investigating the effects of fish oil supplementation in mild/moderate 
asthmatics with EIB; and most studies conducted have focussed on athletes. To address 
these issues related to the impact of EPA/ DHA supplementation on post exercise 
pulmonary function in EIB prone mild-moderate asthmatics, two supplementation studies 
were carried out  in this thesis; (a) EPA/DHA supplementation in EIB males and (b) 
Resolvin supplementation in EIB females.     
 
The LLN derived from the controls in chapter 3 was used alongside the 80% ratio for the 
characterisation of individuals for the n-3 supplementation study (chapter 4) to assess the 
effect of EPA/DHA supplementation on post exercise FEV1 in mild – moderate EIB prone 
males. The study population comprised of EIB-prone individuals (n=9, 18-30 years) who 
were recruited following a positive test for EIB (a drop of >10% in FEV1 following an 
exercise challenge) as well as elevated resting levels of FeNO in expired air (>40 ppb). 
These participants were recruited and tested within a very short time frame (12 weeks) in 
order to control for the possible seasonal variation in outcome measures. A sample size 
estimate to detect a minimum detectable difference of 0.3 litres in FEV1 after exercise 
following the supplementation with EPA/DHA was selected based on previous studies 
showing the effect of n-3 PUFAs on pulmonary function in EIB subjects (Mickleborough et 
al., 2003, 2006). The required number of participants to show such a difference in post 
exercise pulmonary function was eight; therefore, the power requirements were met. All 
the participants in the supplementation study had abnormal pulmonary function and fell 
below the 82% LLN calculated in chapter 3 (mean baseline FEV1/FVC ratio of asthmatics = 
77 ± 1.4%). In addition, the participants showed elevated levels of upper airway 
inflammation confirmed by elevated FeNO (mean FeNO at baseline = 46 ± 2.7 ppb) and 
increased levels of circulating inflammatory cytokines (TNF-α at baseline = 7.2 ± 1.02 
pg/mL, IL-6 = 2.67 ±0.28 pg/mL). The levels of inflammatory cytokines in the asthmatics of 
chapter 4 were higher than the values obtained for asthmatics in chapter 3, however these 
values were still comparable to the values previously observed in the asthma literature 
(Canoz et al., 2008; Halasz et al., 2002; Pukelsheim et al., 2010; Samy et al., 2010; 
Subrrahmanyam et al., 2011). 
 
The differences observed in the level of cytokines measured within the mild-moderate 
asthmatics in chapters 3 and chapter 4 could be due to differences between the samples 
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used in the two studies and the assay methodology used, making direct comparison 
difficult. The differences in the performance of commercially available ELISAs from 
different manufacturers may be attributed to different specificities of antibodies and 
sensitivity of detection. The high sensitivity R&D kit used in chapter 3 for IL-6 had a 
minimum detectable limit of 0.039 pg/mL compared to 0.8pg/mL for the Tepnel (Diaclone) 
kit used in chapter 4 and 5. These differences in the performance of the assays could 
account for differences in the results. Considering these limitations, the study design for 
the intervention (chapter 4 and 5) was such that assay kits from the same manufacturer 
were used and samples from all the time points of the study were analysed on the same 
plate to minimise between plate variations.  
 
Three weeks of dietary n-3 supplementation (3.2 gram EPA and 2.2gram DHA/per day) 
showed a beneficial impact on pulmonary function in EIB participants. The 
supplementation with EPA/DHA improved pulmonary function to below the diagnostic 
threshold value for EIB, i.e. 10% fall in post exercise FEV1. There was approximately 50% 
improvement in post exercise FEV1 at 10 and 15 minutes after exercise and these findings 
confirm  previous reports by Mickleborough et al., (2003, 2006) using a similar dose of 
EPA/DHA where an improvement of approximately 60% and 25% were observed in the 
respective studies. These two studies by Mickleborough et al., conducted in 
athletes/recreationally active participants, have also shown a reduction in asthma 
medication use by end of supplementation or reduced medication use by 3rd week of 
supplementation which is mirrored by the findings of chapter 4 (>50% improvement by the 
third week of supplementation). These results clearly show that EPA/DHA 
supplementation can improve post exercise pulmonary function in EIB-prone males and 
significantly reduce reliance on medication. These observed differences in FEV1 
improvements maybe due to the mixed nature of the participants (males and females) in 
the studies conducted by Mickleborough et al., (2003, 2006). Our study was designed 
considering these issues and recruited only male participants and this may to some extent 
explain the 50% improvement in post exercise pulmonary function compared to the 
inconsistent improvements reported in the previous studies. For future studies, using a 
larger sample size to further elucidate our findings, it is suggested separate groups of 
males and females are included for intervention studies with a control for menstrual cycle 
in the female group.       
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In previous n-3 supplementation studies, bronchodilator use has been considered as a 
study outcome alongside pulmonary function. There have been no effects on asthma 
medication use in a number of studies using different doses of EPA/ DHA (Arm et al., 
1989; Kirsch et al., 1998; McDonald et al., 1990; Schubert et al., 2009; Stenius-Aarniala et 
al., 1989; Thien et al., 1993). Using self-reported asthma status and medication use 
questionnaires, Surette et al., (2008) did report a reduction in medication at a dose (1.13 
gram GLA+ 0.75 gram EPA) in mild-moderate asthmatics by the end of 3 weeks of 
supplementation. This was based on self-reported symptoms; therefore, in the absence of 
any PFT measurements the results from this study require careful interpretation. Studies 
by Emelyanov et al., (2002); Hodge et al., (1998) have shown an improvement in mean 
daytime wheeze/morning PEF in adults and children using <1.5 gram EPA and DHA. 
Thus, there is an encouraging trend to suggest a beneficial effect of EPA/DHA on 
pulmonary function and reduction in bronchodilator usage; however the inconsistencies in 
these studies are likely to be due to factors such as dose, duration and asthma type (sub 
group). In our study the symptom scores were already very low at the start of the 
supplementation trial and therefore the likelihood of seeing improvements in self-reported 
symptoms was minimal. However, by the third week of EPA/DHA supplementation, there 
was a 50% reduction in bronchodilator usage compared to placebo and this reduction was 
statistically significant. These results provide evidence for the bronchodilatory effects of 
EPA/DHA supplementation in mild-moderate EIB individuals.  
 
EPA/DHA dose and duration response in asthma 
 
Asthma supplementation studies have shown inconsistencies in pulmonary function 
outcomes however there is substantial information on the anti-inflammatory effect of n-3 
PUFA in asthma. Arm et al., (1989) demonstrated a reduction in LTB4 generation by 
stimulated neutrophils with supplementation; in addition, Schubert et al., (2009) have 
shown a reduction in CystLTs by activated leukocytes. Similar findings were reported by 
Mickleborough et al., (2006) with a reduction in LTB4 and an increase in LTB5 in stimulated 
polymophonuclear cells. In addition, they showed that there was a reduction in sputum 
levels of PGD2, IL-1β and TNF-α, while in children, Hodge et al., (1998) demonstrated a 
drop in TNF-α production in cultured PBMC. Thus, n-3 supplementation has been shown 
to reduce inflammatory effects although heterogeneity between the studies (i.e. differences 
in dose and duration of supplementation) may be responsible for the different magnitudes 
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of effect seen. Studies with 3 weeks of supplementation, including the present study, have 
shown significant improvement in post exercise pulmonary function, reduction in 
inflammatory cytokines and a decrease in pro inflammatory lipid mediators with 3.2 gram 
EPA+2.2 gram DHA supplementation (Mickleborough et al., 2003, 2006). In atopic and 
allergic asthma 4 -10 weeks of supplementation with a dose between 0.5 mg 
EPA+DHA/day and 3.2 gram+2.2 gram DHA per day has shown beneficial effects on 
pulmonary function, medication usage and in vitro lipid mediator generation (Arm et al., 
1989; Emelyanov et al., 2002; Hodge et al., 1998; Surette et al., 2008; Schubert et al., 
2009). Thus there is no definite dose response relationship between the effects of n-3 
PUFA supplementation in asthma as a range of doses and duration have shown beneficial 
effects.  
 
In a dose response study by Rees et al., (2006) in healthy participants, a dose of 2.7 
gram/day of EPA was shown to reduce ex vivo PGE2 production by stimulated 
mononuclear cells compared to a lower dose of 1.35 grams of EPA/day. A number of 
studies, have shown a threshold for an anti-inflammatory effect to be exerted in the range 
of 1.3 -3.5 grams EPA per day (Calder., 2006, 2012; Dignass et al., 2004; Kelley et al., 
1998; Kew et al., 2004; Kolahi et al., 2010; Grimble et al., 2003). In this thesis, significant 
improvement in post exercise pulmonary function has been observed with a 
supplementation of 3.2 grams EPA and 2.2 grams DHA which provides confirmation of the 
beneficial effects of n-3 PUFA in mild-moderate asthma; however lower doses require 
further investigation. Although there is no consensus about the optimal dose for improving 
lung inflammation, the beneficial results shown by n-3 PUFA in asthma suggest a possible 
anti-inflammatory effect of EPA /DHA and highlight the requirement for future dose 
response and time course trials in asthma to evaluate the impact of supplementation in 
asthma symptoms and inflammation.  
 
The proposed mechanisms for the action of n-3 PUFA are associated with the modification 
of cell membrane composition with n-3 supplementation (Calder, 2012; Calder & Yaqoob, 
2009). Modification of cell membrane phospholipid content can influence the membrane-
linked enzyme systems and cell signalling pathways that affect the physiological 
responses of cells (Mickleborough & Rundell, 2005; Surette, 2008). Dietary 
supplementation with fish oil can alter cell membrane fatty acid profiles and there is an 
increase in overall EPA and DHA in different cell types including PBMC following 
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supplementation (Damsgaard et al., 2008; Yaqoob et al., 2000). Data from time course 
studies have shown that incorporation of EPA and DHA into human inflammatory cells 
starts within days of supplementation and reaches near maximum within four weeks; 
however, incorporation occurs in a dose response manner (Kew et al., 2004; Rees., et al. 
2006; Thies et al., 2001; Yaqoob et al., 2000). Asthma supplementation studies using a 
dose of 3.2 gram EPA and 2.2 gram DHA per day for 3 weeks have previously shown 
significant increases in neutrophil, plasma and RBC phospholipid EPA content usually at 
the expense of AA (Arm et al., 1989; Schubert et al., 2009; Surette et al., 2003, 2006; 
Mickeborough et al., 2006; Hodge et al., 1998).  
 
In this thesis, there was a trend toward an increase of EPA (3 fold) and DHA (2 fold) with a 
reduction in AA (2 fold) in PBMC, but this change was not statistically significant. The 
study was powered to detect a change in post-exercise pulmonary function, and, when 
post hoc power analysis was carried out for total PBMC lipid analysis it reflected a low 
power of 0.4 to detect statistically significant changes in lipid composition. There are 
studies which have previously shown incorporation of EPA/DHA into PBMC total lipids 
following supplementation with a dose of 1-2 grams EPA/DHA per day (Thies et al., 2001; 
Yaqoob et al., 2000). The difference between these studies and our study may be due to 
the duration of supplementation; as it was expected to see incorporation after 3 weeks of 
supplementation at a relatively high dose used in our study. In addition, there were 
limitations in the analytical method (GC-FID) used here which may have resulted in the 
lack of observed statistical significant incorporation.  
 
FADS and n-3 supplementation  
 
The lack of incorporation of EPA and DHA in this study may be attributed to factors other 
than dose/duration of supplementation and limitations of the analytical methods. The delta 
5-and delta 6-desaturase enzymes encoded by FADS1 and FADS2 genes respectively 
have been shown to be critical in the metabolic pathway of n-3 PUFA and have an impact 
on chronic inflammatory diseases particularly in relation to a long chain PUFA (EPA and 
DHA) deficient diet (Aslibekyan  et al., 2012; Lattka et al., 2010). Genome wide association 
studies have shown that the genetic variations in the FADS gene cluster are linked to 
PUFA content in serum phospholipid and RBC membranes in several populations 
including Caucasians, East Asians and Afro Americans (Lemaitre et al., 2011; Martinelli et 
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al., 2008). These variations have an impact on lipid metabolism, glucose metabolism and 
other quantitative characters and may be responsible for the pathogenesis of chronic 
diseases including coronary heart disease (Pizzolo et al., 2008), asthma and atopy 
(Schaeffer et al., 2006; Simopolous., 2009). Polymorphisms in FADS1 and FADS2 have 
shown positive associations with the level of AA and some association with levels of LA 
and n-3 fatty acids including ALA, EPA and DPA (Schaeffer et al., 2006). This particular 
study also reported that carriers of the rare alleles of several FADS1 and FADS2 
polymorphisms and their respective haplotypes have a lower incidence of atopic eczema 
however there was no association with IgE. Thus, there may be a relationship of FADS 
polymorphisms with inflammation.  There is, however, limited information about the 
associations of FADS polymorphism in different asthma ‘sub groups’ including mild-
moderate asthma and EIB and further candidate and genome wide association studies are 
required to investigate the role of FADS in inflammation.  
 
Supplementation of  n-3 PUFA has been reported to affect cell signalling pathways either 
by altering the expression and activity of membrane receptors or by modification of the 
expression of genes by the activation of transcription factors such as NFқB and PPAR-α 
(Michaud & Renier, 2001; Rudkowska  et al., 2009; Tai et al., 2005). To determine the long 
term effect of EPA/DHA on the cellular transcriptome, Bouwen et al., (2009) investigated 
changes in whole genome transcriptional profiles in PBMC and adipose tissue after 26 
weeks of supplementation with 0.4 g EPA/DHA (n=36) and 1.8 g EPA/DHA (n=37) or a 
control oil (high–oleic acid sunflower oil, n=38) in an elderly population (66–80 years). 
Daily supplementation with the higher dose resulted in changes in the expression of 
approximately 1000 genes and there was significant down regulation of genes involved in 
inflammatory pathways, such as eicosanoid synthesis, interleukin signalling, and MAP 
kinase signalling. Additionally, the low dose of supplementation showed gene expression 
changes that were similar to those seen with a high dose which suggest that lower levels 
of supplementation for longer period may have similar effects on PBMC gene expression 
(Bouwen et al., 2009). However, the major limitation of this study was that it comprised of 
only elderly individuals and consequently the results cannot be generalised for all age 
groups. These findings are in line with a small study conducted by Gorjao et al., (2006) 
which showed a reduction in the expression of cytokine-related genes following n-3 
supplementation. Therefore, evidence suggests that long-term n-3 supplementation has 
the potential to reduce the expression of leukocyte inflammatory genes and decrease 
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cytokine production following leukocyte stimulation. These anti-inflammatory effects of n-3 
PUFA have a beneficial role in the management and control of airway inflammation in 
asthma.  
 
In this thesis, levels of inflammatory cytokines (IL-6 and TNF-α) were measured before 
and after EPA/DHA supplementation and there was a significant reduction of 37% in the 
level of serum IL-6. The asthmatic population in this study had elevated levels of 
inflammatory cytokines at baseline and the reduction in the levels of these cytokines 
observed here maybe indicative of the anti-inflammatory effect of n-3 PUFA. In addition, in 
this thesis, there was no change in the level of TNF-α and IL-10 with supplementation. The 
serum IL-10 levels of asthmatics are generally lower than that of healthy controls, which 
indicates that asthmatics may have lower ability to release this cytokine and are unable to 
inhibit the formation of inflammatory factors (Guo et al., 2008). This could be attributed to 
the shorter duration of supplementation however to completely understand the relationship 
between IL-10 and n-3 supplementation dose response and time course studies will be 
required. Furthermore, studies are required to understand the regulation of genes involved 
in the asthma pathophysiology with n-3 supplementation. 
 
The n-6/n-3 ratio vs. absolute amounts  
 
A number of studies have described the n-6/n-3 fatty acid ratio by accumulating all n-6 and 
n-3 PUFAs and this approach assumes that all n-6 and n-3 PUFAs are biologically 
equivalent to one another (Calder & Deckelbaum, 2011; Harris, 2006). Since there is a 
competition between LA and ALA for metabolism by delta 6-desaturase, this ratio may be 
considered important as it is suggestive of the relative rates of metabolism of these two 
fatty acids in vivo.  In those individuals whose dietary oily fish consumption and fish oil 
supplementation is absent, the n-6: n-3 ratio will approximate to the LA: ALA ratio as LA 
constitutes 95% of dietary n-6 while ALA makes up 90% of n-3 intake (Stanley et al., 
2007). Furthermore there are a number of ways of changing the dietary n-6: n-3 ratio, 
either by changing LA intake alone and keeping ALA intake constant or vice versa. 
However, there is limited conversion of ALA to EPA and DHA (Brenna et al., 2009; Burdge 
& Calder, 2005; Goyens et al., 2006). Subsequently, changing the dietary n-6: n-3 ratio by 
modifying ALA can increase plasma, cell and tissue EPA to some extent, but not DHA 
content (Arterburn et al., 2006; Kelley et al., 1993). Thus, a ratio of n-6 to n-3 PUFA can be 
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misleading in relation to diet and biological status and it is suggested that the focus should 
be based on specific fatty acids and the absolute amounts/content rather than ratios. In 
addition, omega 3 index (EPA + DHA as a percentage of fatty acids in RBCs) or a ratio of 
AA: EPA+DHA or in plasma, cells and tissues  could be used as a functional  marker 
(Hibbeln et al., 2006; Rees et al., 2006; Stanley et al., 2007). Considering these 
arguments, the changes in the relative content of EPA, DHA and AA in PBMC total lipid 
reported in chapter 4 to assess the effect of supplementation can be considered a strength 
of the study.  
 
Beneficial effects of resolvins on asthma  
  
The biological effects of n-3 PUFA may be exerted via a range of mechanisms and to 
evaluate the role of newly identified lipid mediators a supplementation study was 
conducted to investigate the effect of EPA-derived bioactive mediators (E series 
Resolvins) on post exercise FEV1 in EIB-prone females. The results showed a significant 
improvement in post exercise FEV1 in EIB-prone females with three weeks of resolvin 
supplementation. There was a significant reduction in serum IL-10 levels but no overall 
reduction in serum TNF- α, IL-6 or FeNO levels. Additionally, there was no relationship 
between contraceptive pill use and any of the study outcomes.   
 
This is the first study to demonstrate a beneficial effect of 3 weeks of supplementation with 
E series resolvins on pulmonary function in EIB prone females. The beneficial effect was 
supported by a markedly significant improvement in post exercise FEV1 which put 
participants below the diagnostic threshold for EIB. Furthermore, there was a reduction in 
the levels of serum IL-10 levels although there was no change in the levels of inflammatory 
cytokines (TNF-α and IL-6). The findings from this study are encouraging as it suggests a 
beneficial role of a short duration supplementation with E series resolvin (100 mg 
Resolvinol per day). This dosage of resolvins is much lower than the required amount of 
EPA/DHA (range 1-3 grams/day) needed to exert anti-inflammatory effect. It is possible, 
based on these preliminary findings, that the newly identified resolvins can exert pro 
resolution effects in relatively small amounts. A short duration of supplementation was 
chosen for participant retention as longer phases have a greater likelihood of participant 
drop out (Max et al., 1991). The fact that there are few prior studies in this area and 
certainly none in asthma, meant that this particular part of the thesis study was 
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experimental in nature. As well as its strength in identifying the positive effect of resolvin 
supplementation on pulmonary function, this study has paved the way for future studies by 
determining an effective dose to promote a response in pulmonary function. However the 
lack of a systematic change in inflammatory mediators measured denotes that the 
mechanisms underlying the change in pulmonary function are not clear.   
 
Fluctuations in pulmonary function are reported during the menstrual cycle and the 
symptoms are more severe during mid-luteal to mid-follicular stages, often with a dip near 
the time of ovulation. The mechanisms underlying the menstrual cycle and asthma and 
AHR are not clear and there appears to be reduced symptoms for those taking oral 
contraceptives (Lim & Kobzik, 2008; Stanford et al., 2006; Tan et al., 1997; Vrieze et al., 
1997). There was no relationship of the pill use with any study outcome but this could be 
attributed to the small sample size.  
 
Dietary Intake 
 
In the supplementation studies (chapter 4 and 5) participants were advised to maintain 
their normal diet throughout their participation in the study. We are, however, unable to 
comment on possible variation in dietary intake during these phases which may have 
confounded these findings. Retrospective dietary recalls including 24-hour diet diaries and 
food frequency questionnaires (FFQs) were originally used for estimation of the dietary 
intake of participants in this study. Data were analysed using McCance & Widdowson’s 
‘The Composition of Foods’ published by the Department of Fisheries, Agriculture and 
Food (1998). One of the original aims of the thesis was to monitor the dietary behaviour to 
confirm the level of n-3 intake. The results of the planned dietary intake studies were found 
to be inconsistent and did not represent a normal daily intake as shown in the literature 
with regard to total energy and fat intake. It is likely that these inconsistencies could be 
due to errors in measurement, data collection and/or participant response. Quantitative 
estimates of dietary intake have been found to be error prone, for example, the co-efficient 
of variation (CV) of differences incurred from asking subjects to recall food portions rather 
than weighing them has been found to be in the 50% range for foods and 20% for nutrients 
(Hodson et al., 2008). It has been suggested that precision can be improved be improved 
by increasing the number of observations in individuals and by maintaining weighed food 
diaries (Bingham, 1991; Bingham et al., 1994; Buzzard, 1998; Todd et al., 1983). Although 
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attempts were made to collect reliable dietary information the inconsistencies in the 
analysis showed that data from these recalls carried possible measurement errors, lacked 
accuracy and may not represent normal dietary behaviour for participants. Consequently, 
on the advice of the examiners, the analysis was excluded from the thesis. The exclusion 
of these dietary data does not affect the primary aims of the thesis, however, due to this 
limitation of the work it is not possible to comment upon variation in dietary intake during 
supplementation (chapter 4 and 5) which may have confounded our findings relating to 
total PBMC lipid composition. For future studies, larger sample size, an improved 
analytical/dietary method and longer duration of study is required.  
 
Relationship of plasma fatty acid content to atopy 
 
Early life exposure to n-3 and n-6 PUFA is hypothesised to have an effect on asthma and 
atopy (Calder et al., 2010; Kremmyda et al., 2011). Evidence from observational studies 
has led to the hypothesis that an increased intake of n-6 PUFA accompanied by a low 
intake of fish oil [omega 3 (n-3) PUFA] may play a causal role in the increased incidence of 
asthma (Black & Sharpe., 1997; Hodge et al., 1994; Peroni et al., 2012). Epidemiological 
studies evaluating the effects of fish oil during infancy and childhood on asthma and atopy 
have been inconsistent, with a number of large-scale studies showing a beneficial effect of 
fish oil in asthma and atopy but some studies showing no effect (Mihrshahi et al., 2003; 
Nagakura et al., 2000; Peat et al., 1994, 2004; Vaisman et al., 2005). The fatty acid 
composition of plasma is affected by diet and various metabolic processes including those 
which regulate the fatty acid composition of the components (Sala-Vila et al., 2008). Thus, 
comparing the differences in the fatty acid composition of plasma between atopic and non-
atopic individuals (asthmatics or healthy) is considered an important method for assessing 
the exposure of body components to fatty acids and may indirectly reflect diet and 
metabolism. There are a number of studies which have reported fatty acid composition in 
plasma and serum lipids in atopic children and adults (Laerum et al., 2007; Leichsenring et 
al., 1995; Wood et al., 2004). The pattern of results is inconsistent; a few studies show 
higher LA and lower AA, EPA and DHA levels in plasma in atopic individuals compared to 
matched controls (Griese et al., 1990; Haidopoulou et al., 2009; Leichsenring et al., 1995). 
In this thesis the asthmatics were not tested for atopy and future studies may incorporate 
tests for atopy within the different ‘sub groups’ of asthma and could compare the 
plasma/inflammatory cell lipid composition of these individuals with healthy controls.  
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6.2 Future directions 
 
Since asthma is a growing health issue, public health interventions are becoming 
increasingly important to reduce its severity and prevalence. Diet and nutrition are 
potential factors that could affect the pathophysiology of asthma, decrease reliance on 
pharmaceutical drugs, and promote health and independence in later life. This study has 
confirmed the beneficial effects of EPA/DHA supplementation in decreasing EIB severity 
thus, there is a potential for using n-3 as a complimentary therapy for improving pulmonary 
function. The supplementation trials in asthma have been limited by sample size however 
there is a positive relationship of n-3 PUFA supplementation on various inflammatory 
outcomes in asthma.  
 
Based on our results which confirm the previous findings of various studies in asthma 
including Arm et al., (1989); Emelyanov et al., (2002); Hodge et al., (1998); Schubert et al., 
(2009); there is a likelihood that if asthmatics with EIB compliment their daily diets with n-3 
either in the form of oily fish or supplements, it may ameliorate their EIB symptoms. A 
number of asthmatics do not engage in physical activity as it triggers their asthma. For this 
population a dietary n-3 intervention may potentially change their lifestyle and activity 
levels with wide ranging health benefits. A large scale RCT in EIB patients with a daily n-3 
intervention may be instrumental to understand the response of dietary n-3 at a population 
level, giving the ability to determine effects in different age groups, different body mass 
classes, with gender and ethnicity. To reduce under classification in younger adults or 
those with mild/moderate/EIB symptoms and over classification in older adults due to fixed 
criteria for asthma diagnosis a LLN criteria maybe used together with the 80% ratio to get 
a more reliable diagnosis of the study population. This requires gathering data on 
appropriate reference populations and translating these data into usable clinical 
guidelines. Correct and timely diagnosis will provide an early opportunity for intervention to 
improve the quality of life of those affected.  
 
The research findings from this thesis along with the previous literature showing the 
beneficial effect of EPA /DHA in asthma were taken forward and a proposal was submitted 
to the ESRC/MRC (Interdisciplinary ESRC / MRC Fellowship) with an aim of 
understanding the interactions between dietary behaviour (omega 3 intake) and the 
severity and prevalence of asthma at the population level. It was emphasised that the 
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Department of Health's (DH) initiative to promote the campaign 'small change, big 
difference' encourages people to make minor changes to their lifestyles to give them a 
better chance of living longer and healthier lives. The proposed method included an 
integrative approach of behavioural sciences, psychology and biological sciences to 
ascertain the level of community preparedness for a dietary change (n-3) by using the 
Community Readiness Model for behavioural change (Edwards et al., 2000; Plested et al., 
2006). Though this grant was not successful, there were positive comments from the 
review committee which supported the concept of the proposed community based 
intervention to meet the DH’s initiatives.  
 
Currently there are no guidelines for the recommended dosage of resolvin required to 
exert anti-inflammatory and pro resolution effects in asthma. The beneficial effects shown 
in this study on female participants are promising for future studies that should investigate 
the effects of dose and time response with resolvins on inflammation. Clinical trials are 
currently underway (Brooks, 2009; Resolvyx, 2012; ClinicalTrials.gov identifier: 
NCT00799552) and the results will hopefully add important data to the growing literature 
base.  
 
6.3 Final Conclusions 
 
The LLN criteria for asthma characterisation is comparable with standard fixed criteria for 
young males with mild-moderate asthma. Therefore, LLN can be used alongside fixed 
criteria for reliable characterisation of asthma in this population. Asthmatics have greater 
inflammation compared to controls, confirmed by their pulmonary function tests, 
symptoms, and circulating IL-6 and TNF-α level. FeNO is an attractive non-invasive 
measure for airway inflammation; further work is required to evaluate the dose and 
duration of EPA/DHA supplementation to reduce FeNO levels and how these changes 
relate to pulmonary function. There was a beneficial effect of 3-weeks of supplementation 
(3.2 gram EPA+ 2.2 grams DHA/day) in the post exercise pulmonary function of mild-
moderate EIB prone asthmatic males which was supported by reduced bronchodilator 
usage and a reduction in circulating IL-6 levels. Three-weeks of supplementation with the 
recently identified E series resolvins (100 mg/day) improved post exercise pulmonary 
function in mild-moderate EIB prone asthmatic females; however, controls for menstrual 
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cycle and pill usage were confounding variables. Studies with a large sample size and 
carefully controlled study methods are required to confirm these findings at a population 
level. 
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Appendix 1 
Appendix 1 contains details of the materials ad reagents required for the biochemical 
procedures used during the study.  
 
Table 1:  Balanced salt solution for PBMC isolation 
 
Table 2: Materials required for TNF-α measurement from blood  
Wash Buffer To avoid crystal formed in the concentrate, the buffer was warmed 
at room temperature and mix gently until the crystals have 
completely dissolved. 100 ml of Wash Buffer Concentrate was 
missed into deionized water to prepare 1000 mol of Wash Buffer. 
Substrate 
Solution 
Lyophilized Substrate was reconstituted with 6.0 ml of Substrate 
Diluent at least 10 minutes before use. The vials were re-stopped, 
capped, and mix thoroughly.  
Amplifier 
Solution 
Lyophilised Amplifier was reconstituted with 6.0 ml of Amplifier 
Diluent at least 10 minutes before use. The vials were re-stopped, 
capped, and mix thoroughly. 
TNF-α 
Standard 
The TNF- α Standard was reconstituted with the volume of 
Calibrator Diluent RD6-13 printed on the Standard vial label to 
produce a stock solution of 32 pg/ml. This reconstitution produced 
a 1X stock solution. The standard was allowed  to sit for a minimum 
of 15 minutes with gentle agitation prior to 
making dilutions.  
 
To prepare dilutions: 500uL of Calibrator Diluent RD6-13 was 
aliquoted into each tube. The stock solution was used to create 
dilutions of 16, 8, 4, 2, 1, and 0.5pg/ml. The undiluted standard 
served as the high standard (32 pg/mL). Calibrator Diluent RD6-13 
served as the zero standard (0 pg/mL). 
 
 
 
 
Stock solution A  Conc. (g/l) 
Anhydrous D-glucose                    0.1%                                 1.0 
CaCl2 × 2H2O                                          5.0 × 10-5 M  0.0074 
MgCl2 × 6H2O         9.8 × 10-4 M                       0.1992 
KCl   54 × 10-3 M                           0.4026 
Tris        0.145 M                                17.565 
Conc. HCl                                                10 N to pH 7.6 
Distilled water*                 to 1 l 
Stock solution B                                                                        Conc. (g/l) 
NaCl                                                        0.14 M                                       8.19 
*Dissolve in approximately 950 ml distilled water and add 10 N HCl until pH is 7.6 before 
adjusting the volume to 1 l.      
To prepare the balanced salt solution, 1 volume Solution A was mixed with nine volumes 
Solution B and sterilized.                             
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Table 3: Materials required for IL-6 measurement from blood  
Wash Buffer To avoid crystal formed in the concentrate, the buffer was warmed 
at room temperature and mix gently until the crystals have 
completely dissolved. 100 ml of Wash Buffer Concentrate was 
mixed into deionized water to prepare 1000 mol of Wash Buffer. 
Substrate 
Solution 
Lyophilized Substrate was reconstituted with 6.0 ml of Substrate 
Diluent at least 10 minutes before use. The vials were re-stopped, 
capped, and mix thoroughly.  
Amplifier 
Solution 
Lyophilised Amplifier was reconstituted with 6.0 ml of Amplifier 
Diluent at least 10 minutes before use. The vials were re-stopped, 
capped, and mix thoroughly. 
IL-6 
Standard 
The IL-6 Standard was reconstituted with 5.0 mL of the calibrator 
Diluent RD6-11 Concentrate. This reconstitution produces a stock 
solution of 10pg/ml. The standard was allowed to sit for a minimum 
of 15 minutes with gentle agitation prior to making dilutions. 500 ul 
of the Calibrator Diluent RD6-11 Concentrate was added into each 
tube. The stock solution to was used to produce a dilution series   
To produce a dilution series of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 
0.156 pg/ml.  The appropriate reconstituted standard serves as the 
high standard (10 pg/mL). The appropriate 
Calibrator Diluent serves as the zero standard (0 pg/mL). 
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Appendix 2 
Appendix 2 illustrates the recruitment flyers, participant information sheet and related 
documents used for recruitment during the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASTHMATICS  NEEDED 
Can Fish Oil Intake Reduce Severity of Asthma? 
 
Who can take part? 
* Males 
* Asthmatics 
* Age 18-65 years 
 
Why? 
Studies suggest that fish oil intake can reduce severity of 
 asthma. This project aims to determine relationship 
between dietary intake of fish oil (Omega-3) and 
asthma/lung  
inflammation at cellular level.  
 
What will the study involve? 
The experiment will involve: 
One visit to the lab (lasting up to an hour) 
Short questionnaires 
Lung function test and a small blood sample 
Where and 
How? 
If interested please 
contact: 
Ash 
a.varma@lboro.ac.uk 
01509 22 81 59 
Department of Human 
Sciences 
Wavy Top building 
Map reference: 49 
?  Help us answer this question? 
Appendix                                                                                                        A Kumar 
259 
 
 
 
 
 
 
Q. Can this help treat Exercise Induced Asthma? 
 
 
 
 
 
 
What is the purpose of the study? 
• The study is designed to look at the effects of taking fish oil supplementation 
(Omega-3) on lung health (Pulmonary Function test). In order to do this we need 
participants to take three different supplements, each for a period of 3 weeks and 
with 3 weeks washout in between the phases. Participants will be asked to come 
into the lab for testing before and after each supplementation period. 
 
• This means a total duration of 15 weeks however, this is only six visits to the lab 
for testing and only 9 weeks of actually taking the supplements. 
 
• The Christmas period will remain free from testing and supplementation so that 
you can carry on your normal holiday activities. 
 
The omega-3 capsules are made of gelatine, which are not suitable for vegetarians.  
 
Who can take part in the study? 
 Males and Females   
 Mild-moderate Asthmatics and healthy individuals  
 Age 18-65 years 
 No self-reported respiratory infection within the past 8 weeks  
 Not taken steroids, of any kind, Hay-fever or other allergy medication (past 7 days) 
 
What will I have to do? 
 All testing will take place in the laboratories within the School of Sport Exercise 
and Health. Short questionnaires (including University health screening) lasting up 
to 20 minutes will be completed.  
 Participants will receive a dose of three different supplements, each for a period of 
3 weeks.      
 For each lab visit (lasting up to a maximum of 2 hours); spirometry measurements 
and exercise challenge testing will be completed. 
 In addition, three blood samples (9ml each) will be collected for associated 
biochemical analysis. 
 
The total supplementation period is 6 weeks. There will be six lab visits required 
lasting up to a maximum of 2 hours.  
 
 
 
 
.  
 
For Information Contact: 
Miss A Varma (PhD student), Email: A.Varma@lboro.ac.uk    (01509 228159)     or  
Dr M R Lindley, Email: M.R.Lindley@lboro.ac.uk 
School of Sport, Exercise and Health Sciences, Loughborough University 
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Participant Information Sheet 
Isolation and Analysis of Peripheral Blood Mononuclear Cell. 
 
What is the purpose of the study? 
Studies suggest that fish oil intake can reduce severity of asthma. This project aims to 
determine relationships and effects of fish oil (Omega-3) on asthma and lung 
inflammation at cellular level. Blood cells (Peripheral blood mononuclear cells) will be 
isolated and Omega 3 constitution of cell membranes will be analysed. These results will 
be compared against pulmonary function test results. This will allow us to investigate any 
possible relationships between fish oil intake and asthma.  
 
Who can take part in the study? 
 Males 
 Both groups - Asthmatics and non-asthmatics  
 Age 18-65 years 
 No respiratory infection within the past 8 weeks 
 Not taken steroids, of any kind, Hay-fever or other allergy medication (past 7 days)  
 
What will I have to do? 
 One visit to the lab(lasting up to an hour) 
 Short questionnaires (including University health screening) 
 Lung function test and a small blood sample  
 
What will I gain from participating in this study? 
You will receive the results from your lung function test as well as the standard ranges.  
 
Are there any risks? 
 The risk involved are minimal  
 Lung Function test will involve a number of maximal breaths.   
 All invasive procedures will follow University Health and Safety guidelines.  
 
What will happen to my test results and information? 
All of your information will be kept confidential and anonymous. The blood sample will be 
used to determine the cell membrane composition and inflammatory markers. Remaining 
samples will be destroyed after completion of the study.  
 
What if I change my mind? 
You are free to withdraw at any time during the study.  
 
Whom do I contact if I have any more questions? 
 
Aishwarya Varma                    Dr Martin Lindley                     Dr S S Mastana 
PhD Student                             Exercise Physiologist      Snr. Lecturer, human Biology  
a.varma@lboro.ac.uk             m.r.lindley@lboro.ac.uk           s.s.mastana@lboro.ac.uk 
Tel: 01509 22 8159                   Tel: 01509 22 3017               Tel: 01509 22 3041             
 
Department of Human Sciences, Wavy Top building, Loughborough University  
LE11 3TU  
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Participant Information Sheet 
Exercise challenge test screening  
 
What is the purpose of the study? 
Exercise related symptoms are very common in young people with even well controlled 
asthma and because they limit participation in physical activity can have quite marked 
effects on the general health, quality of life, mental health and social interactions of young 
people. Exercise challenge test is an important method to assess exercise-induced 
asthma. Exercise related symptoms occur in up to 50% of patients with asthma; they are 
often the most incapacitating aspect of the disease in younger patients. This study aims to 
assess exercise induced asthma symptoms in adults with stable asthma.  
 
Who can take part in the study? 
 Males and females  
 Both groups – Mild-moderate Asthmatics and non-Asthmatics  
 Age 18-65 years 
 No respiratory infection within the past 8 weeks 
 Not taken steroids, of any kind, Hay-fever or other allergy medication (past 7 days)  
 
What will I have to do? 
 One visit to the lab(lasting up to an hour) 
 Short questionnaires (including University health screening) 
 Lung function test using standard spirometry.  
 
What will I gain from participating in this study? 
You will receive the results from your lung function test as well as the standard ranges.  
 
Are there any risks? 
 The risk involved are minimal  
 Exercise challenge will involve maximum exhaustion.  
 Lung Function test will involve a number of maximal breaths.   
 All invasive procedures will follow University Health and Safety guidelines.  
 
What will happen to my test results and information? 
All of your information will be kept confidential and anonymous.  
 
What if I change my mind? 
You are free to withdraw at any time during the study.  
 
Whom do I contact if I have any more questions? 
 
Aishwarya Varma                    Dr Martin Lindley                     Dr S S Mastana 
PhD Student                             Exercise Physiologist      Snr. Lecturer, human Biology  
a.varma@lboro.ac.uk             m.r.lindley@lboro.ac.uk           s.s.mastana@lboro.ac.uk 
Tel: 01509 22 8159                   Tel: 01509 22 3017               Tel: 01509 22 3041             
Department of Sports, Exercise and Health sciences, Wavy Top building, Loughborough 
University, LE11 3TU  
 
 
 
 
 
Appendix                                                                                                        A Kumar 
262 
 
 
 
 
 
Name/Number   ...............…….  
 
Health Screen Questionnaire for Study Volunteers 
 
Note to Investigators:  This HSQ can be used in its entirety but you can also remove some of the 
questions if you know they are not relevant to your study. 
 
As a volunteer participating in a research study, it is important that you are currently in good health 
and have had no significant medical problems in the past.  This is (i) to ensure your own continuing 
well-being and (ii) to avoid the possibility of individual health issues confounding study outcomes. 
 
If you have a blood-borne virus, or think that you may have one, please do not take part in this 
research [only include for projects involving invasive procedures]. 
 
Please complete this brief questionnaire to confirm your fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ..................  Yes  No  
 If Yes , please mention:      
(b) attending your general practitioner .........................  Yes  No  
 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP .....................................................  Yes  No  
(b) attend a hospital outpatient department ..................  Yes  No  
(c) be admitted to hospital  ..........................................  Yes  No  
 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy ............................................... Yes  No  
(b) Asthma  ................................................................... Yes  No  
(c) Eczema  ................................................................... Yes  No  
(d) Diabetes  ................................................................. Yes  No  
(e) A blood disorder  ...................................................... Yes  No  
(f) Head injury  .............................................................. Yes  No  
(g) Digestive problems  .................................................. Yes  No  
(h) Heart problems  ....................................................... Yes  No  
(i) Problems with bones or joints     ............................... Yes  No  
(j) Disturbance of balance/coordination  ........................ Yes  No  
(k) Numbness in hands or feet  ...................................... Yes  No  
(l) Disturbance of vision  ............................................... Yes  No  
(m) Ear / hearing problems  ............................................ Yes  No  
(n) Thyroid problems  .................................................... Yes  No  
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(o) Kidney or liver problems  .......................................... Yes  No  
(p) Allergy to nuts  ......................................................... Yes  No  
 
4. Has any, otherwise healthy, member of your family under the 
age of 35 died suddenly during or soon after exercise?  ... Yes  No  
 
If YES to any question, please describe briefly if you wish (eg to confirm problem was/is 
short-lived, insignificant or well controlled.) 
.............................................................................................................................................................
......................................................................................................................................................... 
 
5. Allergy Information 
(a) are you allergic to any food products? Yes  No  
(b) are you allergic to any medicines? Yes  No  
(c) are you allergic to plasters? Yes  No  
 
If YES to any of the above, please provide additional information on the allergy 
…………………………………………………………………………………………………………………
…………….. 
 
5. Have you ever taken any Omega 3 dietary supplements?  
 
If YES, Please mention which supplements, duration in which taken  etc.  
 
………………………………………………………………………………………………………………. 
 
6 Additional questions for female participants 
(a) are your periods normal/regular?  .............................  Yes  No  
(b) are you on “the pill”?  ...............................................  Yes  No  
(c) could you be pregnant?    .........................................  Yes  No  
(d) are you taking hormone replacement therapy (HRT)? Yes  No  
 
6. Please provide contact details of a suitable person for us to contact in the event of any 
incident or emergency. 
 
Name:  
………………………………………………………………………………………………………………
. 
 
Telephone Number:  
………………………………………………………………………………………………………………
. 
 
 Work  Home  Mobile  
 
Relationship to 
Participant:…………………………………………………………………………………………..........
.. 
7. Are you currently involved in any other research studies at the University? 
 Yes  No  
 
If yes, please provide details of the study 
Yes  No  
Appendix                                                                                                        A Kumar 
264 
 
 
 
INFORMED CONSENT FORM 
(to be completed after Participant Information Sheet has been read) 
 
 
The purpose and details of this study have been explained to me.  I understand that this study is 
designed to further scientific knowledge and that all procedures have been approved by the 
Loughborough University Ethical Advisory Committee. 
 
I have read and understood the information sheet and this consent form. 
 
I have had an opportunity to ask questions about my participation. 
 
I understand that I am under no obligation to take part in the study. 
 
I understand that I have the right to withdraw from this study at any stage for any reason, and that I 
will not be required to explain my reasons for withdrawing. 
 
I understand that all the information I provide will be treated in strict confidence and will be kept 
anonymous and confidential to the researchers unless (under the statutory obligations of the 
agencies which the researchers are working with), it is judged that confidentiality will have to be 
breached for the safety of the participant or others.  
 
 
I agree to participate in this study. 
 
 
 
                    Your name 
 
 
 
              Your signature 
 
 
 
Signature of investigator 
 
 
 
                               Date 
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Participant Information Sheet 
Omega 3 Dietary Supplementation 
 
What is the purpose of the study? 
Several biochemical studies suggest beneficial effects of Omega 3 supplementation on asthmatics. 
Participants will be required to take Omega 3 supplements consisting of 7 gelatine capsules 
containing approximately containing 2.6 grams of Eicosapentaenoic acid (EPA) and 1.4 grams of 
Docosahexaenoic acid (DHA) per day. EPA and DHA are Omega 3 PUFAs that have shown to 
have positive impacts on inflammation with respect to asthma, cystic fibrosis, cardiovascular 
diseases and rheumatic diseases. EPA has possible anti-inflammatory properties. The 
supplementation will be carried for a maximum of 6-week period.  
 
Who can take part in the study? 
 Males and Females   
 Mild-moderate Asthmatics and healthy individuals  
 Age 18-65 years 
 No respiratory infection within the past 8 weeks 
 Not taken steroids, of any kind, Hay-fever or other allergy medication (past 7 days) 
 
Who cannot take part in the study?  
 Children under 18 years of age  
 People over 65 years of age  
 People with mental illness  
 Prisoners/other detained persons 
 Pregnant women 
 
What will I have to do? 
 Short questionnaires (including University health screening) 
 Participants will receive a dose of Omega 3 PUFAs in the form of seven gelatine capsules 
(comprising approximately 2.6 grams of EPA and 1.4 grams of DHA) for a maximum of 6 
weeks.  
 Participants will return to the lab at the beginning of each week for a maximum of 6 weeks 
to collect supplements and undergo additional physiological assessments (lasting for a 
maximum of one and half hour).       
 
What will I gain from participating in this study? 
You will receive your dietary analysis information.  
 
Are there any risks? 
 The risk involved are minimal  
 There is no major adverse health side effect linked with Omega 3 supplementation.   
 
What will happen to my test results and information? 
All of your information will be kept confidential and anonymous.  
 
What if I change my mind? 
You are free to withdraw at any time during the study.  
 
Who do I contact if I have any more questions? 
Dr Martin Lindley                     Aishwarya Varma                    Dr S S Mastana  
Lecturer                                                 PhD Student             Snr. Lecturer, human Biology  
m.r.lindley@lboro.ac.uk           a.varma@lboro.ac.uk             s.s.mastana@lboro.ac.uk 
Tel: 01509 22 3017                 Tel: 01509 22 8159                   Tel: 01509 22 3041             
Department of Sports, Exercise and Health Sciences, Wavy Top building, Loughborough 
University, LE11 3TU  
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Appendix3 
 
This appendix includes supplementary tables and figures from chapter 4 
 
Table 4.1: Percentage change in post exercise FEV1 at all time-points for all participants, all values 
are negative showing percentage (%) drop. 
 
Baseline 
Participant 
ID 
1min 5min 10min 15min 30min 45min 
1 10.09 12.33 10.09 9.19 5.16 0 
2 10.71 22.06 19.33 11.55 3.15 0 
3 + 4.69 1.23 13.58 14.32 + 2.22 + 4.94 
4 5.26 11.37 10.32 11.58 6.11 5.05 
5 + 1.34 5.15 10.96 12.53 8.28 5.37 
6 2.3 12.64 10.11 11.72 5.52 0.69 
7 7.48 14.49 7.01 4.21 6.07 4.21 
8 20.78 22.37 31.28 27.17 4.57 0.46 
9 9.81 12.15 10.87 3.62 5.33 0.85 
Mean ± SD 6.71 ± 7.52 12.64 ± 6.85 13.73 ± 7.40 11.77 ± 6.84 4.66 ± 2.92 1.30 ± 3.21 
       
Placebo 
 1min 5min 10min 15min 30min 45min 
1 5.16 9.19 14.57 17.49 6.73 4.71 
2 2.1 7.98 12.39 14.29 2.94 3.78 
3 +  5.19 + 1.23 2.47 10.37 8.4 + 7.41 
4 +  2.95 17.68 12.63 6.74 2.32 1.89 
5 +  2.46 10.51 10.96 10.51 5.82 + 1.34 
6 12.64 10.11 11.72 6.21 7.59 3.45 
7 14.49 7.01 4.21 6.54 8.88 6.54 
8 1.83 7.31 10.96 11.87 9.13 1.83 
9 12.15 10.87 3.62 2.77 4.05 + 0.21 
Mean ± SD 4.20 ± 7.37 8.83 ± 4.94 9.28 ± 4.54 9.64 ± 4.56 6.20 ± 2.58 1.47 ± 4.11 
 Omega 3  
IDs 1min 5min 10min 15min 30min 45min 
1 10.54 18.39 11.88 9.19 10.31 4.93 
2 0.42 7.35 8.61 4.2 4.41 4.2 
3 +7.65 + 3.96 -3.46 12.84 8.4 + 2.47 
4 + 3.79 1.05 +1.89 0.84 + 0.63 2.95 
5 2.68 1.57 5.59 3.36 + 0.67 0.45 
6 2.3 0.92 2.3 4.6 0.23 0.23 
7 9.35 7.71 3.97 4.21 6.07 + 0.93 
8 + 0.68 0.68 + 0.22 + 5.71 + 7.31 + 6.16 
9 4.69 9.59 2.56 0.64 0.85 + 0.21 
Mean ± SD 1.98 ±  5.82 4.81 ±  6.67 4.03 ±  4.24 3.80 ±  5.26 2.41 ±  5.43 0.33 ±  3.45 
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Figure 4.1: A sample GC-FID trace showing changes in relative percentages of AA, EPA 
and DHA levels in PBMC total lipid profile before and after EPA/DHA supplementation.  
 
Before supplementation  
 
 
 
 
After EPA/DHA supplementation  
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Table 4.3: Mean PBMC total lipid composition of the mild-moderate asthmatics all time points of the intervention study with EPA/DHA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Time-points  RM ANOVA  
Fatty Acids  Baseline  Omega 3  Placebo wash 1 wash 2 F 
value 
error  P value  Post hoc  
significance  
Observed 
power  
SFA                
Capric acid           
Lauric acid 5.81 ± 1.98 3.80  ± 2.15 4.29 ±  2.43 5.81 ± 2.88 4.00 ± 1.33 0.26 28.00 0.89 No 0.10 
Myristic acid 6.84 ±  2.68 8.36  ±  4.28 4.11  ±  1.98 4.90 ± 2.56 3.55 ± 1.67 0.81 28.00 0.53 No 0.23 
Pentadecanoic 1.38  ±  0.47 2.89  ±  1.93 2.58  ±  2.31 2.53 ± 0.95 1.10± 0.68 0.22 28.00 0.93 No 0.09 
Palmitic acid 18.28  ±  
3.24 
15.31  ±  
3.63 
14.90  ±  2.72 14.07 ± 
4.06 
18.48 ± 
2.38 
0.34 28.00 0.85 No 0.16 
Heptadecanoic 
acid 
0.39  ±  0.23 0.81  ±  0.26 0.97  ±  0.44 0.54 ± 0.12 1.17 ±0.62 0.79 12.65 0.57 No 0.21 
Stearic acid 9.74  ±  1.69 4.52  ±  1.18 4.58  ±  0.94 6.42 ± 0.47 6.49 ± 0.63 4.05 28.00 0.01 No 0.86 
MUFA           
Palmitoleic acid 9.39  ±  3.28 3.76  ±  1.19 3.26  ±  1.13 6.70 ± 1.65 4.17 ± 1.80 1.75 28.00 0.21 No 0.30 
Oleic acid  10.13  ±  
1.54 
9.01  ±  2.91 10.39  ±  2.31 7.81 ± 2.95 17.18 ± 
1.52 
2.77 28.00 0.05 Yes, between 
baseline and 
wash 1 
0.64 
PUFA           
Linoleic Acid (LA) 8.83  ±  2.51 9.40  ±  2.70 10.29  ±  
11.36 
8.18 ± 2.88 5.73 ± 0.90 0.56 28.00 0.69 No 0.17 
Alpha - linoleic 
Acid (ALA) 
0.70  ±  0.09 0.73  ±  0.16 0.77  ±  0.12 1.85 ± 0.54 1.13 ± 0.18 3.36 9.85 0.09 No 0.43 
Arachidonic acid 
(AA) 
4.93  ±  0.37 2.28  ±  0.62 6.32  ±  1.64 4.57 ± 0.75 5.61 ± 1.08 2.52 14.32 0.12 No 0.43 
Eicosapentaenoic 
Acid (EPA) 
1.33  ±  0.34 3.06  ±  0.73 1.20  ±  0.26 1.36 ± 0.47 1.36 ± 0.22 2.77 12.35 0.11 No 0.28 
Docosahexaenoic 
Acid (DHA 
0.60 ±  0.06 1.08  ±  0.23 1.54  ±  0.46 0.82 ± 0.14 0.86 ± 0.19 1.53 28.00 0.22 No 0.41 
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Appendix 4:  
Table 5.1: Percentage change in post exercise FEV1 at all time-points for all participants, 
all values are negative showing percentage (%) drop. 
 
Baseline 
Participant 
ID 1min 5min 10min 15min 30min 45min 
1 4.51 15.79 15.04 17.67 14.66 4.89 
2 15.65 11.9 15.25 6.12 6,46 1.36 
3 3.77 13.36 10.96 4.11 1.37 2.05 
4 (+) 2.46 8.42 12.28 10.53 5.26 1.75 
5 6.57 14.19 11.42 13.49 12.8 5.88 
6 5.71 11.11 10.79 7.62 0.63 (+) 0.95 
7 3.85 6.73 11.86 14.1 8.65 3.85 
8 2.96 2.63 11.84 11.18 0.66 2.96 
Mean ± SD 
5.07 ±  
5.06 
10.52 ± 
4.35 
12.43 ±  
1.74 
10.60 ±  
4.50  
6.31 ±  
5.44 
2.72 ±  
2.16 
Placebo 
  1min 5min 10min 15min 30min 45min 
1 2 3.01 20.86 24.23 5.01 (+) 1.50 
2 1.36 11.22 18.03 18.37 4.76 1.36 
3 7.53 12.44 13.41 14.49 7.53 5.82 
4 (+) 0.70 8.07 7.37 4.91 5.26 2.46 
5 2.55 5.11 14.6 10.22 10.22 2.55 
6 (+) 0.23 10.47 12.09 4.19 3.49 1.63 
7 3.85 8,65 6.73 10.9 10.26 3.85 
8 3.67 10 15 11.33 8.33 3 
Mean ± SD 
3.09 ± 
0.52 
8.62 ± 
3.18 
13.51 ± 
4.83 
12.33 ± 
6.67 
6.86 ± 
2.60  
2.40 ± 
2.11 
Omega 3 
IDs 1min 5min 10min 15min 30min 45min 
1 1.52 20.83 15.91 11.36 12.5 (+) 3.03 
2 6.02 12.37 11.71 6.02 2.68 1.34 
3 3.22 5.14 9.97 5.14 1.93 3.54 
4 0.7 14.34 14.69 10.49 6.64 5.24 
5 8.03 8,63 7.55 7.69 6.23 7,27 
6 4.76 1.9 1.27 2.86 0.95 0 
7 3.85 4.17 0.32 (+) 0.96 0.96 (+) 4.17 
8 1.32 1.97 6.25 9.54 6.25 1.64 
Mean ± SD 
2.49  ± 
3.85 
8.67  ± 
5.74 8.46 ± 5.74 
6.52  ± 
4.16 
4.53  ± 
4.26 
1.48 ± 
3.90 
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Appendix 5:  
 
SSHB Conference 
25th May 2011, Loughborough University (Oral Presentation) 
 
Impact of a Three Week Dietary Supplementation with Omega 3 on 
Exercise Induced Asthma in Recreationally Active Males.   
 
Aishwarya Varma, Sarabjit S Mastana, Martin R Lindley , Human Cell and Molecular 
Biology Research Lab, School of Sports, Exercise and Health Sciences, Loughborough 
University.   
 
Abstract 
Omega 3 (n3) and Omega 6 (n6) are Essential Fatty Acids playing integral role in cell 
membrane composition and signalling pathways. To evaluate the possibility of using n3/n6 
ratio as a biomarker for asthma, a double blinded Randomised Crossover Trial was 
conducted. Mild asthmatics (Males, n=9, mean age 21.77 ± 2.71years) with a history of 
Exercise Induced Bronchoconstriction (EIB, >10% drop in post exercise FEV1, >40ppb 
Exhaled breath Nitric Oxide (FeNO)) completed the trial. Institution’s ethics committee 
approved the study.  
 
Participants entered the study on normal diet; they were supplemented with dietary n3 
(comprising 3.2 grams of EPA and 2.2 grams of DHA or placebo) for three weeks before 
they crossed over to alternate diet (2 week wash). Venous blood samples were used to 
isolate Peripheral blood Mononuclear Cells (PBMC), genotyping and measurement of   
inflammatory markers. Standard FFQ and dietary recall was completed to ascertain n3/n6 
intake and Exercise challenge test (ATS/ERS guidelines) were used to assess % change 
in FEV1 after exercise in pre and post supplementation phases.  
 
Significant increase in post exercise FEV1 (p<0.05, Figure 1) and reduction in serum IL-6 
levels were observed post n3 supplementation, with no reduction in serum TNF-α and IL-
10 levels. The n3/n6 ratio in PBMC membrane was not modified significantly, requiring 
further investigation. Data suggests that higher n3/n6 can improve lung function and 
potentially serve as a biomarker for asthma.  
 
Figure 1  
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Fatty acids: medicine and menace YLS 2010 (Oral Presentation) 
Fatty acid conference, Biochemical Society, Charles Darwin House, London.  
27th May 2010 
 
Omega 3/Omega 6  Ratio:  A Biomarker for Asthma? 
Aishwarya Varma, M R Lindley, Sarabjit S Mastana, Human Cell and Molecular Biology Research 
Lab, School of Sports, Exercise and Health Sciences, Loughborough University 
 
Biochemical studies suggest beneficial effects of Omega 3 fatty acids on inflammatory 
diseases such as cardiovascular diseases, diabetes, obesity, asthma and related chronic 
diseases. Therefore, there is a need to investigate the mechanisms guiding the proposed 
effect. This study aims to investigate the relationship between Omega 3(n3) and Omega 
6(n6) ratio in immune function cell [Peripheral Blood Mononuclear Cell (PBMC)] 
membranes and lung function. 
 
Mild-moderate asthmatics (N=17, mean age 26.5±5.1, BMI 24.3±1.8) and healthy 
individuals (N=24, 24.1±7.6, BMI 24±2.8) were recruited from the East Midlands, U.K. The 
study was approved by Loughborough Universities’ ethics committee . Spirometry 
(BTS/ERS) guidelines measured lung function while venous blood was used to isolate 
PBMC and measure inflammatory mediators. Dietary recall was completed to ascertain 
fatty acid intake. A modified method for fatty acid esterification with gas chromatography 
was adapted for PBMC analysis.  
 
The data demonstrates that the total amount of n3 (sum of ALA, EPA and DHA) and n6 
(sum of LA and AA) was significantly different within the two groups (P<0.05). The amount 
of AA was significantly higher in the asthmatic population when compared to the controls; 
however there was no significant difference between the EPA levels of the two groups. 
This suggests that asthmatics have a different cell membrane composition with respect to 
n3/n6; despite the similar dietary n3/n6 intake, as confirmed by the dietary recall analysis.  
 
These findings imply a relationship between n3/n6 in PBMC cell membranes and 
inflammation, indicating that n3/n6 ratio may be used as a possible biomarker for asthma. 
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European Respiratory Society Annual Congress (Thematic Poster) 
Vienna, Austria 
September 2009 
 
Omega 3/Omega 6 ratio in peripheral blood mononuclear cells - a biomarker for 
asthma? 
 
Aishwarya Varma, M R Lindley, Sarabjit S Mastana. Human Cell and Molecular Biology 
Research Lab, School of Sports, Exercise and Health Sciences, Loughborough University, 
Loughborough, Leicestershire, United Kingdom, LE113TU  
 
Biochemical studies suggest beneficial effects of omega 3 fatty acids on asthma and 
related lung inflammatory diseases (Mickleborough et al Clin Nutr. 2009;28(1):71-7). 
Therefore, there is a need to investigate the mechanisms guiding the proposed effect. This 
study aims to investigate the relationship between Omega 3(n3) and Omega 6(n6) ratio in 
peripheral blood mononuclear cell (PBMC) membranes and lung function. Asthmatics 
(mild-moderate, n=21; mean age 26.05±12.19) and healthy individuals (n=22; 27±9.75) 
were recruited from Leicestershire, U.K. Institution's ethics committee approved the study. 
 
Spirometry based on BTS/ERS guidelines measured lung function and venous blood was 
used to isolate PBMC and measure inflammatory mediators, while dietary recall was 
completed to ascertain fatty acid intake. A modified method for fatty acid esterification with 
gas chromatography (Masood et al J Lipid Res.2005;46(10):2299-305) was adapted for 
PBMC analysis. Preliminary findings suggest asthmatics and controls can be distinguished 
based on their n3/n6 ratio. These findings imply a relationship between n3/n6 in PBMC cell 
membranes and inflammation, indicating that n3/n6 ratio may be used as a possible 
biomarker for asthma. 
 
Table1:Preliminary ratio data for Gas chromatography 
  Omega 3 Omega 6 Ratio 
Asthmatics(FEV1/FVC <70%) 1 1.8 0.54 
n=2 1 7.2 0.13 
Controls 1 1.2 0.83 
n=2 1 0.98 1.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
